

Friday, November 30, 2018

Volume 49 No. 11



NOTICE – Items in this issue will be listed online weekly and printed monthly.

NEW COMPANY DESCRIPTIONS

(For details on individual listings, see the News Section of this issue)

Spring Pharmaceutical Group Inc

NAME CHANGES

(For details on individual listings, see the News Section of this issue)

MCBC Holdings Inc (to MasterCraft Boat Holdings Inc)

2U INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	296,674	200,074
Cost & expenses	346,522	230,238
Operating income	(49,848)	(30,164)
Interest income	3,053	267
Interest expense	81	37
Other income (expense), net	(1,493)	(972)
Net before taxes	(48,369)	(30,906)
Income taxes	(5,207)	(974)
Net income	(43,162)	(29,932)
Earnings common share		
Primary	\$(0.78)	\$(0.62)
Fully Diluted	\$(0.78)	\$(0.62)
Common Shares:		
Full Diluted	55,129	47,962
Year-end	57,905	52,136

3D SYSTEMS CORP. (DE)

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	506,948,000	468,805,000
Cost & expenses	543,120,000	517,075,000
Operating income	(36,172,000)	(48,270,000)
Net before taxes	(35,037,000)	(48,393,000)
Income taxes	6,086,000	6,831,000
Net income	(41,123,000)	(55,224,000)
Earnings common share		
Primary	\$(0.37)	\$(0.50)
Fully Diluted	\$(0.37)	\$(0.50)
Common Shares:		
Full Diluted	112,095,000	111,467,000
Year-end	115,683,000	113,816,000

A-MARK PRECIOUS METALS, INC

Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,565,090	2,163,790
Cost & expenses	1,564,334	2,163,460
Operating income	1,685	657
Interest income	4,551	3,161
Interest expense	3,552	2,733
Other income (expense), net	248	61
Foreign currency	(70)	(101)
Net before taxes	1,933	718
Income taxes	499	274
Net income	1,434	444
Earnings common share		
Primary	\$0.21	\$0.07
Fully Diluted	\$0.21	\$0.07
Common Shares:		
Full Diluted	7,092	7,122
Year-end	7,031	7,031

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	22,714	
Inventories	289,805	
Current assets	691,315	

Net property & equip.	7,694
Total assets	726,552
Liabilities:	
Current liabilities	561,129
Long-term debt	87,056
Stockholders' equity	68,090
Net current assets	130,186

AAON, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	321,607	301,072
Cost & expenses	281,698	243,835
Operating income	39,252	56,741
Other income (expense), net	11	86
Net before taxes	39,434	57,042
Income taxes	9,398	18,314
Net income	30,036	38,728
Earnings common share		
Primary	\$0.57	\$0.74
Fully Diluted	\$0.57	\$0.73
Common Shares:		
Full Diluted	52,715	53,103
Year-end	52,210	52,513

ABIOMED, INC.

Earnings, 6 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	361,788,000	265,291,000
Cost & expenses	264,720,000	200,487,000
Operating income	97,068,000	64,804,000
Other income (expense), net	30,000	56,000
Invest. income	3,222,000	1,416,000
Net before taxes	100,320,000	66,276,000
Income taxes	(39,873,000)	4,399,000
Net income	140,193,000	61,877,000
Earnings common share		
Primary	\$3.13	\$1.41
Fully Diluted	\$3.04	\$1.36
Common Shares:		
Full Diluted	46,164,000	45,655,000
Year-end	45,038,453	44,200,784

ACACIA COMMUNICATIONS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	232,758	298,563
Cost & expenses	251,536	266,453
Operating income	(18,778)	32,110
Other income (expense), net	(325)	(60)
Net before taxes	(14,184)	34,312
Income taxes	(10,012)	(24,560)
Net income	(4,172)	58,872
Earnings common share		
Primary	\$(0.10)	\$1.52
Fully Diluted	\$(0.10)	\$1.41
Common Shares:		
Full Diluted	40,217	41,660
Year-end	40,405	39,302

ACADIA HEALTHCARE COMPANY INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	2,268,895,000	1,111,804,000
Cost & expenses	1,977,153,000	830,389,000
Operating income	172,382,000	176,159,000
Net before taxes	172,382,000	176,159,000
Income taxes	16,339,000	46,259,000
Net income	156,043,000	129,900,000

Earnings common share

Primary	\$1.79	\$1.50
Fully Diluted	\$1.78	\$1.50
Common Shares:		
Full Diluted	87,386,000	87,038,000
Year-end	87,363,357	87,045,124

ACADIA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	164,236,000	81,339,000
Net Sales	164,236,000	81,339,000
Cost & expenses	344,405,000	303,740,000
Operating income	(180,169,000)	222,401,000
Other income (expense), net	(1,967,000)	
Net before taxes	(178,458,000)	219,382,000
Income taxes	1,242,000	1,150,000
Net income	(179,700,000)	220,532,000
Earnings common share		
Primary	\$(1.44)	\$(1.81)
Fully Diluted	\$(1.44)	\$(1.81)
Common Shares:		
Full Diluted	124,883,000	122,089,000
Year-end	125,023,015	

ACCELERON PHARMA, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	10,175	9,776
Cost & expenses	97,783	91,122
Operating income	(87,608)	(81,346)
Interest income	4,073	1,474
Other income (expense), net	(592)	(683)
Net before taxes	(84,127)	(80,555)
Income taxes	9	(29)
Net income	(84,136)	(80,526)
Earnings common share		
Primary	\$(1.84)	\$(2.08)
Fully Diluted	\$(1.84)	\$(2.08)
Common Shares:		
Full Diluted	45,787	38,804
Year-end	46,186	

ACCURAY INC (CA)

Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	95,829	90,950
Cost & expenses	100,517	93,002
Operating income	(4,688)	(2,052)
Other income (expense), net	(3,983)	(6,571)
Net before taxes	(8,671)	(8,623)
Income taxes	535	759
Net income	(9,206)	(9,382)
Earnings common share		
Primary	\$(0.11)	\$(0.11)
Fully Diluted	\$(0.11)	\$(0.11)
Common Shares:		
Full Diluted	86,479	83,747
Year-end	86,500	83,755

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	68,545	
Inventories	117,684	
Current assets	271,913	
Net property & equip.	23,126	
Total assets	369,131	
Liabilities:		
Current liabilities	160,477	
Long-term debt	128,926	

Stockholders' equity	47,106	
Net current assets	111,436	

ACELRX PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,538	7,255
Cost & expenses	26,288	38,130
Operating income	(24,750)	(30,875)
Net before taxes	(34,589)	(41,621)
Income taxes	2	2
Net income	(34,591)	(41,623)

Earnings common share

Primary	\$(0.64)	\$(0.91)
Fully Diluted	\$(0.64)	\$(0.91)
Common Shares:		
Full Diluted	54,292	45,701
Year-end	61,790	

ACETO CORP**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	164,405	185,255
Cost & expenses	177,703	178,036
Operating income	(13,298)	7,219
Interest expense	6,138	5,355
Net before taxes	(19,095)	2,138
Income taxes	1,997	1,684
Net income	(21,092)	454

Earnings common share

Primary	\$(0.59)	\$0.01
Fully Diluted	\$(0.59)	\$0.01
Common Shares:		
Full Diluted	35,487	35,259
Year-end	30,801	30,581

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	51,547	
Inventories	156,527	
Current assets	516,600	
Net property & equip.	13,689	
Total assets	774,635	
Liabilities:		
Current liabilities	333,952	
Long-term debt	300,900	
Stockholders' equity	73,762	
Net current assets	182,648	

ACHAOGEN, INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	6,703	9,306
Cost & expenses	152,011	93,528
Operating income	(145,308)	(84,222)
Interest expense	1,335	2,170
Other income (expense), net	7,653	(2,843)
Net income	(138,990)	(89,235)

Earnings common share

Primary	\$(3.10)	\$(2.31)
Fully Diluted	\$(3.21)	\$(2.31)
Common Shares:		
Full Diluted	45,596	38,710
Year-end	45,967	42,361

ACHILLION PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	57,739	65,221
Operating income	(57,739)	(65,221)
Interest income	4,093	3,225
Interest expense	25	37
Net income	(53,671)	(62,033)

Earnings common share

Primary	\$(0.39)	\$(0.45)
Fully Diluted	\$(0.39)	\$(0.45)
Common Shares:		
Full Diluted	138,344	136,947

ACI WORLDWIDE INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	689,830	697,796
Cost & expenses	617,059	654,004
Operating income	9,497	(23,397)

Interest income	8,249	421
Interest expense	31,655	30,198
Other income (expense), net	(3,036)	(2,176)
Net before taxes	(16,945)	(55,350)
Income taxes	1,824	(27,321)
Net income	(18,769)	(28,029)

Earnings common share

Primary	\$(0.16)	\$(0.24)
Fully Diluted	\$(0.16)	\$(0.24)
Common Shares:		
Full Diluted	115,615	117,096
Year-end	115,982	118,294

ACLARIS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	6,422	684
Cost & expenses	102,798	47,665
Operating income	(96,376)	(46,981)
Other income (expense), net	2,189	1,392
Net income	(94,187)	(45,589)

Earnings common share

Primary	\$(3.04)	\$(1.68)
Fully Diluted	\$(3.04)	\$(1.68)
Common Shares:		
Full Diluted	30,938	27,180
Year-end	30,991	30,835

ACORDA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	402,281,000	399,889,000
Net Sales	393,388,000	379,705,000
Cost & expenses	314,494,000	414,625,000
Operating income	87,787,000	(14,736,000)
Interest income	2,412,000	103,000
Other income (expense), net	24,000	
Net before taxes	73,889,000	(28,874,000)
Income taxes	49,802,000	23,421,000
Net income	24,087,000	(52,295,000)

Earnings common share

Primary	\$0.51	\$(1.14)
Fully Diluted	\$0.51	\$(1.14)
Common Shares:		
Full Diluted	47,251,000	45,918,000
Year-end	47,231,025	46,704,327

ACTIVISION BLIZZARD, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	5,119,000	4,974,000
Cost & expenses	3,825,000	3,886,000
Operating income	1,294,000	1,088,000
Other income (expense), net	(40,000)	(12,000)
Net before taxes	1,187,000	967,000
Income taxes	25,000	109,000
Net income	1,162,000	858,000

Earnings common share

Primary	\$1.53	\$1.14
Fully Diluted	\$1.51	\$1.12
Common Shares:		
Full Diluted	771,000	764,000
Year-end	762,989	756,057

ADDUS HOMECARE CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	354,283	290,259
Deprec., depl. & amort.	6,676	4,811
Operating income	17,356	18,688
Interest income	2,468	50
Interest expense	3,836	3,629
Other income (expense), net	165	
Net before taxes	15,988	15,274
Income taxes	3,287	4,908
Net income	12,701	10,366

Earnings common share

Primary	\$1.08	\$0.90
Fully Diluted	\$1.06	\$0.89
Common Shares:		
Full Diluted	12,037	11,616
Year-end	13,097	11,634

ADOBE INC

Acquisition Completed On Oct. 31, 2018, Co. acquired all the issued and outstanding shares of capital stock of Milestone Topco, Inc. ("Topco") and indirect parent company of Marketo, Inc. (collectively with Topco and Topco's other subsidiaries, "Marketo"), a software company focused on account-based marketing, including email, mobile, social, digital ads, web management, and analytics, from the stockholders of Topco, for aggregate purchase price of approximately \$4,750,000,000, subject to certain purchase price adjustments specified in the Purchase Agreement.

ADVANCED EMISSIONS SOLUTIONS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	13,319,000	41,573,000
Cost & expenses	16,306,000	43,966,000
Deprec., depl. & amort.	262,000	687,000
Operating income	(3,249,000)	(3,080,000)
Other income (expense), net	38,003,000	38,581,000
Net before taxes	33,607,000	33,502,000
Income taxes	5,151,000	12,614,000
Net income	28,456,000	20,888,000
Balance for common	28,362,000	20,747,000

Earnings common share

Primary	\$1.41	\$0.96
Fully Diluted	\$1.40	\$0.96
Common Shares:		
Full Diluted	20,228,000	21,598,000
Year-end	19,921,128	21,093,675

ADVANCED ENERGY INDUSTRIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	564,731	491,798
Cost & expenses	408,790	345,914
Operating income	151,983	142,708
Other income (expense), net	(58)	(3,138)
Net before taxes	151,925	139,570
Income taxes	23,998	(25,538)
Income contin. oper.	127,927	165,108
Income discont. oper.	(226)	2,343
Net income	127,701	167,451

Earnings common share

Primary	\$3.25	\$4.21
Fully Diluted	\$3.23	\$4.16
Common Shares:		
Full Diluted	39,594	40,207
Year-end	38,716	39,624

AEGION CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	999,570	1,021,520
Cost & expenses	968,921	1,061,084
Operating income	30,649	(39,564)
Interest income	239	117
Interest expense	13,236	12,014
Other income (expense), net	(10,049)	(1,593)
Net before taxes	7,603	(53,054)
Income taxes	1,740	1,144
Net income	5,863	(54,198)

Earnings common share

Primary	\$0.17	\$(1.70)
Fully Diluted	\$0.16	\$(1.70)
Common Shares:		
Full Diluted	33,058	33,363
Year-end	32,314	

AEGLEA BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	34,046	24,773
Operating income	(30,158)	(21,050)
Interest income	745	332
Other income (expense), net	(37)	(35)
Net income	(29,450)	(20,753)

Earnings common share

Primary	\$(1.49)	\$(1.42)
Fully Diluted	\$(1.49)	\$(1.42)
Common Shares:		
Full Diluted	19,772	14,641
Year-end	22,098	16,473

AERIE PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	9,725	
Net Sales	9,725	
Cost & expenses	167,542	85,379
Operating income	(157,817)	(85,379)
Interest income	2,533	1,293
Interest expense	1,732	1,799
Other income (expense), net	(24,092)	(565)
Net before taxes	(181,108)	(86,450)
Income taxes	3	142
Net income	(181,111)	(86,592)
Earnings common share		
Primary	\$(4.47)	\$(2.48)
Fully Diluted	\$(4.47)	\$(2.48)
Common Shares:		
Full Diluted	40,506	34,933
Year-end	45,451	36,427

AETHLON MEDICAL INC**Earnings, 6 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	149,625	
Cost & expenses	2,593,851	2,396,422
Operating income	(2,444,226)	(2,396,422)
Other income (expense), net		(507,123)
Net income	(2,554,436)	(3,154,128)
Earnings common share		
Primary	\$(0.14)	\$(0.35)
Fully Diluted	\$(0.14)	\$(0.35)
Common Shares:		
Full Diluted	17,771,918	8,939,624
Year-end	17,834,560	9,618,909

AIVI GENOMIC MEDICINE INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	24,285	27,540
Operating income	(24,285)	(27,540)
Other income (expense), net	136	(15)
Net income	(24,149)	(27,555)
Earnings common share		
Primary	\$(0.40)	\$(0.74)
Fully Diluted	\$(0.40)	\$(0.74)
Common Shares:		
Full Diluted	60,241	37,109
Year-end	64,767	37,110

AGILYSYS INC**Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	68,210	63,994
Cost & expenses	71,154	67,949
Operating income	(5,443)	(6,217)
Interest income	152	51
Interest expense	5	4
Other income (expense), net	(228)	147
Net before taxes	(5,524)	(6,023)
Income taxes	4	183
Net income	(5,528)	(6,206)
Earnings common share		
Primary	\$(0.24)	\$(0.27)
Fully Diluted	\$(0.24)	\$(0.27)
Common Shares:		
Full Diluted	23,113	22,740
Year-end	23,531	23,318

AGIOS PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	64,374	33,212
Cost & expenses	330,497	263,876
Operating income	(266,123)	(230,664)
Interest income	11,889	4,279
Net income	(254,234)	(226,385)
Earnings common share		
Primary	\$(4.45)	\$(4.94)
Fully Diluted	\$(4.45)	\$(4.94)
Common Shares:		
Full Diluted	57,158	45,851
Year-end	58,168	48,618

AGROFRESH SOLUTIONS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Net Sales	125,470,000	109,891,000
Cost & expenses	93,879,000	73,376,000
Operating income	(2,751,000)	5,180,000
Interest expense	26,250,000	27,495,000
Other income (expense), net	419,000	(40,000)
Foreign currency	472,000	10,584,000
Net before taxes	(28,110,000)	(11,771,000)
Income taxes	214,000	(11,895,000)
Net income	(28,324,000)	124,000
Earnings common share		
Primary	\$(0.57)	\$.
Fully Diluted	\$(0.57)	\$.
Common Shares:		
Full Diluted	49,671,648	50,134,591
Year-end	50,439,210	50,340,014

AILERON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	24,920	15,967
Operating income	(24,920)	(15,967)
Interest income	407	228
Net income	(24,513)	(15,739)
Balance for common	(24,513)	(15,780)
Earnings common share		
Primary	\$(1.66)	\$(3.16)
Fully Diluted	\$(1.66)	\$(3.16)
Common Shares:		
Full Diluted	14,736	4,991
Year-end	14,737	14,719

AIMMUNE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	156,908	91,634
Operating income	(156,908)	(91,634)
Interest income	3,233	1,475
Net before taxes	(153,675)	
Income taxes	79	
Net income	(153,754)	(90,159)
Earnings common share		
Primary	\$(2.72)	\$(1.79)
Fully Diluted	\$(2.72)	\$(1.79)
Common Shares:		
Full Diluted	56,602	50,254
Year-end	58,651	50,695

AIR TRANSPORT SERVICES GROUP, INC.

Acquisition Completed On Nov. 9, 2018, Co. purchased (the "Acquisition") from Omni Air International Holdings, Inc., a Nevada corporation ("Omni Holdings"), Omni Aviation Leasing Holdings, LLC, a Nevada limited liability company ("OAL Holdings"), T7 Aviation Leasing Holdings, LLC, a Nevada limited liability company ("T7 Holdings") and, together with Omni Holdings and OAL Holdings, "Sellers") through three newly-organized acquisition subsidiaries, all of the issued and outstanding membership interests of Omni Air International, LLC, a Nevada limited liability company ("Omni"), Omni Aviation Leasing, LLC, a Nevada limited liability company ("OAL"), and T7 Aviation Leasing, LLC, a Nevada limited liability company ("T7," and together with Omni and OAL, the "Target Companies"). The Target Companies are engaged, together with Advanced Flight Services, Inc. (the "Subsidiary"), a wholly-owned subsidiary of Omni, in the business of providing passenger airlift services to the U.S. Department of Defense and other U.S. and foreign government agencies, worldwide full service commercial passenger charter, wet lease and aircraft, crew, maintenance and insurance services and other air transportation services to commercial customers. The Target Companies and the Subsidiary are referred to herein collectively, as the "Acquired Companies." The purchase price for the Acquisition (the "Aggregate Purchase Price") was an amount equal to \$845,000,000 plus the cash balances of the Acquired Companies as of 11:59 P.M. (Central Time) on the day immediately prior to the date of the closing (the "Closing") of the Acquisition (the "Measurement Time"), minus the indebtedness of the Acquired Companies as of the Measurement Time (the "Closing Indebtedness"), minus the transaction expenses of the Acquired Companies and Sellers related to the Acquisition, including fees and expenses of attorneys, investment bankers, accountants and other service providers (the "Transaction Expenses"), minus certain bonus or change of control payments triggered by the Acquisition (the "Closing Bonus Payments") and plus or minus, as applicable, the amount of any net working capital adjustment (the "Net Working

Capital Adjustment") based upon the difference between the actual working capital amount of the Acquired Companies as of the Measurement Time (the "Closing Net Working Capital") and a target working capital amount set forth in the Purchase Agreement. At the Closing, Co. paid to Sellers the estimated Aggregate Purchase Price, less the escrow amount. At the Closing, Co. also paid or caused to be paid the Closing Indebtedness, the Transaction Expenses, the Closing Bonus Payments and, to the Escrow Agent (as defined below), the Escrow Amount. Within 60 days after the date of the Closing, Co. will prepare and deliver to the Sellers Representative a written statement setting forth Co.'s calculations of the amount of the Closing Net Working Capital and the Net Working Capital Adjustment. The Sellers Representative will then have 30 days after receipt of such calculations to inform Co. whether he agrees or disagrees with Co.'s calculations. The Purchase Agreement sets forth a process for resolving any disputes with respect to such calculations. Upon final determination of the Closing Net Working Capital and Net Working Capital Adjustment, the Aggregate Purchase Price will be recalculated using the finally determined amounts resulting in an adjustment of the Aggregate Purchase Price (the "Purchase Price Adjustment"). If the Aggregate Purchase Price, as recalculated, is greater than the estimated Aggregate Purchase Price, Co. will pay or cause to be paid to the Sellers Representative the amount of any such excess, for distribution to the Sellers. If the Aggregate Purchase Price, as recalculated, is less than such estimated Aggregate Purchase Price, Sellers will pay or cause to be paid to Co. the amount of such deficiency. If the Aggregate Purchase Price, as recalculated, is equal to the estimated Aggregate Purchase Price, no further payments will be payable by Co. or the Sellers. At the Closing, \$18,000,000 of the Purchase Price was deposited in cash with a bank selected by the parties (the "Escrow Agent") into two separate escrow accounts: (i) \$3,000,000 (the "Working Capital Escrow Amount") was deposited in an escrow account to cover amounts that may be owing by Sellers to the Company as a result of the Purchase Price Adjustment and (ii) \$15,000,000 (the "Indemnification Escrow Amount") was deposited in an escrow account to satisfy claims for indemnification by Co. or other Company indemnitees as a result of breaches of representations and warranties or covenants of the Sellers contained in the Purchase Agreement. The Working Capital Escrow Amount will be distributed in accordance with the joint written instruction of Co. and Sellers Representative to the Escrow Agent. The Indemnification Escrow Amount (less any amount that has been previously paid from the Indemnification Escrow Amount and amounts subject to pending indemnification claims) will be distributed to the Sellers Representative upon receipt by the Escrow Agent of a joint written instruction from Co. and the Sellers Representative fourteen (14) months following the Closing.

AIR TRANSPORT SERVICES GROUP, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	611,566	745,229
Cost & expenses	408,373	567,894
Deprec., depl. & amort.	124,825	111,828
Operating income	78,368	65,507
Interest income	144	85
Interest expense	16,336	11,658
Other income (expense), net	27,242	(107,041)
Net before taxes	89,418	(53,107)
Income taxes	16,339	19,244
Income contin. oper.	73,079	(72,351)
Net income	73,615	(76,622)
Earnings common share		
Primary	\$1.25	\$(1.30)
Fully Diluted	\$0.72	\$(1.30)
Common Shares:		
Full Diluted	68,629	58,965
Year-end	59,080	59,123

AKAMAI TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	2,001,111	1,830,565
Cost & expenses	1,733,881	1,525,310
Operating income	242,211	282,180
Interest income	19,632	13,368
Interest expense	28,620	13,989
Other income (expense), net	(3,207)	414
Net before taxes	230,016	281,973
Income taxes	25,658	86,727
Net income	204,358	195,246
Earnings common share		
Primary	\$1.21	\$1.13
Fully Diluted	\$1.20	\$1.13

Common Shares:		
Full Diluted	170,732	173,371
Year-end	169,893	

AKCEA THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	54,670	21,712
Cost & expenses	213,428	120,884
Operating income	(158,758)	(99,172)
Interest expense	1,731	
Other income (expense), net	(148)	124
Gains or losses	4,089	994
Net before taxes	(154,817)	(99,785)
Income taxes	447	2,066
Net income	(155,264)	(101,851)
Earnings common share		
Primary	\$(4.00)	\$(6.24)
Fully Diluted	\$(4.00)	\$(6.24)
Common Shares:		
Full Diluted	78,793	18,037
Year-end	87,471	66,542

AKEBIA THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	235,895,000	181,952,000
Operating income	(88,003,000)	(91,284,000)
Other income (expense), net	52,000	204,000
Net income	(83,534,000)	(89,194,000)
Earnings common share		
Primary	\$(1.54)	\$(2.11)
Fully Diluted	\$(1.54)	\$(2.11)
Common Shares:		
Full Diluted	54,207,973	42,202,560
Year-end	57,046,563	47,238,001

AKORN INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	540,632	654,988
Cost & expenses	693,208	509,980
Operating income	(192,561)	98,717
Other income (expense), net	(3,930)	(40)
Net before taxes	(228,822)	70,139
Income taxes	(41,951)	29,472
Net income	(186,871)	40,667
Earnings common share		
Primary	\$(1.49)	\$0.33
Fully Diluted	\$(1.49)	\$0.33
Common Shares:		
Full Diluted	125,346	125,046
Year-end	125,492	125,069

AKOUSTIS TECHNOLOGIES INC

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	313,021	300,940
Cost & expenses	7,009,566	5,030,216
Operating income	(6,696,545)	(4,729,276)
Interest income	(481,602)	734
Other income (expense), net	(129,552)	85,344
Net income	(7,307,699)	(4,643,198)
Earnings common share		
Primary	\$(0.33)	\$(0.24)
Fully Diluted	\$(0.33)	\$(0.24)
Common Shares:		
Full Diluted	22,240,748	19,167,500
Year-end	22,374,422	19,184,583

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	9,074,816	
Inventories	48,210	
Current assets	10,634,387	
Net property & equip.	13,291,696	
Total assets	24,617,111	
Liabilities:		
Current liabilities	2,210,053	
Long-term debt	11,866,823	
Stockholders' equity	9,140,008	
Net current assets	8,424,334	

ALARM.COM HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	309,092	250,144
Cost & expenses	289,129	216,581
Operating income	3,809	20,782
Interest expense	2,159	1,548
Other income (expense), net	1,533	716
Net before taxes	3,183	19,950
Income taxes	(10,413)	(8,981)
Net income	13,596	28,931
Balance for common	13,594	28,917
Earnings common share		
Primary	\$0.29	\$0.62
Fully Diluted	\$0.27	\$0.59
Common Shares:		
Full Diluted	49,594	49,074
Year-end	48,000	47,130

ALCENTRA CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	11,094,614	9,748,740
Net income	10,225,404	14,279,366
Earnings common share		
Primary	\$0.74	\$1.03
Fully Diluted	\$0.74	\$1.03
Common Shares:		
Full Diluted	13,815,619	13,825,432
Year-end	13,517,234	14,245,220

ALEXION PHARMACEUTICALS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	3,002,400,000	641,400,000
Cost & expenses	2,536,400,000	882,500,000
Operating income	225,900,000	518,800,000
Interest expense	73,700,000	73,300,000
Other income (expense), net	3,500,000	100,000
Gains or losses	119,400,000	12,900,000
Net before taxes	275,100,000	458,500,000
Income taxes	152,500,000	45,200,000
Net income	122,600,000	413,300,000
Earnings common share		
Primary	\$0.55	\$1.84
Fully Diluted	\$0.55	\$1.83
Common Shares:		
Full Diluted	224,200,000	225,500,000
Year-end	223,100,000	223,000,000

ALIGN TECHNOLOGY INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,432,472	1,052,090
Cost & expenses	1,086,381	808,085
Operating income	346,091	244,005
Interest income	6,327	4,462
Other income (expense), net	(7,759)	4,145
Equity earnings	6,610	4,950
Net before taxes	344,659	252,612
Income taxes	35,206	26,508
Net income	302,843	221,154
Earnings common share		
Primary	\$3.78	\$2.76
Fully Diluted	\$3.71	\$2.71
Common Shares:		
Full Diluted	81,538	81,757
Year-end	79,983	

ALLEGIAN T RAVEL COMPANY

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,255,333	1,132,049
Cost & expenses	982,321	835,612
Deprec., depl. & amort.	92,641	92,571
Operating income	180,371	203,866
Other income (expense), net	408	1,254
Net before taxes	146,850	181,981
Income taxes	26,494	67,208
Net income	120,356	114,773
Balance for common	118,754	112,989
Earnings common share		
Primary	\$7.46	\$7.00
Fully Diluted	\$7.45	\$6.99
Common Shares:		
Full Diluted	15,938	16,160
Year-end	16,160	

ALLENA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	25,813	14,379
Operating income	(25,813)	(14,379)
Other income (expense), net	(622)	(193)
Net income	(26,037)	(14,973)
Balance for common		(14,973)
Earnings common share		
Primary	\$(1.26)	\$(11.19)
Fully Diluted	\$(1.26)	\$(11.19)
Common Shares:		
Full Diluted	20,727	1,343
Year-end	20,756	1,349

ALLIED MOTION TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	236,649	186,657
Cost & expenses	214,146	170,633
Operating income	19,869	13,619
Interest expense	1,839	1,797
Other income (expense), net	118	(135)
Net before taxes	18,148	11,687
Income taxes	4,859	3,746
Net income	13,289	7,941
Earnings common share		
Primary	\$1.44	\$0.87
Fully Diluted	\$1.42	\$0.86
Common Shares:		
Full Diluted	9,337	9,265
Year-end	9,476	9,453

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	1,561,782,000	289,008,000
Cost & expenses	1,585,279,000	207,928,000
Operating income	(60,707,000)	57,740,000
Interest expense	80,843,000	62,722,000
Other income (expense), net	(16,077,000)	165,835,000
Gains or losses	172,787,000	706,000
Net before taxes	15,160,000	170,111,000
Income taxes	(3,020,000)	(1,073,000)
Income contin. oper.	18,180,000	
Net income	21,911,000	169,038,000
Balance for common	(11,041,000)	202,277,000
Earnings common share		
Primary	\$(0.06)	\$(1.12)
Fully Diluted	\$(0.06)	\$(1.12)
Common Shares:		
Full Diluted	176,942,000	180,864,000
Year-end	174,707,000	

ALNYLAM PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	53,875	51,988
Cost & expenses	648,192	404,773
Operating income	(594,317)	(352,785)
Interest income	18,691	8,001
Other income (expense), net	26,032	(3,863)
Net before taxes	(549,594)	
Income taxes	462	
Net income	(550,056)	(348,647)
Earnings common share		
Primary	\$(5.48)	\$(3.93)
Fully Diluted	\$(5.48)	\$(3.93)
Common Shares:		
Full Diluted	100,430	88,672
Year-end	100,968	92,368

ALPHABET INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	97,543,000	78,532,000
Cost & expenses	79,425,000	60,050,000
Operating income	18,118,000	18,482,000
Interest income	1,336,000	912,000
Interest expense	85,000	73,000
Other income (expense), net	5,723,000	48,000
Gains or losses	(139,000)	(93,000)
Foreign currency	(112,000)	(101,000)
Net before taxes	24,841,000	19,175,000

1. Altaia Inc common.

No dividends paid.

ALTAIR ENGINEERING INC

Merger Development On Nov. 5, 2018, Datawatch Corp ("Datawatch"), Co. and Dallas Merger Sub, Inc., a wholly-owned subsidiary of Co. ("Purchaser") entered into an Agreement and Plan of Merger (the "Merger Agreement"). The Merger Agreement provides that, subject to the terms of the Merger Agreement, Purchaser will commence a tender offer (the "Offer") to purchase all of the outstanding shares (the "Shares") of Datawatch common stock, \$0.01 par value, at a price of \$13.10 per share, without interest and subject to any required withholding taxes (the "Offer Price"). Consummation of the Offer is subject to various conditions set forth in the Merger Agreement, including, but not limited to (i) at least one Share more than 50% of the Shares then outstanding being tendered into the Offer, (ii) the receipt of required approvals, waivers and consents, and (iii) other conditions set forth in Annex I to the Merger Agreement. The Offer is not subject to any financing condition. The Offer will expire at midnight, on the 20th business day (calculated in accordance with the rules of the Securities Exchange Act of 1934) following the commencement date of the Offer unless extended in accordance with the terms of the Offer and the Merger Agreement and the applicable rules and regulations of the United States Securities and Exchange Commission (the "SEC"). Following consummation of the Offer, Purchaser will merge with and into Datawatch with Datawatch surviving as a wholly-owned subsidiary of Co. (the "Merger"). At the effective time of the Merger (the "Effective Time"), each outstanding Share that is not tendered and accepted pursuant to the Offer (other than the Shares owned both at the commencement of the Offer and at the Effective Time by Datawatch or by a direct or indirect subsidiary of Datawatch, Shares irrevocably accepted for purchase in the Offer, Shares owned both at the commencement of the Offer and at the Effective Time by Purchaser, Co. or any other direct or indirect wholly owned subsidiary of Co., and Shares as to which appraisal rights have been perfected in accordance with applicable law) will be cancelled and converted into the right to receive the Offer Price, without interest and subject to any required withholding taxes, on the terms and conditions set forth in the Merger Agreement. At the Effective Time, equity awards previously granted pursuant to Datawatch's Third Amended and Restated 2011 Equity Compensation and Incentive plan (as amended, supplemented or modified, the "Plan") shall be cancelled with the following effect: (a) Each outstanding, unexpired and unexercised option (each, a "Datawatch Option") to purchase Shares issued pursuant to the Plan shall be cancelled and, in exchange therefor, each former holder thereof shall be entitled to receive a payment in cash (net of any applicable withholding taxes and without interest) in an amount equal to the product of (i) the total number of Shares subject to such Datawatch Option immediately prior to such cancellation and (ii) the excess, if any, of the Offer Price over the exercise price per Share subject to such Datawatch Option immediately prior to such cancellation. (b) Each outstanding award of restricted stock units (each, a "Datawatch RSU") for Shares granted under the Plan that is vested or that, by the terms of the applicable Plan or award agreement, would automatically become vested as a result of the Merger, shall be cancelled and, in exchange therefor, each former holder thereof shall be entitled to receive a payment in cash (subject to any applicable withholding taxes and without interest) equal to the product of (i) the total number of Shares vested and otherwise then issuable pursuant to Datawatch RSU immediately prior to such cancellation and (ii) the Offer Price. (c) Each outstanding Datawatch RSU for Shares granted under the Plan that is not vested after giving effect to any vesting that is contingent upon the Merger having been consummated shall be cancelled and, in exchange therefor, each former holder thereof shall be entitled to receive a payment in cash (subject to any applicable withholding taxes and without interest) from Co. equal to the product of (i) the total number of Shares unvested pursuant to Datawatch RSU immediately prior to such cancellation and (ii) the Offer Price, with payment made on or after the vesting date when the corresponding portion of Datawatch RSU would otherwise have vested in accordance with its terms had it not been cancelled, but only if such conditions to vesting are satisfied prior to such vesting date.

AMAG PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	385,881	367,243
Cost & expenses	414,091	658,355
Operating income	(28,210)	(291,112)
Interest expense	45,400	52,403
Other income (expense), net	(35,985)	(9,873)
Net before taxes	(106,388)	(351,207)

Income taxes	42,204	(145,317)
Income contin. oper.	(148,592)	(205,890)
Income discount. oper.	105,108	3,202
Net income	(43,484)	(202,688)
Earnings common share		
Primary	\$(1.27)	\$(5.80)
Fully Diluted	\$(1.27)	\$(5.80)
Common Shares:		
Full Diluted	34,339	34,948
Year-end	34,523	

AMAZON.COM INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	160,504,000	117,413,000
Cost & expenses	151,869,000	115,434,000
Operating income	8,635,000	1,979,000
Interest income	290,000	137,000
Interest expense	1,030,000	510,000
Other income (expense), net	16,000	329,000
Equity earnings	(5,000)	4,000
Net before taxes	7,911,000	1,935,000
Income taxes	870,000	755,000
Net income	7,046,000	1,176,000
Earnings common share		
Primary	\$14.49	\$2.46
Fully Diluted	\$14.10	\$2.39
Common Shares:		
Full Diluted	500,000	492,000
Year-end	489,000	

AMC NETWORKS INC

Acquisition Completed On Nov. 1, 2018, Co. acquired RLJ Entertainment Inc ("RLJ Entertainment"), a digital channel company in exchange for \$6.25 in cash for each of RLJ Entertainment's new common share.

AMC NETWORKS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,199,083	2,078,757
Cost & expenses	1,545,264	1,452,905
Operating income	589,785	560,815
Interest income	15,453	10,841
Interest expense	115,607	96,609
Other income (expense), net	30,989	39,444
Net before taxes	520,620	514,491
Income taxes	133,092	173,399
Net income	387,528	341,092
Earnings common share		
Primary	\$6.40	\$4.94
Fully Diluted	\$6.31	\$4.89
Common Shares:		
Full Diluted	59,281	66,651
Year-end	56,509	62,713

AMEDISYS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	1,099,597,000	1,394,000
Operating income	118,721,000	48,778,000
Interest income	263,000	104,000
Interest expense	5,834,000	3,600,000
Other income (expense), net	9,243,000	6,431,000
Net before taxes	122,393,000	51,713,000
Income taxes	29,984,000	17,324,000
Net income	92,409,000	34,389,000
Earnings common share		
Primary	\$2.78	\$1.02
Fully Diluted	\$2.71	\$1.00
Common Shares:		
Full Diluted	33,852,000	34,255,000
Year-end	31,877,278	33,913,558

AMERCO**Earnings, 6 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,124,084	2,000,611
Cost & expenses	1,397,454	1,269,991
Operating income	455,648	458,876
Interest expense	70,284	62,368
Other income (expense), net	(507)	(464)
Net before taxes	384,857	396,044
Income taxes	93,466	145,198
Net income	291,391	250,846

Balance for common	291,391	250,846
Earnings common share		
Primary	\$14.87	\$12.81
Fully Diluted	\$14.87	\$12.81
Common Shares:		
Full Diluted	19,591	19,588
Year-end	19,608	19,608

AMERICAN INTERNATIONAL VENTURES, INC. (DE)**Earnings, 3 mos. to Aug 31(Consol. - \$):**

	2018	2017
Net Sales		41,310
Cost & expenses	549,837	308,729
Operating income	(559,288)	(267,419)
Net income	(560,029)	(283,750)
Earnings common share		
Common Shares:		
Full Diluted	342,462,445	273,323,858
Year-end	360,399,945	273,399,945

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		2,669
Current assets		45,213
Net property & equip.		82,419
Total assets		910,254
Liabilities:		
Current liabilities		147,793
Stockholders' equity		953,767
Net current assets		(102,580)

AMERICAN PUBLIC EDUCATION INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	220,757	221,163
Cost & expenses	186,505	184,779
Operating income	21,094	22,224
Equity earnings	483	(105)
Net before taxes	23,022	22,267
Income taxes	5,993	9,668
Net income	16,546	12,704
Earnings common share		
Primary	\$1.01	\$0.78
Fully Diluted	\$1.00	\$0.78
Common Shares:		
Full Diluted	16,628	16,352
Year-end	16,424	16,249

AMERICAN RAILCAR INDUSTRIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	362,750	344,447
Cost & expenses	302,454	280,835
Operating income	60,296	63,612
Other income (expense), net	2,247	3,892
Net before taxes	48,042	52,190
Income taxes	12,786	21,865
Net income	35,256	30,325
Earnings common share		
Primary	\$1.85	\$1.59
Fully Diluted	\$1.85	\$1.59
Common Shares:		
Full Diluted	19,084	19,084
Year-end	19,084	19,084

AMERICAN RAILCAR INDUSTRIES INC

Merger Development On Oct. 22, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with STL Parent Corp., a Delaware corporation (the "Parent"), pursuant to which a to be formed North Dakota corporation that will be a wholly-owned subsidiary of Parent ("Merger Sub"), will be merged with and into Co., with Co. continuing as the surviving corporation in the merger (the "Merger"). Following the consummation of the Merger, Co. will be a wholly-owned subsidiary of Parent. Parent is a wholly-owned subsidiary of ITE Rail Fund L.P., which is managed by ITE Management L.P. ITE Management L.P. is an investment firm targeting industrial and transportation assets and companies. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value \$0.01 per share, of Co. issued and outstanding immediately prior to the Effective Time (each, a "Share"), will be cancelled and each such Share (other than (i) Shares owned by Parent, Merger Sub or any of their respective subsidiaries or affiliates (other than Co.), (ii) Shares owned by Co. or Co.'s subsidiaries, or (iii) Shares owned by holders who have

properly exercised appraisal rights under North Dakota law) will be converted into the right to receive \$70.00 per Share in cash, without interest (the "Merger Consideration"). The Merger Consideration may be increased in the event that interest is determined to be payable as a result of Parents failure to timely deposit funds into escrow.

AMERICAN RAILCAR INDUSTRIES INC

Merger Development On Oct. 22, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with STL Parent Corp. (the "Parent"), pursuant to which a to be formed North Dakota corporation that will be a wholly-owned subsidiary of Parent ("Merger Sub"), will be merged with and into Co., with Co. continuing as the surviving corporation in the merger (the "Merger"). Following the consummation of the Merger, Co. will be a wholly-owned subsidiary of Parent. Parent is a wholly-owned subsidiary of ITE Rail Fund L.P., which is managed by ITE Management L.P., an investment firm targeting industrial and transportation assets and companies. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value \$0.01 per share, of Co. issued and outstanding immediately prior to the Effective Time (each, a "Share"), will be cancelled and each such Share (other than (i) Shares owned by Parent, Merger Sub or any of their respective subsidiaries or affiliates (other than Co.), (ii) Shares owned by Co. or Co.'s subsidiaries, or (iii) Shares owned by holders who have properly exercised appraisal rights under North Dakota law) will be converted into the right to receive \$70.00 per Share in cash, without interest (the "Merger Consideration"). The transaction is valued at approximately \$1,750,000,000 (including Co.'s net indebtedness) and expected to close in the fourth quarter of 2018, subject to termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and other customary closing conditions. The transaction is not subject to any further due diligence or any financing conditions.

AMERICAN SUPERCONDUCTOR CORP.

Earnings, 6 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	27,483,000	19,971,000
Cost & expenses	7,713,000	42,457,000
Operating income	19,600,000	(22,499,000)
Other income (expense), net	752,000	(1,101,000)
Gains or losses		951,000
Net before taxes	20,785,000	(22,604,000)
Income taxes	2,964,000	(71,000)
Net income	17,821,000	(22,533,000)
Earnings common share		
Primary	\$0.88	\$(1.26)
Fully Diluted	\$0.87	\$(1.26)
Common Shares:		
Full Diluted	20,560,000	17,925,000
Year-end	21,364,053	20,925,142

AMERISAFE INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	283,084	280,271
Cost & expenses	218,280	215,831
Operating income	64,804	64,440
Net before taxes	64,804	64,440
Income taxes	11,978	18,858
Net income	52,826	45,582
Earnings common share		
Primary	\$2.75	\$2.38
Fully Diluted	\$2.74	\$2.37
Common Shares:		
Full Diluted	19,281	19,236
Year-end	19,270	19,244

AMGEN INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	17,517,000	17,047,000
Cost & expenses	9,636,000	9,319,000
Operating income	7,881,000	7,728,000
Interest expense	1,040,000	972,000
Net before taxes	7,360,000	7,383,000
Income taxes	894,000	1,140,000
Net income	6,466,000	6,243,000
Earnings common share		
Primary	\$9.67	\$8.52
Fully Diluted	\$9.61	\$8.46
Common Shares:		
Full Diluted	673,000	738,000
Year-end	640,500	726,600

AMICUS THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	58,601,000	22,201,000
Cost & expenses	314,880,000	394,023,000
Operating income	(259,294,000)	374,308,000
Interest income	7,371,000	2,702,000
Interest expense	13,763,000	12,820,000
Other income (expense), net	(6,332,000)	5,054,000
Net before taxes	(272,018,000)	379,372,000
Income taxes	(1,104,000)	164,578,000
Net income	(270,914,000)	214,794,000
Balance for common	(270,914,000)	214,794,000
Earnings common share		
Primary	\$(1.47)	\$(1.44)
Fully Diluted	\$(1.47)	\$(1.44)
Common Shares:		
Full Diluted	184,606,790	148,963,864
Year-end	189,254,341	

AMPHASTAR PHARMACEUTICALS INC (DE)

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	204,976	179,773
Cost & expenses	215,144	179,296
Operating income	(10,168)	477
Interest income	335	302
Interest expense	242	692
Other income (expense), net	(440)	2,307
Net before taxes	(10,515)	2,394
Income taxes	(2,137)	(466)
Net income	(8,378)	2,860
Earnings common share		
Primary	\$(0.16)	\$0.06
Fully Diluted	\$(0.16)	\$0.06
Common Shares:		
Full Diluted	46,437	48,046
Year-end	46,160	

ANI PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	144,454,000	129,556,000
Cost & expenses	95,484,000	87,700,000
Deprec., depl. & amort.	25,056,000	20,906,000
Operating income	23,914,000	20,950,000
Interest expense	11,132,000	9,009,000
Other income (expense), net	(71,000)	58,000
Net before taxes	12,711,000	11,999,000
Income taxes	2,647,000	3,446,000
Net income	10,064,000	8,553,000
Earnings common share		
Primary	\$0.85	\$0.74
Fully Diluted	\$0.85	\$0.73
Common Shares:		
Full Diluted	11,767,000	11,666,000
Year-end	11,846,735	11,648,242

ANSYS INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	878,204	792,914
Cost & expenses	571,145	493,359
Operating income	296,638	290,049
Interest income	7,674	4,827
Other income (expense), net	57	(13)
Foreign currency	(2,346)	(1,499)
Net before taxes	302,023	293,364
Income taxes	35,811	86,698
Net income	266,212	206,666
Earnings common share		
Primary	\$3.17	\$2.43
Fully Diluted	\$3.09	\$2.38
Common Shares:		
Full Diluted	86,060	86,902
Year-end	84,022	84,834

APOGEE ENTERPRISES INC

Earnings, 6 mos. to (Consol. – \$000):

	09/01/18	09/02/17
Net Sales	698,664	616,214
Cost & expenses	648,010	564,334
Operating income	50,654	51,880
Interest income	910	284

Interest expense	4,573	2,095
Other income (expense), net	196	256
Net before taxes	47,187	50,325
Income taxes	11,300	16,813
Net income	35,887	33,512
Earnings common share		
Primary	\$1.28	\$1.16
Fully Diluted	\$1.26	\$1.16
Common Shares:		
Full Diluted	28,377	28,885
Year-end	28,260	28,643

APPFOLIO INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	139,706	105,906
Cost & expenses	111,963	89,611
Operating income	16,959	6,948
Other income (expense), net	(20)	(93)
Net before taxes	17,570	7,232
Income taxes	252	93
Net income	17,318	7,139
Earnings common share		
Primary	\$0.51	\$0.21
Fully Diluted	\$0.49	\$0.20
Common Shares:		
Full Diluted	35,524	35,091
Year-end	34,234	33,942

APPIAN CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	166,527	126,175
Cost & expenses	199,944	151,031
Operating income	(33,417)	(24,856)
Other income (expense), net	(1,785)	1,658
Net before taxes	(35,336)	(23,649)
Income taxes	212	489
Net income	(35,548)	(24,138)
Balance for common	(35,548)	(24,495)
Earnings common share		
Primary	\$(0.58)	\$(0.53)
Fully Diluted	\$(0.58)	\$(0.53)
Common Shares:		
Full Diluted	61,584	45,855
Year-end	63,588	60,277

APPLE INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	09/29/18	09/30/17	09/24/16
		(revised)	(revised)
Net sales	265,595,000	229,234,000	215,639,000
Cost of sales	163,756,000	141,048,000	131,376,000
Gross margin	101,839,000	88,186,000	84,263,000
Research & development expense	14,236,000	11,581,000	10,045,000
Selling, general & administrative expense	16,705,000	15,261,000	14,194,000
Total operating expenses	30,941,000	26,842,000	24,239,000
Operating income (loss)	70,898,000	61,344,000	60,024,000
Interest & dividend income	5,686,000	5,201,000	3,999,000
Interest expense	3,240,000	2,323,000	1,456,000
Other income (expense), net	(441,000)	(133,000)	(1,195,000)
Income (loss) before provision for income taxes	72,903,000	64,089,000	61,372,000
Current federal income tax expense (benefit)	41,425,000	7,842,000	7,652,000
Deferred federal income tax expense (benefit)	(33,819,000)	5,980,000	5,043,000
Total federal income tax expense (benefit)	7,606,000	13,822,000	12,695,000
Current state income tax expense (benefit)	551,000	259,000	990,000

Deferred state income tax expense (benefit)	48,000	2,000	(138,000)
Total state income tax expense (benefit)	599,000	261,000	852,000
Current foreign income tax expense (benefit)	3,986,000	1,671,000	2,105,000
Deferred foreign income tax expense (benefit)	1,181,000	(16,000)	33,000
Total foreign income tax expense (benefit)	5,167,000	1,655,000	2,138,000
Provision for (benefit from) income taxes	13,372,000	15,738,000	15,685,000
Net income (loss)	59,531,000	48,351,000	45,687,000
Weighted average shares outstanding - basic	4,955,377	5,217,242	5,470,820
Weighted average shares outstanding - diluted	5,000,109	5,251,692	5,500,281
Year end shares outstanding	4,754,986	5,126,201	5,336,166
Net earnings (loss) per common share - basic	\$12.01	\$9.27	\$8.35
Net earnings (loss) per common share - diluted	\$11.91	\$9.21	\$8.31
Cash dividends declared per common share	\$2.72	\$2.40	\$2.18
Number of full time employees	132,000	123,000	116,000
Number of common stockholders	23,710	25,333	25,641
Foreign currency translation adjustments	(525,000)	224,000	...

□ As is; □ Approximately; □ Approximate; □ Full-time equivalent employees; □ As of October 26, 2018; □ As of October 20, 2017; □ As of October 14, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	09/29/18	09/30/17 (revised)
Cash & cash equivalents	25,913,000	20,289,000
Marketable securities	40,388,000	53,892,000
Accounts receivable, net	23,186,000	17,874,000
Inventories	3,956,000	4,855,000
Vendor non-trade receivables	25,809,000	17,799,000
Other current assets	12,087,000	13,936,000
Total current assets	131,339,000	128,645,000
Marketable securities	170,799,000	194,714,000
Land & buildings	16,216,000	13,587,000
Machinery, equipment, & internal-use software	65,982,000	54,210,000
Leasehold improvements	8,205,000	7,279,000
Gross property, plant & equipment	90,403,000	75,076,000
Accumulated depreciation & amortization	49,099,000	41,293,000
Property, plant & equipment, net	41,304,000	33,783,000
Other non-current assets	22,283,000	18,177,000
Total non-current assets	234,386,000	246,674,000
Total assets	365,725,000	375,319,000
Accounts payable	55,888,000	44,242,000
Deferred revenue	7,543,000	7,548,000
Other current liabilities	32,687,000	30,551,000
Commercial paper	11,964,000	11,977,000
Current portion of long-term debt	8,784,000	6,496,000
Total current liabilities	116,866,000	100,814,000
Deferred revenue	2,797,000	2,836,000
Floating & fixed-rate notes	104,193,000	104,021,000
Unamortized discount	(218,000)	(225,000)

Hedge accounting fair value adjustments	(1,456,000)	(93,000)
Less: current portion of long-term debt	8,784,000	6,496,000
Term debt	93,735,000	97,207,000
Long-term taxes payable	33,589,000	257,000
Deferred tax liabilities	426,000	31,504,000
Other non-current liabilities	11,165,000	8,654,000
Total non-current liabilities	141,712,000	140,458,000
Total liabilities	258,578,000	241,272,000
Common stock	40,201,000	35,867,000
Retained earnings	70,400,000	98,330,000
Cumulative foreign currency translation	(1,055,000)	(354,000)
Unrecognized gains (losses) on derivative instruments	810,000	(124,000)
Unrealized gains (losses) on marketable securities	(3,209,000)	328,000
Accumulated other comprehensive income (loss)	(3,454,000)	(150,000)
Total shareholders' equity	107,147,000	134,047,000

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Apple Inc common.

ExDate	Amt	Declared	Record	Payable
02/05/2015	0.47	01/27/2015	02/09/2015	02/12/2015
05/07/2015	0.52	04/27/2015	05/11/2015	05/14/2015
08/06/2015	0.52	07/21/2015	08/10/2015	08/13/2015
11/05/2015	0.52	10/27/2015	11/09/2015	11/12/2015
02/04/2016	0.52	01/26/2016	02/08/2016	02/11/2016
05/05/2016	0.57	04/26/2016	05/09/2016	05/12/2016
08/04/2016	0.57	07/26/2016	08/08/2016	08/11/2016
11/03/2016	0.57	10/25/2016	11/07/2016	11/10/2016
02/09/2017	0.57	01/31/2017	02/13/2017	02/16/2017
05/11/2017	0.63	05/02/2017	05/15/2017	05/18/2017
08/10/2017	0.63	08/01/2017	08/14/2017	08/17/2017
11/10/2017	0.63	11/02/2017	11/13/2017	11/16/2017
02/09/2018	0.63	02/01/2018	02/12/2018	02/15/2018
05/11/2018	0.73	05/01/2018	05/14/2018	05/17/2018
08/10/2018	0.73	07/31/2018	08/13/2018	08/16/2018
11/08/2018	0.73	11/01/2018	11/12/2018	11/15/2018

Annual Dividends:

1. Apple Inc common.

2015	2.03	2016	2.23	2017	2.46
2018	2.82				

APPLIED OPTOELECTRONICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	209,447	302,474
Operating income	207,938	225,843
Interest expense	1,509	76,631
Other income (expense), net	624	792
Gains or losses	517	294
Net before taxes	5	(51)
Income taxes	2,428	75,107
Net income	(3,994)	6,872
Earnings common share	6,422	68,235
Primary	\$0.33	\$3.59
Fully Diluted	\$0.32	\$3.39
Common Shares:		
Full Diluted	20,039	20,134
Year-end	19,758	19,359

APPROACH RESOURCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	41,543	41,344
Deprec., depl. & amort.	47,029	54,348
Operating income	3,088	(18,760)
Interest expense	18,522	15,683
Other income (expense), net	(10,098)	6,200
Net before taxes	(25,532)	(28,243)
Income taxes	(4,753)	129,933

Net income	(20,779)	(158,176)
Earnings common share		
Primary	\$(0.22)	\$(1.95)
Fully Diluted	\$(0.22)	\$(1.95)
Common Shares:		
Full Diluted	94,528	81,143
Year-end	94,478	86,502

APTIO INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	172,338	136,152
Operating income	187,159	154,671
Interest income	(14,821)	(18,519)
Interest expense	2,375	859
Other income (expense), net	4,021	21
Foreign currency	81	(27)
Net before taxes	(797)	159
Income taxes	(17,183)	(17,549)
Net income	783	614
Balance for common	(17,966)	(18,163)
Earnings common share	(17,966)	(18,163)
Primary	\$(0.41)	\$(0.46)
Fully Diluted	\$(0.41)	\$(0.46)
Common Shares:		
Full Diluted	43,830	39,240
Year-end	45,081	...

APTIO INC

Sale Development On Nov. 12, 2018, Co. announced that it agreed to be bought by private equity firm Vista Equity Partners for \$1,940,000,000 in cash. Co.'s board has approved the deal, which is expected to close in the first quarter of 2019.

AQUESTIVE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	50,606	54,723
Operating income	87,191	47,580
Interest income	(36,585)	7,143
Interest expense	238	...
Other income (expense), net	5,809	5,737
Net income	(5,276)	(309)
Balance for common	(47,432)	1,097
Earnings common share	(47,432)	(757)
Primary	\$(2.45)	\$.....
Fully Diluted	\$(2.45)	\$.....
Common Shares:		
Full Diluted	19,336	...
Year-end	24,942	...

ARATANA THERAPEUTICS, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	30,506	15,116
Operating income	34,286	44,489
Interest income	(4,168)	(29,608)
Interest expense	441	311
Other income (expense), net	2,357	2,601
Net income	(4)	(14)
Earnings common share	(6,088)	(31,912)
Primary	\$(0.13)	\$(0.80)
Fully Diluted	\$(0.13)	\$(0.80)
Common Shares:		
Full Diluted	46,128	39,821
Year-end	47,981	42,461

ARAVIVE INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Total Revenues	2018	2017
Cost & expenses	2018	2017
Operating income	24,176	115,596
Interest income	(24,176)	(115,596)
Other income (expense), net	703	661
Net before taxes	(1,906)	(1,044)
Income taxes	...	(115,979)
Net income	128	...
Earnings common share	(25,379)	(116,107)
Primary	\$(4.23)	\$(19.72)
Fully Diluted	\$(4.23)	\$(19.72)
Common Shares:		
Full Diluted	5,998	5,889
Year-end	6,040	5,968

ARCBEST CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	2,319,509	2,115,736
Cost & expenses	2,165,874	1,996,306
Deprec., depl. & amort.	81,699	76,821
Operating income	71,936	42,609
Other income (expense), net	(4,038)	(3,548)
Net before taxes	63,716	35,556
Income taxes	11,753	12,398
Net income	51,963	23,158
Earnings common share		
Primary	\$2.02	\$0.90
Fully Diluted	\$1.94	\$0.87
Common Shares:		
Full Diluted	26,708	26,373
Year-end	25,690	25,627

ARCHROCK PARTNERS LP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	451,901	415,741
Cost & expenses	315,550	306,878
Deprec., depl. & amort.	102,319	108,947
Operating income	34,032	(84)
Net before taxes	34,032	(84)
Income taxes	648	2,970
Net income	33,384	(3,054)
Earnings common share		
Common Shares:		
Full Diluted	66,298	71,608
Year-end	71,653	71,608

ARDELYX INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	2,522	
Cost & expenses	66,093	76,077
Operating income	(63,571)	(76,077)
Other income (expense), net	141	1,624
Net before taxes	(63,430)	
Income taxes	6	
Net income	(63,436)	(74,453)
Earnings common share		
Primary	\$(1.17)	\$(1.57)
Fully Diluted	\$(1.17)	\$(1.57)
Common Shares:		
Full Diluted	54,205	47,404
Year-end	62,106	47,504

ARENA PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	9,322,000	5,973,000
Cost & expenses	109,461,000	84,340,000
Operating income	(100,139,000)	(78,367,000)
Interest income	5,800,000	63,000
Interest expense	4,344,000	4,624,000
Other income (expense), net	1,403,000	1,344,000
Income contin. oper.	(97,280,000)	(81,584,000)
Net income	(98,110,000)	(78,777,000)
Earnings common share		
Primary	\$(2.12)	\$(2.24)
Fully Diluted	\$(2.12)	\$(2.24)
Common Shares:		
Full Diluted	46,243,000	34,692,000
Year-end	49,406,452	

AROTECH CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	72,967,596	69,726,579
Cost & expenses	68,908,277	67,062,880
Operating income	2,760,746	934,743
Other income (expense), net	(690,354)	(763,465)
Net before taxes	2,070,392	171,278
Income taxes	650,765	745,995
Net income	1,419,627	(574,717)
Earnings common share		
Primary	\$0.05	\$(0.02)
Fully Diluted	\$0.05	\$(0.02)
Common Shares:		
Full Diluted	26,466,948	26,202,386
Year-end	26,486,152	

ARQUE INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	27,874	20,449
Operating income	(5,051)	(20,449)
Interest income	843	125
Interest expense	1,235	1,119
Other income (expense), net	(1,552)	
Net income	(6,995)	(21,443)
Earnings common share		
Primary	\$(0.07)	\$(0.30)
Fully Diluted	\$(0.07)	\$(0.30)
Common Shares:		
Full Diluted	95,678	71,282
Year-end	108,994	73,172

ARRAY BIOPHARMA INC.**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	56,910,000	29,746,000
Cost & expenses	80,635,000	65,252,000
Operating income	(23,725,000)	(35,506,000)
Interest income	1,524,000	525,000
Interest expense	2,580,000	3,213,000
Other income (expense), net	(65,000)	200,000
Invest. income	35,000	
Net income	(24,811,000)	(37,994,000)
Earnings common share		
Primary	\$(0.12)	\$(0.22)
Fully Diluted	\$(0.12)	\$(0.22)
Common Shares:		
Full Diluted	212,193,000	174,772,000
Year-end	213,026,650	196,125,505

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	130,507,000	
Current assets	476,210,000	
Net property & equip.	6,860,000	
Total assets	484,219,000	
Liabilities:		
Current liabilities	84,766,000	
Long-term debt	131,093,000	
Stockholders' equity	219,068,000	
Net current assets	391,444,000	

ASCENT CAPITAL GROUP, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	405,922	419,909
Cost & expenses	425,199	205,774
Operating income	(188,628)	28,804
Interest income	1,879	1,575
Interest expense	120,017	114,011
Other income (expense), net	(4,495)	242
Net before taxes	(311,261)	(83,390)
Income taxes	4,039	8,241
Income contin. oper.	(91,631)	(91,631)
Net income	(315,300)	(91,539)
Earnings common share		
Primary	\$(25.57)	\$(7.52)
Fully Diluted	\$(25.57)	\$(7.52)
Common Shares:		
Full Diluted	12,329	12,170
Year-end	12,434	12,329

ASPEN TECHNOLOGY INC**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	114,169	126,487
Cost & expenses	77,179	70,774
Operating income	36,990	55,713
Interest income	7,069	6,306
Other income (expense), net	128	(615)
Net before taxes	42,373	60,198
Income taxes	4,307	19,677
Net income	38,066	40,521
Earnings common share		
Primary	\$0.54	\$0.55
Fully Diluted	\$0.53	\$0.55
Common Shares:		
Full Diluted	72,015	73,609
Year-end	70,862	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	52,048	
Current assets	459,724	
Net property & equip.	9,006	
Total assets	939,668	
Liabilities:		
Current liabilities	275,107	
Stockholders' equity	473,119	
Net current assets	184,617	

ASSERTIO THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	269,171,000	286,317,000
Cost & expenses	136,099,000	218,608,000
Operating income	56,741,000	(9,495,000)
Other income (expense), net	62,000,000	(5,364,000)
Net before taxes	67,446,000	(69,952,000)
Income taxes	6,400,000	(560,000)
Net income	61,046,000	(69,392,000)
Earnings common share		
Primary	\$0.96	\$(1.11)
Fully Diluted	\$0.93	\$(1.11)
Common Shares:		
Full Diluted	82,282,000	62,556,000
Year-end	63,939,066	63,013,451

ASTRONICS CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	09/29/18	09/30/17
Cost & expenses	555,234	413,759
Operating income	45,105	39,387
Other income (expense), net	(1,091)	(931)
Net before taxes	36,688	34,706
Income taxes	2,370	9,374
Net income	34,318	25,332
Earnings common share		
Primary	\$1.06	\$0.77
Fully Diluted	\$1.04	\$0.74
Common Shares:		
Full Diluted	32,969	33,350
Year-end	32,315	32,203

ATARA BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	155,295	85,730
Operating income	(155,295)	(85,730)
Net before taxes	(150,684)	(84,176)
Income taxes	3	2
Net income	(150,687)	(84,178)
Earnings common share		
Primary	\$(3.49)	\$(2.84)
Fully Diluted	\$(3.49)	\$(2.84)
Common Shares:		
Full Diluted	43,148	29,597
Year-end	45,645	30,596

ATHENAHEALTH INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	982,200	891,100
Cost & expenses	858,800	859,200
Operating income	123,400	31,900
Other income (expense), net	(6,800)	(4,300)
Net before taxes	116,600	27,600
Income taxes	22,700	6,100
Net income	93,900	21,500
Earnings common share		
Primary	\$2.32	\$0.54
Fully Diluted	\$2.28	\$0.53
Common Shares:		
Full Diluted	41,200	40,600
Year-end	40,600	40,000

ATHENAHEALTH INC

Sale Development On Nov. 12, 2018, Co. announced that it will be acquired by private equity firm Veritas Capital and hedge fund Elliott Management for about \$5,700,000,000 in cash. The transaction is expected to close in the first quarter of 2019.

ATLAS AIR WORLDWIDE HOLDINGS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,912,766	1,528,508
Cost & expenses	1,600,900	1,272,369
Operating income	155,985	135,226
Interest income	4,704	4,286
Other income (expense), net	(914)	(36,035)
Net before taxes	76,471	36,363
Income taxes	16,828	21,479
Income contin. oper.	59,643	14,884
Net income	59,593	14,025
Earnings common share		
Primary	\$2.33	\$0.56
Fully Diluted	\$2.27	\$0.54
Common Shares:		
Full Diluted	26,274	25,822
Year-end	25,590	25,283

ATRICURE INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	148,737,000	128,654,000
Cost & expenses	163,257,000	151,498,000
Operating income	(14,520,000)	(22,844,000)
Interest income	350,000	160,000
Other income (expense), net	(103,000)	132,000
Net before taxes	(17,560,000)	(24,246,000)
Income taxes	147,000	66,000
Net income	(17,707,000)	(24,312,000)
Earnings common share		
Primary	\$(0.53)	\$(0.75)
Fully Diluted	\$(0.53)	\$(0.75)
Common Shares:		
Full Diluted	33,280,000	32,297,000
Year-end	35,653,000	34,474,000

AUDENTES THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	96,774	66,296
Operating income	(96,774)	(66,296)
Interest income	3,662	483
Other income (expense), net	(117)	(50)
Net income	(93,229)	(65,863)
Earnings common share		
Primary	\$(2.57)	\$(2.59)
Fully Diluted	\$(2.57)	\$(2.59)
Common Shares:		
Full Diluted	36,303	25,476
Year-end	37,453	

AUTOMATIC DATA PROCESSING INC.**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,323,200	3,077,200
Cost & expenses	2,690,300	2,554,900
Operating income	646,800	564,500
Interest income	28,500	25,800
Other income (expense), net	(13,700)	16,400
Gains or losses		400
Invest. income	(900)	
Net before taxes	646,800	564,900
Income taxes	141,400	152,300
Net income	505,400	412,600
Earnings common share		
Primary	\$1.16	\$0.93
Fully Diluted	\$1.15	\$0.93
Common Shares:		
Full Diluted	439,900	445,000
Year-end	438,200	444,000

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	1,490,300
Current assets	29,955,900
Net property & equip.	787,700
Total assets	37,416,700
Liabilities:	
Current liabilities	29,037,300
Long-term debt	2,002,400
Stockholders' equity	4,678,800
Net current assets	918,600

AVID TECHNOLOGY, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	300,598	311,745
Cost & expenses	297,900	310,192
Operating income	1,609	465
Net before taxes	(15,753)	(13,000)
Income taxes	824	(326)
Net income	(16,577)	(12,674)
Earnings common share		
Primary	\$(0.40)	\$(0.31)
Fully Diluted	\$(0.40)	\$(0.31)
Common Shares:		
Full Diluted	41,596	40,954
Year-end	41,853	

AVIS BUDGET GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	7,074,000	6,829,000
Cost & expenses	4,927,000	4,708,000
Operating income	264,000	210,000
Net before taxes	264,000	210,000
Income taxes	112,000	69,000
Net income	152,000	141,000
Earnings common share		
Primary	\$1.90	\$1.68
Fully Diluted	\$1.88	\$1.65
Common Shares:		
Full Diluted	81,000	85,500
Year-end	78,000	82,000

AVNET INC**Earnings, 3 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Net Sales	5,089,879	4,660,943
Cost & expenses	4,943,063	4,596,375
Operating income	146,816	64,568
Other income (expense), net	(1,892)	18,921
Net before taxes	114,831	61,474
Income taxes	31,302	3,292
Income contin. oper.	83,529	58,182
Net income	83,724	58,303
Earnings common share		
Primary	\$0.73	\$0.48
Fully Diluted	\$0.72	\$0.47
Common Shares:		
Full Diluted	116,471	123,984
Year-end	113,031	121,235

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	365,852
Inventories	3,395,194
Current assets	7,557,990
Net property & equip.	525,873
Total assets	9,453,774
Liabilities:	
Current liabilities	2,864,832
Long-term debt	1,554,722
Stockholders' equity	4,621,073
Net current assets	4,693,158

AWARE INC. (MA)**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	12,073,000	12,405,000
Cost & expenses	12,035,000	10,627,000
Operating income	38,000	1,778,000
Interest income	587,000	281,000
Other income (expense), net		36,000
Net before taxes	625,000	2,095,000
Income taxes	31,000	535,000
Net income	594,000	1,560,000
Earnings common share		
Primary	\$0.03	\$0.07
Fully Diluted	\$0.03	\$0.07
Common Shares:		
Full Diluted	21,604,000	21,967,000
Year-end	21,545,113	21,612,591

AXCELIS TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	336,892	294,165
Cost & expenses	288,455	257,087
Operating income	48,437	37,078

Interest income	1,518	399
Interest expense	3,787	3,784
Other income (expense), net	(1,710)	
Net before taxes	44,458	33,693
Income taxes	7,036	(1,586)
Net income	37,422	35,279
Earnings common share		
Primary	\$1.16	\$1.15
Fully Diluted	\$1.10	\$1.07
Common Shares:		
Full Diluted	34,032	33,048
Year-end	32,398	31,433

AXON ENTERPRISE INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	305,277,000	249,147,000
Cost & expenses	282,429,000	243,772,000
Operating income	22,848,000	5,375,000
Net before taxes	25,090,000	8,695,000
Income taxes	(2,032,000)	1,417,000
Net income	27,122,000	7,278,000
Earnings common share		
Primary	\$0.49	\$0.14
Fully Diluted	\$0.47	\$0.14
Common Shares:		
Full Diluted	57,254,000	53,762,000
Year-end	58,419,742	52,853,920

AXT INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	80,165	72,341
Cost & expenses	67,380	63,436
Operating income	12,785	8,905
Other income (expense), net	(200)	(1,790)
Net before taxes	12,999	7,449
Income taxes	1,111	661
Net income	11,888	6,788
Balance for common	10,583	6,882
Earnings common share		
Primary	\$0.27	\$0.19
Fully Diluted	\$0.26	\$0.18
Common Shares:		
Full Diluted	40,320	38,469
Year-end	39,538	38,891

B RILEY FINANCIAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	320,960	211,999
Cost & expenses	269,042	197,372
Operating income	51,918	14,627
Interest income	736	358
Interest expense	23,926	5,195
Other income (expense), net	5,049	(157)
Net before taxes	33,777	9,633
Income taxes	8,412	(7,753)
Net income	25,365	17,386
Earnings common share		
Primary	\$0.94	\$0.80
Fully Diluted	\$0.91	\$0.76
Common Shares:		
Full Diluted	26,776	23,385
Year-end	26,526	

B RILEY FINANCIAL INC

Merger Completed On Nov. 14, 2018, Co.'s wholly-owned subsidiary, B. R. Acquisition Ltd. ("Merger Sub"), merged with and into magicJack VocalTec Ltd. ("magicJack"), with magicJack continuing as the surviving corporation and became an indirect wholly-owned subsidiary of Co. As the result of the merger, each ordinary share of magicJack ("magicJack Stock") issued and outstanding immediately prior to the Effective Time (other than shares owned by Co. or Merger Sub, or by any wholly-owned subsidiary of Co., Merger Sub, or magicJack, if any, except to the extent such shares were held for the benefit of any third party), automatically converted into the right to receive cash in an amount, equal to \$8.71, without interest (the "Per Share Merger Consideration"). In addition, subject to certain exceptions each option (or portion thereof) to purchase shares of magicJack Stock ("magicJack Stock Option") granted under any magicJack equity plan, that was outstanding, but unexercised, immediately prior to the Effective Time became, at the Effective Time, fully vested, to the

extent not previously vested, and, subject to certain exceptions, all outstanding options, automatically and without any required action on the part of the holder thereof, were cancelled and converted into the right to receive a cash payment equal to the product of (x) the total number of shares of magicJack Stock subject to such cancelled magicJack Stock Option as of immediately prior to the Effective Time and (y) the excess, if any, of (A) the Per Share Merger Consideration over (B) the exercise price per share subject to such cancelled magicJack Stock Option, without interest, and less any required tax withholdings; provided, however, that any such magicJack Stock Option with respect to which the exercise price per share was equal to or greater than the Per Share Merger Consideration was cancelled in exchange for no consideration. Also, each award of shares of magicJack Stock outstanding immediately prior to the Effective Time that was then subject to forfeiture or other restrictions ("Restricted Shares") granted pursuant to any magicJack equity plan became vested as a result of the Merger, if and to the extent provided by the terms of the award or applicable magicJack equity plan, and any portion of the award that did not become so vested was forfeited. Each vested Restricted Share was, automatically and without any required action on the part of the holder thereof, cancelled and converted into the right to receive, following the Effective Time, a cash payment equal to the Per Share Merger Consideration, without interest, and less any required tax withholdings. The aggregate consideration paid in cash by Co. in the Merger was approximately \$143,000,000, without giving effect to related transaction fees and expenses, which amount was funded by Co. with cash on hand.

BALCHEM CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	480,140	435,526
Cost & expenses	399,644	364,937
Operating income	80,496	70,589
Other income (expense), net	(793)	(926)
Net before taxes	73,767	63,966
Income taxes	15,528	15,870
Net income	58,239	48,096
Earnings common share		
Primary	\$1.82	\$1.51
Fully Diluted	\$1.79	\$1.49
Common Shares:		
Full Diluted	32,452	32,203
Year-end	32,250	31,998

BANDWIDTH INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	151,770	120,489
Cost & expenses	141,748	108,083
Operating income	10,022	12,406
Other income (expense), net	242	(1,950)
Net before taxes	10,264	10,456
Income taxes	(8,949)	3,886
Net income	19,213	6,570
Balance for common	19,213	5,712
Earnings common share		
Primary	\$1.05	\$0.48
Fully Diluted	\$0.91	\$0.42
Common Shares:		
Full Diluted	21,066	13,488
Year-end	19,349	17,621

BASSETT FURNITURE INDUSTRIES, INC**Earnings, 9 mos. to (Consol. - \$000):**

	08/25/18	08/26/17
Net Sales	340,208	334,278
Cost & expenses	328,171	314,754
Operating income	12,037	19,524
Other income (expense), net	(1,352)	(3,078)
Invest. income	3,267	3,267
Net before taxes	10,685	19,713
Income taxes	4,364	6,431
Net income	6,321	13,282
Earnings common share		
Primary	\$0.59	\$1.25
Fully Diluted	\$0.59	\$1.24
Common Shares:		
Full Diluted	10,731	10,723
Year-end	10,638	10,735

BEASLEY BROADCAST GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	181,926,003	173,656,015
Cost & expenses	156,746,702	131,520,640
Deprec., depl. & amort.	4,801,859	4,575,646
Operating income	20,377,442	37,559,729
Other income (expense), net	(566,084)	441,936
Net before taxes	8,306,885	23,704,752
Income taxes	3,917,689	6,242,531
Net income	4,389,196	17,462,221
Earnings common share		
Primary	\$0.16	\$0.63
Fully Diluted	\$0.16	\$0.63
Common Shares:		
Full Diluted	27,664,999	27,886,984
Year-end	27,484,013	28,787,132

BEL FUSE INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	405,451,000	371,671,000
Cost & expenses	383,848,000	355,256,000
Operating income	21,603,000	16,415,000
Interest expense	3,917,000	4,476,000
Net before taxes	17,207,000	11,219,000
Income taxes	523,000	2,329,000
Net income	16,684,000	8,890,000
Balance for common	14,214,000	6,419,000
Earnings common share		
Primary	\$2.71	\$1.44
Fully Diluted	\$2.71	\$1.44
Common Shares:		
Full Diluted	12,066,000	12,031,000
Year-end	12,247,264	12,035,714

BELLEROPHON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	23,196	17,290
Operating income	(23,196)	(17,290)
Other income (expense), net	21,201	(13,455)
Net before taxes	(1,713)	(30,659)
Income taxes	(5,439)	
Net income	3,726	(30,659)
Earnings common share		
Primary	\$0.06	\$(0.92)
Fully Diluted	\$(0.27)	\$(0.92)
Common Shares:		
Full Diluted	65,855	33,505
Year-end	58,679	

BELLICUM PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	808	254
Cost & expenses	69,707	68,196
Operating income	(68,899)	(67,942)
Interest income	1,196	788
Interest expense	3,113	2,707
Net income	(70,816)	(69,861)
Balance for common	(70,816)	(69,861)
Earnings common share		
Primary	\$(1.81)	\$(2.24)
Fully Diluted	\$(1.81)	\$(2.24)
Common Shares:		
Full Diluted	39,169	31,205
Year-end	43,351	33,252

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	53,027	
Current assets	115,539	
Net property & equip.	22,402	
Total assets	143,972	
Liabilities:		
Current liabilities	14,423	
Long-term debt	35,711	
Stockholders' equity	92,457	
Net current assets	101,116	

BENEFITFOCUS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	183,950	168,963
Cost & expenses	214,012	203,270
Operating income	(30,062)	(34,307)

Interest income	199	129
Other income (expense), net	15	(140)
Net before taxes	(39,639)	(43,429)
Income taxes	22	10
Net income	(39,661)	(43,439)
Earnings common share		
Primary	\$(1.25)	\$(1.40)
Fully Diluted	\$(1.25)	\$(1.40)
Common Shares:		
Full Diluted	31,678	30,974
Year-end	31,900	

BGC PARTNERS INC

Acquisition Development On Oct. 29, 2018, Co. announced that it has entered into an agreement to acquire Ed Broking Group Limited ("Ed"), an independent Lloyd's of London insurance broker with a strong reputation across Accident and Health, Aerospace, Cargo, Energy, Financial and Political Risks, Marine, Professional and Executive Risk, Property and Casualty, Specialty and Reinsurance. Under the terms of the agreement, Co. will acquire 100% of Ed, which includes broking operations under the Ed brand in UK, Singapore, Hong Kong, Dubai, Miami and China; Ed's German marine broking arm Junge & Co. Versicherungsmakler GmbH; Ed's managing general agent (MGA) operations Globe Underwriting Limited based in the UK; and Cooper Gay (France) SAS, which is based in Paris. Further details of the transaction were not disclosed, and completion of the transaction is subject to legal and regulatory approvals and certain closing conditions.

BGC PARTNERS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	2,893,976,000	459,122,000
Cost & expenses	2,627,731,000	267,118,000
Operating income	276,244,000	196,551,000
Other income (expense), net	151,907,000	101,914,000
Gains or losses		561,000
Net before taxes	418,152,000	294,479,000
Income taxes	108,427,000	55,084,000
Net income	309,725,000	239,395,000
Balance for common	214,263,000	171,274,000
Earnings common share		
Primary	\$0.67	\$0.60
Fully Diluted	\$0.64	\$0.59
Common Shares:		
Full Diluted	482,711,000	451,348,000
Year-end	328,360,000	

BIG 5 SPORTING GOODS CORP**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Net Sales	740,480	766,746
Cost & expenses	735,808	742,458
Operating income	4,672	24,288
Interest expense	2,309	1,095
Net before taxes	2,363	23,193
Income taxes	805	9,139
Net income	1,558	14,054
Earnings common share		
Primary	\$0.07	\$0.65
Fully Diluted	\$0.07	\$0.65
Common Shares:		
Full Diluted	21,021	21,752
Year-end	21,428	21,474

BIO-TECHNE CORP**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	162,970,000	144,613,000
Cost & expenses	137,207,000	118,582,000
Operating income	25,763,000	26,031,000
Interest income	102,000	76,000
Interest expense	5,239,000	2,243,000
Other income (expense), net	(3,040,000)	(897,000)
Net before taxes	17,586,000	22,967,000
Income taxes	183,000	7,104,000
Net income	17,403,000	15,863,000
Earnings common share		
Primary	\$0.46	\$0.42
Fully Diluted	\$0.45	\$0.42
Common Shares:		
Full Diluted	38,813,000	37,705,000
Year-end	37,802,998	37,409,328

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	94,674,000
Inventories	90,918,000
Current assets	383,112,000
Net property & equip.	146,511,000
Total assets	1,872,198,000
Liabilities:	
Current liabilities	83,442,000
Long-term debt	548,973,000
Stockholders' equity	1,109,469,000
Net current assets	299,670,000

BIOPEN INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	9,926,600	8,966,900
Cost & expenses	4,875,400	4,292,400
Operating income	4,445,500	3,879,600
Interest income	81,400	54,200
Interest expense	151,200	188,800
Other income (expense), net	(8,800)	(9,400)
Gains or losses	132,000	(15,000)
Foreign currency	(13,800)	8,400
Net before taxes	4,485,100	3,729,000
Income taxes	956,000	892,600
Net income	3,529,100	2,836,400
Earnings common share		
Primary	\$16.86	\$13.32
Fully Diluted	\$16.83	\$13.30
Common Shares:		
Full Diluted	207,000	213,300
Year-end	201,483	211,477

BIOMARIN PHARMACEUTICAL INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,137,998	955,341
Cost & expenses	1,181,365	1,001,992
Operating income	(85,376)	(72,747)
Interest expense	35,918	31,043
Other income (expense), net	4,759	3,286
Net before taxes	(99,394)	(90,473)
Income taxes	(24,833)	(24,823)
Net income	(73,561)	(65,650)
Earnings common share		
Primary	\$(0.42)	\$(0.38)
Fully Diluted	\$(0.42)	\$(0.38)
Common Shares:		
Full Diluted	176,767	174,071
Year-end	177,903	175,495

BIOSCRIP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	525,335	634,608
Cost & expenses	500,898	620,798
Operating income	(36,351)	(59,580)
Other income (expense), net		(13,453)
Gains or losses	330	(652)
Net before taxes	(36,021)	(60,232)
Income taxes	191	1,397
Income contin. oper.	(36,212)	(61,629)
Net income	(36,330)	(62,235)
Balance for common	(44,602)	(69,670)
Earnings common share		
Primary	\$(0.35)	\$(0.57)
Fully Diluted	\$(0.35)	\$(0.57)
Common Shares:		
Full Diluted	127,893	122,519
Year-end	128,064	

BIOSIG TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	11,548,171	7,822,774
Operating income	(11,556,977)	(7,831,674)
Other income (expense), net		(320,131)
Net income	(11,554,686)	(8,151,736)
Balance for common	(12,335,032)	(8,220,651)
Earnings common share		
Primary	\$(0.89)	\$(0.83)
Fully Diluted	\$(0.89)	\$(0.83)
Common Shares:		
Full Diluted	13,784,553	9,905,060
Year-end	16,337,936	10,565,498

BIOTELEMETRY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	295,869	195,033
Cost & expenses	260,634	189,484
Operating income	35,235	5,549
Other income (expense), net	305	(3,600)
Net before taxes	28,558	(673)
Income taxes	(2,923)	(31)
Net income	31,481	(642)
Earnings common share		
Primary	\$1.00	\$(0.01)
Fully Diluted	\$0.91	\$(0.01)
Common Shares:		
Full Diluted	35,566	29,682
Year-end	33,212	32,408

BLACK BOX CORP. (DE)

Merger Development On Nov. 11, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with AGC Networks Pte Ltd. ("Top Parent"), a company organized under the laws of Singapore which operates as an information, communications, and technology solutions provider and integrator worldwide, BBX Main Inc. ("Parent"), a wholly-owned subsidiary of Top Parent, BBX Inc. ("BBX Intermediate"), a wholly-owned subsidiary of Parent, and Host Merger Sub Inc., a wholly-owned subsidiary of BBX Intermediate ("Merger Sub"), and, together with Top Parent, Parent and BBX Intermediate, the "Parent Entities" and each, a "Parent Entity"). Pursuant to the terms of the Merger Agreement, Top Parent, Parent and BBX Intermediate have agreed to cause Merger Sub to commence a tender offer (as it may be extended, amended or supplemented from time to time, the "Offer") to purchase any and all of the outstanding shares of common stock, par value \$0.001 per share, of Co. (the "Shares"), at a price of \$1.08 per Share, net to the holder thereof, in cash, without interest thereon (such amount, the "Offer Price"). Following the consummation of the Offer, Merger Sub will merge with and into Co. (the "Merger") in accordance with the General Corporation Law of the State of Delaware (the "DGCL") and Section 251(h) thereof. Each Share that is not tendered and accepted pursuant to the Offer (other than Shares owned by BBX Intermediate, Merger Sub or Co., or by any of their direct or indirect wholly-owned subsidiaries, and Shares held by stockholders of Co. who are entitled to demand and who will have properly and validly demanded their statutory rights of appraisal in compliance in all respects with Section 262 of the DGCL) will be automatically converted into the right to receive the Offer Price at the time of the Merger (such time, the "Effective Time"), and Co. will survive the Merger as a wholly-owned subsidiary of BBX Intermediate, all upon the terms and subject to the conditions set forth in the Merger Agreement. The transaction is expected to close prior to the end of the calendar year.

BLACKBAUD, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	627,388	571,085
Cost & expenses	578,943	520,702
Operating income	44,738	48,219
Interest expense	11,960	8,685
Other income (expense), net	(1,254)	338
Gains or losses		472
Net before taxes	33,137	41,115
Income taxes	(2,370)	4,120
Net income	35,507	36,995
Earnings common share		
Primary	\$0.75	\$0.76
Fully Diluted	\$0.74	\$0.74
Common Shares:		
Full Diluted	48,075	47,679
Year-end	48,567	48,078

BLACKLINE INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	165,472	125,586
Cost & expenses	186,884	151,777
Operating income	(21,412)	(26,191)
Interest expense	4	13
Other income (expense), net		(3,490)
Net before taxes	(19,942)	(28,945)
Income taxes	130	(60)
Net income	(20,072)	(28,885)
Earnings common share		
Primary	\$(0.37)	\$(0.56)

Fully Diluted	\$(0.37)	\$(0.56)
Common Shares:		
Full Diluted	53,660	51,910
Year-end	54,643	

BLACKROCK TCP CAPITAL CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	142,116,543	128,862,576
Cost & expenses	72,093,272	45,376,638
Net income	70,023,271	83,485,938
Earnings common share		
Primary	\$0.79	\$0.96
Fully Diluted	\$0.79	\$0.96
Common Shares:		
Full Diluted	58,824,514	56,390,954
Year-end	58,800,001	58,792,364

BLOOMIN' BRANDS INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	09/24/17
Total Revenues	3,113,300	3,146,756
Cost & expenses	2,837,995	2,880,882
Operating income	123,832	123,395
Interest expense	33,229	29,389
Other income (expense), net	(6)	14,501
Net before taxes	90,597	108,507
Income taxes	(6,516)	17,744
Net income	97,113	90,763
Earnings common share		
Primary	\$1.04	\$0.91
Fully Diluted	\$1.02	\$0.88
Common Shares:		
Full Diluted	94,489	101,497
Year-end	91,854	91,164

BLUCORA, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	459,198,000	411,708,000
Cost & expenses	348,937,000	321,278,000
Operating income	81,171,000	62,558,000
Interest income	217,000	76,000
Other income (expense), net	364,000	(21,588,000)
Net before taxes	69,321,000	23,409,000
Income taxes	2,052,000	5,952,000
Net income	67,269,000	17,457,000
Balance for common	63,078,000	16,991,000
Earnings common share		
Primary	\$1.34	\$0.39
Fully Diluted	\$1.28	\$0.36
Common Shares:		
Full Diluted	49,292,000	46,813,000
Year-end	47,816,000	46,077,000

BLUE HILLS BANCORP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	61,064	53,527
Operating income	25,646	21,857
Net before taxes	25,646	21,857
Income taxes	6,817	6,661
Net income	18,829	15,196
Balance for common	18,829	15,196
Earnings common share		
Primary	\$0.78	\$0.63
Fully Diluted	\$0.75	\$0.62
Common Shares:		
Full Diluted	25,021	24,378
Year-end	26,900	26,869

BLUEBIRD BIO INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	35,336	31,259
Cost & expenses	450,398	246,652
Operating income	(415,062)	(215,393)
Other income (expense), net	45	(1,180)
Net income	(406,602)	(218,415)
Earnings common share		
Primary	\$(7.95)	\$(5.14)
Fully Diluted	\$(7.95)	\$(5.14)
Common Shares:		
Full Diluted	51,130	42,524
Year-end	54,678	

BLUEPRINT MEDICINES CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	207,374	120,952
Interest expense	69	178
Other income (expense), net	7,635	2,240
Net income	(156,320)	(99,092)
Earnings common share		
Primary	\$(3.57)	\$(2.67)
Fully Diluted	\$(3.57)	\$(2.67)
Common Shares:		
Full Diluted	43,825	37,053
Year-end	43,945	39,179

BMC STOCK HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	2,822,927	2,525,087
Cost & expenses	2,652,804	2,404,302
Operating income	129,537	76,283
Interest expense	17,916	18,960
Other income (expense), net	7,830	2,366
Net before taxes	119,451	59,689
Income taxes	27,829	19,906
Net income	91,622	39,783
Earnings common share		
Primary	\$1.36	\$0.60
Fully Diluted	\$1.35	\$0.59
Common Shares:		
Full Diluted	67,743	67,341
Year-end	67,300	66,900

BOINGO WIRELESS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	183,013	147,021
Cost & expenses	180,346	161,585
Operating income	160	(17,237)
Net before taxes	9	(17,363)
Income taxes	198	507
Net income	(189)	(17,870)
Balance for common	(1,636)	(18,347)
Earnings common share		
Primary	\$(0.04)	\$(0.46)
Fully Diluted	\$(0.04)	\$(0.46)
Common Shares:		
Full Diluted	41,890	39,468
Year-end	42,478	40,788

BOJANGLES' INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/30/18	09/24/17
Total Revenues	416,662	406,756
Cost & expenses	394,219	357,465
Operating income	10,979	36,984
Interest income	2	15
Net before taxes	5,931	31,783
Income taxes	1,514	8,918
Net income	4,417	22,865
Earnings common share		
Primary	\$0.12	\$0.62
Fully Diluted	\$0.12	\$0.59
Common Shares:		
Full Diluted	38,221	38,561
Year-end	37,473	

BOJANGLES' INC

Merger Development On Nov. 6, 2018, Co. issued a joint press release announcing the entry into an Agreement and Plan of Merger (the "Merger Agreement") with Walker Parent, Inc., a Delaware corporation ("Parent"), and Walker Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Parent and Merger Sub are affiliates of investment funds affiliated with Durational Capital Management LP and The Jordan Company, L.P. Under the terms of the agreement, Durational Capital Management LP and The Jordan Company, L.P. will acquire Co. in an all cash transaction. Co. stockholders will receive \$16.10 per share, representing a 39% premium to the closing share price of Feb. 12, 2018, a day prior to initial speculation regarding a potential transaction involving Co. and a premium of approximately 30% to the 90-day volume weighted average price ending on Feb. 12, 2018. The offer represents a 15% premium to the closing share price of Sept. 27, 2018, a day prior to a published report that Co. is exploring strategic alternatives. The acquisition, which has been unanimously approved by Co.'s Board

of Directors, is subject to stockholder approval and other customary closing conditions. Concurrently with the execution of the acquisition agreement, Co.'s majority stockholder executed a customary voting agreement whereby it agreed (among other things) to vote its shares in favor of the acquisition. The transaction is expected to be completed in the first quarter of fiscal year 2019. Upon closing of the transaction, Co. will continue to be operated as an independent, privately-held company and will remain based in Charlotte, N.C.

BOOKING HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	1,131,314,385,000	877,989,000
Cost & expenses	6,798,909,000	661,255,000
Deprec., depl. & amort.	317,397,000	265,212,000
Operating income	4,198,079,000	551,522,000
Interest income	141,210,000	110,296,000
Interest expense	203,242,000	182,997,000
Other income (expense), net	(40,174,000)	(21,249,000)
Gains or losses	107,221,000	
Net before taxes	4,203,094,000	457,572,000
Income taxes	850,934,000	561,349,000
Net income	3,352,160,000	896,223,000
Earnings common share		
Primary	\$70.00	\$58.99
Fully Diluted	\$69.07	\$57.85
Common Shares:		
Full Diluted	48,530,000	50,064,000
Year-end	46,626,667	48,752,343

BOTTOMLINE TECHNOLOGIES (DELAWARE) INC**Earnings, 3 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	102,437	91,296
Cost & expenses	98,582	85,609
Operating income	(1,471)	499
Interest income	134	54
Interest expense	1,121	4,589
Other income (expense), net	206	252
Net before taxes	(2,252)	(3,784)
Income taxes	(1,334)	457
Net income	(918)	(4,241)
Earnings common share		
Primary	\$(0.02)	\$(0.11)
Fully Diluted	\$(0.02)	\$(0.11)
Common Shares:		
Full Diluted	39,689	37,730
Year-end	40,406	37,915

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	76,371	
Current assets	187,284	
Net property & equip.	28,777	
Total assets	615,157	
Liabilities:		
Current liabilities	107,762	
Long-term debt	110,000	
Stockholders' equity	349,264	
Net current assets	79,522	

BRIGHTCOVE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	123,969	115,812
Cost & expenses	134,543	134,177
Operating income	(10,574)	(18,365)
Interest expense	5	22
Other income (expense), net	(579)	453
Net before taxes	(11,001)	(17,842)
Income taxes	410	305
Net income	(11,411)	(18,147)
Earnings common share		
Primary	\$(0.32)	\$(0.53)
Fully Diluted	\$(0.32)	\$(0.53)
Common Shares:		
Full Diluted	35,564	34,270
Year-end	36,469	34,622

BROADCOM INC (DE)

Merger Completed On Nov. 5, 2018, Co.'s wholly-owned subsidiary, Collic Acquisition Corp. ("Merger Sub"), merged with and into CA, Inc. ("CA"), with CA continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, each issued and outstanding share of

common stock, par value \$0.10 per share, of CA ("CA Common Stock") (other than shares of CA Common Stock (i) owned or held in treasury by CA or owned by Co. or Merger Sub, or (ii) owned by any subsidiary of Co. or of CA) was canceled and automatically converted into the right to receive \$44.50 per share in cash, without interest (the "Merger Consideration"). The aggregate consideration paid by Co. in the Merger was approximately \$18,700,000,000, without giving effect to the related transaction fees and expenses. In addition, each CA option ("CA Option") that was vested and outstanding as of immediately prior to the Effective Time was cancelled, and the holder of such CA Option became entitled to receive, within five business days following the Effective Date, an amount in cash equal to (i) the number of shares of CA Common Stock subject to such CA Option immediately prior to the Effective Time multiplied by (ii) the excess (if any) of the Merger Consideration over the per share exercise price applicable to CA Option. Each CA Option that was unvested and outstanding as of immediately prior to the Effective Time was assumed and converted automatically into an option to purchase shares of Co. common stock (each such option, an "Adjusted Option"). Each Adjusted Option was subject to the same terms and conditions that were applicable to CA Option, except that (i) the number of shares of Co. common stock, par value \$0.001 per share ("Co. Common Stock"), subject to the Adjusted Option was equal to the product obtained by multiplying (A) the number of shares of CA Common Stock subject to such CA Option immediately prior to the Effective Time, by (B) 0.2010 (the "Equity Award Exchange Ratio"), which ratio was determined as the Merger Consideration divided by the volume weighted average closing sale price per share of Co. Common Stock as reported on NASDAQ for the ten consecutive trading days ending on the day immediately preceding the Effective Time, rounded to four decimal places, with any fractional share rounded down to the nearest whole share and (ii) the Adjusted Option has an exercise price per share of Co. common stock equal to (A) the per share exercise price for shares of CA Common Stock subject to the corresponding CA Option immediately prior to the Effective Time divided by (B) the Equity Award Exchange Ratio, rounded up to the nearest whole cent. Each CA deferred stock unit award ("DSU Award") that was outstanding immediately prior to the Effective Time and that was held by a non-employee director of CA vested and was cancelled, and the holder of such DSU Award became entitled to receive, at the time or times elected by the applicable non-employee director, the Merger Consideration in respect of each share of CA Common Stock subject to such DSU Award immediately prior to the Effective Time. Each CA restricted stock unit award ("RSU Award") and each CA performance share unit award ("PSU Award") that was outstanding immediately prior to the Effective Time was assumed and converted automatically into a restricted stock unit award with respect to shares of Co. Common Stock (each such award, an "Adjusted RSU Award"). Each Adjusted RSU Award was subject to the same terms and conditions that were applicable to the RSU Award or the PSU Award, as applicable, except that (i) the number of shares of Co. Common Stock subject to the Adjusted RSU Award was equal to the product obtained by multiplying (A) the total number of shares of CA Common Stock subject to the RSU Award or the PSU Award (with such number of shares subject to the PSU Award determined based on the achievement of target performance), as applicable, immediately prior to the Effective Time, by (B) the Equity Award Exchange Ratio, with the result rounded up to the nearest whole share and (ii) any Adjusted RSU Award that replaced a PSU Award was no longer subject to any performance based vesting conditions and will instead vest solely based on continued service following the Merger. Each CA restricted share award ("RS Award") that was outstanding immediately prior to the Effective Time was assumed and converted automatically into an award of restricted shares of Co. Common Stock (each such award, an "Adjusted RS Award"). Each Adjusted RS Award was subject to the same terms and conditions that were applicable to the RS Award, except that the number of shares of Co. Common Stock subject to the Adjusted RS award was equal to the product obtained by multiplying (i) the total number of shares of CA Common Stock subject to the RS Award immediately prior to the Effective Time, by (ii) the Equity Award Exchange Ratio, with the result rounded up to the nearest whole share. At the Effective Time, each restricted share of CA Common Stock that was outstanding immediately prior to the Effective Time and underlying a RS Award was cancelled without the payment of any consideration therefor.

BROOKS AUTOMATION INC

Merger Completed On Nov. 15, 2018, Co.'s subsidiary, Darwin Acquisition Company, an exempted company with limited liability incorporated under the Laws of the Cayman Islands ("Merger Sub") merged with and into GENEWIZ Group, an ex-

emerged company with limited liability incorporated under the Laws of the Cayman Islands ("GENEWIZ"), with GENEWIZ surviving the merger as the surviving corporation and a wholly owned subsidiary of Co. (the "Merger"). As a result of the Merger, Co. paid a total cash purchase price at closing of \$450,000,000, which is subject to adjustment based on GENEWIZ's cash, transaction expenses, net working capital, indebtedness, accounts receivables and other amounts as of the closing.

BRUKER CORP

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	1,342,000,000	1,235,400,000
Cost & expenses	1,186,000,000	1,111,200,000
Operating income	156,000,000	124,200,000
Other income (expense), net	(1,600,000)	
Foreign currency	(1,600,000)	(3,900,000)
Net before taxes	144,500,000	109,200,000
Income taxes	41,400,000	25,900,000
Net income	103,100,000	83,300,000
Earnings common share		
Primary	\$0.65	\$0.52
Fully Diluted	\$0.65	\$0.51
Common Shares:		
Full Diluted	157,200,000	159,900,000
Year-end	156,512,202	156,173,417

BUILDERS FIRSTSOURCE INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Net Sales	5,908,791	5,255,270
Cost & expenses	5,630,300	5,034,968
Operating income	278,491	220,302
Interest expense	84,805	103,703
Net before taxes	193,686	116,599
Income taxes	40,516	35,117
Net income	153,170	81,482
Earnings common share		
Primary	\$1.34	\$0.73
Fully Diluted	\$1.31	\$0.71
Common Shares:		
Full Diluted	116,614	115,310
Year-end	114,725	112,931

CA INC

Earnings, 6 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	1,833,000	2,059,000
Cost & expenses	1,401,000	1,324,000
Operating income	269,000	545,000
Interest expense	39,000	49,000
Net before taxes	230,000	496,000
Income taxes	(65,000)	134,000
Net income	295,000	362,000
Balance for common	291,000	357,000
Earnings common share		
Primary	\$0.70	\$0.86
Fully Diluted	\$0.70	\$0.86
Common Shares:		
Full Diluted	416,000	416,000
Year-end	413,477	413,717

CA INC

Merger Completed On Nov. 5, 2018, Broadcom Inc. ("Broadcom") wholly-owned subsidiary, Collie Acquisition Corp. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Broadcom. As the result of the merger, each issued and outstanding share of common stock, par value \$0.10 per share, of Co. ("Co. Common Stock") (other than shares of Co. Common Stock (i) owned or held in treasury by Co. or owned by Broadcom or Merger Sub, or (ii) owned by any subsidiary of Broadcom or of Co.) was canceled and automatically converted into the right to receive \$44.50 per share in cash, without interest (the "Merger Consideration"). The aggregate consideration paid by Broadcom in the Merger was approximately \$18,700,000,000, without giving effect to the related transaction fees and expenses. In addition, each Co. option ("Co. Option") that was vested and outstanding as of immediately prior to the Effective Time was cancelled, and the holder of such Co. Option became entitled to receive, within five business days following the Effective Date, an amount in cash equal to (i) the number of shares of Co. Common Stock subject to such Co. Option immediately prior to the Effective Time multiplied by (ii) the excess (if any) of the Merger Consideration over the per share exercise price applicable to Co. Option. Each

Co. Option that was unvested and outstanding as of immediately prior to the Effective Time was assumed and converted automatically into an option to purchase shares of Broadcom common stock (each such option, an "Adjusted Option"). Each Adjusted Option was subject to the same terms and conditions that were applicable to Co. Option, except that (i) the number of shares of Broadcom common stock, par value \$0.001 per share ("Broadcom Common Stock"), subject to the Adjusted Option was equal to the product obtained by multiplying (A) the number of shares of Co. Common Stock subject to such Co. Option immediately prior to the Effective Time, by (B) 0.2010 (the "Equity Award Exchange Ratio"), which ratio was determined as the Merger Consideration divided by the volume weighted average closing sale price per share of Broadcom Common Stock as reported on NASDAQ for the ten consecutive trading days ending on the day immediately preceding the Effective Time, rounded to four decimal places, with any fractional share rounded down to the nearest whole share and (ii) the Adjusted Option has an exercise price per share of Broadcom common stock equal to (A) the per share exercise price for shares of Co. Common Stock subject to the corresponding Co. Option immediately prior to the Effective Time divided by (B) the Equity Award Exchange Ratio, rounded up to the nearest whole cent. Each Co. deferred stock unit award ("DSU Award") that was outstanding immediately prior to the Effective Time and that was held by a non-employee director of Co. vested and was cancelled, and the holder of such DSU Award became entitled to receive, at the time or times elected by the applicable non-employee director, the Merger Consideration in respect of each share of Co. Common Stock subject to such DSU Award immediately prior to the Effective Time. Each Co. restricted stock unit award ("RSU Award") and each Co. performance share unit award ("PSU Award") that was outstanding immediately prior to the Effective Time was assumed and converted automatically into a restricted stock unit award with respect to shares of Broadcom Common Stock (each such award, an "Adjusted RSU Award"). Each Adjusted RSU Award was subject to the same terms and conditions that were applicable to the RSU Award or the PSU Award, as applicable, except that (i) the number of shares of Broadcom Common Stock subject to the Adjusted RSU Award was equal to the product obtained by multiplying (A) the total number of shares of Co. Common Stock subject to the RSU Award or the PSU Award (with such number of shares subject to the PSU Award determined based on the achievement of target performance), as applicable, immediately prior to the Effective Time, by (B) the Equity Award Exchange Ratio, with the result rounded up to the nearest whole share and (ii) any Adjusted RSU Award that replaced a PSU Award was no longer subject to any performance based vesting conditions and will instead vest solely based on continued service following the Merger. Each Co. restricted share award ("RS Award") that was outstanding immediately prior to the Effective Time was assumed and converted automatically into an award of restricted shares of Broadcom Common Stock (each such award, an "Adjusted RS Award"). Each Adjusted RS Award was subject to the same terms and conditions that were applicable to the RS Award, except that the number of shares of Broadcom Common Stock subject to the Adjusted RS Award was equal to the product obtained by multiplying (i) the total number of shares of Co. Common Stock subject to the RS Award immediately prior to the Effective Time, by (ii) the Equity Award Exchange Ratio, with the result rounded up to the nearest whole share. At the Effective Time, each restricted share of Co. Common Stock that was outstanding immediately prior to the Effective Time and underlying a RS Award was cancelled without the payment of any consideration therefor.

CABOT MICROELECTRONICS CORP

Merger Completed On Nov. 15, 2018, Co.'s subsidiary, Cobalt Merger Sub Corporation, a Texas corporation merged with and into KMG Chemicals, Inc., a Texas corporation ("KMG"), with KMG becoming a direct, wholly owned subsidiary of Co. (the "Merger"). As a result of the Merger, each outstanding share of KMG common stock, par value \$0.01 per share ("KMG Common Stock"), other than (i) any shares of KMG Common Stock held by KMG, the Company and their subsidiaries at the Effective Time and (ii) shares subject to a KMG Equity Award (as defined below), was automatically converted into the right to receive the following consideration (collectively, the "Merger Consideration"), without interest: (i) \$55.65 in cash (the "Cash Consideration"); and (ii) 0.2000 shares of common stock of Co., par value \$0.001 per share ("CMC Common Stock"). Immediately prior to closing, each restricted stock unit award and performance stock award relating to shares of KMG Common Stock (each, a "KMG Equity Award") granted prior to Aug. 14, 2018 vested (with any applicable performance targets deemed satisfied at the level specified in the applicable award agreement) and were can-

celled in exchange for the Merger Consideration in respect of each share of KMG Common Stock underlying the applicable KMG Equity Award. In addition, at the Effective Time, each KMG Equity Award granted on or following Aug. 14, 2018 was converted into a corresponding award relating to shares of CMC Common Stock and will continue to vest post-closing in accordance with the terms of the applicable award agreement (which will include vesting on a qualifying termination of employment). The aggregate amount paid by Co. as Merger Consideration was approximately \$901,000,000 in cash and approximately 3,200,000 shares of CMC Common Stock.

CADENCE DESIGN SYSTEMS INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	1,568,172	1,441,310
Cost & expenses	1,275,035	1,187,488
Operating income	282,519	242,677
Other income (expense), net	4,055	14,370
Net before taxes	267,753	238,095
Income taxes	20,401	19,552
Net income	247,352	218,543
Earnings common share		
Primary	\$0.90	\$0.80
Fully Diluted	\$0.88	\$0.78
Common Shares:		
Full Diluted	281,391	279,554
Year-end	282,142	282,360

CAFEPRESS INC

Sale Completed On Nov. 9, 2018, Co. was acquired by Snapfish Merger Sub, Inc. ("Merger Sub"), a Delaware corporation and a wholly-owned subsidiary of Snapfish, LLC, a California limited liability company ("Parent") through the merger of Merger Sub with and into Co., with Co. continuing as the surviving corporation (the "Surviving Corporation") and became a new subsidiary of Parent (the "Merger"). Merger Sub commenced a tender offer (the "Offer") and purchased all of the outstanding shares (the "Shares") of Co's common stock, \$0.0001 par value, at a price of \$1.48 per share in cash, without interest (the "Offer Price"), subject to any applicable withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated Oct. 12, 2018 (as amended or supplemented from time to time), and in the related Letter of Transmittal (as amended or supplemented from time to time). The Offer expired at midnight, New York time at the end of Nov. 8, 2018 (the "Expiration Time"). The depositary and paying agent for the Offer advised that, as of the Expiration Time, a total of 14,235,152 Shares had been validly tendered and not properly withdrawn pursuant to the Offer, which tendered Shares represented approximately 82.9% of the outstanding Shares as of the Expiration Time (not including 90,620 Shares delivered through Notices of Guaranteed Delivery, representing approximately 0.5% of the Shares outstanding). Merger Sub accepted for exchange all such Shares validly tendered and not properly withdrawn pursuant to the Offer.

CALITHERA BIOSCIENCES, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	22,254	18,701
Cost & expenses	59,311	36,845
Operating income	(37,057)	(18,144)
Interest income	1,927	1,292
Net income	(35,130)	(16,852)
Earnings common share		
Primary	\$(0.98)	\$(0.53)
Fully Diluted	\$(0.98)	\$(0.53)
Common Shares:		
Full Diluted	36,021	32,072
Year-end	37,204	35,477

CALUMET SPECIALTY PRODUCT PARTNERS LP

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Net Sales	2,649,500	2,880,000
Cost & expenses	2,543,000	2,753,500
Operating income	106,500	126,500
Interest expense	120,400	135,800
Other income (expense), net	(53,200)	1,500
Gains or losses	(2,000)	(5,000)
Net before taxes	(69,100)	(12,800)
Income taxes	1,000	(200)
Income contin. oper.	(70,100)	(12,600)
Net income	(73,200)	(20,200)
Earnings common share		
Primary	\$(0.92)	\$(0.25)

Fully Diluted	\$(0.92)	\$(0.25)
Common Shares:		
Full Diluted	77,643	77,538
Year-end	77,133	

CAPITAL PROPERTIES, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	4,037,000	3,890,000
Cost & expenses	1,922,000	2,557,000
Operating income	2,115,000	1,333,000
Net before taxes	2,115,000	1,333,000
Income taxes	542,000	464,000
Income contin. oper.	1,573,000	869,000
Net income	2,172,000	5,748,000
Earnings common share		
Primary	\$0.33	\$0.87
Common Shares:		
Year-end	6,599,912	6,599,912

CAPSTAR FINANCIAL HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	41,887,000	45,011,000
Operating income	12,065,000	1,550,000
Net before taxes	12,065,000	1,550,000
Income taxes	1,702,000	141,000
Net income	10,363,000	1,409,000
Earnings common share		
Primary	\$0.87	\$0.13
Fully Diluted	\$0.79	\$0.11
Common Shares:		
Full Diluted	13,052,758	12,758,091
Year-end	12,125,122	11,346,498

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	52,589,000
Current assets	57,019,000
Net property & equip.	9,584,000
Total assets	1,416,907,000
Liabilities:	
Current liabilities	1,126,403,000
Long-term debt	125,000,000
Stockholders' equity	157,510,000
Net current assets	(1,069,384,000)

CARA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	7,936	911
Cost & expenses	63,341	45,825
Operating income	(55,405)	(44,914)
Other income (expense), net	1,780	788
Net before taxes	(53,625)	(44,126)
Income taxes	(264)	(178)
Net income	(53,361)	(43,948)
Earnings common share		
Primary	\$(1.54)	\$(1.43)
Fully Diluted	\$(1.54)	\$(1.43)
Common Shares:		
Full Diluted	34,697	30,730
Year-end	39,390	32,608

CARBON BLACK INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	152,841	116,145
Cost & expenses	207,914	154,709
Operating income	(55,073)	(38,564)
Other income (expense), net	(9,385)	294
Net before taxes	(63,266)	(38,265)
Income taxes	241	108
Net income	(63,507)	(38,373)
Balance for common	(262,999)	(54,124)
Earnings common share		
Primary	\$(6.34)	\$(5.27)
Fully Diluted	\$(6.34)	\$(5.27)
Common Shares:		
Full Diluted	41,494	10,264
Year-end	67,896	

CARGURUS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	328,068	226,264
Cost & expenses	317,003	209,113
Operating income	9,001	15,242
Other income (expense), net	15	(243)
Net before taxes	10,587	15,565
Income taxes	(36,464)	4,633
Net income	47,051	10,932
Balance for common	47,051	4,486
Earnings common share		
Primary	\$0.43	\$0.11
Fully Diluted	\$0.42	\$0.10
Common Shares:		
Full Diluted	113,351	46,311
Year-end	109,963	42,152

CARRIZO OIL & GAS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	792,628,000	499,117,000
Cost & expenses	429,794,000	213,949,000
Deprec., depl. & amort.	217,005,000	181,018,000
Operating income	145,829,000	104,150,000
Net before taxes	145,829,000	
Income taxes	1,682,000	
Net income	144,147,000	104,150,000
Balance for common	120,956,000	101,901,000
Earnings common share		
Primary	\$1.45	\$1.44
Fully Diluted	\$1.42	\$1.43
Common Shares:		
Full Diluted	85,221,000	71,147,000
Year-end	91,619,733	81,454,621

CARROLS RESTAURANT GROUP INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Net Sales	871,553	804,565
Cost & expenses	801,962	744,780
Deprec., depl. & amort.	43,426	40,172
Operating income	26,165	19,613
Interest expense	17,752	15,767
Other income (expense), net	230	
Net before taxes	8,643	3,846
Income taxes	346	608
Net income	8,297	3,238
Earnings common share		
Primary	\$0.18	\$0.07
Fully Diluted	\$0.18	\$0.07
Common Shares:		
Full Diluted	45,293	44,966
Year-end	35,742	35,433

CASA SYSTEMS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	229,302	233,613
Cost & expenses	167,168	151,784
Operating income	62,134	81,829
Interest income	4,596	1,674
Interest expense	14,579	12,937
Other income (expense), net	978	632
Foreign currency	(445)	773
Net before taxes	52,684	71,971
Income taxes	(5,406)	12,334
Net income	58,090	59,637
Balance for common	58,090	7,689
Earnings common share		
Primary	\$0.69	\$0.23
Fully Diluted	\$0.62	\$0.18
Common Shares:		
Full Diluted	93,180	43,198
Year-end	84,847	

CASELLA WASTE SYSTEMS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	485,936,000	448,087,000
Cost & expenses	389,493,000	424,217,000
Deprec., depl. & amort.	51,572,000	46,307,000
Operating income	44,871,000	(22,437,000)
Interest income	161,000	180,000
Other income (expense), net	(6,755,000)	50,000
Net before taxes	18,930,000	(41,259,000)

Income taxes	(1,166,000)	561,000
Net income	20,096,000	(41,820,000)
Earnings common share		
Primary	\$0.47	\$(1.00)
Fully Diluted	\$0.46	\$(1.00)
Common Shares:		
Full Diluted	43,938,000	41,783,000
Year-end	42,920,000	42,043,000

CASS INFORMATION SYSTEMS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	84,346	75,465
Operating income	27,788	25,992
Net before taxes	27,788	25,992
Income taxes	4,577	6,309
Net income	23,211	19,683
Earnings common share		
Primary	\$1.90	\$1.61
Fully Diluted	\$1.87	\$1.58
Common Shares:		
Full Diluted	12,440	12,257
Year-end	12,302	12,063

CDK GLOBAL INC**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	554,500	565,700
Cost & expenses	397,100	427,900
Operating income	157,400	137,800
Other income (expense), net	2,600	5,300
Net before taxes	127,800	119,800
Income taxes	35,500	36,700
Net income	92,300	83,100
Earnings common share		
Primary	\$0.70	\$0.58
Fully Diluted	\$0.69	\$0.57
Common Shares:		
Full Diluted	130,400	141,400
Year-end	128,800	139,000

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	312,800
Current assets	812,000
Net property & equip.	141,200
Total assets	3,090,900
Liabilities:	
Current liabilities	500,600
Long-term debt	2,673,600
Stockholders' equity	(314,700)
Net current assets	311,400

CDW CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	12,165,700	11,080,800
Cost & expenses	11,421,300	10,435,200
Operating income	744,400	645,600
Interest expense	111,500	113,400
Other income (expense), net	1,000	(55,500)
Net before taxes	633,900	476,700
Income taxes	150,200	148,400
Net income	483,700	328,300
Earnings common share		
Primary	\$3.19	\$2.10
Fully Diluted	\$3.14	\$2.06
Common Shares:		
Full Diluted	154,100	159,200
Year-end	150,900	152,900

CECO ENVIRONMENTAL CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	231,819,000	250,650,000
Operating income	4,272,000	16,235,000
Interest expense	5,442,000	4,951,000
Other income (expense), net	(119,000)	141,000
Net before taxes	(1,289,000)	11,425,000
Income taxes	6,764,000	2,865,000
Net income	(8,053,000)	8,560,000
Earnings common share		
Primary	\$(0.23)	\$0.25
Fully Diluted	\$(0.23)	\$0.25
Common Shares:		

Full Diluted	34,681,262	34,665,053
Year-end	34,812,543	34,561,396

CELGENE CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	11,244,000,009	520,000,000
Cost & expenses	7,519,000,006	761,000,000
Operating income	3,384,000,008	509,000,000
Interest expense	551,000,000	380,000,000
Other income (expense), net	852,000,000	(18,000,000)
Net before taxes	3,715,000,008	183,000,000
Income taxes	742,000,000	162,000,000
Net income	2,973,000,008	21,000,000
Earnings common share		
Primary	\$4.12	\$3.87
Fully Diluted	\$4.02	\$3.72
Common Shares:		
Full Diluted	740,400,000	812,600,000
Year-end	698,900,000	787,100,000

CELLDEX THERAPEUTICS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	7,774,000	9,287,000
Cost & expenses	151,863,000	104,616,000
Operating income	(144,313,000)	(96,001,000)
Other income (expense), net	1,767,000	1,611,000
Net before taxes	(142,546,000)	(94,390,000)
Income taxes	(765,000)	(5,200,000)
Net income	(141,781,000)	(89,190,000)
Earnings common share		
Primary	\$(0.94)	\$(0.71)
Fully Diluted	\$(0.94)	\$(0.71)
Common Shares:		
Full Diluted	150,636,000	125,856,000
Year-end	168,575,504	132,108,478

CELLULAR BIOMEDICINE GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	198,705	268,126
Cost & expenses	30,892,846	20,408,354
Operating income	(30,694,141)	(20,140,228)
Interest income	140,457	113,688
Other income (expense), net	132,300	1,461,265
Net before taxes	(30,421,384)	(18,565,275)
Income taxes	4,879	2,450
Net income	(30,426,263)	(18,567,725)
Earnings common share		
Primary	\$(1.76)	\$(1.30)
Fully Diluted	\$(1.76)	\$(1.30)
Common Shares:		
Full Diluted	17,281,240	14,310,344
Year-end	18,532,475	14,091,181

CENTURY ALUMINUM CO.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	1,406,300	1,155,200
Cost & expenses	1,396,900	1,104,600
Operating income	9,400	50,600
Other income (expense), net	1,800	(1,000)
Gains or losses	2,800	(17,100)
Equity earnings	(3,200)	(500)
Net before taxes	(1,400)	16,800
Income taxes	3,000	4,500
Net income	(1,200)	12,800
Earnings common share		
Primary	\$(0.01)	\$0.13
Fully Diluted	\$(0.01)	\$0.13
Common Shares:		
Full Diluted	87,600	88,100
Year-end	87,608	

CERNER CORP.**Earnings, 9 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Total Revenues	4,000,661	3,828,487
Cost & expenses	3,324,131	3,018,941
Operating income	610,658	741,420
Other income (expense), net	18,404	4,054
Net before taxes	629,062	745,474
Income taxes	130,323	215,154

Net income	498,739	530,320
Earnings common share		
Primary	\$1.51	\$1.60
Fully Diluted	\$1.49	\$1.57
Common Shares:		
Full Diluted	334,493	337,946
Year-end	329,430	332,313

CEVA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	56,476	65,906
Cost & expenses	59,217	52,253
Operating income	(3,417)	12,726
Net before taxes	(882)	14,873
Income taxes	847	1,008
Net income	(1,729)	13,865
Earnings common share		
Primary	\$(0.08)	\$0.64
Fully Diluted	\$(0.08)	\$0.62
Common Shares:		
Full Diluted	22,091	22,480
Year-end	21,902	21,971

CHART INDUSTRIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	794,200	573,500
Cost & expenses	712,700	548,900
Operating income	65,800	17,600
Interest expense	17,900	13,000
Other income (expense), net	(1,000)	(1,000)
Foreign currency	200	(3,100)
Net before taxes	47,100	500
Income taxes	9,700	600
Income contin. oper.	37,400	(100)
Net income	42,100	2,500
Earnings common share		
Primary	\$1.30	\$0.04
Fully Diluted	\$1.25	\$0.04
Common Shares:		
Full Diluted	32,140	31,290
Year-end	31,203	30,768

CHARTER COMMUNICATIONS INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	32,403,000	30,979,000
Cost & expenses	20,837,000	20,231,000
Operating income	3,782,000	2,902,000
Interest expense	2,630,000	2,250,000
Other income (expense), net	172,000	(55,000)
Net before taxes	1,324,000	597,000
Income taxes	178,000	99,000
Net income	1,146,000	498,000
Balance for common	934,000	342,000
Earnings common share		
Primary	\$3.99	\$1.31
Fully Diluted	\$3.93	\$1.29
Common Shares:		
Full Diluted	237,344	266,364
Year-end	239,426	248,610

CHEFS' WAREHOUSE INC (THE)**Earnings, 9 mos. to (Consol. - \$000):**

	09/28/18	09/29/17
Net Sales	1,050,553	944,422
Cost & expenses	1,019,597	918,644
Operating income	30,956	25,778
Interest expense	15,036	17,406
Gains or losses	(30)	(10)
Net before taxes	15,890	8,362
Income taxes	4,370	3,479
Net income	11,520	4,883
Earnings common share		
Primary	\$0.40	\$0.19
Fully Diluted	\$0.40	\$0.19
Common Shares:		
Full Diluted	29,620	26,064
Year-end	29,970	26,564

CHEMBO DIAGNOSTICS INC

Acquisition Completed On Nov. 6, 2018, Co. acquired all the outstanding equity shares of opTricon GmbH ("opTricon"),

a developer and manufacturer of handheld analyzers for rapid diagnostic tests, for \$5,500,000 in cash, of which (a) \$100,000 was deposited in escrow for a potential purchase price adjustment based on the working capital of opTricon and (b) \$750,000 was deposited in escrow to satisfy certain claims that Co. may make against the sellers in accordance with the terms of the Purchase Agreement.

CHEMOCENTRYX, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	33,543	26,196
Cost & expenses	62,417	48,995
Operating income	(28,874)	(22,799)
Interest income	2,471	1,003
Interest expense	778	
Net income	(27,181)	(21,796)
Earnings common share		
Primary	\$(0.55)	\$(0.45)
Fully Diluted	\$(0.55)	\$(0.45)
Common Shares:		
Full Diluted	49,579	48,314
Year-end	50,429	48,773

CHURCHILL DOWNS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	790,000,000	703,700,000
Cost & expenses	613,200,000	545,300,000
Operating income	176,800,000	158,400,000
Other income (expense), net	24,900,000	23,500,000
Gains or losses	54,900,000	
Net before taxes	227,400,000	145,900,000
Income taxes	52,100,000	57,900,000
Income contin. oper.	175,300,000	88,000,000
Net income	341,400,000	102,300,000
Balance for common	341,400,000	102,300,000
Earnings common share		
Primary	\$24.64	\$6.43
Fully Diluted	\$24.50	\$6.32
Common Shares:		
Full Diluted	13,900,000	16,200,000
Year-end	13,600,000	

CHUY'S HOLDINGS INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	09/24/17
Total Revenues	301,366	273,570
Cost & expenses	284,836	242,613
Deprec., depl. & amort.	14,705	12,951
Operating income	1,825	18,006
Interest expense	59	48
Net before taxes	1,766	17,958
Income taxes	(363)	4,884
Net income	2,129	13,074
Earnings common share		
Primary	\$0.13	\$0.77
Fully Diluted	\$0.12	\$0.77
Common Shares:		
Full Diluted	17,081	16,998
Year-end	16,950	16,907

CIRRUS LOGIC INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/18	09/23/17
Net Sales	620,788	746,272
Cost & expenses	571,367	608,084
Operating income	49,421	138,188
Interest expense	539	615
Other income (expense), net	(168)	(1,135)
Net before taxes	52,225	138,372
Income taxes	(1,676)	22,160
Net income	53,901	116,212
Earnings common share		
Primary	\$0.88	\$1.82
Fully Diluted	\$0.86	\$1.74
Common Shares:		
Full Diluted	62,810	66,761
Year-end	59,844	63,665

CISCO SYSTEMS INC**Earnings, 3 mos. to (Consol. - \$000):**

	10/27/18	10/28/17
Net Sales	13,072,000	12,136,000
Cost & expenses	9,233,000	9,319,000
Operating income	3,805,000	2,756,000
Other income (expense), net	(13,000)	(6,000)
Gains or losses	(6,000)	68,000
Net before taxes	3,909,000	2,962,000
Income taxes	360,000	568,000
Net income	3,549,000	2,394,000

Earnings common share		
Primary	\$0.78	\$0.48
Fully Diluted	\$0.77	\$0.48
Common Shares:		
Full Diluted	4,614,000	4,994,000
Year-end	4,517,000	4,951,000

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	8,410,000
Inventories	1,572,000
Current assets	55,686,000
Net property & equip.	2,956,000
Total assets	105,429,000
Liabilities:	
Current liabilities	26,414,000
Long-term debt	18,323,000
Stockholders' equity	43,848,000
Net current assets	29,272,000

CITRIX SYSTEMS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	2,172,033,000	1,946,829,000
Cost & expenses	1,684,796,000	1,546,460,000
Operating income	475,489,000	381,298,000
Interest income	29,029,000	19,045,000
Interest expense	60,840,000	35,286,000
Other income (expense), net	(1,847,000)	3,166,000
Net before taxes	441,831,000	368,223,000
Income taxes	31,882,000	62,349,000
Income contin. oper.	305,874,000	
Net income	409,949,000	263,170,000
Earnings common share		
Primary	\$3.00	\$1.73
Fully Diluted	\$2.80	\$1.68
Common Shares:		
Full Diluted	146,554,000	156,384,000
Year-end	134,659,000	150,629,000

CLEAN ENERGY FUELS CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	250,190,000	252,299,000
Cost & expenses	210,354,000	324,071,000
Deprec., depl. & amort.	39,496,000	43,757,000
Operating income	340,000	115,229,000
Interest income	2,193,000	1,156,000
Interest expense	13,126,000	13,466,000
Other income (expense), net	(4,028,000)	3,067,000
Gains or losses		69,886,000
Net before taxes	(14,621,000)	(54,886,000)
Income taxes	266,000	(2,183,000)
Net income	(14,887,000)	(52,703,000)
Earnings common share		
Primary	\$(0.06)	\$(0.34)
Fully Diluted	\$(0.06)	\$(0.34)
Common Shares:		
Full Diluted	172,946,896	150,128,204
Year-end	203,472,977	

CLEARSIDE BIOMEDICAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues		290
Cost & expenses	61,313	42,377
Operating income	(61,313)	(42,087)
Other income (expense), net	133	(395)
Net income	(61,180)	(42,482)
Earnings common share		
Primary	\$(2.02)	\$(1.68)
Fully Diluted	\$(2.02)	\$(1.68)
Common Shares:		
Full Diluted	30,293	25,300
Year-end	32,024	

CLOVIS ONCOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	301,885	212,898
Operating income	(236,848)	(174,427)
Interest expense	9,592	7,796
Other income (expense), net	(22,556)	(114,763)
Foreign currency	(34)	(127)
Net before taxes	(269,030)	(297,113)
Income taxes	(280)	(2,599)
Net income	(268,750)	(294,514)
Earnings common share		
Primary	\$(5.18)	\$(6.39)
Fully Diluted	\$(5.18)	\$(6.39)
Common Shares:		
Full Diluted	51,844	46,062
Year-end	52,709	49,002

CME GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,072,800	2,744,700
Cost & expenses	958,300	814,100
Operating income	1,957,700	1,773,700
Other income (expense), net	(302,000)	(125,400)
Gains or losses	559,800	391,200
Net before taxes	2,107,300	1,951,600
Income taxes	530,600	827,400
Net income	1,576,700	1,124,200
Earnings common share		
Primary	\$4.64	\$3.32
Fully Diluted	\$4.62	\$3.31
Common Shares:		
Full Diluted	340,907	340,114
Year-end	339,863	

COCA-COLA BOTTLING CO. CONSOLIDATED**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Net Sales	3,510,997	3,197,519
Cost & expenses	3,465,911	3,096,442
Operating income	45,086	101,077
Interest expense	37,617	30,607
Other income (expense), net	(3,612)	(36,595)
Foreign currency	10,170	
Net before taxes	14,027	33,875
Income taxes	3,387	11,800
Net income	10,640	22,075
Earnings common share		
Primary	\$0.75	\$2.00
Fully Diluted	\$0.75	\$1.99
Common Shares:		
Full Diluted	11,659	11,597
Year-end	9,354	9,334

CODEXIS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	44,526	28,301
Cost & expenses	55,177	52,151
Operating income	(10,651)	(23,850)
Interest income	444	96
Other income (expense), net	(221)	(80)
Net before taxes	(10,428)	(23,834)
Income taxes	(11)	132
Net income	(10,417)	(23,966)
Earnings common share		
Primary	\$(0.20)	\$(0.53)
Fully Diluted	\$(0.20)	\$(0.53)
Common Shares:		
Full Diluted	51,609	45,568
Year-end	53,935	48,343

COGENT COMMUNICATIONS HOLDINGS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	263,614	247,984
Operating income	64,250	55,382
Net before taxes	30,520	22,639
Income taxes	8,953	10,536
Net income	21,567	12,103
Earnings common share		
Primary	\$0.48	\$0.27
Fully Diluted	\$0.47	\$0.27

Common Shares:

Full Diluted	45,591	45,084
Year-end	46,461	45,946

COGNEX CORP**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Total Revenues	613,052	583,161
Cost & expenses	437,157	375,075
Operating income	175,895	208,086
Other income (expense), net	(98)	(344)
Gains or losses	10,736	6,625
Foreign currency	(708)	(574)
Net before taxes	185,825	213,793
Income taxes	11,976	9,334
Net income	173,849	204,459
Earnings common share		
Primary	\$1.01	\$1.18
Fully Diluted	\$0.98	\$1.14
Common Shares:		
Full Diluted	178,021	179,124
Year-end	172,191	

COGNIZANT TECHNOLOGY SOLUTIONS CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	9,548,000	8,861,000
Operating income	2,108,000	1,824,000
Interest income	128,000	97,000
Interest expense	19,000	18,000
Other income (expense), net	(2,000)	(2,000)
Equity earnings	(1,000)	(1,000)
Foreign currency	(233,000)	41,000
Net before taxes	1,982,000	1,942,000
Income taxes	530,000	421,000
Net income	1,453,000	1,522,000
Earnings common share		
Primary	\$2.49	\$2.56
Fully Diluted	\$2.48	\$2.55
Common Shares:		
Full Diluted	585,000	596,000
Year-end	580,000	590,000

COHERUS BIOSCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues		1,556
Cost & expenses	143,914	187,226
Operating income	(143,914)	(185,670)
Other income (expense), net	4,351	3,605
Net income	(146,813)	(189,217)
Earnings common share		
Primary	\$(2.39)	\$(3.68)
Fully Diluted	\$(2.39)	\$(3.68)
Common Shares:		
Full Diluted	61,415	51,378
Year-end	68,025	57,945

COHU INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Net Sales	281,131	268,614
Cost & expenses	250,541	238,532
Operating income	30,590	30,082
Net before taxes	31,470	30,499
Income taxes	6,897	4,273
Income contin. oper.		26,226
Net income	24,573	25,948
Earnings common share		
Primary	\$0.85	\$0.94
Fully Diluted	\$0.83	\$0.91
Common Shares:		
Full Diluted	29,650	28,640
Year-end	28,901	28,213

COLLEGIUM PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	238,672	75,546
Operating income	(31,686)	(57,864)
Interest income	1,198	402
Interest expense	17,726	
Net income	(48,214)	(57,462)
Earnings common share		

Primary	\$(1.46)	\$(1.95)
Fully Diluted	\$(1.46)	\$(1.95)
Common Shares:		
Full Diluted	32,951	29,517
Year-end	33,245	30,765

COLUMBUS MCKINNON CORP. (NY)

Earnings, 6 mos. to Sep 30 (Consol. – \$000):	2018	2017
Net Sales	442,134	416,554
Cost & expenses	396,149	370,101
Operating income	38,328	38,814
Other income (expense), net	347	988
Gains or losses	379	108
Foreign currency	(231)	(393)
Net before taxes	29,968	29,309
Income taxes	6,350	5,145
Net income	23,618	24,164
Earnings common share		
Primary	\$1.02	\$1.07
Fully Diluted	\$1.00	\$1.05
Common Shares:		
Full Diluted	23,621	23,013
Year-end	23,346	22,995

COMCAST CORP

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	66,661,000	62,954,000
Cost & expenses	44,346,000	41,544,000
Operating income	14,495,000	13,889,000
Interest expense	2,413,000	2,279,000
Other income (expense), net	92,000	299,000
Net before taxes	12,174,000	11,909,000
Income taxes	2,894,000	4,038,000
Net income	9,280,000	7,871,000
Earnings common share		
Primary	\$2.00	\$1.64
Fully Diluted	\$1.98	\$1.61
Common Shares:		
Full Diluted	4,655,000	4,806,000
Year-end	4,549,505	

COMMERCIAL VEHICLE GROUP INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	674,135	566,893
Cost & expenses	620,084	543,096
Operating income	53,071	22,807
Net before taxes	44,024	8,021
Income taxes	8,393	2,498
Net income	35,631	5,523
Earnings common share		
Primary	\$1.18	\$0.18
Fully Diluted	\$1.17	\$0.18
Common Shares:		
Full Diluted	30,575	30,379
Year-end	30,219	29,877

COMMScope HOLDING CO., INC.

Acquisition Development On Nov. 8, 2018, Co. and ARRIS, a public limited company organized under the laws of England and Wales ("ARRIS"), issued a joint press release announcing that they had entered into a bid conduct agreement (the "Bid Conduct Agreement"), pursuant to which Co. has agreed to acquire all of the issued and to be issued ordinary shares, 0.01 nominal value per share, of ARRIS for \$31.75 per Ordinary Share.

COMMScope HOLDING CO., INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Net Sales	3,510,778	3,440,150
Cost & expenses	2,910,686	2,855,471
Operating income	400,639	381,789
Other income (expense), net	(4,490)	(9,248)
Net before taxes	214,867	183,556
Income taxes	51,367	43,373
Net income	163,500	140,183
Earnings common share		
Primary	\$0.85	\$0.73
Fully Diluted	\$0.84	\$0.71
Common Shares:		
Full Diluted	195,370	197,387
Year-end	192,223	190,762

COMVAULT SYSTEMS INC

Earnings, 6 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	345,255	334,112
Cost & expenses	345,825	338,373
Deprec., depl. & amort.	5,233	4,755
Operating income	(5,803)	(9,016)
Interest income	2,039	972
Interest expense		466
Other income (expense), net		(123)
Net before taxes	(3,764)	(8,633)
Income taxes	3,912	(7,339)
Net income	(7,676)	(1,294)
Earnings common share		
Primary	\$(0.17)	\$(0.03)
Fully Diluted	\$(0.17)	\$(0.03)
Common Shares:		
Full Diluted	45,666	45,364
Year-end	46,034	45,695

COMPUTER PROGRAMS & SYSTEMS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	208,085,000	198,864,000
Cost & expenses	184,954,000	177,757,000
Operating income	15,236,000	13,303,000
Interest expense	5,615,000	5,807,000
Other income (expense), net	593,000	242,000
Net before taxes	10,214,000	7,738,000
Income taxes	170,000	3,617,000
Net income	10,044,000	4,121,000
Balance for common	9,706,000	4,027,000
Earnings common share		
Primary	\$0.72	\$0.30
Fully Diluted	\$0.72	\$0.30
Common Shares:		
Full Diluted	13,547,000	13,409,000
Year-end	14,086,000	13,756,000

COMPUTER SERVICES, INC.

Earnings, 6 mos. to Aug 31 (Consol. – \$000):	2018	2017
Total Revenues	131,955	125,869
Cost & expenses	106,266	97,175
Operating income	25,689	28,694
Other income (expense), net	3,858	
Net before taxes	29,836	28,758
Income taxes	6,738	11,211
Net income	23,099	17,547
Earnings common share		
Primary	\$1.66	\$1.26
Common Shares:		
Year-end	13,925	13,967

COMPUTER TASK GROUP, INC.

Earnings, 9 mos. to (Consol. – \$000):	09/28/18	09/30/17
Total Revenues	265,640	226,566
Cost & expenses	262,592	223,970
Operating income	3,048	2,596
Gains or losses	807	
Net before taxes	3,227	2,226
Income taxes	785	1,001
Net income	2,442	1,225
Earnings common share		
Primary	\$0.17	\$0.08
Fully Diluted	\$0.17	\$0.08
Common Shares:		
Full Diluted	14,603	15,408
Year-end	14,297	15,490

CONCERT PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	10,492	143,879
Cost & expenses	46,013	38,493
Operating income	(35,521)	105,386
Other income (expense), net	(1,359)	(1,432)
Gains or losses	2,003	742
Net before taxes	(34,877)	103,882
Income taxes	298	2,177
Net income	(35,175)	101,705
Balance for common	(35,175)	101,272
Earnings common share		

Primary	\$(1.51)	\$4.49
Fully Diluted	\$(1.51)	\$4.37
Common Shares:		
Full Diluted	23,349	23,195
Year-end	23,428	22,751

CONFORMIS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	67,740	57,364
Cost & expenses	98,062	101,519
Operating income	(30,322)	(44,155)
Interest income	475	367
Interest expense	2,289	1,397
Foreign currency	(1,285)	3,606
Net before taxes	(33,421)	(41,579)
Income taxes	74	143
Net income	(33,495)	(41,722)
Earnings common share		
Primary	\$(0.58)	\$(0.97)
Fully Diluted	\$(0.58)	\$(0.97)
Common Shares:		
Full Diluted	58,225	43,182
Year-end	63,638	45,293

CONMED CORP.

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Net Sales	617,191	573,837
Cost & expenses	571,709	550,078
Operating income	45,482	23,759
Net before taxes	30,359	10,436
Income taxes	5,158	1,645
Net income	25,201	8,791
Earnings common share		
Primary	\$0.90	\$0.31
Fully Diluted	\$0.87	\$0.31
Common Shares:		
Full Diluted	28,872	28,124
Year-end	28,123	27,927

CONNECTONE BANCORP INC (NEW)

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Cost & expenses	113,827	91,491
Operating income	48,824	45,248
Net before taxes	48,824	45,248
Income taxes	7,144	12,608
Net income	41,680	32,640
Earnings common share		
Primary	\$1.30	\$1.02
Fully Diluted	\$1.29	\$1.01
Common Shares:		
Full Diluted	32,313	32,167
Year-end	32,240	32,015

CONSOLIDATED COMMUNICATIONS HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	1,054,324	703,214
Cost & expenses	711,269	484,190
Deprec., depl. & amort.	328,759	187,084
Operating income	14,296	31,940
Other income (expense), net	1,961	301
Gains or losses	28,999	23,068
Net before taxes	(53,823)	(44,587)
Income taxes	(17,250)	(9,862)
Net income	(36,573)	(34,725)
Balance for common	(37,518)	(35,152)
Earnings common share		
Primary	\$(0.53)	\$(0.62)
Fully Diluted	\$(0.53)	\$(0.62)
Common Shares:		
Full Diluted	70,598	56,955
Year-end	71,253	70,836

CONTROL4 CORP

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	199,971	176,043
Cost & expenses	186,497	169,313
Operating income	13,474	6,730
Interest income	819	224
Other income (expense), net	(864)	183

Net before taxes	13,429	7,137
Income taxes	112	(2,459)
Net income	13,317	9,596
Earnings common share		
Primary	\$0.51	\$0.39
Fully Diluted	\$0.48	\$0.36
Common Shares:		
Full Diluted	27,489	26,393
Year-end	26,707	

CORBUS PHARMACEUTICALS HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):	2018	2017
Cost & expenses	42,051,681	24,141,085
Operating income	(39,156,715)	(21,700,890)
Foreign currency	52,716	(77,071)
Net income	(38,365,947)	(21,727,922)
Earnings common share		
Primary	\$(0.67)	\$(0.44)
Fully Diluted	\$(0.67)	\$(0.44)
Common Shares:		
Full Diluted	56,917,897	48,946,335
Year-end	57,237,496	50,223,010

CORE MARK HOLDING CO INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):	2018	2017
Net Sales	12,305,600	11,615,600
Cost & expenses	12,243,200	11,569,900
Operating income	54,800	39,700
Foreign currency	500	1,900
Net before taxes	44,700	33,900
Income taxes	11,300	11,200
Net income	33,400	22,700
Earnings common share		
Primary	\$0.72	\$0.49
Fully Diluted	\$0.72	\$0.49
Common Shares:		
Full Diluted	46,200	46,400
Year-end	45,809	46,191

CORNERSTONE ONDEMAND, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):	2018	2017
Total Revenues	399,644	350,029
Cost & expenses	410,011	393,849
Operating income	(10,367)	(43,820)
Interest income	6,143	2,021
Interest expense	22,826	10,015
Other income (expense), net	(2,029)	921
Net before taxes	(29,079)	(50,893)
Income taxes	1,591	1,438
Net income	(30,670)	(52,331)
Earnings common share		
Primary	\$(0.53)	\$(0.92)
Fully Diluted	\$(0.53)	\$(0.92)
Common Shares:		
Full Diluted	57,994	57,072
Year-end	58,812	57,763

CORVEL CORP

Earnings, 6 mos. to Sep 30 (Consol. - \$):	2018	2017
Total Revenues	298,574,000	274,043,000
Cost & expenses	266,762,000	247,807,000
Operating income	31,812,000	26,236,000
Net before taxes	31,812,000	26,236,000
Income taxes	7,245,000	9,068,000
Net income	24,567,000	17,168,000
Earnings common share		
Primary	\$1.30	\$0.91
Fully Diluted	\$1.29	\$0.90
Common Shares:		
Full Diluted	19,095,000	18,983,000
Year-end	18,826,375	18,824,953

CORVUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):	2018	2017
Cost & expenses	38,051	44,335
Operating income	(38,051)	(44,335)
Net income	(36,430)	(43,734)
Earnings common share		
Primary	\$(1.35)	\$(2.14)

Fully Diluted	\$(1.35)	\$(2.14)
Common Shares:		
Full Diluted	26,906	20,426
Year-end	29,282	20,944

COSTAR GROUP, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):	2018	2017
Total Revenues	876,261	711,239
Cost & expenses	685,406	574,539
Operating income	167,907	123,058
Net before taxes	174,446	116,367
Income taxes	19,621	37,876
Net income	154,825	78,491
Earnings common share		
Primary	\$4.30	\$2.42
Fully Diluted	\$4.25	\$2.40
Common Shares:		
Full Diluted	36,439	32,705
Year-end	36,426	36,145

COSTCO WHOLESALE CORP**Annual Report Consolidated Income Statement, Years Ended (\$000):**

	09/02/18	¹ 09/03/17 (revised)	08/28/16 (revised)
Net sales	138,434,000	126,172,000	116,073,000
Membership fees	3,142,000	2,853,000	2,646,000
Total revenue	141,576,000	129,025,000	118,719,000
Merchandise costs	123,152,000	111,882,000	102,901,000
Selling, general & administrative expenses	13,876,000	12,950,000	12,068,000
Preopening expenses	68,000	82,000	78,000
Operating income	4,480,000	4,111,000	3,672,000
Interest expense	159,000	134,000	133,000
Interest income, net	75,000	50,000	41,000
Foreign-currency transactions gains (losses), net	23,000	(5,000)	28,000
Other interest income & other income, net	23,000	17,000	11,000
Income before income taxes - Domestic, including Puerto Rico	3,182,000	2,988,000	2,622,000
Income before income taxes - Foreign	1,260,000	1,051,000	997,000
Income before income taxes	4,442,000	4,039,000	3,619,000
Federal income taxes provision (benefit) - current	636,000	802,000	468,000
Federal income taxes provision (benefit) - deferred	(35,000)	7,000	233,000
Total federal income taxes provision (benefit)	601,000	809,000	701,000
State income taxes provision (benefit) - current	190,000	161,000	108,000
State income taxes provision (benefit) - deferred	22,000	8,000	21,000
Total state income taxes provision (benefit)	212,000	169,000	129,000
Foreign income taxes provision (benefit) - current	487,000	389,000	398,000
Foreign income taxes provision (benefit) - deferred	(37,000)	(42,000)	15,000
Total foreign income taxes provision (benefit)	450,000	347,000	413,000
Provision for income taxes	1,263,000	1,325,000	1,243,000

Net income (loss) including noncontrolling interests	3,179,000	2,714,000	2,376,000
Net loss (income) attributable to noncontrolling interests	(45,000)	(35,000)	(26,000)
Net income attributable to Costco Wholesale Corp	3,134,000	2,679,000	2,350,000
Weighted average shares outstanding - basic	438,515	438,437	438,585
Weighted average shares outstanding - diluted	441,834	440,937	441,263
Year end shares outstanding	438,189	437,204	437,524
Net income (loss) per common share - basic	\$7.15	\$6.11	\$5.36
Net income (loss) per common share - diluted	\$7.09	\$6.08	\$5.33
Cash dividends declared per common share	\$2.14	\$8.90	\$1.70
Number of full time employees	² 143,000	² 133,000	² 126,000
Number of part time employees	² 102,000	² 98,000	² 92,000
Total number of employees	² 245,000	² 231,000	² 218,000
Number of common stockholders	² 8,829	² 8,629	² 8,572
Foreign currency translation adjustments	(192,000)	98,000	26,000

¹ For 53 weeks; ² As is; ³ As of Oct. 18, 2018; ⁴ As of October 10, 2017; ⁵ As of October 4, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	09/02/18	¹ 09/03/17 (revised)
Cash & cash equivalents	6,055,000	4,546,000
Short-term investments	1,204,000	1,233,000
Receivables, net	1,669,000	1,432,000
Merchandise inventories - United States	8,081,000	7,091,000
Merchandise inventories - Canada	1,189,000	1,040,000
Merchandise inventories - Foreign	1,770,000	1,703,000
Merchandise inventories	11,040,000	9,834,000
Other current assets	321,000	272,000
Total current assets	20,289,000	17,317,000
Land	6,193,000	5,690,000
Buildings & improvements	16,107,000	15,127,000
Equipment & fixtures	7,274,000	6,681,000
Construction in progress	1,140,000	843,000
Gross property & equipment	30,714,000	28,341,000
Less accumulated depreciation & amortization	11,033,000	10,180,000
Net property & equipment	19,681,000	18,161,000
Other assets	860,000	869,000
Total assets	40,830,000	36,347,000
Accounts payable	11,237,000	9,608,000
Accrued salaries & benefits	2,994,000	2,703,000
Accrued member rewards	1,057,000	961,000
Deferred membership fees	1,624,000	1,498,000
Other current liabilities	3,014,000	2,725,000
Total current liabilities	19,926,000	17,495,000
Senior notes	5,964,000	5,957,000
Other long-term debt	613,000	702,000
Less: current portion	90,000	86,000
Long-term debt, excluding current portion	6,487,000	6,573,000
Other liabilities	1,314,000	1,200,000

Total liabilities	27,727,000	25,268,000
Common stock	4,000	4,000
Additional paid-in capital	6,107,000	5,800,000
Accumulated other comprehensive income (loss)	(1,199,000)	(1,014,000)
Retained earnings	7,887,000	5,988,000
Total Costco Wholesale Corp stockholders' equity	12,799,000	10,778,000
Noncontrolling interests	304,000	301,000
Total equity	13,103,000	11,079,000

□ For 53 weeks; □ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Costco Wholesale Corp common.

ExDate	Amt	Declared	Record	Payable
02/11/2015	0.35	01/29/2015	02/13/2015	02/27/2015
02/05/2015	5.00	01/30/2015	02/09/2015	02/27/2015
04/29/2015	0.40	04/17/2015	05/01/2015	05/15/2015
08/12/2015	0.40	07/27/2015	08/14/2015	08/28/2015
11/10/2015	0.40	10/29/2015	11/13/2015	11/27/2015
02/10/2016	0.40	01/29/2016	02/12/2016	02/26/2016
04/27/2016	0.45	04/14/2016	04/29/2016	05/13/2016
08/10/2016	0.45	07/25/2016	08/12/2016	08/26/2016
11/02/2016	0.45	10/12/2016	11/04/2016	11/18/2016
02/08/2017	0.45	01/27/2017	02/10/2017	02/24/2017
05/08/2017	7.00	04/25/2017	05/10/2017	05/26/2017
05/10/2017	0.50	04/25/2017	05/12/2017	05/26/2017
08/16/2017	0.50	07/31/2017	08/18/2017	09/01/2017
11/16/2017	0.50	10/30/2017	11/17/2017	12/01/2017
02/15/2018	0.50	01/30/2018	02/16/2018	03/02/2018
05/10/2018	0.57	04/24/2018	05/11/2018	05/25/2018
08/30/2018	0.57	08/17/2018	08/31/2018	09/14/2018
11/08/2018	0.57	10/24/2018	11/09/2018	11/23/2018

Annual Dividends:

1. Costco Wholesale Corp common.

2015	6.56	2016	1.75	2017	8.95
2018	2.21				

COWEN INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	706,985	454,331
Cost & expenses	698,171	494,507
Operating income	(28,478)	(70,697)
Other income (expense), net	(556)	
Gains or losses	123,270	124,606
Foreign currency	250	(299)
Net before taxes	94,792	53,909
Income taxes	15,999	3,407
Net income	78,793	50,502
Balance for common	32,646	9,996
Earnings common share		
Primary	\$1.10	\$0.34
Fully Diluted	\$1.07	\$0.33
Common Shares:		
Full Diluted	30,613	30,011
Year-end	29,143	31,087

CRA INTERNATIONAL INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	308,885	273,059
Cost & expenses	280,495	250,001
Deprec., depl. & amort.	7,300	6,652
Operating income	21,090	16,406
Other income (expense), net	72	(233)
Gains or losses		250
Net before taxes	20,602	16,062
Net income	15,633	9,962
Balance for common	15,551	9,814
Earnings common share		
Primary	\$1.91	\$1.18
Fully Diluted	\$1.81	\$1.15
Common Shares:		
Full Diluted	8,615	8,530
Year-end	8,297	8,056

CRAFT BREW ALLIANCE INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales	162,199,000	161,490,000
Cost & expenses	155,619,000	158,465,000
Operating income	6,580,000	3,025,000
Interest expense	348,000	533,000
Other income (expense), net	42,000	(46,000)
Net before taxes	6,274,000	2,446,000
Income taxes	1,600,000	758,000
Net income	4,674,000	1,688,000
Earnings common share		
Primary	\$0.24	\$0.09
Fully Diluted	\$0.24	\$0.09
Common Shares:		
Full Diluted	19,525,000	19,401,000
Year-end	19,381,762	19,296,521

CRAY INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	292,593,000	225,866,000
Cost & expenses	353,083,000	295,782,000
Operating income	(60,490,000)	(69,916,000)
Interest income	2,279,000	2,732,000
Interest expense	(9,000)	77,000
Other income (expense), net	199,000	9,747,000
Net before taxes	(58,003,000)	(57,514,000)
Income taxes	348,000	(21,227,000)
Net income	(58,351,000)	(36,287,000)
Earnings common share		
Primary	\$(1.44)	\$(0.91)
Fully Diluted	\$(1.44)	\$(0.91)
Common Shares:		
Full Diluted	40,611,000	40,082,000
Year-end	40,825,905	

CREE INC

Earnings, 3 mos. to (Consol. - \$):

	09/23/18	09/24/17
Total Revenues	408,267,000	360,398,000
Cost & expenses	399,247,000	367,714,000
Operating income	525,000	(14,108,000)
Other income (expense), net	98,000	236,000
Gains or losses	(6,645,000)	(3,222,000)
Foreign currency	(597,000)	767,000
Net before taxes	(8,980,000)	(15,176,000)
Income taxes	2,154,000	4,697,000
Net income	(11,134,000)	(19,873,000)
Earnings common share		
Primary	\$(0.11)	\$(0.20)
Fully Diluted	\$(0.11)	\$(0.20)
Common Shares:		
Full Diluted	101,884,000	97,811,000
Year-end	102,520,000	98,039,000

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	336,317,000
Inventories	306,389,000
Current assets	1,229,798,000
Net property & equip.	668,299,000
Total assets	2,967,614,000
Liabilities:	
Current liabilities	293,596,000
Long-term debt	452,590,000
Stockholders' equity	2,193,820,000
Net current assets	936,202,000

CROCS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	872,216	824,401
Cost & expenses	795,335	776,688
Operating income	76,881	47,713
Interest income	847	576
Interest expense	371	539
Other income (expense), net	229	187
Foreign currency	1,587	181
Net before taxes	79,173	48,118
Income taxes	17,850	13,519
Net income	61,323	34,599
Balance for common	41,150	19,336
Earnings common share		
Primary	\$0.60	\$0.26
Fully Diluted	\$0.58	\$0.26
Common Shares:		

Full Diluted	71,104	74,160
Year-end	67,600	

CROSS COUNTRY HEALTHCARE INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Cost & expenses	595,578	619,978
Operating income	11,235	18,071
Interest expense	4,225	2,975
Other income (expense), net	333	(4,853)
Gains or losses		1,581
Net before taxes	7,343	11,824
Income taxes	3,717	1,278
Net income	3,626	10,546
Balance for common	2,740	9,563
Earnings common share		
Primary	\$0.08	\$0.28
Fully Diluted	\$0.08	\$0.24
Common Shares:		
Full Diluted	35,881	36,179
Year-end	36,251	35,758

CSG SYSTEMS INTERNATIONAL INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	627,792	584,378
Cost & expenses	538,992	494,766
Operating income	75,507	79,637
Interest expense	13,202	12,638
Other income (expense), net	(3,141)	(3,270)
Net before taxes	61,420	66,039
Income taxes	16,188	19,641
Net income	45,232	46,398
Earnings common share		
Primary	\$1.39	\$1.43
Fully Diluted	\$1.37	\$1.41
Common Shares:		
Full Diluted	32,939	32,825
Year-end	33,451	33,575

CUMBERLAND PHARMACEUTICALS INC

Acquisition Completed On Nov. 12, 2018, Theravance Biopharma, Inc. ("Theravance") direct or indirect wholly-owned subsidiaries, Theravance Biopharma Ireland Ltd. and Theravance Biopharma US, Inc. (collectively, "Sellers,") sold Theravance's assets related to the manufacture, marketing and sale of Theravance's proprietary antibiotic, VIBATIV® (telavancin) ("VIBATIV" or the "Product"), consisting, among other things, (i) intellectual property rights relating to the Product, (ii) active pharmaceutical ingredient for the Product, work-in-process and finished drug product, (iii) the U.S. marketing authorization for the Product, (iv) certain assigned contracts relating to the manufacture and commercialization of the Product, and (v) books and records related to the Product, to Co., for \$20,000,000. In addition, pursuant to the Agreement, Co. would pay Sellers (i) \$5,000,000 on or before Apr. 1, 2019 and (ii) tiered royalties of up to 20% of U.S. net sales of the Product until such time as royalties cumulatively total \$100,000,000. Co. also assumed certain clinical study obligations related to the Product and post-closing liabilities and obligations relating to the Product as described in the Agreement.

CURIS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	7,673	6,636
Cost & expenses	31,432	48,939
Operating income	(24,185)	(42,632)
Other income (expense), net		(104)
Net income	(26,634)	(45,289)
Earnings common share		
Primary	\$(0.80)	\$(1.57)
Fully Diluted	\$(0.80)	\$(1.57)
Common Shares:		
Full Diluted	33,117	28,824
Year-end	33,113	28,469

CUTERA INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	117,251	103,861
Cost & expenses	125,153	97,328
Operating income	(7,902)	6,533
Net before taxes	(7,982)	7,279
Income taxes	(3,505)	166
Net income	(4,477)	7,113

Earnings common share		
Primary	\$(0.33)	\$0.51
Fully Diluted	\$(0.33)	\$0.48
Common Shares:		
Full Diluted	13,717	14,733
Year-end	13,891	13,906

CYBEROPTICS CORP.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	46,657	40,157
Cost & expenses	44,736	39,147
Operating income	1,886	960
Net before taxes	2,078	819
Income taxes	444	10
Net income	1,634	809
Earnings common share		
Primary	\$0.23	\$0.12
Fully Diluted	\$0.23	\$0.11
Common Shares:		
Full Diluted	7,176	7,041
Year-end	7,064	6,973

CYPRESS SEMICONDUCTOR CORP.

Earnings, 9 mos. to (Consol. – \$000):

	09/30/18	10/01/17
Total Revenues	1,879,366	1,730,224
Cost & expenses	1,717,678	1,693,825
Operating income	161,688	36,399
Other income (expense), net	4,203	4,800
Equity earnings	10,873	14,842
Net before taxes	114,332	(17,986)
Income taxes	15,829	13,930
Net income	87,630	(46,758)
Earnings common share		
Primary	\$0.24	\$(0.14)
Fully Diluted	\$0.23	\$(0.14)
Common Shares:		
Full Diluted	373,064	329,787
Year-end	361,665	

CYRUSONE INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	600,100	491,500
Cost & expenses	289,000	303,200
Operating income	74,900	200
Interest expense	69,400	48,000
Other income (expense), net	103,500	(36,500)
Net before taxes	109,000	(84,300)
Income taxes	2,000	2,000
Net income	107,000	(86,300)
Balance for common	106,200	(87,000)
Earnings common share		
Primary	\$1.09	\$(0.99)
Fully Diluted	\$1.08	\$(0.99)
Common Shares:		
Full Diluted	98,400	87,500
Year-end	105,834	91,289

CYTKINETICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	22,124	13,386
Cost & expenses	89,582	90,255
Operating income	(67,458)	(76,869)
Net income	(79,821)	(87,305)
Earnings common share		
Primary	\$(1.47)	\$(1.82)
Fully Diluted	\$(1.47)	\$(1.82)
Common Shares:		
Full Diluted	54,329	47,879
Year-end	54,642	53,863

CYTMX THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	48,031	44,550
Cost & expenses	100,095	89,562
Operating income	(52,064)	(45,012)
Other income (expense), net	(50)	(101)
Net before taxes	(46,980)	(43,713)
Income taxes	5,391	7
Net income	(52,371)	(43,720)

Earnings common share		
Primary	\$(1.29)	\$(1.19)
Fully Diluted	\$(1.29)	\$(1.19)
Common Shares:		
Full Diluted	40,528	36,757
Year-end	44,997	

DAWSON GEOPHYSICAL CO (NEW)

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	126,486,000	119,114,000
Cost & expenses	116,454,000	121,306,000
Operating income	(13,165,000)	(31,942,000)
Other income (expense), net	172,000	136,000
Net before taxes	(12,980,000)	(31,637,000)
Income taxes	(389,000)	(4,635,000)
Net income	(12,591,000)	(27,002,000)
Earnings common share		
Primary	\$(0.55)	\$(1.19)
Fully Diluted	\$(0.55)	\$(1.19)
Common Shares:		
Full Diluted	22,901,558	22,765,548
Year-end	22,943,639	

DECIPHERA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	70,269	30,597
Operating income	(70,269)	(30,597)
Interest expense	64	72
Other income (expense), net	2,778	297
Net income	(67,555)	(30,372)
Earnings common share		
Primary	\$(1.95)	\$(2.61)
Fully Diluted	\$(1.95)	\$(2.61)
Common Shares:		
Full Diluted	34,624	11,626
Year-end	37,661	32,592

DEEP DOWN INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	11,722,000	14,458,000
Cost & expenses	13,193,000	15,112,000
Operating income	(1,659,000)	(892,000)
Other income (expense), net		94,000
Gains or losses	439,000	574,000
Net before taxes	(1,192,000)	(178,000)
Income taxes	15,000	15,000
Net income	(1,207,000)	(193,000)
Earnings common share		
Primary	\$(0.09)	\$(0.01)
Fully Diluted	\$(0.09)	\$(0.01)
Common Shares:		
Full Diluted	13,507,000	15,074,000
Year-end	15,738,660	13,436,243

DENTSPLY SIRONA INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	2,926,600	2,902,400
Cost & expenses	3,966,500	3,758,300
Operating income	(1,039,900)	(855,900)
Interest income	1,600	1,700
Interest expense	27,900	28,700
Other income (expense), net	30,400	(7,700)
Net before taxes	(1,035,800)	(890,600)
Income taxes	(23,400)	9,500
Net income	(1,012,400)	(900,100)
Earnings common share		
Primary	\$(4.50)	\$(3.92)
Fully Diluted	\$(4.50)	\$(3.92)
Common Shares:		
Full Diluted	224,900	229,600
Year-end	222,500	229,600

DERMIRA INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	40,096	3,198
Net Sales	717	
Cost & expenses	183,581	249,848
Operating income	(143,485)	(246,650)
Interest expense	12,408	4,184

Net before taxes	(149,924)	
Income taxes	(194)	
Net income	(149,730)	(247,249)
Earnings common share		
Primary	\$(3.57)	\$(6.15)
Fully Diluted	\$(3.57)	\$(6.15)
Common Shares:		
Full Diluted	41,939	40,172
Year-end	42,121	41,674

DEXCOM INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	693,600,000	497,500,000
Cost & expenses	715,300,000	552,000,000
Operating income	(21,700,000)	(54,500,000)
Interest expense	14,500,000	8,100,000
Other income (expense), net	(4,600,000)	3,500,000
Gains or losses	85,000,000	
Net before taxes	50,400,000	(57,200,000)
Income taxes	(2,200,000)	(16,400,000)
Net income	52,600,000	(40,800,000)
Earnings common share		
Primary	\$0.60	\$(0.47)
Fully Diluted	\$0.59	\$(0.47)
Common Shares:		
Full Diluted	89,300,000	86,100,000
Year-end	88,800,000	86,900,000

DIAMONDBACK ENERGY, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	1,544,497,000	805,917,000
Cost & expenses	337,296,000	192,879,000
Operating income	815,800,000	391,357,000
Interest expense	49,345,000	29,662,000
Other income (expense), net	89,170,000	9,472,000
Gains or losses	(134,140,000)	20,376,000
Net before taxes	721,485,000	391,543,000
Income taxes	82,750,000	4,393,000
Net income	638,735,000	387,150,000
Earnings common share		
Primary	\$5.47	\$3.81
Fully Diluted	\$5.45	\$3.80
Common Shares:		
Full Diluted	98,820,000	96,752,000
Year-end	98,673,563	98,167,289

DIGIMARC CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	15,965	20,355
Cost & expenses	41,227	38,258
Operating income	(25,262)	(17,903)
Other income (expense), net	799	408
Net before taxes	(24,463)	(17,495)
Income taxes	29	(94)
Net income	(24,492)	(17,401)
Balance for common	(24,492)	(17,401)
Earnings common share		
Primary	\$(2.16)	\$(1.67)
Fully Diluted	\$(2.16)	\$(1.67)
Common Shares:		
Full Diluted	11,333	10,410
Year-end	11,888	11,324

DIODES, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	899,543,000	785,774,000
Cost & expenses	775,058,000	714,774,000
Operating income	110,622,000	56,902,000
Interest income	1,431,000	992,000
Other income (expense), net	6,073,000	1,128,000
Foreign currency	(3,384,000)	(6,734,000)
Net before taxes	107,123,000	41,795,000
Income taxes	31,726,000	11,651,000
Net income	75,397,000	30,144,000
Balance for common	74,502,000	28,846,000
Earnings common share		
Primary	\$1.50	\$0.59
Fully Diluted	\$1.46	\$0.58
Common Shares:		
Full Diluted	50,883,000	50,061,000
Year-end	50,190,959	49,091,693

DISCOVERY INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	7,744,000	5,009,000
Cost & expenses	5,520,000	3,219,000
Deprec., depl. & amort.	1,001,000	240,000
Operating income	1,223,000	1,550,000
Interest income	15,000	
Interest expense	558,000	318,000
Other income (expense), net	(104,000)	(178,000)
Gains or losses	11,000	(79,000)
Net before taxes	528,000	913,000
Income taxes	146,000	89,000
Net income	382,000	824,000
Earnings common share		
Primary	\$0.47	\$1.40
Fully Diluted	\$0.47	\$1.39
Common Shares:		
Full Diluted	679,000	581,000
Year-end	523,500	379,055

DISH NETWORK CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	10,314,473	10,907,447
Cost & expenses	8,108,645	8,973,348
Operating income	1,664,869	1,308,474
Interest income	30,461	33,979
Interest expense	11,235	59,809
Other income (expense), net	(5,880)	895
Gains or losses	15,869	44,467
Invest. income	2,108	2,811
Net before taxes	1,696,192	1,330,817
Income taxes	397,987	566,715
Net income	1,298,205	764,102
Earnings common share		
Primary	\$2.65	\$1.53
Fully Diluted	\$2.35	\$1.42
Common Shares:		
Full Diluted	525,752	521,639
Year-end	467,672	466,353

DORMAN PRODUCTS INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/29/18	09/30/17
Net Sales	713,363	675,502
Cost & expenses	586,857	542,671
Operating income	126,506	132,831
Other income (expense), net	286	472
Net before taxes	126,792	133,303
Income taxes	27,789	48,671
Net income	99,003	84,632
Earnings common share		
Primary	\$2.98	\$2.48
Fully Diluted	\$2.98	\$2.47
Common Shares:		
Full Diluted	33,267	34,202
Year-end	33,140	33,801

DUNKIN' BRANDS GROUP INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/29/18	09/30/17
Total Revenues	1,001,993	960,605
Cost & expenses	655,713	630,627
Operating income	315,273	298,881
Gains or losses	(700)	370
Net before taxes	222,714	226,429
Income taxes	45,997	89,874
Net income	176,717	136,555
Earnings common share		
Primary	\$2.10	\$1.50
Fully Diluted	\$2.07	\$1.48
Common Shares:		
Full Diluted	85,366	92,387
Year-end	82,412	

DURECT CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	14,937	29,632
Cost & expenses	31,664	40,439
Operating income	(16,727)	(10,807)
Net income	(18,023)	(11,930)
Earnings common share		

Primary	\$(0.11)	\$(0.08)
Fully Diluted	\$(0.11)	\$(0.08)
Common Shares:		
Full Diluted	159,091	143,873
Year-end	162,060	148,546

EAGLE PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	157,258,000	189,922,000
Net Sales	50,042,000	34,895,000
Cost & expenses	136,372,000	126,374,000
Operating income	20,886,000	63,548,000
Interest income	36,000	52,000
Interest expense	2,118,000	594,000
Net before taxes	18,804,000	63,006,000
Income taxes	(509,000)	20,148,000
Net income	19,313,000	42,858,000
Earnings common share		
Primary	\$1.30	\$2.82
Fully Diluted	\$1.25	\$2.68
Common Shares:		
Full Diluted	15,482,768	16,015,051
Year-end	14,920,617	14,920,998

EASTERN CO.**Earnings, 9 mos. to** (Consol. – \$):

	09/29/18	09/30/17
Net Sales	177,663,291	150,095,975
Cost & expenses	164,362,490	141,799,671
Operating income	13,300,801	8,296,304
Interest expense	918,897	659,884
Other income (expense), net	673,287	69,278
Net before taxes	13,055,191	7,705,698
Income taxes	2,929,858	2,491,674
Net income	10,125,333	5,214,024
Earnings common share		
Primary	\$1.62	\$0.83
Fully Diluted	\$1.61	\$0.83
Common Shares:		
Full Diluted	6,291,649	6,294,957
Year-end	6,246,378	6,261,415

EBAY INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	7,869,000	7,220,000
Cost & expenses	6,292,000	5,591,000
Operating income	1,541,000	1,601,000
Net before taxes	2,202,000	1,714,000
Income taxes	437,000	130,000
Net income	1,770,000	1,584,000
Earnings common share		
Primary	\$1.78	\$1.48
Fully Diluted	\$1.76	\$1.45
Common Shares:		
Full Diluted	1,005,000	1,091,000
Year-end	963,000	

EBIX INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	361,499	259,290
Cost & expenses	242,186	170,827
Operating income	111,449	80,140
Interest income	309	1,614
Interest expense	18,064	9,038
Other income (expense), net	60	
Foreign currency	(2,919)	2,705
Net before taxes	90,835	75,421
Income taxes	6,027	363
Net income	84,808	75,058
Earnings common share		
Primary	\$2.69	\$2.34
Fully Diluted	\$2.67	\$2.33
Common Shares:		
Full Diluted	31,638	31,743
Year-end	31,501	31,464

ECHOSTAR CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,560,702	1,379,460
Cost & expenses	913,334	845,566

Operating income	202,810	153,955
Interest expense	186,371	156,498
Other income (expense), net	(7,852)	23,831
Invest. income	33,426	30,664
Net before taxes	98,250	82,294
Income taxes	25,235	9,073
Income contin. oper.		73,221
Income discont. oper.		6,454
Net income	73,015	79,675
Balance for common	71,723	80,533
Earnings common share		
Primary	\$0.75	\$0.84
Fully Diluted	\$0.74	\$0.83
Common Shares:		
Full Diluted	96,971	96,626
Year-end	96,235	95,719

EDGE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Cost & expenses	37,053,686	35,843,480
Operating income	(37,053,686)	(35,843,480)
Interest income	696,035	479,297
Interest expense	1,425,255	1,591,998
Net income	(37,782,906)	(36,956,181)
Earnings common share		
Primary	\$(1.21)	\$(1.23)
Fully Diluted	\$(1.21)	\$(1.23)
Common Shares:		
Full Diluted	31,198,804	30,091,640
Year-end	31,328,128	30,859,200

EDITAS MEDICINE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	113,292	93,552
Operating income	(87,474)	(83,491)
Other income (expense), net	332	458
Net income	(84,899)	(84,135)
Balance for common	(84,899)	(84,135)
Earnings common share		
Primary	\$(1.81)	\$(2.13)
Fully Diluted	\$(1.81)	\$(2.13)
Common Shares:		
Full Diluted	46,791	39,559
Year-end	47,504	

EDUCATIONAL DEVELOPMENT CORP.**Earnings, 6 mos. to Aug 31**(Consol. – \$):

	2018	2017
Total Revenues	54,703,300	51,128,100
Cost & expenses	50,463,200	47,685,500
Operating income	4,531,400	3,664,900
Interest expense	483,400	576,200
Other income (expense), net	774,700	798,500
Net before taxes	4,531,400	3,664,900
Income taxes	1,224,100	1,402,700
Net income	3,307,300	2,262,200
Balance for common	3,307,300	2,262,200
Earnings common share		
Primary	\$0.40	\$0.28
Fully Diluted	\$0.40	\$0.28
Common Shares:		
Full Diluted	8,188,920	8,184,507
Year-end	8,189,702	

EHEALTH INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	116,478	107,588
Cost & expenses	154,027	137,062
Operating income	(39,094)	(30,254)
Other income (expense), net	776	875
Net before taxes	(38,318)	(29,379)
Income taxes	(12,487)	(26,777)
Net income	(25,831)	(2,602)
Earnings common share		
Primary	\$(1.36)	\$(0.14)
Fully Diluted	\$(1.36)	\$(0.14)
Common Shares:		
Full Diluted	19,059	18,473
Year-end	19,406	

EL POLLO LOCO HOLDINGS INC**Earnings, 9 mos. to** (Consol. – \$000):

	09/26/18	09/27/17
Total Revenues	329,567	306,499
Cost & expenses	294,975	276,364
Operating income	21,529	16,489
Interest income	29	17
Interest expense	2,717	2,488
Other income (expense), net	777	(107)
Net before taxes	19,618	13,911
Income taxes	5,202	5,254
Net income	14,416	8,657
Earnings common share		
Primary	\$0.37	\$0.23
Fully Diluted	\$0.37	\$0.22
Common Shares:		
Full Diluted	39,102	39,101
Year-end	39,067	38,653

ELDORADO RESORTS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,384,247	1,050,897
Cost & expenses	1,061,666	916,209
Operating income	223,377	65,053
Interest expense	96,579	69,380
Other income (expense), net	(162)	(37,347)
Net before taxes	126,636	(41,674)
Income taxes	31,281	(26,116)
Net income	95,355	(15,558)
Earnings common share		
Primary	\$1.23	\$(0.24)
Fully Diluted	\$1.22	\$(0.24)
Common Shares:		
Full Diluted	78,208	63,822
Year-end	77,391	

ELECTRONIC ARTS, INC.

Earnings, 6 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	2,423,000	2,408,000
Cost & expenses	1,853,000	1,703,000
Operating income	558,000	702,000
Net before taxes	595,000	711,000
Income taxes	47,000	89,000
Net income	548,000	622,000
Earnings common share		
Primary	\$1.80	\$2.01
Fully Diluted	\$1.77	\$1.99
Common Shares:		
Full Diluted	309,000	313,000
Year-end	304,000	308,000

ELLIS (PERRY) INTERNATIONAL INC

Merger Completed On Oct. 22, 2018, Feldenkreis Holdings LLC ("Parent"), an entity owned by George Feldenkreis, Co.'s founder and member of the board of Director, and Oscar Feldenkreis, Co.'s Chief Executive Officer, President and a director of Co., wholly-owned subsidiary, GF Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of common stock, par value \$.01 per share ("Co. Common Stock"), of Co. owned immediately prior to the Effective Time, other than as provided below, was converted into the right to receive \$27.50 in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes. The following shares of Co. Common Stock were not converted into the right to receive the per share merger consideration in connection with the Merger: (i) shares of Co. Common Stock held by Co. or any of its wholly-owned subsidiaries or Parent or its subsidiaries; (ii) shares of Co. Common Stock held by the Rollover Investors; and (iii) shares of Co. Common Stock whose holders did not vote in favor of adopting the Merger Agreement and have demanded and perfected their appraisal rights in accordance with, and have complied in all respects with, the Florida Business Corporation Act ("Dissenting Shares"). In addition, (i) each stock option and stock appreciation right, whether or not then exercisable or vested, was converted into the right to receive at the closing cash equal to the product of (a) the excess, if any, of the merger consideration over the per share exercise price of the applicable option or stock appreciation right and (b) the number of shares of Co. Common Stock underlying such option or stock appreciation right; (ii) each restricted stock award not subject to any performance-based vesting condition held by an employee was automatically vested and converted into the right to receive at the closing cash equal

to the product of (a) the per share merger consideration and (b) the number of shares of Co. Common Stock subject to such restricted stock award; (iii) each restricted stock award not subject to any performance-based vesting condition held by a non-employee member of the board of directors of Co. vested on a prorated basis based on the number of days that elapsed since the grant date of such award and was converted into the right to receive at the closing cash equal to the product of (a) the per share merger consideration and (b) such pro-rated number of shares; and (iv) with the exception of certain management members described below, each restricted stock award subject to any performance-based vesting condition was converted into a right to receive a restricted cash award from the surviving corporation that would vest and be payable (without regard to any performance goals but subject to applicable service vesting conditions in the prior award) at the end of its applicable vesting period, with the cash payment therefor equal to the product of: (a) the per share merger consideration and (b) the number of shares of Co. Common Stock subject to such restricted stock award that would have vested based on target level achievement. Such restricted cash award would accelerate upon a termination without cause or for good reason prior to the scheduled vesting date. Each restricted stock award subject to any performance-based vesting condition held by Mr. Jorge Narino or Ms. Tricia McDermott Thompkins was converted into a right to receive at the closing a cash payment equal to the product of: (a) the per share merger consideration and (b) the number of shares of Co. Common Stock subject to such restricted stock award that would have vested based on target level achievement. All outstanding restricted stock units held by George Feldenkreis were cancelled. The aggregate merger consideration was approximately \$437,000,000.

ELLIS (PERRY) INTERNATIONAL INC

Privately Held On Oct. 23, 2018, Co. was privately held.

EMMIS COMMUNICATIONS CORP

Earnings, 6 mos. to Aug 31(Consol. – \$000):

	2018	2017
Total Revenues	60,062	83,012
Cost & expenses	20,792	(6,279)
Operating income	37,692	87,432
Interest expense	4,356	9,214
Other income (expense), net	(719)	(2,509)
Net before taxes	32,617	75,709
Income taxes	7,946	4,372
Net income	24,671	71,337
Earnings common share		
Primary	\$1.85	\$5.67
Fully Diluted	\$1.71	\$5.59
Common Shares:		
Full Diluted	13,495	12,463
Year-end	12,792	

EMPIRE RESORTS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	142,606	50,668
Cost & expenses	177,250	69,583
Operating income	(59,175)	(20,030)
Interest income	635	2,337
Net income	(91,925)	(34,239)
Balance for common	(92,021)	(34,335)
Earnings common share		
Primary	\$(2.82)	\$(1.11)
Fully Diluted	\$(2.82)	\$(1.11)
Common Shares:		
Full Diluted	32,653	30,975
Year-end	32,717	31,178

ENDURANCE INTERNATIONAL GROUP HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	862,896	882,617
Cost & expenses	751,101	857,446
Operating income	111,795	25,171
Interest expense	111,923	121,022
Other income (expense), net		(600)
Equity earnings	2	(72)
Net before taxes	592	(95,945)
Income taxes	8,826	11,384
Net income	(8,236)	(107,257)
Earnings common share		
Primary	\$(0.06)	\$(0.84)
Fully Diluted	\$(0.06)	\$(0.84)
Common Shares:		
Full Diluted	141,947	136,688
Year-end	143,306	

ENSIGN GROUP INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,502,884	1,361,612
Cost & expenses	1,373,698	1,273,758
Operating income	94,041	55,142
Interest income	1,477	973
Interest expense	11,471	10,017
Net before taxes	84,047	46,098
Income taxes	18,078	16,487
Net income	65,969	29,611
Earnings common share		
Primary	\$1.27	\$0.58
Fully Diluted	\$1.22	\$0.56
Common Shares:		
Full Diluted	54,176	52,674
Year-end	52,248	51,082

ENTEGRIS INC

Earnings, 9 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Net Sales	1,148,855	991,970
Cost & expenses	882,372	788,302
Operating income	221,381	170,665
Interest income	2,613	323
Interest expense	24,442	24,418
Other income (expense), net	(4,826)	(3,762)
Net before taxes	194,726	142,808
Income taxes	34,755	29,401
Net income	159,971	113,407
Earnings common share		
Primary	\$1.13	\$0.80
Fully Diluted	\$1.12	\$0.79
Common Shares:		
Full Diluted	143,308	143,472
Year-end	141,607	141,474

EPLUS INC

Earnings, 6 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	701,575,000	744,719,000
Cost & expenses	651,003,000	691,192,000
Operating income	45,041,000	49,335,000
Other income (expense), net	419,000	130,000
Net before taxes	45,460,000	49,465,000
Income taxes	12,184,000	18,821,000
Net income	33,276,000	30,644,000
Earnings common share		
Primary	\$2.47	\$2.21
Fully Diluted	\$2.45	\$2.19
Common Shares:		
Full Diluted	13,597,000	14,021,000
Year-end	13,727,000	14,171,000

EQUILLIUM INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

	2017
Research & development	1,333,721
General & administrative expenses	378,328
Total operating expenses	1,712,049
Income (loss) from operations	(1,712,049)
Interest expense	379,385
Change in fair value of Biocon anti-dilution right	170,440
Total other income (expense)	(549,825)
Net income (loss)	(2,261,874)
Weighted average shares outstanding - basic	8,030,029
Weighted average shares outstanding - diluted	8,030,029
Year end shares outstanding	10,708,074
Net earnings (loss) per share - basic	\$(0.28)
Net earnings (loss) per share - diluted	\$(0.28)
Total number of employees	7

From March 16, 2017 (inception); As of June 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

	2017
Cash & cash equivalents	7,103,553
Prepaid expenses & other current assets	45,813
Total current assets	7,149,366

Property & equipment, net	2,077
Total assets	7,151,443
Accounts payable	243,741
Accrued payroll & other employee benefits	15,548
Accrued interest	88,372
Preclinical studies	36,000
Accrued taxes	184,527
Other accruals	632
Accrued expenses	325,079
Total current liabilities	568,820
Long term convertible promissory notes	6,994,847
Long-term convertible promissory notes, related party	1,064,019
Biocon anti-dilution right	775,842
Total liabilities	9,403,528
Common stock	124
Additional paid-in capital	9,665
Retained earnings (accumulated deficit)	(2,261,874)
Total shareholders' (deficit) equity	(2,252,085)

Recent Dividends:**1. Equillium Inc common.**

No dividends paid.

Annual Dividends:**1. Equillium Inc common.**

No dividends paid.

EQUILLIUM INC**Earnings, 6 mos. to Jun 30(Consol. - \$):**

	2018	2017
Cost & expenses	2,161,608	988,537
Operating income	(2,161,608)	(988,537)
Interest income	29,926	
Interest expense	1,108,197	7,069
Other income (expense), net	(102,280)	(18,887)
Net income	(3,342,159)	(1,014,493)
Earnings common share		
Primary	\$(0.31)	\$(0.19)
Fully Diluted	\$(0.31)	\$(0.19)
Common Shares:		
Full Diluted	10,711,788	5,307,596
Year-end	10,975,764	

EQUINIX INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,761,571	3,168,207
Cost & expenses	3,054,905	2,591,236
Operating income	706,666	576,971
Interest income	11,480	9,820
Interest expense	391,516	352,554
Other income (expense), net	(29,668)	(41,558)
Net before taxes	296,962	192,679
Income taxes	41,625	24,912
Net income	255,337	167,767
Earnings common share		
Primary	\$3.21	\$2.20
Fully Diluted	\$3.19	\$2.18
Common Shares:		
Full Diluted	79,956	76,948
Year-end	79,993	78,234

ESCALADE, INC.**Earnings, 9 mos. to (Consol. - \$000):**

	10/06/18	10/07/17
Net Sales	124,788	128,648
Cost & expenses	114,921	117,980
Operating income	8,800	9,456
Interest expense	390	601
Other income (expense), net	29	846
Gains or losses	13,020	
Net before taxes	21,459	9,701
Income taxes	4,597	3,099
Net income	16,862	6,602
Earnings common share		
Primary	\$1.17	\$0.46
Fully Diluted	\$1.17	\$0.46
Common Shares:		
Full Diluted	14,447	14,380
Year-end	14,440	14,371

ESSENDANT INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	3,788,907	3,839,018
Cost & expenses	3,835,369	4,090,070
Operating income	(46,462)	(251,052)
Net before taxes	(72,213)	(272,377)
Income taxes	(16,181)	(6,943)
Net income	(56,032)	(265,434)
Earnings common share		
Primary	\$(1.52)	\$(7.23)
Fully Diluted	\$(1.52)	\$(7.23)
Common Shares:		
Full Diluted	36,940	36,692
Year-end	37,643	37,616

ETSY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	403,665	304,963
Cost & expenses	358,368	311,357
Operating income	45,297	(6,394)
Foreign currency	(2,973)	26,952
Net before taxes	32,202	13,999
Income taxes	(4,038)	(23,051)
Net income	36,240	37,050
Earnings common share		
Primary	\$0.30	\$0.32
Fully Diluted	\$0.29	\$0.31
Common Shares:		
Full Diluted	126,497	121,347
Year-end	120,245	121,067

EURONET WORLDWIDE INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,887,244	1,647,777
Cost & expenses	1,521,765	1,353,379
Deprec., depl. & amort.	78,726	69,520
Operating income	286,753	224,878
Interest income	1,000	2,009
Interest expense	28,936	25,058
Other income (expense), net	(117)	
Gains or losses	26	35
Foreign currency	(21,459)	21,035
Net before taxes	237,267	222,899
Income taxes	65,031	43,130
Net income	172,236	179,769
Earnings common share		
Primary	\$3.36	\$3.43
Fully Diluted	\$3.17	\$3.23
Common Shares:		
Full Diluted	54,521	55,583
Year-end	51,459	

EVELO BIOSCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	42,110	19,464
Operating income	(42,110)	(19,464)
Other income (expense), net	(406)	(224)
Net income	(41,503)	(19,904)
Balance for common	(45,440)	(24,259)
Earnings common share		
Primary	\$(2.45)	\$(6.52)
Fully Diluted	\$(2.45)	\$(6.52)
Common Shares:		
Full Diluted	18,532	3,722
Year-end	31,758	

EXONE CO. (THE)**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	39,339	37,555
Cost & expenses	54,789	55,386
Operating income	(15,450)	(17,831)
Interest expense	179	69
Other income (expense), net	936	(134)
Net before taxes	(14,693)	(18,034)
Income taxes	52	23
Net income	(14,745)	(18,057)
Earnings common share		
Primary	\$(0.91)	\$(1.13)
Fully Diluted	\$(0.91)	\$(1.13)
Common Shares:		
Full Diluted	16,157	16,048
Year-end	16,233	16,092

EXPEDIA GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	8,664,000	7,741,000
Cost & expenses	7,831,000	7,026,000
Operating income	618,000	511,000
Interest income	61,000	25,000
Interest expense	149,000	130,000
Other income (expense), net	(101,000)	(65,000)
Net before taxes	429,000	341,000
Income taxes	56,000	22,000
Net income	373,000	319,000
Earnings common share		
Primary	\$2.59	\$2.13
Fully Diluted	\$2.54	\$2.06
Common Shares:		
Full Diluted	153,404	156,520
Year-end	149,220	

EXPRESS SCRIPTS HOLDING CO**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	72,212,000	70,774,200
Operating income	3,762,400	3,911,600
Net before taxes	3,339,900	3,500,400
Income taxes	760,800	1,299,600
Net income	2,579,100	2,200,800
Earnings common share		
Primary	\$4.57	\$3.74
Fully Diluted	\$4.54	\$3.72
Common Shares:		
Full Diluted	566,800	588,400
Year-end	563,600	566,400

EXTENDED STAY AMERICA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	985,344	980,220
Cost & expenses	522,997	538,140
Operating income	302,695	269,291
Other income (expense), net	(48)	426
Net before taxes	207,575	172,759
Income taxes	35,218	40,721
Net income	172,357	132,038
Balance for common	151,810	128,752
Earnings common share		
Primary	\$0.80	\$0.67
Fully Diluted	\$0.80	\$0.66
Common Shares:		
Full Diluted	190,111	194,001
Year-end	188,517	192,294

EXTREME NETWORKS INC**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	239,886	211,715
Cost & expenses	242,763	205,609
Operating income	(5,018)	4,492
Interest income	394	647
Interest expense	3,526	2,215
Other income (expense), net	487	3,127
Net before taxes	(7,663)	6,051
Income taxes	1,402	1,675
Net income	(9,065)	4,376
Earnings common share		
Primary	\$(0.08)	\$0.04
Fully Diluted	\$(0.08)	\$0.04
Common Shares:		
Full Diluted	117,368	118,431
Year-end	118,270	113,305

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	140,167
Inventories	55,580
Current assets	395,801
Net property & equip.	76,224
Total assets	731,884
Liabilities:	
Current liabilities	322,040
Long-term debt	176,498
Stockholders' equity	117,131
Net current assets	73,761

FARO TECHNOLOGIES INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	290,783,000	254,494,000
Cost & expenses	277,408,000	246,248,000
Deprec., depl. & amort.	13,467,000	12,075,000
Operating income	(92,000)	(3,829,000)
Other income (expense), net	(868,000)	(320,000)
Net before taxes	(755,000)	(3,900,000)
Income taxes	73,000	(442,000)
Net income	(828,000)	(3,458,000)
Earnings common share		
Primary	\$(0.05)	\$(0.21)
Fully Diluted	\$(0.05)	\$(0.21)
Common Shares:		
Full Diluted	16,976,459	16,697,729
Year-end	17,252,160	16,711,152

FASTENAL CO.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	3,733,500,000	3,020,000,000
Cost & expenses	2,967,700,000	2,623,500,000
Operating income	765,800,000	678,500,000
Interest income	300,000	300,000
Interest expense	8,900,000	6,500,000
Net before taxes	757,200,000	672,300,000
Income taxes	174,100,000	246,100,000
Net income	583,100,000	426,200,000
Earnings common share		
Primary	\$2.03	\$1.48
Fully Diluted	\$2.03	\$1.48
Common Shares:		
Full Diluted	287,458,408	288,591,574
Year-end	287,056,618	287,383,174

FATE THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	53,430	32,960
Operating income	(50,351)	(29,881)
Interest income	1,046	400
Interest expense	1,266	856
Other income (expense), net		(118)
Net income	(50,571)	(30,455)
Earnings common share		
Primary	\$(0.95)	\$(0.74)
Fully Diluted	\$(0.95)	\$(0.74)
Common Shares:		
Full Diluted	53,365	41,408
Year-end	64,503	

FEDERAL SCREW WORKS**Annual Report****Consolidated Income Statement, Years Ended Jun. 30 (\$):**

	2018	2017	2016
Net sales	75,408,220	77,341,472	77,524,869
Cost of products sold	67,687,428	69,446,900	69,195,437
Selling, general & administrative	3,252,879	4,081,036	4,082,603
Interest expense	552,185	605,876	781,999
Other income (expense)	99,351	805,011	745,315
Earnings (loss) before income taxes	4,015,079	4,012,671	4,210,145
Federal income tax expense (benefit)	171,827	939,248	(2,877,008)
Net earnings (loss)	3,843,252	3,073,423	7,087,153
Weighted average shares outstanding - basic	1,381,595	1,381,595	1,381,595
Year end shares outstanding	1,381,595	1,381,595	1,381,595
Net earnings (loss) per share - basic	\$2.78	\$2.22	\$5.13
Cash dividends declared	Ⓜ\$0.40
Number of full time employees	221
Total number of employees	221	219	222

Ⓜ Special dividend

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

	2018	2017
Cash	307,271	85,511
Accounts receivables, gross	12,188,512	12,312,681
Allowance for uncollectible accounts receivable	50,000	50,000
Accounts receivable, net	12,138,512	12,262,681
Finished products	4,299,953	3,999,265
In-process products	14,059,690	13,371,600
Raw materials & supplies	1,570,303	1,809,444
Total inventories	19,929,946	19,180,309
Prepaid expenses & other current assets	188,226	388,990
Assets held for sale	5,171	5,171
Total current assets	32,569,126	31,922,662
Company owned life insurance	1,662,252	1,630,292
Deferred federal income taxes	1,893,708	2,021,656
Other assets	190,781	221,530
Land	387,467	387,467
Buildings & improvements	12,010,463	11,994,164
Machinery & equipment	113,952,580	108,531,423
Property, plant & equipment, gross	126,350,510	120,913,054
Less: accumulated depreciation	96,139,068	93,427,657
Property, plant & equipment, net	30,211,442	27,485,397
Total assets	66,527,309	63,281,537
Accounts payable	7,357,718	7,869,285
Payroll & employee benefits	4,070,875	4,186,970
Taxes, other than income taxes	508,076	557,305
Other accrued liabilities	184,056	221,407
Current portion of long-term debt	2,483,366	2,342,719
Current portion of postretirement benefits	898,812	940,287
Total current liabilities	15,502,903	16,117,973
Notes payable to bank	18,553,448	17,125,532
Less current maturities	2,483,366	2,342,719
Employee benefits	698,636	814,223
Postretirement benefits	8,730,441	10,600,706
Pension benefits	7,058,791	10,551,573
Other liabilities	1,278,760	1,322,309
Total long-term liabilities	33,836,710	38,071,624
Common stock	1,381,595	1,381,595
Additional capital	3,269,476	3,269,476
Retained earnings (accumulated deficit)	31,210,481	27,367,229
Unrecognized (loss) & prior service costs in pensions	(18,068,860)	(20,898,870)
Unrecognized (loss) & prior service costs in postretirement benefit	(604,996)	(2,027,490)
Accumulated other comprehensive income (loss)	(18,673,856)	(22,926,360)
Total stockholders' equity (deficit)	17,187,696	9,091,940

Recent Dividends:**1. Federal Screw Works common.**

ExDate	Amt	Declared	Record	Payable
09/05/2018	0.40	08/31/2018	09/06/2018	10/05/2018

Annual Dividends:**1. Federal Screw Works common.**

2018	0.40
------	------

FEDERAL SCREW WORKS**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	17,899,000	17,263,000
Cost & expenses	17,630,000	16,881,000
Operating income	329,000	382,000

Other income (expense), net	60,000	
Net before taxes	329,000	382,000
Net income	260,000	252,000
Earnings common share		
Primary	\$0.19	\$0.18
Common Shares:		
Year-end	1,381,595	1,381,595

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	132,667
Inventories	19,514,939
Current assets	32,639,646
Net property & equip.	30,710,927
Total assets	67,070,903
Liabilities:	
Current liabilities	13,731,618
Long-term debt	18,836,613
Stockholders' equity	16,874,121
Net current assets	18,908,028

FEDNAT HOLDING CO**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	299,651,000	289,910,000
Cost & expenses	267,049,000	290,550,000
Operating income	32,602,000	(640,000)
Net before taxes	32,602,000	(640,000)
Income taxes	8,587,000	(358,000)
Net income	24,015,000	(282,000)
Earnings common share		
Primary	\$1.90	\$0.13
Fully Diluted	\$1.88	\$0.13
Common Shares:		
Full Diluted	12,866,000	13,302,000
Year-end	12,774,444	13,053,281

FIDUS INVESTMENT CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	30,373,000	25,528,000
Operating income	23,844,000	26,019,000
Net before taxes	23,844,000	26,019,000
Income taxes	28,000	29,000
Net income	23,816,000	25,990,000
Earnings common share		
Primary	\$0.97	\$1.12
Fully Diluted	\$0.97	\$1.12
Common Shares:		
Full Diluted	24,474,632	23,201,533
Year-end	24,463,119	24,492,880

FINISAR CORP

Merger Development On Nov. 8, 2018, Co., II-VI Inc. ("Parent") and Mutation Merger Sub Inc. ("Merger Subsidiary"), a wholly-owned subsidiary of Parent, entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other things, Merger Subsidiary will be merged with and into Co. (the "Merger"), with Co. surviving the Merger as a wholly-owned subsidiary of Parent. At the time the Merger becomes effective (the "Effective Time"), each issued and outstanding share of common stock, par value \$0.001 per share, of Co. ("Co. Stock") (other than shares of Co. Stock owned by Parent or Merger Subsidiary or any direct or indirect wholly owned subsidiary of Parent, which will be cancelled without consideration, and holders of Co. Stock, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger will be automatically cancelled and converted into the right to receive, for each share of Co. Stock, at the stockholder's election and subject to proration in the event the cash consideration or Parent Common Stock (as defined below) consideration is oversubscribed, either (i) \$26.00 in cash (the "Cash Election Consideration"), (ii) 0.5546 of a share of common stock, no par value, of Parent ("Parent Common Stock") (the "Stock Election Consideration"), or (iii) a combination of (A) 0.2218 of a share of Parent Common Stock (the "Exchange Ratio") and (B) \$15.60 in cash, without interest (the "Mixed Election Consideration"). On an average basis across all shares of Co. Stock (including the Options (as defined below) and Performance RSUs (as defined below)), at the closing of the Merger, 60% of the aggregate amount of the outstanding shares of Co. Stock (including the Options and Performance RSUs) will be converted into the right to receive the Cash Election Consideration, with the remaining 40% converted into the right to receive the Stock Election Consideration. Pursuant to the Merger

Agreement, at the Effective Time, each outstanding and unexercised option to purchase Co. Stock (whether vested or unvested) (an "Option") shall automatically be cancelled and terminated and converted into the right to receive an amount of Mixed Election Consideration equal to the product of (i) the excess, if any, of the Cash Election Consideration over the exercise price per share of such Option multiplied by (ii) the number of shares of Co. Stock subject to such Option, payable no later than Co.'s next payroll date after the closing of the Merger. Further, as of the Effective Time, each award of restricted stock units of Co. that is outstanding immediately prior to the Effective Time and is subject to a performance-based vesting condition (a "Performance RSU") that relates solely to the value of Co. Stock will vest as to a number of shares determined under the terms of the award and will be cancelled and extinguished and converted into the right to receive the Cash Election Consideration, the Stock Election Consideration or the Mixed Election Consideration in accordance with the election made by the holder of such Performance RSU. At the Effective Time, each other award of restricted stock units of Co. that is outstanding and unvested will be assumed by Parent and continue to be subject to substantially the same terms and conditions (including vesting requirements) as in effect immediately prior to the Effective Time, except that the number of shares of Parent Common Stock subject to such assumed restricted stock unit awards will be equal to the product of (i) the number of shares of Co. Stock underlying such unvested restricted stock unit award as of immediately prior to the Effective Time multiplied by (ii) the sum of the (A) Exchange Ratio plus (B) the quotient obtained by dividing \$15.60 by the Equity Award Measurement Price. The "Equity Award Measurement Price" means the volume weighted average price per share of Parent Common Stock on NASDAQ for the ten (10) consecutive trading days ending on (and including) the third trading day immediately prior to the Effective Time. The transaction is expected to close in the middle of calendar year 2019, subject to approval by each company's shareholders, antitrust regulatory approvals and other customary closing conditions. The transaction values Co. at \$26.00 per share, or approximately \$3,200,000,000 in equity value and represents a premium of 37.7% to Co.'s closing price on Nov. 8, 2018.

FIREEYE INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	613,417	573,847
Cost & expenses	759,118	754,771
Operating income	(145,701)	(180,924)
Other income (expense), net	(14,390)	112
Net before taxes	(190,582)	(211,385)
Income taxes	4,144	3,385
Net income	(194,726)	(214,770)
Balance for common	(194,726)	(214,770)
Earnings common share		
Primary	\$(1.03)	\$(1.22)
Fully Diluted	\$(1.03)	\$(1.22)
Common Shares:		
Full Diluted	189,526	176,232
Year-end	193,601	

FIRST HARTFORD CORP**Earnings, 3 mos. to Jul 31**(Consol. – \$):

	2018	2017
Total Revenues	27,815,519	31,019,368
Cost & expenses	19,542,361	27,761,938
Operating income	8,273,158	3,257,430
Interest expense	2,632,510	2,629,789
Other income (expense), net	673,038	(124,463)
Net before taxes	6,313,686	503,178
Income taxes	1,791,385	365,489
Net income	4,522,301	137,689
Earnings common share		
Primary	\$1.85	\$0.10
Fully Diluted	\$1.85	\$0.10
Common Shares:		
Full Diluted	2,315,799	2,328,299
Year-end	2,315,799	2,315,799

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	7,688,661
Current assets	14,192,336
Total assets	248,670,785
Liabilities:	
Current liabilities	18,134,565
Long-term debt	223,268,593
Stockholders' equity	3,385,909
Net current assets	(3,942,229)

FIRST HAWAIIAN INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	347,703	299,396
Operating income	276,206	274,095
Net before taxes	276,206	274,095
Income taxes	71,807	102,097
Net income	204,399	171,998
Earnings common share		
Primary	\$1.48	\$1.23
Fully Diluted	\$1.48	\$1.23
Common Shares:		
Full Diluted	137,810	139,670
Year-end	134,874	139,586

FIRST SOLAR INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	1,552,803	2,602,143
Cost & expenses	1,523,698	2,389,221
Operating income	29,105	212,922
Interest income	45,145	22,364
Interest expense	14,445	19,692
Other income (expense), net	7,635	25,180
Equity earnings	(35,105)	(5,462)
Foreign currency	(2,478)	(6,166)
Net before taxes	64,962	234,608
Income taxes	7,857	(26,769)
Net income	92,210	266,839
Earnings common share		
Primary	\$0.88	\$2.56
Fully Diluted	\$0.87	\$2.54
Common Shares:		
Full Diluted	106,211	104,889
Year-end	104,814	

FIRSTHAND TECHNOLOGY VALUE FUND INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	2,354,260	1,043,461
Cost & expenses	18,665,062	3,099,817
Operating income	(16,310,802)	(2,056,356)
Net before taxes	(16,310,802)	
Net income	(15,862,594)	(2,056,356)
Earnings common share		
Primary	\$(2.17)	\$(0.28)
Common Shares:		
Year-end	7,276,036	7,430,697

FISERV INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	4,272,000	4,180,000
Cost & expenses	2,950,000	3,073,000
Operating income	1,322,000	1,107,000
Interest expense	137,000	131,000
Other income (expense), net	(2,000)	2,000
Equity earnings	(8,000)	(31,000)
Net before taxes	1,183,000	978,000
Income taxes	290,000	309,000
Net income	901,000	700,000
Earnings common share		
Primary	\$2.21	\$1.65
Fully Diluted	\$2.16	\$1.62
Common Shares:		
Full Diluted	416,600	433,400
Year-end	401,000	417,600

FIVE PRIME THERAPEUTICS, INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	151,711	147,760
Operating income	(105,874)	(121,470)
Interest income	4,212	2,162
Other income (expense), net	(32)	
Net before taxes		(119,308)
Income taxes		1,703
Net income	(101,694)	(121,011)
Earnings common share		
Primary	\$(3.01)	\$(4.34)
Fully Diluted	\$(3.01)	\$(4.34)
Common Shares:		
Full Diluted	33,740	27,883
Year-end	34,532	28,072

FIVE9, INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	185,329	144,822
Cost & expenses	184,306	150,709
Operating income	1,023	(5,887)
Interest expense	6,783	2,635
Net before taxes	(3,804)	(8,196)
Income taxes	150	142
Net income	(3,954)	(8,338)
Earnings common share		
Primary	\$(0.07)	\$(0.15)
Fully Diluted	\$(0.07)	\$(0.15)
Common Shares:		
Full Diluted	57,790	54,579
Year-end	58,749	55,631

FLEX PHARMA INC**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	675,075	991,671
Cost & expenses	20,728,159	27,624,337
Operating income	(20,053,084)	(26,632,666)
Interest income	139,612	227,535
Net income	(19,913,472)	(26,405,131)
Balance for common	(19,913,472)	(26,405,131)
Earnings common share		
Primary	\$(1.11)	\$(1.54)
Fully Diluted	\$(1.11)	\$(1.54)
Common Shares:		
Full Diluted	17,999,877	17,131,887
Year-end	18,066,767	

FLEXION THERAPEUTICS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Net Sales	12,981,000	
Cost & expenses	134,226,000	81,904,000
Operating income	(121,245,000)	(81,904,000)
Interest income	3,572,000	2,450,000
Interest expense	11,775,000	7,363,000
Other income (expense), net	364,000	(136,000)
Net income	(129,084,000)	(86,953,000)
Earnings common share		
Primary	\$(3.42)	\$(2.73)
Fully Diluted	\$(3.42)	\$(2.73)
Common Shares:		
Full Diluted	37,712,000	31,821,000
Year-end	37,825,275	

FLEXSTEEL INDUSTRIES, INC.**Earnings, 3 mos. to Sep 30**(Consol. – \$):

	2018	2017
Net Sales	113,487,000	119,834,000
Cost & expenses	111,892,000	110,095,000
Operating income	1,595,000	9,739,000
Other income (expense), net	181,000	141,000
Net before taxes	1,776,000	9,880,000
Income taxes	480,000	3,700,000
Net income	1,296,000	6,180,000
Earnings common share		
Primary	\$0.16	\$0.79
Fully Diluted	\$0.16	\$0.78
Common Shares:		
Full Diluted	7,921,000	7,937,000
Year-end	7,883,777	7,845,239

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	23,349,000
Inventories	90,284,000
Current assets	183,639,000
Net property & equip.	99,178,000
Total assets	287,148,000
Liabilities:	
Current liabilities	43,789,000
Stockholders' equity	241,658,000
Net current assets	139,850,000

FLIR SYSTEMS, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,327,223	1,305,650
Cost & expenses	1,094,513	1,092,848
Operating income	232,710	212,802
Interest income	2,591	1,114
Interest expense	12,086	12,744
Other income (expense), net	(229)	2,465
Net before taxes	222,986	203,637
Income taxes	39,077	46,124
Net income	183,909	157,513
Earnings common share		
Primary	\$1.33	\$1.15
Fully Diluted	\$1.31	\$1.13
Common Shares:		
Full Diluted	140,613	138,853
Year-end	138,332	

FLUENT INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	179,459,000	155,167,000
Cost & expenses	161,680,000	167,202,000
Operating income	7,758,000	(21,771,000)
Interest expense	6,209,000	7,098,000
Income contin. oper.	1,549,000	(28,869,000)
Net income	(19,575,000)	(47,229,000)
Earnings common share		
Primary	\$(0.26)	\$(0.86)
Fully Diluted	\$(0.26)	\$(0.86)
Common Shares:		
Full Diluted	73,941,595	54,665,776
Year-end	75,291,330	

FLUIDIGM CORP (DE)

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	80,639	74,193
Cost & expenses	117,685	123,818
Operating income	(37,046)	(49,625)
Interest expense	9,824	4,367
Other income (expense), net	465	571
Net before taxes	(46,405)	(53,421)
Income taxes	(2,167)	(3,343)
Net income	(44,238)	(50,078)
Earnings common share		
Primary	\$(1.13)	\$(1.61)
Fully Diluted	\$(1.13)	\$(1.61)
Common Shares:		
Full Diluted	39,033	31,051
Year-end	39,316	38,622

FORESCOUT TECHNOLOGIES INC

Acquisition Completed On Nov. 7, 2018, Co. acquired all the capital stock of SecurityMatters B.V. ("SecurityMatters"), a company that provides organizations with device visibility, continuous network monitoring, and threat and anomaly detection specific to operational technology and industrial environments using passive collection techniques that don't impact operations, for \$113,250,000 in cash, subject to certain customary closing adjustments. As the result, SecurityMatters became a wholly-owned subsidiary of Co.

FORMFACTOR INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	388,788	416,540
Cost & expenses	364,475	375,636
Operating income	24,313	40,904
Interest income	952	283
Interest expense	2,654	3,446
Other income (expense), net	(341)	19
Net before taxes	22,270	37,760
Income taxes	3,334	2,435
Net income	18,936	35,325
Earnings common share		
Primary	\$0.26	\$0.49
Fully Diluted	\$0.25	\$0.48
Common Shares:		
Full Diluted	74,628	73,540
Year-end	74,102	72,973

FORRESTER RESEARCH INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	258,992	247,296
Cost & expenses	238,485	221,841
Operating income	13,681	20,098
Other income (expense), net	472	248
Gains or losses	(62)	(997)
Net before taxes	14,091	19,349
Income taxes	4,086	6,302
Net income	10,005	13,047
Earnings common share		
Primary	\$0.55	\$0.73
Fully Diluted	\$0.55	\$0.72
Common Shares:		
Full Diluted	18,353	18,212
Year-end	18,262	17,902

FORTINET INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,294,200	1,078,300
Cost & expenses	1,148,300	1,010,700
Operating income	145,900	67,600
Interest income	17,200	9,500
Other income (expense), net	(4,300)	1,900
Net before taxes	158,800	79,000
Income taxes	9,200	18,600
Net income	149,600	60,400
Earnings common share		
Primary	\$0.89	\$0.34
Fully Diluted	\$0.86	\$0.34
Common Shares:		
Full Diluted	173,700	179,000
Year-end	170,300	174,625

FOSSIL GROUP INC

Earnings, 9 mos. to (Consol. - \$):

	09/29/18	09/30/17
Net Sales	1,754,566,000	867,358,000
Cost & expenses	1,759,181,000	342,876,000
Operating income	(4,615,000)	475,518,000
Other income (expense), net	(5,338,000)	11,501,000
Net before taxes	(41,611,000)	496,113,000
Income taxes	7,209,000	100,746,000
Net income	(48,820,000)	395,367,000
Earnings common share		
Primary	\$(1.04)	\$(8.22)
Fully Diluted	\$(1.04)	\$(8.22)
Common Shares:		
Full Diluted	49,107,000	48,439,000
Year-end	49,393,000	48,524,000

FOX FACTORY HOLDING CORP

Earnings, 9 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Total Revenues	462,415	354,540
Cost & expenses	386,170	301,467
Operating income	71,678	50,984
Interest expense	2,379	1,696
Other income (expense), net	(380)	(285)
Net before taxes	68,919	49,003
Income taxes	3,919	8,677
Net income	65,000	40,326
Earnings common share		
Primary	\$1.69	\$1.08
Fully Diluted	\$1.64	\$1.04
Common Shares:		
Full Diluted	38,913	38,700
Year-end	37,988	37,514

FREIGHTCAR AMERICA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	228,684	330,233
Cost & expenses	249,535	348,575
Operating income	(20,851)	(18,342)
Other income (expense), net	1,421	219
Net before taxes	(19,515)	(18,222)
Income taxes	(4,603)	(6,798)
Net income	(14,912)	(11,424)
Earnings common share		
Primary	\$(1.20)	\$(0.92)
Fully Diluted	\$(1.20)	\$(0.92)
Common Shares:		
Full Diluted	12,316	12,283
Year-end	12,464	12,396

FRESHPET INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	141,594,158	112,530,942
Cost & expenses	148,370,075	116,899,510
Operating income	(6,775,917)	(4,368,568)
Other income (expense), net	(24,302)	(515,473)
Net before taxes	(7,061,526)	(5,714,973)
Income taxes	57,096	62,261
Net income	(7,118,622)	(5,777,234)
Balance for common	(7,118,622)	(5,777,234)
Earnings common share		
Primary	\$(0.20)	\$(0.17)
Fully Diluted	\$(0.20)	\$(0.17)
Common Shares:		
Full Diluted	35,259,365	34,316,161
Year-end	35,510,161	34,835,698

FTD COMPANIES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	766,712	805,943
Cost & expenses	923,388	875,540
Operating income	(159,987)	(81,056)
Interest income	354	359
Interest expense	12,920	7,671
Other income (expense), net	842	324
Net before taxes	(171,711)	(88,044)
Income taxes	(15,820)	(7,464)
Net income	(155,891)	(80,580)
Earnings common share		
Primary	\$(5.59)	\$(2.93)
Fully Diluted	\$(5.59)	\$(2.93)
Common Shares:		
Full Diluted	27,886	27,459
Year-end	28,224	

GAMING & LEISURE PROPERTIES, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	752,410	730,610
Cost & expenses	199,740	189,897
Operating income	469,926	455,401
Other income (expense), net	(3,473)	
Net before taxes	297,779	293,745
Income taxes	4,194	6,406
Net income	293,585	287,339
Balance for common	293,174	286,869
Earnings common share		
Primary	\$1.37	\$1.37
Fully Diluted	\$1.37	\$1.35
Common Shares:		
Full Diluted	214,718	212,098
Year-end	214,038	212,603

GENMARK DIAGNOSTICS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	51,381,000	36,497,000
Cost & expenses	88,541,000	82,051,000
Operating income	(37,160,000)	(45,554,000)
Other income (expense), net	(49,000)	227,000
Net before taxes	(38,878,000)	(47,244,000)
Income taxes	59,000	68,000
Net income	(38,937,000)	(47,312,000)
Earnings common share		
Primary	\$(0.70)	\$(0.95)
Fully Diluted	\$(0.70)	\$(0.95)
Common Shares:		
Full Diluted	55,535,000	49,908,000
Year-end	55,955,000	54,792,000

GENOMIC HEALTH INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	275,032	261,887
Operating income	14,470	(8,600)
Other income (expense), net	1,639	792
Gains or losses		2,807
Net before taxes	17,601	(4,374)
Income taxes	834	1,362
Net income	16,767	(5,736)
Earnings common share		
Primary	\$0.47	\$(0.17)

Fully Diluted	\$0.45	\$(0.17)
Common Shares:		
Full Diluted	37,044	34,373
Year-end	36,123	

GENTEX CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	1,380,654,978	1,335,302,109
Cost & expenses	998,028,730	945,937,823
Operating income	382,626,248	389,364,286
Other income (expense), net	578,655	(1,071,628)
Gains or losses	8,062,421	5,348,052
Net before taxes	391,267,324	393,640,710
Income taxes	59,658,782	117,317,687
Net income	331,608,542	276,323,023
Earnings common share		
Primary	\$1.23	\$0.97
Fully Diluted	\$1.22	\$0.96
Common Shares:		
Full Diluted	272,733,502	289,061,501
Year-end	262,116,951	283,902,844

GENTHERM INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	732,652	652,388
Operating income	51,955	76,110
Interest expense	3,661	3,633
Other income (expense), net	(9,938)	145
Net before taxes	39,077	50,702
Income taxes	9,807	10,233
Net income	29,270	40,469
Earnings common share		
Primary	\$0.80	\$1.10
Fully Diluted	\$0.80	\$1.10
Common Shares:		
Full Diluted	36,470	36,831
Year-end	35,749	36,678

GERON CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	22,175	22,343
Operating income	(21,484)	(21,469)
Other income (expense), net	(404)	(59)
Net income	(19,717)	(20,487)
Earnings common share		
Primary	\$(0.11)	\$(0.13)
Fully Diluted	\$(0.11)	\$(0.13)
Common Shares:		
Full Diluted	173,188	159,187
Year-end	186,348	

GEVO INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	26,238,000	20,856,000
Cost & expenses	41,724,000	39,330,000
Operating income	(15,486,000)	(18,474,000)
Other income (expense), net	(2,892,000)	382,000
Net income	(20,874,000)	(20,244,000)
Earnings common share		
Primary	\$(5.75)	\$(27.91)
Fully Diluted	\$(5.75)	\$(27.91)
Common Shares:		
Full Diluted	3,629,370	725,323
Year-end	8,095,120	993,413

GIBRALTAR INDUSTRIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	761,459	728,806
Cost & expenses	685,938	658,504
Operating income	75,521	70,302
Interest expense	9,305	10,612
Other income (expense), net	50	(811)
Net before taxes	66,266	58,879
Income taxes	15,574	21,090
Income contin. oper.	37,789	
Income discont. oper.	(405)	
Net income	50,692	37,384
Earnings common share		
Primary	\$1.59	\$1.18

Fully Diluted	\$1.56	\$1.16
Common Shares:		
Full Diluted	32,524	32,216
Year-end	32,064	32,275

GILEAD SCIENCES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	16,332,000	20,158,000
Cost & expenses	9,276,000	8,325,000
Operating income	7,056,000	11,833,000
Other income (expense), net	547,000	391,000
Net before taxes	6,783,000	11,403,000
Income taxes	1,326,000	2,923,000
Net income	5,457,000	8,480,000
Earnings common share		
Primary	\$4.19	\$6.50
Fully Diluted	\$4.15	\$6.44
Common Shares:		
Full Diluted	1,313,000	1,319,000
Year-end	1,294,000	1,307,000

GLADSTONE INVESTMENT CORP**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	31,667,000	14,833,000
Net income	(3,936,000)	11,185,000
Earnings common share		
Primary	\$(0.12)	\$0.35
Fully Diluted	\$(0.12)	\$0.35
Common Shares:		
Full Diluted	32,792,816	32,003,128
Year-end	32,822,459	32,526,223

GLOBAL BLOOD THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	130,658	77,330
Operating income	(130,658)	(77,330)
Interest income	5,768	1,856
Net income	(124,991)	(75,772)
Earnings common share		
Primary	\$(2.47)	\$(1.81)
Fully Diluted	\$(2.47)	\$(1.81)
Common Shares:		
Full Diluted	50,537	41,832
Year-end	52,120	43,376

GLOBAL WATER RESOURCES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	27,262	23,408
Cost & expenses	14,243	12,621
Operating income	7,524	5,623
Interest income	37	14
Interest expense	3,893	3,889
Other income (expense), net	669	1,296
Net before taxes	4,337	3,044
Income taxes	1,128	1,227
Net income	3,209	1,817
Earnings common share		
Primary	\$0.16	\$0.09
Fully Diluted	\$0.16	\$0.09
Common Shares:		
Full Diluted	20,170	19,632
Year-end	21,471	19,631

GLU MOBILE INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	270,921	206,615
Cost & expenses	281,777	265,524
Operating income	(10,856)	(58,909)
Other income (expense), net	(521)	(340)
Net before taxes	(11,377)	(59,249)
Income taxes	500	(1,246)
Net income	(11,877)	(58,003)
Earnings common share		
Primary	\$(0.08)	\$(0.43)
Fully Diluted	\$(0.08)	\$(0.43)
Common Shares:		
Full Diluted	140,685	135,047
Year-end	143,142	

GLYCOMIMETICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	36,544,971	24,396,418
Operating income	(36,544,971)	(24,396,418)
Other income (expense), net	2,178,253	373,208
Net income	(34,366,718)	(24,023,210)
Earnings common share		
Primary	\$(0.85)	\$(0.86)
Fully Diluted	\$(0.85)	\$(0.86)
Common Shares:		
Full Diluted	40,345,071	27,814,781
Year-end	43,137,227	32,737,799

GOLD RESOURCE CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	71,902,000	58,858,000
Operating income	14,316,000	16,541,000
Other income (expense), net	49,000	32,000
Gains or losses	(782,000)	(195,000)
Net before taxes	13,919,000	16,808,000
Income taxes	5,489,000	6,987,000
Net income	8,430,000	9,821,000
Earnings common share		
Primary	\$0.15	\$0.17
Fully Diluted	\$0.14	\$0.17
Common Shares:		
Full Diluted	58,252,652	57,617,030
Year-end	57,718,676	56,891,484

GOLDEN ENTERTAINMENT INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	641,669,000	323,428,000
Cost & expenses	524,749,000	291,644,000
Operating income	45,499,000	10,285,000
Other income (expense), net	5,895,000	
Net before taxes	4,294,000	4,717,000
Income taxes	(106,000)	(10,893,000)
Net income	4,400,000	15,610,000
Earnings common share		
Primary	\$0.16	\$0.70
Fully Diluted	\$0.15	\$0.67
Common Shares:		
Full Diluted	29,192,000	23,447,000
Year-end	27,952,000	

GOODYEAR TIRE & RUBBER CO.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	11,599,000	11,306,000
Cost & expenses	10,961,000	10,661,000
Operating income	808,000	577,000
Interest income	12,000	10,000
Other income (expense), net	151,000	(82,000)
Gains or losses	1,000	14,000
Foreign currency	7,000	4,000
Net before taxes	809,000	591,000
Income taxes	211,000	136,000
Net income	598,000	455,000
Earnings common share		
Primary	\$2.45	\$1.76
Fully Diluted	\$2.42	\$1.73
Common Shares:		
Full Diluted	241,000	255,000
Year-end	233,000	246,000

GOOSEHEAD INSURANCE INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	45,431,000	31,576,000
Cost & expenses	59,723,000	24,466,000
Operating income	(15,331,000)	6,493,000
Interest expense	3,598,000	1,734,000
Other income (expense), net	(22,000)	3,541,000
Net before taxes	(18,951,000)	
Income taxes	318,000	
Net income	(19,269,000)	8,300,000
Earnings common share		
Primary	\$(0.66)	\$
Fully Diluted	\$(0.66)	\$
Common Shares:		
Full Diluted	13,533,000	
Year-end	36,280,000	

GOPRO INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	770,959	844,945
Cost & expenses	897,888	950,094
Operating income	(126,929)	(105,149)
Interest expense	13,804	9,152
Other income (expense), net	(268)	705
Net before taxes	(141,001)	(113,596)
Income taxes	(296)	13,429
Net income	(140,705)	(127,025)
Earnings common share		
Primary	\$(1.01)	\$(0.92)
Fully Diluted	\$(1.01)	\$(0.92)
Common Shares:		
Full Diluted	139,028	138,450
Year-end	129,873	136,752

GOVERNMENT PROPERTIES INCOME TRUST**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	170,164	95,756
Deprec., depl. & amort.	129,444	61,949
Operating income	23,296	51,657
Other income (expense), net	41,589	(804)
Equity earnings	1,112	(533)
Net before taxes	(4,154)	9,097
Income taxes	124	65
Net income	35,811	30,081
Balance for common	35,440	30,081
Earnings common share		
Primary	\$0.36	\$0.38
Fully Diluted	\$0.36	\$0.38
Common Shares:		
Full Diluted	99,075	79,852
Year-end	99,205	

GRAND CANYON EDUCATION INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	667,953	702,716
Cost & expenses	489,953	511,308
Operating income	178,000	191,408
Interest expense	961	1,642
Net before taxes	193,206	191,952
Income taxes	39,726	56,889
Net income	153,480	135,063
Earnings common share		
Primary	\$3.22	\$2.87
Fully Diluted	\$3.17	\$2.80
Common Shares:		
Full Diluted	48,429	48,197
Year-end	48,134	48,120

GREAT ELM CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	8,212	8,876
Net income	12,629	11,142
Earnings common share		
Primary	\$1.19	\$0.93
Fully Diluted	\$1.19	\$0.93
Common Shares:		
Full Diluted	10,652	11,988
Year-end	10,652	10,730

GREEN BANCORP INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	112,451	93,267
Operating income	52,928	48,339
Net before taxes	52,928	48,339
Income taxes	11,548	16,822
Net income	41,380	31,517
Earnings common share		
Primary	\$1.11	\$0.85
Fully Diluted	\$1.10	\$0.85
Common Shares:		
Full Diluted	37,652	37,273
Year-end	37,368	37,096

GREEN PLAINS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	3,032,224,000	675,182,000
Cost & expenses	2,939,725,000	560,755,000
Deprec., depl. & amort.	84,010,000	80,105,000
Operating income	8,489,000	34,322,000
Other income (expense), net	2,362,000	2,811,000
Net before taxes	(54,561,000)	(31,621,000)
Income taxes	(31,438,000)	(60,905,000)
Net income	(23,123,000)	29,284,000
Earnings common share		
Primary	\$(0.94)	\$0.36
Fully Diluted	\$(0.94)	\$0.48
Common Shares:		
Full Diluted	40,189,000	50,693,000
Year-end	41,420,454	

GREEN PLAINS INC.

Interest Sale Completed On Nov. 15, 2018, Co. closed (i) the sale of three ethanol plants located in Bluffton, Indiana, Lakota, Iowa, and Riga, Michigan to Valero Renewable Fuels Company, LLC ("Valero") (the "Valero Transaction") and (ii) separate asset purchase agreement with Green Plains Partners LP "Partnership") to acquire the storage assets and assign the rail transportation assets to be disposed of in the sale to Valero. Co. received as consideration from Valero approximately \$319,000,000, while the Partnership received as consideration from Co. 8,700,000 Green Plains units and a portion of the general partner interest equating to 200,000 hypothetical limited partner units to maintain the general partners 2% interest. The Partnership will receive as additional consideration approximately \$2,600,000 in cash related to the present value gain on railcars transferred, subject to certain post-closing adjustments.

GREEN PLAINS PARTNERS LP

Interest Sale Completed On Nov. 15, 2018, Co. sold the storage assets and assign the rail transportation assets to be disposed of in the sale to Valero Renewable Fuels Company, LLC ("Valero") for \$120,900,000 and received as consideration 8,700,000 Green Plains Inc.'s unit and a portion of the general partner interest equating to 200,000 hypothetical limited partner units to maintain the general partners 2% interest. Co. will receive as additional consideration approximately \$2,600,000 in cash related to the present value gain on railcars transferred, subject to certain post-closing adjustments.

GRIFFIN INDUSTRIAL REALTY INC**Earnings, 9 mos. to Aug 31**(Consol. – \$000):

	2018	2017
Total Revenues	25,397	35,020
Cost & expenses	21,687	23,241
Operating income	3,710	11,779
Interest expense	4,566	4,200
Gains or losses	75	344
Net before taxes	(781)	7,923
Income taxes	733	2,806
Net income	(1,514)	5,117
Earnings common share		
Primary	\$(0.30)	\$1.02
Fully Diluted	\$(0.30)	\$1.02
Common Shares:		
Full Diluted	5,013	5,037
Year-end	5,045	5,001

GROUPON INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,836,819	1,970,711
Cost & expenses	1,844,656	1,991,002
Operating income	(7,837)	(20,291)
Interest income	4,858	2,155
Interest expense	16,434	15,423
Other income (expense), net	(16,088)	(4,597)
Gains or losses		7,624
Foreign currency	(12,168)	19,063
Net before taxes	(47,669)	(11,469)
Income taxes	205	11,001
Income contin. oper.		(22,470)
Net income	(47,874)	(24,221)
Earnings common share		
Primary	\$(0.10)	\$(0.06)
Fully Diluted	\$(0.10)	\$(0.06)
Common Shares:		
Full Diluted	565,228	559,726
Year-end	570,198	

GSI TECHNOLOGY INC**Earnings, 6 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	24,098	20,334
Cost & expenses	26,151	23,657
Operating income	(2,053)	(3,323)
Interest income	292	196
Other income (expense), net	(124)	5
Net before taxes	(1,885)	(3,122)
Income taxes	112	130
Net income	(1,997)	(3,252)
Earnings common share		
Primary	\$(0.09)	\$(0.16)
Fully Diluted	\$(0.09)	\$(0.16)
Common Shares:		
Full Diluted	21,707	20,922
Year-end	21,948	21,074

GUARDANT HEALTH INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31** (\$000):

	2017	2016
Revenues: precision oncology testing	42,088	24,496
Revenues: development services	7,754	753
Total revenues	49,842	25,249
Cost of precision oncology testing	28,883	22,065
Cost of development services	2,735	59
Research & development	25,562	10,859
Selling & marketing expenses	32,497	26,192
General & administrative expenses	36,777	9,921
Total costs & operating expenses	...	69,096
Income (loss) from operations	(76,612)	(43,847)
Interest income	2,234	733
Interest expense	2,702	3,018
Gain (loss) on debt extinguishment	(5,075)	...
Other income (expense), net	(1,059)	(1)
Income (loss) before provision for income taxes	(83,214)	(46,133)
Deferred state income taxes	7	6
Deferred income taxes	7	6
Provision for (benefit from) income taxes	7	6
Net income (loss)	(83,221)	(46,139)
Deemed dividend related to repurchase of Series A convertible preferred stock	4,716	...
Deemed dividend related to change in conversion rate of Series D convertible preferred stock	1,058	...
Net income (loss) attributable to common stockholders	(88,995)	(46,139)
Weighted average shares outstanding - basic	12,582	13,053
Weighted average shares outstanding - diluted	12,582	13,053
Year end shares outstanding	11,897	13,184
Net earnings (loss) per share - basic	\$(7.07)	\$(3.53)
Net earnings (loss) per share - diluted	\$(7.07)	\$(3.53)
Number of full time employees	348	...

□ As Is; □ As of June 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	72,280	33,591
Short-term marketable securities	149,040	61,665
Accounts receivable, net	12,787	3,495
Inventories	7,287	2,769
Prepaid expenses & other current assets	1,541	1,571
Total current assets	242,935	103,091
Long-term marketable securities	73,254	...
Machinery & equipment	15,676	9,620
Computer hardware	1,939	1,409
Leasehold improvements	6,766	6,682
Furniture & fixtures	1,347	1,338
Computer software	655	71
Construction in progress	349	...
Total property & equipment, gross	26,732	19,120
Less: Accumulated depreciation & amortization	10,696	6,486
Property & equipment, net	16,036	12,634
Capitalized license fees	8,739	...
Other assets	1,974	840
Total assets	342,938	116,565
Accounts payable	4,998	3,157
Accrued compensation	4,911	2,563
Accrued royalty obligations	766	55
Accrued litigation settlement expense	3,000	...
Accrued legal expenses	561	354
Accrued tax liabilities	905	345
Accrued information technology expenses	316	56
Accrued professional services	336	475
Other accrued expenses	522	509
Accrued expenses	6,406	1,794
Capital lease, current	199	131
Deferred rent, current	...	707
Deferred revenues	3,113	1,898
Royalty liability	...	4,028
Total current liabilities	19,627	14,278
Senior term loan	...	16,482
Capital lease, net of current portion	460	426
Deferred rent, net of current portion	6,537	5,626
Obligation related to royalty	7,708	...
Other long-term liabilities	...	57
Total liabilities	34,332	36,869
Convertible preferred stock	499,974	179,997
Additional paid-in capital	4,900	7,410
Accumulated other comprehensive income (loss)	(532)	(86)
Retained earnings (accumulated deficit)	(195,736)	(107,625)
Total stockholders' equity	308,606	79,696

Recent Dividends:**1. Guardant Health Inc common.**

No dividends paid.

Annual Dividends:**1. Guardant Health Inc common.**

No dividends paid.

GUARDANT HEALTH INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Total Revenues	36,074	18,708
Cost & expenses	77,424	51,025
Operating income	(41,350)	(32,317)
Interest income	1,974	565
Interest expense	648	2,095

	2018	2017
Other income (expense), net	4,544	(5,724)
Net before taxes	(35,480)	...
Income taxes	3	...
Net income	(35,483)	(39,571)
Balance for common	(35,483)	(40,629)
Earnings common share		
Primary	\$(2.92)	\$(3.07)
Fully Diluted	\$(2.92)	\$(3.07)
Common Shares:		
Full Diluted	12,155	13,224
Year-end	12,523	...

GULF ISLAND FABRICATION, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	161,016	133,745
Cost & expenses	183,081	164,084
Operating income	(22,065)	(30,339)
Interest expense	166	262
Other income (expense), net	6,954	(209)
Net before taxes	(15,277)	(30,810)
Net income	(15,696)	(20,488)
Balance for common	(15,696)	(20,388)
Earnings common share		
Primary	\$(1.05)	\$(1.38)
Fully Diluted	\$(1.05)	\$(1.38)
Common Shares:		
Full Diluted	15,017	14,821
Year-end	15,044	14,852

GULF ISLAND FABRICATION, INC.

Interest Sale Completed On Nov. 15, 2018, Co. sold its North Yard facilities in Aransas Pass, TX and certain associated equipment (collectively, the "Texas North Yard"), consisting of approximately 160 acres and approximately 3,000 linear feet of water frontage, including approximately 1,000 feet of steel bulkhead, to Berry GP, Inc. ("Purchaser"), an affiliate of Berry Contracting, L.P. d/b/a Bay Ltd ("Berry"), a company that operates as a construction, fabrication, and maintenance contractor, for \$28,000,000 in cash. Co. received approximately \$26,500,000 in net proceeds at closing plus \$500,000 of earnest money received in Sept. 2018, which was applied at closing, for total net proceeds of approximately \$27,000,000. As part of the sale, Co. retained certain assets with a net book value of approximately \$17,000,000 (the "Remaining Assets") which it would continue to actively market for sale. The Remaining Assets primarily consisted of three 660-ton crawler cranes, a barge, a plate bending roll machine, and panel line equipment.

GULFPORT ENERGY CORP.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	939,094,000	922,455,000
Cost & expenses	348,561,000	292,227,000
Deprec., depl. & amort.	352,848,000	254,887,000
Operating income	237,685,000	375,341,000
Interest income	162,000	927,000
Other income (expense), net	159,565,000	(20,082,000)
Net before taxes	296,490,000	281,389,000
Income taxes	(69,000)	2,763,000
Net income	296,559,000	278,626,000
Earnings common share		
Primary	\$1.69	\$1.56
Fully Diluted	\$1.68	\$1.56
Common Shares:		
Full Diluted	176,440,461	179,130,570
Year-end	173,218,643	183,081,776

HABIT RESTAURANTS INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/25/18	09/26/17
Total Revenues	299,439	246,537
Cost & expenses	278,065	225,735
Deprec., depl. & amort.	17,952	13,492
Operating income	3,422	7,310
Other income (expense), net	(1,473)	(688)
Net before taxes	1,200	6,241
Income taxes	(1,454)	1,397
Net income	2,654	4,844
Earnings common share		
Primary	\$0.10	\$0.16
Fully Diluted	\$0.10	\$0.16
Common Shares:		
Full Diluted	20,578	20,311
Year-end	26,049	...

HAIN CELESTIAL GROUP INC**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	560,833	589,219
Cost & expenses	581,032	555,404
Operating income	(24,104)	29,241
Other income (expense), net	(600)	3,127
Equity earnings	175	(11)
Net before taxes	(32,409)	26,086
Income taxes	(9,483)	7,484
Income contin. oper.	(23,101)	18,613
Income discont. oper.	(14,324)	1,233
Net income	(37,425)	19,846
Earnings common share		
Primary	\$(0.36)	\$0.19
Fully Diluted	\$(0.36)	\$0.19
Common Shares:		
Full Diluted	103,962	104,476
Year-end	104,002	103,748

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	55,871	...
Inventories	414,479	...
Current assets	1,014,861	...
Net property & equip.	315,926	...
Total assets	2,903,030	...
Liabilities:		
Current liabilities	438,213	...
Long-term debt	693,429	...
Stockholders' equity	1,685,424	...
Net current assets	576,648	...

HALCON RESOURCES CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	166,265,000	352,688,000
Cost & expenses	117,452,000	493,650,000
Operating income	(3,584,000)	745,550,000
Other income (expense), net	(66,603,000)	(57,926,000)
Net before taxes	...	623,816,000
Income taxes	...	(5,000,000)
Net income	(100,709,000)	628,816,000
Balance for common	(100,709,000)	580,809,000
Earnings common share		
Primary	\$(0.64)	\$4.56
Fully Diluted	\$(0.64)	\$4.52
Common Shares:		
Full Diluted	156,628,000	128,410,000
Year-end	160,676,356	149,665,527

HARMONIC, INC.**Earnings, 9 mos. to (Consol. - \$000):**

	09/28/18	09/29/17
Total Revenues	289,903	257,272
Cost & expenses	299,843	317,711
Operating income	(12,336)	(62,786)
Other income (expense), net	(698)	(1,828)
Net before taxes	(21,526)	(72,678)
Income taxes	2,839	(1,568)
Net income	(24,365)	(71,110)
Earnings common share		
Primary	\$(0.29)	\$(0.88)
Fully Diluted	\$(0.29)	\$(0.88)
Common Shares:		
Full Diluted	85,188	80,618
Year-end	86,687	...

HARVARD BIOSCIENCE INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	86,916	55,761
Cost & expenses	83,691	55,612
Operating income	(758)	(1,009)
Other income (expense), net	(3,399)	(117)
Foreign currency	(28)	(488)
Net before taxes	(8,020)	(2,146)
Income taxes	(416)	(141)
Income contin. oper.	(7,604)	(2,005)
Net income	(5,784)	(1,864)
Earnings common share		
Primary	\$(0.16)	\$(0.05)
Fully Diluted	\$(0.16)	\$(0.05)
Common Shares:		
Full Diluted	36,170	34,706
Year-end	37,287	...

HASBRO, INC.**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Total Revenues	3,190,485	3,613,671
Cost & expenses	2,816,688	3,035,994
Operating income	320,505	539,271
Interest income	17,227	16,042
Interest expense	68,391	73,752
Other income (expense), net	6,189	26,003
Net before taxes	275,530	507,564
Income taxes	63,862	105,659
Net income	211,668	401,905
Earnings common share		
Primary	\$1.68	\$3.21
Fully Diluted	\$1.67	\$3.16
Common Shares:		
Full Diluted	126,774	127,248
Year-end	126,716	124,555

HAWKINS INC**Earnings, 6 mos. to (Consol. - \$):**

	09/30/18	10/01/17
Net Sales	295,124,000	259,126,000
Cost & expenses	270,815,000	239,606,000
Operating income	24,309,000	19,520,000
Net before taxes	22,640,000	17,954,000
Income taxes	6,108,000	6,913,000
Net income	16,532,000	11,041,000
Earnings common share		
Primary	\$1.55	\$1.04
Fully Diluted	\$1.54	\$1.04
Common Shares:		
Full Diluted	10,714,381	10,641,731
Year-end	10,679,469	10,608,563

HEALTH INSURANCE INNOVATIONS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	213,487	180,986
Cost & expenses	190,307	152,307
Operating income	19,525	25,721
Other income (expense), net	(809)	(27)
Net before taxes	18,755	25,696
Income taxes	4,757	4,220
Net income	13,998	21,476
Earnings common share		
Primary	\$0.83	\$1.31
Fully Diluted	\$0.76	\$1.21
Common Shares:		
Full Diluted	13,303	11,693
Year-end	16,057	

HEALTHCARE SERVICES GROUP, INC.**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	1,512,413,000	366,721,000
Cost & expenses	1,451,333,000	272,957,000
Operating income	64,903,000	98,287,000
Net before taxes	64,903,000	98,287,000
Income taxes	12,931,000	30,247,000
Net income	51,972,000	68,040,000
Earnings common share		
Primary	\$0.70	\$0.93
Fully Diluted	\$0.70	\$0.92
Common Shares:		
Full Diluted	74,598,000	74,252,000
Year-end	73,788,000	73,265,000

HEALTHSTREAM INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	171,791,000	159,630,000
Cost & expenses	141,040,000	133,860,000
Operating income	12,654,000	7,896,000
Other income (expense), net	241,000	481,000
Net before taxes	12,895,000	8,377,000
Income taxes	2,575,000	2,709,000
Income contin. oper.	10,320,000	5,668,000
Income discount. oper.	19,107,000	388,000
Net income	29,427,000	6,056,000
Earnings common share		
Primary	\$0.91	\$0.19
Fully Diluted	\$0.91	\$0.19
Common Shares:		

Full Diluted	32,308,000	32,183,000
Year-end	32,325,000	

HEMISPHERE MEDIA GROUP INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	101,065,000	100,512,000
Cost & expenses	64,080,000	62,329,000
Deprec., depl. & amort.	12,040,000	12,223,000
Operating income	24,945,000	25,960,000
Interest expense	8,976,000	8,089,000
Other income (expense), net	(25,198,000)	(2,983,000)
Net before taxes	(9,229,000)	14,888,000
Income taxes	4,490,000	6,280,000
Net income	(13,719,000)	8,608,000
Earnings common share		
Primary	\$(0.35)	\$0.21
Fully Diluted	\$(0.35)	\$0.21
Common Shares:		
Full Diluted	38,982,000	40,831,000
Year-end	38,959,957	41,490,991

HERITAGE-CRYSTAL CLEAN INC**Earnings, 9 mos. to (Consol. - \$):**

	09/08/18	09/09/17
Total Revenues	283,123,000	250,166,000
Cost & expenses	254,870,000	210,969,000
Operating income	17,175,000	26,696,000
Interest expense	742,000	775,000
Net before taxes	16,433,000	25,921,000
Income taxes	3,996,000	9,361,000
Net income	12,437,000	16,560,000
Earnings common share		
Primary	\$0.53	\$0.73
Fully Diluted	\$0.52	\$0.72
Common Shares:		
Full Diluted	23,299,000	22,813,000
Year-end	23,050,109	22,879,830

HIBBETT SPORTS INC

Acquisition Completed On Nov. 5, 2018, Co.'s wholly-owned subsidiary, Hibbett Sporting Goods, Inc., acquired all the outstanding warrants and equity interests, other than certain preferred membership interests, of City Gear, LLC ("City Gear"), a city specialty retailer of premium athletic footwear, apparel and accessories with 135 stores in 15 states, from the members and warrant holders of City Gear, for a purchase price of \$88,000,000 in cash. The aggregate consideration payable by Co. to the Sellers in connection with the transaction also included two contingent earnout payments based on City Gear's achievement of certain EBITDA thresholds for the 52-week periods ended Feb. 1, 2020 and Jan. 30, 2021, respectively. The aggregate amount of both contingent earnout payments, if any, would not exceed \$25,000,000. As the result, City Gear became an indirect wholly-owned subsidiary of Co.

HMS HOLDINGS CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	381,377	319,728
Operating income	35,390	31,166
Interest expense	8,562	7,734
Net before taxes	27,428	23,633
Income taxes	5,830	9,302
Net income	21,598	14,331
Earnings common share		
Primary	\$0.26	\$0.17
Fully Diluted	\$0.25	\$0.17
Common Shares:		
Full Diluted	85,241	85,586
Year-end	83,925	84,079

HOLOGIC INC**Annual Report****Consolidated Income Statement, Years Ended (\$):**

	09/29/18	09/30/17	09/24/16
		(revised)	(revised)
Product revenues	2,643,900,000	2,538,000,000	2,379,000,000
Service & other revenues	574,000,000	520,800,000	453,700,000
Total revenues	3,217,900,000	3,058,800,000	2,832,700,000
Product	886,600,000	881,800,000	756,800,000
Amortization of intangible assets	319,400,000	297,100,000	293,400,000
Service & other			

revenues	315,200,000	258,900,000	219,200,000
Gross profit	1,696,700,000	1,621,000,000	1,563,300,000
Research & development expense	218,700,000	232,800,000	232,100,000
Selling & marketing expense	544,600,000	498,600,000	415,100,000
General & administrative expense	366,100,000	343,300,000	267,300,000
Amortization of intangible assets	59,300,000	62,500,000	89,700,000
Impairment of intangible assets	46,000,000
Impairment of goodwill	685,700,000
Gain on sale of business	...	899,700,000	...
Restructuring charges	14,200,000	13,300,000	10,500,000
Total operating expenses	1,934,600,000	250,800,000	1,014,700,000
Income (loss) from operations	(237,900,000)	1,370,200,000	548,600,000
Interest income	6,300,000	3,800,000	700,000
Interest expense	148,700,000	153,200,000	155,300,000
Debt extinguishment gains (losses)	(45,900,000)	(3,200,000)	(5,300,000)
Other income (expense), net	7,600,000	12,900,000	26,600,000
Income (loss) before income taxes - domestic	(581,900,000)	1,105,800,000	310,700,000
Income (loss) before income taxes - foreign	163,300,000	124,700,000	104,600,000
Income (loss) before income taxes	(418,600,000)	1,230,500,000	415,300,000
Federal provision (benefit) for income taxes - current	137,100,000	701,100,000	209,000,000
Federal provision (benefit) for income taxes - deferred	(461,900,000)	(276,900,000)	(122,700,000)
Total federal provision (benefit) for income taxes	(324,800,000)	424,200,000	86,300,000
State provision (benefit) for income taxes - current	11,000,000	53,100,000	16,600,000
State provision (benefit) for income taxes - deferred	(11,300,000)	(15,900,000)	(22,700,000)
Total state provision (benefit) for income taxes	(300,000)	37,200,000	(6,100,000)
Foreign provision (benefit) for income taxes - current	21,900,000	13,900,000	14,700,000
Foreign provision (benefit) for income taxes - deferred	(4,100,000)	(300,000)	(10,400,000)
Total foreign provision (benefit) for income taxes	17,800,000	13,600,000	4,300,000
Provision (benefit) for income taxes	(307,300,000)	475,000,000	84,500,000
Net income (loss)	(111,300,000)	755,500,000	330,800,000
Weighted average shares outstanding - basic	275,105,000	279,811,000	280,213,000
Weighted average shares outstanding - diluted	275,105,000	285,653,000	286,156,000
Year end shares outstanding	270,088,000	275,293,000	277,726,000
Net income (loss) per common share - basic	\$(0.40)	\$2.70	\$1.18

Net income (loss) per common share - diluted	\$(0.40)	\$2.64	\$1.16
Number of full time employees	6,252	6,233	5,333
Number of common stockholders	1,031	1,077	1,142

□ Reclassified to conform with 2018 presentation; □ Approximately; □ As of November 15, 2018; □ As of November 14, 2017; □ As of November 11, 2016

Consolidated Balance Sheet, Years Ended (\$):

	09/29/18	09/30/17 (revised)
Cash & cash equivalents	666,700,000	540,600,000
Accounts receivable, gross	595,400,000	543,300,000
Less: reserves	16,200,000	9,800,000
Accounts receivable, net	579,200,000	533,500,000
Raw materials	134,900,000	95,700,000
Work-in-process	52,100,000	45,000,000
Finished goods	197,100,000	190,900,000
Inventories	384,100,000	331,600,000
Prepaid income taxes	31,700,000	22,400,000
Prepaid expense & other current assets	61,500,000	50,500,000
Total current assets	1,723,200,000	1,478,600,000
Equipment	391,900,000	357,900,000
Equipment under customer usage agreements	399,600,000	368,700,000
Buildings & improvements	175,100,000	172,000,000
Leasehold improvements	63,000,000	60,600,000
Land	46,300,000	46,300,000
Furniture & fixtures	18,400,000	20,800,000
Property, plant & equipment, at cost	1,094,300,000	1,026,300,000
Less: accumulated depreciation & amortization	616,100,000	553,500,000
Property, plant & equipment, net	478,200,000	472,800,000
Intangible assets, net	2,398,600,000	2,772,300,000
Goodwill	2,533,200,000	3,171,200,000
Life insurance contracts	44,200,000	41,000,000
Manufacturing access fees	4,600,000	7,100,000
Cost-method equity investments	8,800,000	3,000,000
Deferred tax assets	12,900,000	9,100,000
Other assets	27,200,000	24,500,000
Total assets	7,230,900,000	7,979,600,000
Term loan	74,700,000	121,300,000
Revolver	300,000,000	345,000,000
Securitization program	225,000,000	200,000,000
Convertible notes	484,500,000	
Current portion of long-term debt	599,700,000	1,150,800,000
Accounts payable	192,200,000	166,600,000
Accrued compensation & employee benefits	196,000,000	176,700,000
Accrued income taxes & other taxes	57,200,000	66,900,000
Other accrued expenses	182,900,000	131,700,000
Accrued expenses	436,100,000	375,300,000
Deferred revenue	172,900,000	171,200,000
Current portion of capital lease obligations	1,700,000	1,600,000
Total current liabilities	1,402,600,000	1,865,500,000
Term loan	1,376,300,000	1,190,500,000
Senior notes	1,328,300,000	981,600,000
Long-term debt, net of current portion	2,704,600,000	2,172,100,000
Capital lease obligations, net of current portion	20,900,000	22,700,000
Deferred income tax liabilities	498,200,000	973,600,000
Deferred revenue	18,200,000	20,800,000
Reserve for income tax uncertainties	92,600,000	88,300,000
Accrued lease obligation - long-term	35,500,000	34,100,000
Pension liabilities	9,900,000	10,000,000
Other long-term		

liabilities	19,600,000	7,800,000
Other long-term liabilities	157,600,000	140,200,000
Common stock	2,900,000	2,900,000
Additional paid-in-capital	5,671,300,000	5,630,800,000
Retained earnings (accumulated deficit)	(2,494,000,000)	(2,382,700,000)
Treasury stock, at cost	725,900,000	450,100,000
Foreign currency translation	(26,600,000)	(18,500,000)
Marketable securities		(400,000)
Pension plans	(1,100,000)	(1,600,000)
Hedged Interest rate caps, net	2,200,000	4,300,000
Accumulated other comprehensive income (loss)	(25,500,000)	(16,200,000)
Total stockholders' equity (deficit)	2,428,800,000	2,784,700,000

□ Restated to reflect adoption of ASU 2016-19

Recent Dividends:

1. Hologic Inc common.

No dividends paid.

Annual Dividends:

1. Hologic Inc common.

No dividends paid.

HOMESTREET INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	354,639	362,726
Operating income	31,006	49,147
Net before taxes	31,006	49,147
Income taxes	6,206	15,116
Net income	24,800	34,031
Earnings common share		
Primary	\$0.92	\$1.27
Fully Diluted	\$0.91	\$1.26
Common Shares:		
Full Diluted	27,166	27,077
Year-end	26,990	26,884

HORIZON BANCORP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	100,482	80,956
Operating income	47,892	34,545
Net before taxes	47,892	34,545
Income taxes	7,908	9,078
Net income	39,984	25,467
Balance for common	39,984	25,467
Earnings common share		
Primary	\$1.04	\$0.76
Fully Diluted	\$1.04	\$0.75
Common Shares:		
Full Diluted	38,503	33,684
Year-end	38,368	34,988

HORIZON TECHNOLOGY FINANCE CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	12,383	9,697
Net income	9,902	9,917
Earnings common share		
Primary	\$0.86	\$0.86
Common Shares:		
Year-end	11,531	11,517

HORTONWORKS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	252,578	186,804
Cost & expenses	367,150	339,848
Operating income	(114,572)	(153,044)
Other income (expense), net	1,273	(2,134)
Net before taxes	(113,299)	(155,178)
Income taxes	1,527	1,101
Net income	(114,826)	(156,279)
Earnings common share		
Primary	\$(1.45)	\$(2.41)
Fully Diluted	\$(1.45)	\$(2.41)
Common Shares:		

Full Diluted	79,166	64,747
Year-end	83,045	69,413

HOSPITALITY PROPERTIES TRUST

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,743,737	1,636,793
Cost & expenses	1,094,337	1,041,643
Operating income	206,314	184,826
Interest income	1,093	590
Interest expense	145,589	135,329
Other income (expense), net	1,718	11,226
Gains or losses	89,348	
Equity earnings	(881)	(533)
Net before taxes	295,662	184,826
Income taxes	1,949	1,761
Net income	294,594	183,598
Balance for common	294,594	172,270
Earnings common share		
Primary	\$1.79	\$1.05
Fully Diluted	\$1.79	\$1.05
Common Shares:		
Full Diluted	164,242	164,168
Year-end	164,442	164,349

HOUGHTON MIFFLIN HARCOURT CO.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	1,073,379	1,093,284
Cost & expenses	1,068,955	1,116,915
Operating income	(15,814)	(45,958)
Interest income	900	641
Other income (expense), net	(14)	3,888
Net before taxes	(48,963)	(73,409)
Income taxes	2,104	10,482
Income contin. oper.	(51,067)	(83,891)
Net income	(38,234)	(77,019)
Earnings common share		
Primary	\$(0.31)	\$(0.63)
Fully Diluted	\$(0.31)	\$(0.63)
Common Shares:		
Full Diluted	123,401	122,913
Year-end	123,561	

HUDSON GLOBAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	50,357	44,371
Cost & expenses	55,012	44,897
Deprec., depl. & amort.	3	238
Operating income	(4,658)	(764)
Other income (expense), net	(184)	(71)
Net before taxes	(4,680)	(842)
Income taxes	393	850
Income contin. oper.	(5,073)	(1,692)
Net income	8,487	(936)
Earnings common share		
Primary	\$0.26	\$(0.03)
Fully Diluted	\$0.26	\$(0.03)
Common Shares:		
Full Diluted	32,746	32,120
Year-end	32,048	

HURON CONSULTING GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	649,319,000	602,505,000
Cost & expenses	588,017,000	754,284,000
Operating income	35,021,000	180,328,000
Other income (expense), net	(5,131,000)	3,204,000
Net before taxes	15,254,000	190,935,000
Income taxes	4,365,000	(49,740,000)
Income contin. oper.	10,889,000	141,195,000
Net income	10,585,000	140,505,000
Earnings common share		
Primary	\$0.49	\$(6.56)
Fully Diluted	\$0.48	\$(6.56)
Common Shares:		
Full Diluted	21,947,000	21,413,000
Year-end	22,554,917	22,131,497

IAC/INTERACTIVECORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	3,158,789	2,356,654
Cost & expenses	2,610,290	2,184,907
Operating income	431,219	94,106
Other income (expense), net	174,635	(7,700)
Net before taxes	524,383	11,850
Income taxes	(15,887)	(322,809)
Net income	540,270	334,659
Earnings common share		
Primary	\$5.22	\$3.43
Fully Diluted	\$4.55	\$2.82
Common Shares:		
Full Diluted	91,418	84,502
Year-end	83,490	

ICF INTERNATIONAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	960,063	907,988
Cost & expenses	877,480	824,095
Operating income	62,829	62,237
Interest expense	6,073	6,663
Other income (expense), net	(565)	24
Net before taxes	56,191	55,598
Income taxes	13,486	19,792
Net income	42,705	35,806
Earnings common share		
Primary	\$2.27	\$1.90
Fully Diluted	\$2.22	\$1.86
Common Shares:		
Full Diluted	19,256	19,218
Year-end	18,868	18,639

ICONIX BRAND GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	210,140,000	718,090,000
Operating income	(66,944,000)	546,369,000
Interest expense	44,320,000	45,787,000
Other income (expense), net	88,474,000	(18,290,000)
Foreign currency	(453,000)	(2,755,000)
Net before taxes	(22,939,000)	612,784,000
Income taxes	(128,000)	(29,220,000)
Income contin. oper.	(559,707,000)	
Income discount. oper.		46,369,000
Net income	(31,446,000)	559,707,000
Earnings common share		
Primary	\$(0.62)	\$(9.02)
Fully Diluted	\$(0.81)	\$(9.02)
Common Shares:		
Full Diluted	123,096,000	57,081,000
Year-end	74,831,000	57,319,000

ICU MEDICAL INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,059,662	922,489
Net Sales	1,059,662	921,544
Cost & expenses	1,025,907	979,106
Operating income	33,755	(56,617)
Other income (expense), net	1,650	69,741
Net before taxes	34,857	11,381
Income taxes	(1,291)	(7,558)
Net income	36,148	18,939
Earnings common share		
Primary	\$1.78	\$0.97
Fully Diluted	\$1.67	\$0.92
Common Shares:		
Full Diluted	21,588	20,603
Year-end	20,489	20,021

IDENTIV INC

Merger Completed On Nov. 1, 2018, Co.'s wholly-owned subsidiary, TSS Merger Sub, Inc. ("Merger Sub 1"), merged with and into Thursby Software Systems, Inc. ("TSS"), an Arlington, Texas-based provider of security software for mobile devices, with TSS became a wholly-owned subsidiary of Co. ("Merger 1"), following which TSS merged with and into Co.'s wholly-owned subsidiary, TSS Merger, LLC ("Merger Sub 2"), with Merger Sub 2 continuing as the surviving corporation ("Merger 2" and together with Merger 1, the "Merger"). As the result the merger, the aggregate consideration to be paid by Co. at the closing of the Merger was approximately \$5,000,000, consisting of (i) approximately \$2,500,000 in cash, subject to adjustments based on TSS's closing

working capital, and (ii) the issuance of shares of Co.'s common stock with a value of approximately \$2,500,000. Additionally, in the event that revenue from TSS products were greater than \$8,000,000, \$11,000,000, or \$15,000,000 in product shipments in 2019, Co. would be obligated to issue earn-out consideration of up to a maximum of \$7,500,000 payable in shares of Co.'s common stock (subject to certain conditions) (collectively, all consideration issuable in connection with the Merger, the "Merger Consideration"). In the event that such revenue was less than \$15,000,000 in 2019, but 2020 revenue from TSS products exceeds \$15,000,000, then Co. would be obligated to issue an additional \$2,500,000 in earnout consideration in the form of stock. The maximum total earnout consideration payable for all periods was \$7,500,000 in the aggregate, payable in Co. common stock. \$500,000 of Co.'s common stock issuable at the closing of the transaction will be held back for 12 months following the closing for the satisfaction of certain indemnification claims.

IDENTIV INC

Merger Development On Oct. 25, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Co., TSS Merger Sub, Inc., a wholly owned subsidiary of Co. ("Merger Sub 1"), TSS Acquisition, LLC, a wholly owned subsidiary of Co. ("Merger Sub 2" and together with Merger Sub 1, the "Merger Subs"), Thursby Software Systems, Inc. ("TSS"), a provider of security software for mobile devices, and William Thursby as the sole Stockholder of TSS. Pursuant to the terms and conditions set forth in the Merger Agreement, at the effective time of the merger, Merger Sub 1 will merge with and into TSS and TSS will become a wholly-owned subsidiary of Co. ("Merger 1"), following which TSS will merge with and into Merger Sub 2, whereupon which the separate corporate existence of TSS will cease with Merger Sub 2 surviving the merger ("Merger 2" and together with Merger 1, the "Merger"). Under the terms of the Merger Agreement, the aggregate consideration to be paid by Co. at the closing of the Merger is approximately \$5,000,000, consisting of (i) approximately \$2,500,000 in cash, subject to adjustments based on TSS's closing working capital, and (ii) the issuance of shares of Co.'s common stock with a value of approximately \$2,500,000. Additionally, in the event that revenue from TSS products is greater than \$8,000,000, \$11,000,000, or \$15,000,000 in product shipments in 2019, Co. will be obligated to issue earn-out consideration of up to a maximum of \$7,500,000 payable in shares of Co.'s common stock (subject to certain conditions) (collectively, all consideration issuable in connection with the Merger, the "Merger Consideration"). In the event that such revenue is less than \$15,000,000 in 2019, but 2020 revenue from TSS products exceeds \$15,000,000, then Co. will be obligated to issue an additional \$2,500,000 in earnout consideration in the form of stock. The maximum total earnout consideration payable for all periods is \$7,500,000 in the aggregate, payable in Co. common stock. \$500,000 of Co.'s common stock issuable at the closing of the transaction will be held back for 12 months following the closing for the satisfaction of certain indemnification claims. Completion of the Merger is subject to customary closing conditions, and the Merger is expected to close on or about Nov. 1, 2018 (the "Closing").

IDEXX LABORATORIES, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	1,663,856,000	462,937,000
Cost & expenses	1,287,868,000	147,717,000
Operating income	375,988,000	315,220,000
Interest income	893,000	3,659,000
Interest expense	26,184,000	27,508,000
Net before taxes	350,697,000	291,371,000
Income taxes	59,327,000	66,392,000
Net income	291,370,000	224,979,000
Earnings common share		
Primary	\$3.35	\$2.56
Fully Diluted	\$3.29	\$2.51
Common Shares:		
Full Diluted	88,687,000	89,735,000
Year-end	86,546,000	87,301,000

II-VI INC

Earnings, 3 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	314,433	261,503
Cost & expenses	282,091	234,604
Operating income	32,342	26,899
Net before taxes	32,342	26,899
Income taxes	6,193	5,758
Net income	26,149	21,141
Earnings common share		

Primary	\$0.41	\$0.34
Fully Diluted	\$0.40	\$0.32
Common Shares:		
Full Diluted	66,158	65,283
Year-end	63,578	62,179

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	271,343
Inventories	265,101
Current assets	817,359
Net property & equip.	541,519
Total assets	1,880,643
Liabilities:	
Current liabilities	225,300
Long-term debt	517,144
Stockholders' equity	1,043,588
Net current assets	592,059

II-VI INC

Merger Development On Nov. 8, 2018, Finisar Corp. ("Finisar"), Co. and Mutation Merger Sub Inc. ("Merger Subsidiary"), a wholly-owned subsidiary of Co., entered into an Agreement and Plan of Merger (the "Merger Agreement"), pursuant to which, among other things, Merger Subsidiary will be merged with and into Finisar (the "Merger"), with Finisar surviving the Merger as a wholly-owned subsidiary of Co. At the time the Merger becomes effective (the "Effective Time"), each issued and outstanding share of common stock, par value \$0.001 per share, of Finisar ("Finisar Stock") (other than shares of Finisar Stock owned by Co. or Merger Subsidiary or any direct or indirect wholly owned subsidiary of Co., which will be cancelled without consideration, and holders of Finisar Stock, if any, who properly exercise their appraisal rights under the General Corporation Law of the State of Delaware) outstanding immediately prior to the Merger will be automatically cancelled and converted into the right to receive, for each share of Finisar Stock, at the stockholder's election and subject to proration in the event the cash consideration or Co. Common Stock (as defined below) consideration is oversubscribed, either (i) \$26.00 in cash (the "Cash Election Consideration"), (ii) 0.5546 of a share of common stock, no par value, of Co. ("Co. Common Stock") (the "Stock Election Consideration"), or (iii) a combination of (A) 0.2218 of a share of Co. Common Stock (the "Exchange Ratio") and (B) \$15.60 in cash, without interest (the "Mixed Election Consideration"). On an average basis across all shares of Finisar Stock (including the Options (as defined below) and Performance RSUs (as defined below)), at the closing of the Merger, 60% of the aggregate amount of the outstanding shares of Finisar Stock (including the Options and Performance RSUs) will be converted into the right to receive the Cash Election Consideration, with the remaining 40% converted into the right to receive the Stock Election Consideration. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised option to purchase Finisar Stock (whether vested or unvested) (an "Option") shall automatically be cancelled and terminated and converted into the right to receive an amount of Mixed Election Consideration equal to the product of (i) the excess, if any, of the Cash Election Consideration over the exercise price per share of such Option multiplied by (ii) the number of shares of Finisar Stock subject to such Option, payable no later than Finisar's next payroll date after the closing of the Merger. Further, as of the Effective Time, each award of restricted stock units of Finisar that is outstanding immediately prior to the Effective Time and is subject to a performance-based vesting condition (a "Performance RSU") that relates solely to the value of Finisar Stock will vest as to a number of shares determined under the terms of the award and will be cancelled and extinguished and converted into the right to receive the Cash Election Consideration, the Stock Election Consideration or the Mixed Election Consideration in accordance with the election made by the holder of such Performance RSU. At the Effective Time, each other award of restricted stock units of Finisar that is outstanding and unvested will be assumed by Co. and continue to be subject to substantially the same terms and conditions (including vesting requirements) as in effect immediately prior to the Effective Time, except that the number of shares of Co. Common Stock subject to such assumed restricted stock unit awards will be equal to the product of (i) the number of shares of Finisar Stock underlying such unvested restricted stock unit award as of immediately prior to the Effective Time multiplied by (ii) the sum of the (A) Exchange Ratio plus (B) the quotient obtained by dividing \$15.60 by the Equity Award Measurement Price. The "Equity Award Measurement Price" means the volume weighted average price per share of Co. Common Stock on NASDAQ for the ten (10) consecutive trading days ending on (and including) the third trading day immediately prior to the Effective

time. The transaction is expected to close in the middle of calendar year 2019, subject to approval by each company's shareholders, antitrust regulatory approvals and other customary closing conditions. The transaction values Finisar at \$26.00 per share, or approximately \$3,200,000,000 in equity value and represents a premium of 37.7% to Finisar's closing price on Nov. 8, 2018.

ILLUMINA INC

Acquisition Development On Nov. 1, 2018, Co. announced that it has plans to acquire Pacific Biosciences of California Inc ("Pacific Biosciences") for approximately \$1,200,000,000 in cash. Under the agreement, which has been approved by both companies' boards of directors, Co. will pay \$8.00 per Pacific Biosciences share, representing a 71% premium over Pacific Biosciences 30 trading-day volume weighted average share price as of the market close on Oct. 31, and a total value of about \$1,200,000,000 on a fully diluted basis.

ILLUMINA INC

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Total Revenues	2,466,000	1,975,000
Cost & expenses	1,780,000	1,599,000
Operating income	686,000	376,000
Interest expense	31,000	13,000
Interest expense	37,000	26,000
Other income (expense), net	5,000	457,000
Net before taxes	685,000	820,000
Income taxes	100,000	199,000
Net income	585,000	621,000
Earnings common share		
Primary	\$4.20	\$4.49
Fully Diluted	\$4.15	\$4.45
Common Shares:		
Full Diluted	148,000	148,000
Year-end	147,000	146,000

IMMUNOGEN, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	40,030,000	75,999,000
Cost & expenses	161,056,000	125,145,000
Operating income	(121,026,000)	(49,146,000)
Other income (expense), net	(590,000)	(20,826,000)
Gains or losses	2,845,000	551,000
Net income	(127,044,000)	(82,894,000)
Earnings common share		
Primary	\$(0.92)	\$(0.93)
Fully Diluted	\$(0.92)	\$(0.93)
Common Shares:		
Full Diluted	137,472,000	89,133,000
Year-end	149,049,000	115,563,000

IMMUNOMEDICS, INC.

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	57,169,000	690,000
Cost & expenses	57,169,000	22,288,000
Operating income	(57,169,000)	(21,598,000)
Interest expense	10,142,000	2,647,000
Other income (expense), net	1,408,000	(95,017,000)
Foreign currency	84,000	
Net income	(64,209,000)	118,762,000
Earnings common share		
Primary	\$(0.34)	\$(0.97)
Fully Diluted	\$(0.34)	\$(0.97)
Common Shares:		
Full Diluted	186,937,000	122,550,000
Year-end	187,079,000	

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	580,594,000
Current assets	594,014,000
Net property & equip.	18,587,000
Total assets	612,662,000
Liabilities:	
Current liabilities	44,171,000
Long-term debt	19,799,000
Stockholders' equity	343,753,000
Net current assets	549,843,000

IMPINJ INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	88,015	98,437
Cost & expenses	116,691	105,932

Operating income	(28,676)	(7,495)
Interest expense	970	904
Other income (expense), net	561	563
Net before taxes	(29,085)	(7,836)
Income taxes	159	152
Net income	(29,244)	(7,988)
Earnings common share		
Primary	\$(1.37)	\$(0.39)
Fully Diluted	\$(1.37)	\$(0.39)
Common Shares:		
Full Diluted	21,287	20,604
Year-end	21,482	20,955

INCYTE CORPORATION

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,353,481	1,092,060
Cost & expenses	1,306,233	1,203,029
Operating income	47,248	(110,969)
Other income (expense), net	(1,430)	(46,517)
Net before taxes	44,630	(164,013)
Income taxes	4,200	(500)
Net income	40,430	(163,513)
Earnings common share		
Primary	\$0.19	\$(0.81)
Fully Diluted	\$0.19	\$(0.81)
Common Shares:		
Full Diluted	215,516	202,399
Year-end	212,754	211,019

INFINITY PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	25,474,000	34,425,000
Operating income	(3,474,000)	(28,425,000)
Interest expense	93,000	890,000
Other income (expense), net	534,000	(5,219,000)
Net income	(3,033,000)	(34,534,000)
Earnings common share		
Primary	\$(0.06)	\$(0.68)
Fully Diluted	\$(0.06)	\$(0.68)
Common Shares:		
Full Diluted	54,918,963	50,505,783
Year-end	56,855,548	

INNERWORKINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	827,356,000	832,994,000
Cost & expenses	856,535,000	792,855,000
Deprec., depl. & amort.	10,438,000	9,403,000
Operating income	(39,617,000)	30,736,000
Interest expense	135,000	77,000
Interest expense	4,854,000	3,239,000
Net before taxes	(46,070,000)	26,612,000
Income taxes	851,000	9,444,000
Net income	(46,921,000)	17,168,000
Earnings common share		
Primary	\$(0.90)	\$0.32
Fully Diluted	\$(0.90)	\$0.31
Common Shares:		
Full Diluted	52,384,000	55,127,000
Year-end	51,746,000	

INNOPHOS HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	609,099	528,923
Cost & expenses	563,796	475,159
Operating income	45,303	53,764
Other income (expense), net	42	42
Foreign currency	(409)	35
Net before taxes	35,406	49,406
Income taxes	4,155	15,678
Net income	31,251	33,728
Balance for common	31,139	33,540
Earnings common share		
Primary	\$1.60	\$1.73
Fully Diluted	\$1.57	\$1.70
Common Shares:		
Full Diluted	19,791	19,696
Year-end	19,613	19,529

INNOVIVA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

Net Sales	1,081,900	953,000
Cost & expenses	991,300	865,200
Operating income	90,600	87,800
Interest expense	5,300	6,300
Other income (expense), net	4,300	6,400
Net before taxes	89,600	87,900
Income taxes	25,000	21,300
Net income	64,600	66,600
Earnings common share		
Primary	\$2.65	\$2.76
Fully Diluted	\$2.63	\$2.71
Common Shares:		
Full Diluted	24,580	24,569
Year-end	24,424	24,138

Net Sales	1,081,900	953,000
Cost & expenses	991,300	865,200
Operating income	90,600	87,800
Interest expense	5,300	6,300
Other income (expense), net	4,300	6,400
Net before taxes	89,600	87,900
Income taxes	25,000	21,300
Net income	64,600	66,600
Earnings common share		
Primary	\$2.65	\$2.76
Fully Diluted	\$2.63	\$2.71
Common Shares:		
Full Diluted	24,580	24,569
Year-end	24,424	24,138

INNOVIVA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	181,146	147,697
Cost & expenses	20,115	30,502
Operating income	161,031	117,195
Other income (expense), net	(5,686)	(7,108)
Net income	137,113	75,758
Earnings common share		
Primary	\$1.30	\$0.71
Fully Diluted	\$1.19	\$0.67
Common Shares:		
Full Diluted	113,444	120,120
Year-end	101,039	108,002

INOGEN, INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	271,580	185,651
Net Sales	255,283	167,141
Cost & expenses	238,463	163,251
Operating income	33,117	22,400
Interest income	2,111	468
Other income (expense), net	(596)	994
Net before taxes	34,632	23,862
Income taxes	(7,168)	2,254
Net income	41,800	21,608
Earnings common share		
Primary	\$1.97	\$1.05
Fully Diluted	\$1.86	\$0.99
Common Shares:		
Full Diluted	22,512	21,833
Year-end	21,503	20,852

INOVALON HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	391,362	334,739
Cost & expenses	328,443	267,131
Deprec., depl. & amort.	69,857	38,514
Operating income	(6,938)	29,094
Interest income	1,874	4,045
Interest expense	34,274	4,549
Gains or losses	(1,841)	(381)
Net before taxes	(41,179)	28,209
Income taxes	(13,035)	10,840
Net income	(28,144)	17,369
Balance for common	(28,144)	16,905
Earnings common share		
Primary	\$(0.19)	\$0.12
Fully Diluted	\$(0.19)	\$0.12
Common Shares:		
Full Diluted	144,662	143,327
Year-end	152,436	145,897

INSIGHT ENTERPRISES INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	5,331,090	4,919,548
Cost & expenses	5,156,266	4,785,821
Operating income	174,824	133,727
Other income (expense), net	(1,019)	(980)
Foreign currency	(19)	(972)
Net before taxes	157,190	118,824
Income taxes	40,554	42,309
Net income	116,636	76,515
Earnings common share		
Primary	\$3.27	\$2.14

Fully Diluted	\$3.24	\$2.11
Common Shares:		
Full Diluted	36,012	36,186
Year-end	35,459	35,792

employees	810	803	848
Number of common stockholders	550	582	675

As of: As of October 23, 2018; As of October 25, 2017; As of October 25, 2016

INSMED INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Cost & expenses	219,616,000	123,567,000
Operating income	(219,616,000)	123,567,000
Interest expense	18,805,000	4,459,000
Other income (expense), net	(1,659,000)	206,000
Gains or losses	7,510,000	649,000
Net before taxes	(232,570,000)	127,171,000
Income taxes	134,000	94,000
Net income	(232,704,000)	127,265,000
Earnings common share		
Primary	\$(3.03)	\$(2.01)
Fully Diluted	\$(3.03)	\$(2.01)
Common Shares:		
Full Diluted	76,819,000	63,199,000
Year-end	77,085,715	76,568,368

INSTEEL INDUSTRIES, INC.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/29/18	09/30/17	10/01/16
Net sales	453,217	388,871	418,547
Cost of sales	382,410	329,090	333,359
Gross profit (loss)	70,807	59,781	85,188
Selling, general & administrative expense	28,304	25,508	26,069
Pension plan settlement loss	2,539
Restructuring charges, net	...	164	115
Other income (expense), net	(274)	(53)	(183)
Interest expense	114	136	158
Interest income	515	248	166
Earnings (loss) before income taxes	42,630	34,168	56,290
Current provision (benefit) for income taxes - federal	8,265	8,269	17,075
Current provision (benefit) for income taxes - state	906	848	1,434
Total current provision (benefit) for income taxes	9,171	9,117	18,509
Deferred provision (benefit) for income taxes - federal	(2,862)	2,455	396
Deferred provision (benefit) for income taxes - state	55	48	140
Total deferred provision (benefit) for income taxes	(2,807)	2,503	536
Provision (benefit) for income taxes	6,364	11,620	19,045
Net earnings (loss)	36,266	22,548	37,245
Weighted average shares			
outstanding-basic	19,079	19,011	18,754
Weighted average shares			
outstanding-diluted	19,277	19,217	19,055
Year end shares outstanding	19,223	19,041	18,976
Net earnings (loss) per share basic	\$1.90	\$1.19	\$1.99
Net earnings (loss) per share diluted	\$1.88	\$1.17	\$1.95
Cash dividends per share	\$1.12	\$1.37	\$1.12
Total number of			

Consolidated Balance Sheet, Years Ended (\$000):

	09/29/18	09/30/17
Cash & cash equivalents	43,941	32,105
Accounts receivable, gross	51,779	40,485
Less allowance for doubtful accounts	295	201
Accounts receivable, net	51,484	40,284
Raw materials	61,008	51,808
Work in process	4,779	2,637
Finished goods	28,370	27,408
Inventories, net	94,157	81,853
Prepaid insurance	3,845	3,796
Income taxes receivable	...	925
Other current assets	2,050	1,228
Total current assets	195,477	160,191
Land & land improvements	14,438	12,177
Buildings	54,684	50,373
Machinery & equipment	160,068	153,484
Construction in progress	9,672	5,641
Property, plant & equipment, gross	238,862	221,675
Less accumulated depreciation	132,714	123,005
Property, plant & equipment, net	106,148	98,670
Intangibles, net	9,703	7,913
Goodwill	8,293	6,965
Cash surrender value of life insurance policies	9,769	9,026
Capitalized financing costs, net	40	105
Other assets	104	203
Total assets	329,534	283,073
Accounts payable	60,059	33,651
Accrued salaries, wages & related expenses	6,775	5,520
Accrued property taxes	1,585	1,384
Accrued customer rebates	1,531	1,015
Accrued workers' compensation	113	116
Accrued sales allowance reserve	804	21
Accrued income taxes	469	...
Other accrued expenses	652	611
Total current liabilities	71,988	42,318
Deferred compensation	10,541	9,276
Deferred income taxes	5,340	8,103
Common stock	19,223	19,041
Additional paid-in capital	72,852	69,817
Retained earnings (accumulated deficit)	151,084	135,851
Accumulated other comprehensive income (loss)	(1,494)	(1,333)
Total shareholders' equity	241,665	223,376

Recent Dividends:**1. Insteel Industries, Inc. common (stated value: \$1.00).**

ExDate	Amt	Declared	Record	Payable
03/11/2015	0.03	02/17/2015	03/13/2015	03/27/2015
06/10/2015	0.03	05/12/2015	06/12/2015	06/26/2015
09/09/2015	0.03	08/18/2015	09/11/2015	09/25/2015
12/09/2015	0.03	11/11/2015	12/11/2015	12/29/2015
12/09/2015	1.00	11/11/2015	12/11/2015	01/08/2016
03/09/2016	0.03	02/11/2016	03/11/2016	03/25/2016
06/08/2016	0.03	05/17/2016	06/10/2016	06/24/2016
09/14/2016	0.03	08/16/2016	09/16/2016	09/30/2016
12/12/2016	0.03	11/15/2016	12/14/2016	01/06/2017
12/12/2016	1.25	11/15/2016	12/14/2016	01/06/2017
03/15/2017	0.03	02/07/2017	03/17/2017	03/31/2017
06/14/2017	0.03	05/09/2017	06/16/2017	06/30/2017
09/14/2017	0.03	08/15/2017	09/15/2017	09/29/2017

12/19/2017	0.03	11/07/2017	12/20/2017	01/05/2018
12/19/2017	1.00	10/19/2017	12/20/2017	01/05/2018
03/15/2018	0.03	02/13/2018	03/16/2018	03/30/2018
06/14/2018	0.03	05/15/2018	06/15/2018	06/29/2018
09/13/2018	0.03	08/14/2018	09/14/2018	09/28/2018

Annual Dividends:**1. Insteel Industries, Inc. common (stated value: \$1.00).**

2015	0.12	2016	1.09	2017	1.37
2018	1.12				

INSULET CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	398,916	333,244
Cost & expenses	387,726	339,863
Operating income	11,190	(6,619)
Other income (expense), net	5,202	1,478
Net before taxes	(5,662)	(19,653)
Income taxes	939	318
Net income	(6,601)	(19,971)
Earnings common share		
Primary	\$(0.11)	\$(0.34)
Fully Diluted	\$(0.11)	\$(0.34)
Common Shares:		
Full Diluted	58,780	57,925
Year-end	59,069	58,156

INSYS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	65,723,000	109,208,000
Cost & expenses	144,480,000	307,578,000
Operating income	(78,757,000)	198,370,000
Other income (expense), net	(472,000)	(44,000)
Net before taxes	(77,759,000)	197,004,000
Income taxes	455,000	(16,096,000)
Net income	(78,214,000)	180,908,000
Earnings common share		
Primary	\$(1.06)	\$(2.50)
Fully Diluted	\$(1.06)	\$(2.50)
Common Shares:		
Full Diluted	73,997,016	72,366,618
Year-end	74,265,661	...

INTEGRA LIFESCIENCES HOLDINGS CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	1,089,126,000	819,634,000
Cost & expenses	996,292,000	767,072,000
Operating income	76,890,000	37,586,000
Interest income	325,000	160,000
Interest expense	50,750,000	18,073,000
Other income (expense), net	6,422,000	(3,691,000)
Net before taxes	32,887,000	15,982,000
Income taxes	(2,776,000)	(4,406,000)
Net income	35,663,000	20,388,000
Earnings common share		
Primary	\$0.43	\$0.27
Fully Diluted	\$0.43	\$0.26
Common Shares:		
Full Diluted	83,142,000	78,973,000
Year-end	85,133,000	78,385,000

INTEGRATED DEVICE TECHNOLOGY INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Total Revenues	464,000	401,111
Cost & expenses	381,300	357,929
Operating income	82,700	43,182
Interest income	2,345	1,593
Interest expense	14,230	13,731
Other income (expense), net	(237)	3,337
Net before taxes	70,578	34,381
Income taxes	4,358	(1,013)
Net income	66,220	35,394
Earnings common share		
Primary	\$0.51	\$0.27
Fully Diluted	\$0.49	\$0.26
Common Shares:		
Full Diluted	133,957	136,434
Year-end	128,999	132,991

INTEL CORP**Earnings, 9 mos. to (Consol. - \$Millions):**

	09/29/18	09/30/17
Total Revenues	52,191	45,708
Cost & expenses	34,949	32,969
Operating income	17,092	12,615
Interest income	308	349
Other income (expense), net	619	1,846
Net before taxes	17,682	14,317
Income taxes	1,824	4,029
Net income	15,858	10,288
Earnings common share		
Primary	\$3.42	\$2.19
Fully Diluted	\$3.35	\$2.12
Common Shares:		
Full Diluted	4,728	4,849
Year-end	4,564	4,680

INTELGEX TECHNOLOGIES CORP

National Marketing Authorization On Oct. 31, 2018, Co. announced that its commercialization partner for RIZAPORT (10mg) in Spain, Grupo Juste, which is now part of Excelsis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product. RIZAPORT is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor. Following the approval of the manufacturing site transfer of RIZAPORT from the European contract manufacturer listed in the initial manufacturing site transfer application to Co.'s GMP compliant facility in Montreal, Canada, this marketing authorization will enable Co.'s marketing partner, Excelsis Healthcare, to commercialize the product in Spain. Co. believed that recently reported results from a successful study, demonstrating that RIZAPORT is bioequivalent to the European reference, Maxalt-Lingua, will further support the site transfer application in Spain.

INTELGEX TECHNOLOGIES CORP

Over-Allotment Option Exercised On Oct. 26, 2018, Co. announced that in connection with its previously announced public offering (the "Offering") of units of Co. (the "Units") for aggregate gross proceeds of approximately US\$12,000,000, Echelon Wealth Partners Inc. ("Echelon"), who acted as Co.'s exclusive placement agent in Canada in connection with the Offering, has exercised its option to place a further 903,610 Units pursuant to its over-allotment option (the "Over-Allotment Option"), resulting in additional gross proceeds to Co. of US\$632,527. Each Unit was issued at a price of US\$0.70 and was comprised of one share of common stock (the "Offered Shares") and one half of one warrant (a "Warrant"), each whole Warrant entitling the holder to purchase one share of common stock of Co. at an exercise price of US\$1.00 per share. The Warrants are exercisable immediately and will expire on Oct. 22, 2021. The Units were distributed under a final prospectus supplement to the U.S. registration statement on Form S-3 (File No. 333-227498) which was declared effective on Oct. 15, 2018 (the "Registration Statement") and a final Canadian MJDS prospectus supplement to the Canadian MJDS short-form base shelf dated Oct. 18, 2018 filed by Co. in connection with the Offering. Including the net proceeds from the exercise of the Over-Allotment Option, Co. expected the aggregate net proceeds of the Offering to be approximately US\$11,000,000. Co. intended to use the net proceeds from the Offering for its 2a Montelukast Study, its Tadalafil 505(b)(2) submission to the U.S. Food and Drug Administration, and working capital.

INTELGEX TECHNOLOGIES CORP

Private Placement On Oct. 22, 2018, Co. announced that it has closed its offering (the "Offering") of 17,144,314 units (the "Units") at a price of US\$0.70 (the "Offering Price") for gross proceeds of approximately US\$12,000,000 in the United States and the Canadian provinces of Alberta, British Columbia, Manitoba, Ontario and Quebec. Each Unit consisted of one share of common stock (the "Offered Shares") and one half of one warrant (a "Warrant"), each whole Warrant entitling the holder to purchase one share of common stock of Co. at an exercise price of US\$1.00 per share. The Warrants were exercisable immediately and would expire on the third anniversary of the date of their issuance. The Offering was conducted, on a best efforts basis, by H.C. Wainwright & Co. ("Wainwright"), in its capacity as the exclusive placement agent for the Units offered in the United States, and Echelon Wealth Partners Inc., in its capacity as the exclusive placement agent for the Units offered in Canada ("Echelon") and collectively with Wainwright, the "Agents"). Co. has granted Echelon an over-allotment option exercisable, in whole or in part, at

the sole discretion of Echelon, at any time prior to 5:00 p.m. (Montreal time) on the date that is the 30th day after the closing of the date hereof, to purchase shares of common stock of Co. and/or Warrants in an amount representing up to an additional 15% of the number of Units sold pursuant to the Offering, at the Offering Price to cover over-allocations, if any, and for market stabilization purposes. The TSX Venture Exchange (the "TSXV") has conditionally approved the listing of the common stock that would be issued by Co. in the Offering, including the shares of common stock issuable upon the exercise of the Warrants. Listing on the TSXV will be subject to Co. fulfilling all of the listing requirements of the TSXV within 30 days of the closing of the Offering. After the payment of the Agents' commissions and the reimbursement of certain of the Agents' Offering expenses and the payment of other Offering expenses, Co. expected the net proceeds from the Offering to be approximately US\$10,500,000. Co. intended to use the net proceeds from the Offering for its 2a Montelukast Study, its Tadalafil 505(b)(2) submission to the U.S. Food and Drug Administration, and working capital.

INTELGEX TECHNOLOGIES CORP

Private Placement On Nov. 13, 2018, Co. announced that it closed a Private Placement through the issuance of 1,428,571 common shares ("Common Shares") at a subscription price of US\$0.70 per Common Share for gross proceeds of US\$1,000,000.

INTELGEX TECHNOLOGIES CORP

Stock Interest Change Development On Nov. 13, 2018, Tilray, Inc. ("Tilray") acquired 1,428,571 common shares of Co., through a private placement, at US\$0.70 per common share. The Common Shares issued to Tilray were subject to a four-month statutory hold period which expires Mar. 14, 2019. Additionally, under the Private Placement purchase agreement, Tilray agreed that until May 14, 2019 it would not cause or permit any transfer of any Common Shares.

INTELLIA THERAPEUTICS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	22,554	19,449
Cost & expenses	92,678	64,289
Operating income	(70,124)	(44,840)
Net income	(66,277)	(43,580)
Earnings common share		
Primary	\$(1.55)	\$(1.25)
Fully Diluted	\$(1.55)	\$(1.25)
Common Shares:		
Full Diluted	42,684	34,945
Year-end	43,369	36,085

INTER PARFUMS, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales	498,347,000	441,725,000
Cost & expenses	414,203,000	367,916,000
Operating income	84,144,000	73,809,000
Interest expense	1,553,000	1,494,000
Foreign currency	185,000	(1,308,000)
Net before taxes	86,097,000	73,795,000
Income taxes	25,550,000	24,314,000
Net income	60,547,000	49,481,000
Earnings common share		
Primary	\$1.46	\$1.19
Fully Diluted	\$1.45	\$1.19
Common Shares:		
Full Diluted	31,502,000	31,281,000
Year-end	31,333,842	31,182,458

INTERCEPT PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	126,524,000	93,269,000
Cost & expenses	330,043,000	323,912,000
Operating income	(203,519,000)	(230,643,000)
Other income (expense), net	5,051,000	3,388,000
Net income	(221,237,000)	(249,095,000)
Earnings common share		
Primary	\$(7.89)	\$(9.96)
Fully Diluted	\$(7.89)	\$(9.96)
Common Shares:		
Full Diluted	28,057,000	25,021,000
Year-end	29,654,468	25,102,079

INTERFACE INC.

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Net Sales	842,514	730,233

Cost & expenses	770,038	649,622
Operating income	72,476	80,611
Other income (expense), net	(5,350)	(3,143)
Net before taxes	57,919	72,318
Income taxes	14,061	23,394
Net income	43,858	48,924
Earnings common share		
Primary	\$0.74	\$0.78
Fully Diluted	\$0.74	\$0.78
Common Shares:		
Full Diluted	59,594	62,672
Year-end	59,520	60,251

INTERMOLECULAR INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	27,339	26,655
Cost & expenses	28,806	37,598
Operating income	(1,467)	(10,943)
Other income (expense), net	241	243
Net before taxes	(813)	(10,518)
Income taxes	1	1
Net income	(814)	(10,519)
Earnings common share		
Primary	\$(0.02)	\$(0.21)
Fully Diluted	\$(0.02)	\$(0.21)
Common Shares:		
Full Diluted	49,668	49,543
Year-end	49,749	49,560

INTERNAP CORP

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	239,135,000	210,682,000
Cost & expenses	166,857,000	153,915,000
Operating income	5,181,000	(829,000)
Interest expense	47,786,000	37,581,000
Equity earnings		(1,207,000)
Foreign currency	(5,000)	(485,000)
Net before taxes	(42,610,000)	(38,895,000)
Income taxes	404,000	689,000
Net income	(43,014,000)	(38,377,000)
Earnings common share		
Primary	\$(2.16)	\$(2.04)
Fully Diluted	\$(2.16)	\$(2.04)
Common Shares:		
Full Diluted	19,968,000	18,645,000
Year-end	21,302,000	20,826,250

INTERNATIONAL ISOTOPES INC

New Accountant On Nov. 16, 2018, Co. dismissed Eide Bailly LLP and engaged Haynie & Company as its new independent public accounting firm.

INTERSECT ENT, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	75,689	66,772
Cost & expenses	95,042	80,865
Operating income	(19,353)	(14,093)
Net income	(17,892)	(13,211)
Earnings common share		
Primary	\$(0.59)	\$(0.46)
Fully Diluted	\$(0.59)	\$(0.46)
Common Shares:		
Full Diluted	30,208	28,978
Year-end	30,529	29,385

INTERSECTIONS INC

Merger Development On Oct. 31, 2018, Co. announced that it had entered into an Agreement and Plan of Merger (the "Merger Agreement") with WC SACD One Parent, Inc. ("Parent") and WC SACD One Merger Sub, Inc. ("Merger Sub"), a wholly-owned subsidiary of Parent, pursuant to which, among other things, subject to the terms and conditions of the Merger Agreement, Merger Sub has agreed to make a cash tender offer (the "Offer") to purchase all of the outstanding shares of Co.'s Common Stock, par value \$0.01 (the "Shares"), at a purchase price of \$3.68 per Share in cash, other than certain shares held by certain affiliates of Co. Parent and Merger Sub are affiliates of WC SACD One, Inc., a joint venture formed by iSubscribed, WndrCo Holdings, LLC and certain General Catalyst funds. The transaction has been unanimously approved by a Special Committee of the Board of Directors of Co. comprised of independent and disinterested directors. The transaction is expected to close during the first quarter of 2019.

INTRA-CELLULAR THERAPIES INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	240,782	240,782
Cost & expenses	119,643,828	70,372,647
Operating income	(119,643,828)	(70,131,865)
Interest income	5,266,053	2,564,747
Net before taxes	(114,377,775)	(67,567,118)
Income taxes	1,600	(2,416)
Net income	(114,379,375)	(67,564,702)
Earnings common share		
Primary	\$(2.09)	\$(1.56)
Fully Diluted	\$(2.09)	\$(1.56)
Common Shares:		
Full Diluted	54,693,827	43,410,072
Year-end	54,713,831	43,427,344

INTREXON CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	117,389	153,953
Cost & expenses	286,117	265,351
Operating income	(168,728)	(111,398)
Other income (expense), net	(36,874)	2,420
Net before taxes	(192,519)	(95,039)
Income taxes	(19,535)	(2,164)
Net income	(172,984)	(92,875)
Earnings common share		
Primary	\$(1.31)	\$(0.75)
Fully Diluted	\$(1.31)	\$(0.75)
Common Shares:		
Full Diluted	128,844	119,741
Year-end	137,145	120,624

INTUIT INC**Earnings, 3 mos. to Oct 31(Consol. – \$000):**

	2018	2017
Total Revenues	1,016,000	910,000
Cost & expenses	1,024,000	944,000
Operating income	(10,000)	(35,000)
Gains or losses	(5,000)	2,000
Net before taxes	(14,000)	(37,000)
Income taxes	(48,000)	(35,000)
Net income	34,000	(2,000)
Earnings common share		
Primary	\$0.13	\$(0.01)
Fully Diluted	\$0.13	\$(0.01)
Common Shares:		
Full Diluted	264,000	256,000
Year-end	259,571	255,667

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	1,084,000	1,084,000
Current assets	2,232,000	2,232,000
Net property & equip.	805,000	805,000
Total assets	4,928,000	4,928,000
Liabilities:		
Current liabilities	1,586,000	1,586,000
Long-term debt	375,000	375,000
Stockholders' equity	2,782,000	2,782,000
Net current assets	646,000	646,000

INVUITY INC

Merger Completed On Oct. 23, 2018, Stryker Corp. ("Stryker") wholly-owned subsidiary, Accipiter Corp. ("Purchaser"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Stryker. As the result of the merger, each issued and outstanding Share (other than Shares (i) owned by Co. as treasury stock or owned by Stryker or Purchaser, which Shares were automatically cancelled and retired and ceased to exist, or (ii) held by any person who was entitled to and has properly demanded appraisal for such Shares in accordance with Section 262 of the DGCL) was converted into the right to receive an amount equal to \$7.40 per Share in cash, without interest, and subject to any required withholding of taxes (the "Offer Price"), payable to the holder thereof in cash, without interest. The aggregate cash consideration paid in the Offer and the Merger was approximately \$228,000,000 (including payments for options, restricted stock units and all outstanding principal, interest and other amounts due under the Credit Agreements).

IOVANCE BIOTHERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Cost & expenses	93,315,000	66,806,000
Operating income	(93,315,000)	(66,806,000)
Net income	(91,005,000)	(66,210,000)
Earnings common share		
Primary	\$(1.01)	\$(1.06)
Fully Diluted	\$(1.01)	\$(1.06)
Common Shares:		
Full Diluted	89,927,000	62,697,000
Year-end	97,425,721	71,954,843

IPG PHOTONICS CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	1,129,823	1,047,834
Cost & expenses	702,470	644,989
Operating income	427,353	402,845
Other income (expense), net	1,252	(47)
Net before taxes	433,530	403,449
Income taxes	104,827	108,817
Net income	328,703	294,632
Earnings common share		
Primary	\$6.12	\$5.51
Fully Diluted	\$5.97	\$5.40
Common Shares:		
Full Diluted	54,995	54,570
Year-end	54,363	53,918

IRHYTHM TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	104,138	70,327
Cost & expenses	136,207	86,976
Operating income	(32,069)	(16,649)
Interest expense	2,580	2,522
Other income (expense), net	1,082	900
Net income	(33,567)	(18,271)
Earnings common share		
Primary	\$(1.41)	\$(0.81)
Fully Diluted	\$(1.41)	\$(0.81)
Common Shares:		
Full Diluted	23,764	22,446
Year-end	24,149	22,446

IROBOT CORP**Earnings, 9 mos. to (Consol. – \$000):**

	09/29/18	09/30/17
Total Revenues	707,919	557,014
Cost & expenses	631,079	507,223
Operating income	76,035	49,618
Other income (expense), net	2,363	4,290
Net before taxes	78,398	53,908
Income taxes	15,597	7,565
Net income	62,801	46,343
Earnings common share		
Primary	\$2.27	\$1.68
Fully Diluted	\$2.19	\$1.61
Common Shares:		
Full Diluted	28,629	28,719
Year-end	27,671	27,874

ITRON INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	1,789,073	1,467,421
Cost & expenses	1,813,583	1,345,596
Operating income	(78,209)	106,681
Interest expense	44,320	10,076
Other income (expense), net	(2,598)	(7,951)
Net before taxes	(123,402)	90,122
Income taxes	(1,692)	32,247
Net income	(121,710)	57,875
Earnings common share		
Primary	\$(3.14)	\$1.44
Fully Diluted	\$(3.14)	\$1.41
Common Shares:		
Full Diluted	39,177	39,339
Year-end	39,400	38,725

J2 GLOBAL INC (NEW)**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	861,236,000	801,458,000
Cost & expenses	703,640,000	631,966,000

Operating income	157,596,000	169,492,000
Interest expense	46,428,000	51,406,000
Other income (expense), net	(6,150,000)	(660,000)
Equity earnings	3,581,000	3,581,000
Net before taxes	105,018,000	117,426,000
Income taxes	23,365,000	27,872,000
Net income	78,072,000	89,554,000
Balance for common	77,007,000	88,426,000
Earnings common share		
Primary	\$1.61	\$1.86
Fully Diluted	\$1.57	\$1.81
Common Shares:		
Full Diluted	49,068,653	48,745,680
Year-end	48,018,663	47,623,709

JACK HENRY & ASSOCIATES, INC.**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	392,543	361,284
Cost & expenses	289,321	264,227
Operating income	103,222	97,057
Interest expense	147	189
Net before taxes	103,366	97,015
Income taxes	19,815	30,145
Net income	83,551	66,870
Earnings common share		
Primary	\$1.08	\$0.87
Fully Diluted	\$1.08	\$0.86
Common Shares:		
Full Diluted	77,537	77,646
Year-end	77,291	77,291

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	114,872	114,872
Current assets	457,839	457,839
Net property & equip.	286,497	286,497
Total assets	2,033,102	2,033,102
Liabilities:		
Current liabilities	420,226	420,226
Stockholders' equity	1,368,564	1,368,564
Net current assets	37,613	37,613

K2M GROUP HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	212,815	190,230
Cost & expenses	246,004	214,806
Operating income	(33,189)	(24,576)
Interest expense	6,615	5,211
Foreign currency	(552)	1,518
Net before taxes	(40,356)	(28,269)
Income taxes	(2,351)	128
Net income	(38,005)	(28,397)
Earnings common share		
Primary	\$(0.88)	\$(0.67)
Fully Diluted	\$(0.88)	\$(0.67)
Common Shares:		
Full Diluted	43,209	42,628
Year-end	43,734	43,328

K2M GROUP HOLDINGS INC

Sale Completed On Nov. 9, 2018, Co. was acquired as a new subsidiary of Stryker Corporation, a Michigan corporation ("Stryker") through the merger of Austin Merger Sub Corp., a Delaware corporation and wholly owned direct or indirect subsidiary of Stryker with and into Co., with Co. continuing as the surviving corporation. The total aggregate consideration for the transaction was approximately \$1,400,000,000.

KARYOPHARM THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	30,130	71
Cost & expenses	152,558	91,157
Operating income	(122,428)	(91,086)
Interest income	2,260	1,266
Other income (expense), net	(20)	(70)
Net before taxes	(120,188)	(89,890)
Income taxes	9	54
Net income	(120,197)	(89,944)
Earnings common share		
Primary	\$(2.17)	\$(2.00)
Fully Diluted	\$(2.17)	\$(2.00)
Common Shares:		
Full Diluted	55,465	44,975
Year-end	60,665	47,154

KCAP FINANCIAL INC

Earnings, 9 mos. to Sep 30(Consol. – \$):		
	2018	2017
Cost & expenses	12,889,477	13,331,068
Net income	7,944,193	8,356,404
Earnings common share		
Primary	\$0.21	\$0.23
Fully Diluted	\$0.21	\$0.23
Common Shares:		
Full Diluted	37,354,449	37,202,011
Year-end	37,349,224	37,317,815

KELLY SERVICES, INC.

Earnings, 9 mos. to (Consol. – \$000):		
	09/30/18	10/01/17
Cost & expenses	4,044,900	3,897,200
Operating income	54,300	54,900
Other income (expense), net	800	700
Gains or losses	(13,000)	
Foreign currency	(900)	(1,900)
Net before taxes	39,500	52,400
Income taxes	(3,300)	100
Net income	46,800	53,900
Balance for common	46,300	53,000
Earnings common share		
Primary	\$1.20	\$1.38
Fully Diluted	\$1.19	\$1.37
Common Shares:		
Full Diluted	38,800	38,800
Year-end	38,800	38,400

KFORCE INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):		
	2018	2017
Total Revenues	1,060,369	1,015,354
Cost & expenses	995,128	959,030
Operating income	59,349	50,111
Other income (expense), net	(3,639)	(3,906)
Net before taxes	55,710	46,205
Income taxes	14,086	19,060
Net income	41,624	27,145
Earnings common share		
Primary	\$1.68	\$1.07
Fully Diluted	\$1.65	\$1.06
Common Shares:		
Full Diluted	25,252	25,565
Year-end	26,061	26,607

KIMBALL ELECTRONICS INC

Earnings, 3 mos. to Sep 30(Consol. – \$000):		
	2018	2017
Net Sales	265,620	253,204
Cost & expenses	258,588	243,681
Operating income	7,032	9,523
Interest income	6	18
Interest expense	389	116
Other income (expense), net	(290)	1,107
Gains or losses	119	303
Net before taxes	6,478	10,835
Income taxes	1,409	2,355
Net income	5,069	8,480
Earnings common share		
Primary	\$0.19	\$0.32
Fully Diluted	\$0.19	\$0.31
Common Shares:		
Full Diluted	26,628	27,028
Year-end	26,458	26,839

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		74,969
Inventories		188,572
Current assets		492,377
Net property & equip.		134,831
Total assets		662,876
Liabilities:		
Current liabilities		280,062
Stockholders' equity		358,884
Net current assets		212,315

KIMBALL INTERNATIONAL, INC.

Earnings, 3 mos. to Sep 30(Consol. – \$000):		
	2018	2017
Net Sales	194,123	175,360
Cost & expenses	180,429	159,403

Operating income	13,694	15,957
Other income (expense), net	327	286
Net before taxes	14,390	16,446
Income taxes	3,514	5,489
Net income	10,876	10,957
Earnings common share		
Primary	\$0.29	\$0.29
Fully Diluted	\$0.29	\$0.29
Common Shares:		
Full Diluted	37,392	37,733
Year-end	37,048	37,188

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		42,643
Inventories		42,125
Current assets		199,986
Net property & equip.		85,188
Total assets		325,608
Liabilities:		
Current liabilities		111,193
Long-term debt		136
Stockholders' equity		198,684
Net current assets		88,793

KINSALE CAPITAL GROUP INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):		
	2018	2017
Total Revenues	165,210	136,034
Cost & expenses	129,839	108,738
Operating income	35,371	27,296
Net before taxes	35,371	27,296
Income taxes	6,032	8,319
Net income	29,339	18,977
Earnings common share		
Primary	\$1.39	\$0.90
Fully Diluted	\$1.35	\$0.88
Common Shares:		
Full Diluted	21,671	21,461
Year-end	21,227	21,029

KIRKLAND'S INC

Earnings, 6 mos. to (Consol. – \$000):		
	08/04/18	07/29/17
Net Sales	276,353	264,524
Cost & expenses	283,396	269,148
Operating income	(10,581)	(7,974)
Interest expense	131	126
Other income (expense), net	601	219
Net before taxes	(10,111)	(7,881)
Income taxes	(2,514)	(2,674)
Net income	(7,597)	(5,207)
Earnings common share		
Primary	\$(0.48)	\$(0.33)
Fully Diluted	\$(0.48)	\$(0.33)
Common Shares:		
Full Diluted	15,925	15,943
Year-end	15,742	15,907

KLA-TENCOR CORP

Earnings, 3 mos. to Sep 30(Consol. – \$000):		
	2018	2017
Total Revenues	1,093,260	969,581
Cost & expenses	649,355	607,236
Operating income	427,568	336,152
Interest expense	26,362	30,576
Other income (expense), net	10,025	4,383
Net before taxes	427,568	336,152
Income taxes	31,624	55,216
Net income	395,944	280,936
Earnings common share		
Primary	\$2.55	\$1.79
Fully Diluted	\$2.54	\$1.78
Common Shares:		
Full Diluted	156,083	157,846
Year-end	153,075	156,708

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		1,649,514
Inventories		993,527
Current assets		4,521,044
Net property & equip.		291,232
Total assets		5,645,109
Liabilities:		
Current liabilities		1,310,930

Long-term debt	2,237,890
Stockholders' equity	1,567,369
Net current assets	3,210,114

KLX ENERGY SERVICES HOLDINGS INC

Acquisition Completed On Nov. 5, 2018, Co.'s wholly-owned subsidiary, KLX Energy Services LLC, acquired 100% of the outstanding units of Motley Services, LLC ("Motley"), a provider of well completion and intervention services in the Permian Basin, from District 5 Investments, LP ("D5"), 3M Capital, Inc. ("3M") and Marco D. Davis ("Davis") and, together with D5 and 3M, each individually, a "Seller" and collectively, the "Sellers"), for \$139,200,000 in cash, subject to certain purchase price adjustments, and \$9,000,000 of shares (the "Consideration Shares") of Co.'s common stock payable to certain employees of Motley.

KRAFT HEINZ CO (THE)

Earnings, 9 mos. to (Consol. – \$Millions):		
	09/29/18	09/30/17
Net Sales	19,368	19,241
Cost & expenses	15,488	14,626
Operating income	3,880	4,615
Interest expense	962	926
Other income (expense), net	196	510
Net before taxes	3,114	4,199
Income taxes	738	1,205
Net income	2,376	2,994
Balance for common	2,379	2,996
Earnings common share		
Primary	\$1.95	\$2.46
Fully Diluted	\$1.94	\$2.44
Common Shares:		
Full Diluted	1,227	1,229
Year-end	1,219	

KRAFT HEINZ CO (THE)

Interest Sale Development On Oct. 24, 2018, Co. announced that it has agreed to sell some of its Indian brands to Zydu Wellness Ltd. jointly with Cadila Healthcare Ltd. in a transaction valued at approximately \$46,000,000,000 (\$625,000,000) on a debt- and cash-free basis. The transaction is expected to close in early 2019 and remains subject to regulatory approvals and other closing conditions. Under the terms of the agreement, Co. is selling 100% of its equity shares in Heinz India Private Ltd., which includes the brands Complian, Glucon-D, Nycil and Sampriti, and two manufacturing facilities, with approximately 900 employees associated with the brands and operations. The business generates approximately \$150,000,000 in net sales and approximately \$30,000,000 in adjusted EBITDA at current foreign currency exchange rates. The sale is not expected to have a material impact on Co.'s fiscal-year results.

KRAFT HEINZ CO (THE)

Interest Sale Development On Nov. 6, 2018, Co. announced that it has entered into a definitive agreement to sell its Canadian natural cheese business to Parmalat SpA for a purchase price of C\$1,620,000,000 (approximately \$1,230,000,000 at current FX rates). The agreement includes the sale of natural cheese brands Cracker Barrel, PStit Quebec and aMOOza! in the Canadian market. The proposed transaction is expected to close in the first half of 2019, subject to regulatory review and approval. Under the terms of the agreement, Co. will sell its production facility located in Ingleside, Ontario. Kraft Heinz Canada will also transfer approximately 400 employees from that facility to Parmalat SpA.

KRATOS DEFENSE & SECURITY SOLUTIONS, INC.

Earnings, 9 mos. to (Consol. – \$000):		
	09/30/18	10/01/17
Total Revenues	453,600	437,000
Cost & expenses	433,900	434,000
Operating income	19,700	3,000
Interest expense	15,800	23,100
Other income (expense), net	(600)	(1,200)
Net before taxes	3,300	(21,300)
Income taxes	4,400	1,600
Income contin. oper.	(1,100)	(22,900)
Net income	(8,200)	(20,500)
Earnings common share		
Primary	\$(0.08)	\$(0.24)
Fully Diluted	\$(0.08)	\$(0.24)
Common Shares:		
Full Diluted	103,800	85,000
Year-end	103,753	

KURA ONCOLOGY INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	46,249	25,082
Operating income	(555)	(585)
Interest income	2,121	449
Other income (expense), net	555	585
Net income	(44,350)	(24,686)
Earnings common share		
Primary	\$(1.30)	\$(1.16)
Fully Diluted	\$(1.30)	\$(1.16)
Common Shares:		
Full Diluted	34,218	21,217
Year-end	38,014	29,127

KVH INDUSTRIES, INC.**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Net Sales	127,010,000	121,110,000
Cost & expenses	132,297,000	128,749,000
Operating income	(5,287,000)	(7,639,000)
Interest income	464,000	491,000
Interest expense	1,290,000	1,081,000
Other income (expense), net	371,000	(321,000)
Net before taxes	(5,742,000)	(8,550,000)
Income taxes	668,000	799,000
Net income	(6,410,000)	(9,349,000)
Earnings common share		
Primary	\$(0.38)	\$(0.57)
Fully Diluted	\$(0.38)	\$(0.57)
Common Shares:		
Full Diluted	17,025,000	16,393,000
Year-end	17,739,431	17,095,706

LAM RESEARCH CORP**Earnings, 3 mos. to** (Consol. - \$000):

	09/23/18	09/24/17
Total Revenues	2,330,691	2,478,140
Cost & expenses	1,738,940	1,784,918
Operating income	591,751	693,222
Interest income	18,933	20,209
Other income (expense), net	2,427	1,194
Foreign currency	51	(3,000)
Net before taxes	591,374	687,720
Income taxes	58,014	97,030
Net income	533,360	590,690
Earnings common share		
Primary	\$3.43	\$3.64
Fully Diluted	\$3.23	\$3.21
Common Shares:		
Full Diluted	165,327	183,880
Year-end	153,384	162,144

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	2,568,085
Inventories	1,874,194
Current assets	7,515,873
Net property & equip.	951,376
Total assets	10,957,577
Liabilities:	
Current liabilities	2,824,965
Long-term debt	1,805,091
Stockholders' equity	5,322,825
Net current assets	4,690,908

LAMAR ADVERTISING CO (NEW)**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	1,199,324	1,142,785
Cost & expenses	702,128	652,422
Operating income	329,945	335,360
Other income (expense), net	(15,429)	(71)
Net before taxes	217,508	239,769
Income taxes	7,969	9,257
Net income	209,539	230,512
Balance for common	209,266	230,239
Earnings common share		
Primary	\$2.12	\$2.35
Fully Diluted	\$2.12	\$2.34
Common Shares:		
Full Diluted	98,870	98,340
Year-end	99,143	98,096

LANCASTER COLONY CORP.**Earnings, 3 mos. to Sep 30**(Consol. - \$):

	2018	2017
Net Sales	316,654,000	298,916,000
Cost & expenses	267,534,000	254,740,000
Operating income	49,120,000	44,176,000
Other income (expense), net	1,314,000	508,000
Net before taxes	50,434,000	44,684,000
Income taxes	11,406,000	15,298,000
Net income	39,028,000	29,386,000
Balance for common	38,946,000	29,339,000
Earnings common share		
Primary	\$1.42	\$1.07
Fully Diluted	\$1.42	\$1.07
Common Shares:		
Full Diluted	27,514,000	27,451,000
Year-end	27,489,554	27,442,147

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	217,935,000
Inventories	102,822,000
Current assets	410,470,000
Net property & equip.	195,772,000
Total assets	840,183,000
Liabilities:	
Current liabilities	107,501,000
Stockholders' equity	674,019,000
Net current assets	302,969,000

LANDMARK INFRASTRUCTURE PARTNERS LP**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Cost & expenses	5,847,000	6,369,000
Operating income	18,617,000	10,074,000
Interest expense	19,586,000	12,931,000
Other income (expense), net	5,267,000	(111,000)
Gains or losses	100,039,000	
Net before taxes	118,656,000	10,074,000
Income taxes	663,000	72,000
Net income	117,993,000	10,002,000
Balance for common	109,644,000	5,024,000
Earnings common share		
Primary	\$4.51	\$0.22
Fully Diluted	\$4.18	\$0.22
Common Shares:		
Full Diluted	26,658,000	22,755,000
Year-end	25,266,060	

LATTICE SEMICONDUCTOR CORP**Earnings, 9 mos. to** (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	302,822	290,695
Cost & expenses	290,240	311,817
Operating income	(1,400)	(46,899)
Other income (expense), net	(246)	(2,104)
Net before taxes	(17,228)	(63,115)
Net income	(19,201)	(63,349)
Earnings common share		
Primary	\$(0.15)	\$(0.52)
Fully Diluted	\$(0.15)	\$(0.52)
Common Shares:		
Full Diluted	125,578	122,393
Year-end	129,275	123,138

LAUREATE EDUCATION INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	2,436,514	2,434,687
Cost & expenses	2,285,339	2,332,810
Operating income	151,175	101,877
Interest income	9,358	9,702
Interest expense	181,764	256,677
Other income (expense), net	3,334	(8,993)
Gains or losses	92,112	19,187
Equity earnings		(1)
Foreign currency	(43,942)	(2,221)
Net before taxes	30,273	(137,125)
Income taxes	65,822	13,668
Income contin. oper.	(35,549)	(150,792)
Net income	298,814	(106,745)
Balance for common	311,206	(296,521)
Earnings common share		
Primary	\$1.49	\$(1.77)
Fully Diluted	\$1.43	\$(1.77)
Common Shares:		
Full Diluted	209,129	167,261
Year-end	224,041	

LAWSON PRODUCTS, INC.**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	263,371	225,274
Cost & expenses	258,246	215,581
Operating income	5,125	9,693
Interest expense	755	393
Other income (expense), net	(320)	953
Net before taxes	4,050	10,253
Income taxes	436	802
Net income	3,614	9,451
Earnings common share		
Primary	\$0.41	\$1.07
Fully Diluted	\$0.39	\$1.04
Common Shares:		
Full Diluted	9,250	9,112
Year-end	8,920	8,888

LEGACY RESERVES INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	421,967,000	299,209,000
Cost & expenses	275,974,000	209,072,000
Deprec., depl. & amort.	114,274,000	90,200,000
Operating income	31,719,000	(63,000)
Interest income	31,000	44,000
Other income (expense), net	22,527,000	36,653,000
Net before taxes	(31,063,000)	(27,734,000)
Income taxes	3,116,000	837,000
Net income	(34,179,000)	(28,571,000)
Earnings common share		
Primary	\$(0.33)	\$(0.29)
Fully Diluted	\$(0.33)	\$(0.29)
Common Shares:		
Full Diluted	104,336,000	99,985,000
Year-end	106,113,000	72,694,620

LEMAITRE VASCULAR INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Net Sales	77,179	74,714
Cost & expenses	56,163	59,933
Operating income	21,016	14,781
Interest income	452	100
Foreign currency	(275)	(103)
Net before taxes	21,193	14,778
Income taxes	4,275	1,885
Net income	16,918	12,893
Earnings common share		
Primary	\$0.87	\$0.69
Fully Diluted	\$0.84	\$0.65
Common Shares:		
Full Diluted	20,258	19,970
Year-end	19,582	19,262

LENDINGTREE INC (NEW)

Acquisition Completed On Oct. 31, 2018, Co.'s subsidiary, LendingTree, LLC ("Buyer") acquired QuoteWizard.com, LLC, a Delaware limited liability company ("QuoteWizard") from all of the members of QuoteWizard (collectively, the "Sellers"). Buyer paid \$300,000,000 of cash consideration to the Sellers, which amount was and remains subject to adjustments for working capital, in exchange for all of the membership interests of QuoteWizard. Buyer paid \$125,000,000 of the purchase price using funds borrowed under the Revolving Credit Facility and the balance using cash on hand. A portion of the closing consideration was deposited into escrow to secure the Sellers obligations under the Unit Purchase Agreement to make certain indemnification and purchase price adjustment payments. In addition, pursuant to the Unit Purchase Agreement, Sellers are eligible to receive three earnout payments based on QuoteWizard achieving certain adjusted EBITDA-based targets during three consecutive twelve-month periods, the first of which begins on the first day of the first full month following the closing of the transaction. The Sellers are eligible to receive up to \$70,200,000 in aggregate earnout payments. The earnout payments are payable in cash. Buyer has also committed to pay up to \$4,800,000 as cash bonuses to employees based on achievement of the adjusted EBITDA-based targets during the three earnout periods.

LENDINGTREE INC (NEW)**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	562,193	456,782
Cost & expenses	489,603	409,131
Operating income	53,763	33,308
Interest expense	8,305	4,048
Other income (expense), net	(106)	(215)
Net before taxes	45,352	29,045
Income taxes	(63,716)	3,109
Income contin. oper.	109,068	25,936
Net income	99,799	23,304
Earnings common share		
Primary	\$8.02	\$1.95
Fully Diluted	\$6.98	\$1.71
Common Shares:		
Full Diluted	14,299	13,625
Year-end	12,946	11,968

LEVEL 3 COMMUNICATIONS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	6,149,000	6,169,000
Cost & expenses	4,170,000	4,217,000
Operating income	684,000	1,039,000
Interest expense	381,000	399,000
Other income (expense), net	21,000	(30,000)
Net before taxes	374,000	621,000
Income taxes	184,000	215,000
Net income	190,000	406,000
Earnings common share		
Common Shares:		

LEXARIA BIOSCIENCE CORP

New Products On Nov. 13, 2018, Co. announced the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder packet formulation designed to be added to any drink, in any location, creating many innovative-use applications.

LEXARIA BIOSCIENCE CORP

Private Placement On Nov. 6, 2018, Co. announced that due to strong demand it has increased the size of its previously announced non-brokered private placement, closing on gross proceeds of US\$1,515,440 (the "Offering"). The Offering is comprised of 947,150 units (each, a "Unit") at an issue price of US\$1.60 per Unit. Each Unit consists of one common share of Co. (a "Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to acquire one common share of Co. at a price of US\$2.25 per common share for a period of 24 months following the closing of the Offering. Finder's fees of US\$45,080 and 28,175 finder's warrants were paid on a portion of the proceeds raised, with each finder's warrant having exercise terms identical to the Warrants issued. The net proceeds of the Offering will be used to fund construction and development of Co.'s new Canadian-based laboratory; to accelerate Co.'s developed R&D; and for general corporate purposes.

LEXICON PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	45,816,000	57,288,000
Cost & expenses	137,254,000	163,184,000
Operating income	(91,438,000)	105,896,000
Interest expense	15,553,000	4,821,000
Net before taxes	(109,324,000)	1,312,000
Income taxes	(8,652,000)	
Net income	(104,293,000)	100,672,000
Earnings common share		
Primary	\$(0.99)	\$(0.96)
Fully Diluted	\$(0.99)	\$(0.96)
Common Shares:		
Full Diluted	105,800,000	105,119,000
Year-end	105,898,000	105,588,000

LGI HOMES, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	1,079,240,000	852,985,000
Cost & expenses	934,558,000	737,936,000
Operating income	144,682,000	115,049,000
Other income (expense), net	(1,793,000)	1,312,000
Net before taxes	142,889,000	116,361,000
Income taxes	30,256,000	38,695,000
Net income	112,633,000	77,666,000
Earnings common share		
Primary	\$5.07	\$3.60
Fully Diluted	\$4.57	\$3.32
Common Shares:		

Full Diluted	24,642,882	23,413,467
Year-end	22,717,153	21,737,859

LHC GROUP INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	1,223,758	709,438
Operating income	76,363	62,024
Interest expense	7,916	2,615
Net before taxes	68,447	59,409
Income taxes	14,832	20,410
Net income	53,615	38,999
Balance for common	43,022	31,678
Earnings common share		
Primary	\$1.63	\$1.79
Fully Diluted	\$1.61	\$1.77
Common Shares:		
Full Diluted	26,641	17,932
Year-end	30,674	17,745

LIBERTY BROADBAND CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	18,680	9,643
Cost & expenses	23,292	26,281
Operating income	(6,921)	(19,482)
Other income (expense), net	130,694	30,146
Gains or losses	(35,165)	(42,515)
Net before taxes	72,154	(45,531)
Income taxes	17,005	(18,245)
Net income	55,149	(27,286)
Earnings common share		
Primary	\$0.30	\$(0.15)
Fully Diluted	\$0.30	\$(0.15)
Common Shares:		
Full Diluted	182,586	183,164
Year-end	181,353	181,846

LIBERTY EXPEDIA HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	8,845,000	7,905,000
Cost & expenses	8,002,000	6,795,000
Deprec., depl. & amort.	1,442,000	1,669,000
Operating income	(599,000)	(559,000)
Other income (expense), net	(38,000)	(71,000)
Net before taxes	(740,000)	(718,000)
Income taxes	(231,000)	(259,000)
Net income	(509,000)	(459,000)
Earnings common share		
Primary	\$(1.98)	\$(1.70)
Fully Diluted	\$(1.98)	\$(1.70)
Common Shares:		
Full Diluted	58,000	58,000
Year-end	57,314	

LIBERTY MEDIA CORP (DE)**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	6,031,000	5,600,000
Cost & expenses	4,218,000	3,922,000
Operating income	1,132,000	1,063,000
Interest expense	453,000	448,000
Other income (expense), net	109,000	169,000
Gains or losses	180,000	(43,000)
Net before taxes	968,000	741,000
Income taxes	134,000	280,000
Net income	834,000	461,000
Earnings common share		
Common Shares:		
Year-end	610,199	615,126

LIBERTY TRIPADVISOR HOLDINGS, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	1,269,000	1,248,000
Cost & expenses	1,032,000	1,065,000
Operating income	119,000	22,000
Interest expense	20,000	18,000
Other income (expense), net	2,000	2,000
Gains or losses	(56,000)	(8,000)
Net before taxes	45,000	(2,000)
Income taxes	45,000	21,000
Net income		(23,000)

Earnings common share		
Primary	\$(0.75)	\$(0.37)
Fully Diluted	\$(0.75)	\$(0.37)
Common Shares:		
Full Diluted	75,000	75,000
Year-end	75,060	

LIFEPPOINT HEALTH INC

Merger Completed On Nov. 16, 2018, RegionalCare Hospital Partners Holdings, Inc. (D/B/A RCCH HealthCare Partners) ("Parent"), a company owned by certain funds managed by Apollo Management VIII, L.P. (the "Apollo Funds"), which is an affiliate of Apollo Global Management, LLC, wholly-owned subsidiary, Legend Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each share of Co.'s common stock ("Common Shares") outstanding immediately prior to the Effective Time (other than Common Shares held (i) directly by Parent, (ii) by Co. as treasury stock or (iii) by any subsidiary of either Co. or Parent (such shares collectively, the "Excluded Shares")) ceased to be outstanding and was converted into the right to receive \$65.00 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). In addition, (i) each of Co.'s stock options was fully vested and canceled and converted into the right to receive an amount in cash, without interest and less applicable withholding taxes, equal to the product of (x) the excess, if any, of the Merger Consideration over the applicable exercise price per share of such stock option and (y) the number of Common Shares subject to such option (and any option having an exercise price greater than or equal to the Merger Consideration was canceled at the Effective Time for no consideration or payment), (ii) each of Co.'s restricted stock units was fully vested and canceled and converted into the right to receive an amount in cash, without interest and less applicable withholding taxes, equal to the product of (x) the Merger Consideration and (y) (1) in the case of unvested performance restricted stock units, the number of Common Shares subject to such performance restricted stock unit as set forth in the applicable award agreement or (2) in the case of vested performance restricted stock units, the number of Common Shares subject to such performance restricted stock unit based on the actual level of achievement of performance goals in accordance with the terms of the applicable award agreement. As the result, Co. changed its name to "Legacy LifePoint Health, Inc." and, immediately following the Effective Time, Parent changed its name to "LifePoint Health, Inc."

LIFETIME BRANDS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Net Sales	476,268	396,706
Cost & expenses	480,582	392,388
Operating income	(4,314)	4,318
Other income (expense), net	(66)	(110)
Equity earnings	(417)	(672)
Net before taxes	(16,793)	1,094
Income taxes	(4,669)	863
Net income	(11,707)	903
Earnings common share		
Primary	\$(0.61)	\$0.06
Fully Diluted	\$(0.61)	\$0.06
Common Shares:		
Full Diluted	19,123	14,900
Year-end	20,762	14,797

LIFEWAY FOODS, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Net Sales	80,318,000	92,636,000
Cost & expenses	79,943,000	89,454,000
Operating income	(115,000)	2,678,000
Interest expense	220,000	180,000
Other income (expense), net	11,000	
Gains or losses	42,000	(39,000)
Net before taxes	(282,000)	2,459,000
Income taxes	(8,000)	1,056,000
Net income	(274,000)	1,403,000
Earnings common share		
Primary	\$(0.02)	\$0.09
Fully Diluted	\$(0.02)	\$0.09

Common Shares:		
Full Diluted	16,354,000	16,218,000
Year-end	15,838,000	16,037,000

LIGAND PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	191,863,000	90,638,000
Cost & expenses	48,976,000	42,786,000
Operating income	130,578,000	39,726,000
Other income (expense), net	118,563,000	(4,535,000)
Net before taxes	230,119,000	26,566,000
Income taxes	44,316,000	7,000,000
Net income	185,803,000	19,566,000
Earnings common share		
Primary	\$8.77	\$0.93
Fully Diluted	\$7.61	\$0.84
Common Shares:		
Full Diluted	24,429,571	23,261,857
Year-end	21,095,174	21,094,836

LIMELIGHT NETWORKS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	149,368	141,226
Deprec., depl. & amort.	1,837	1,789
Operating income	473	(6,842)
Interest income	440	365
Interest expense	76	42
Other income (expense), net	14,545	249
Net before taxes	15,382	(6,270)
Income taxes	347	448
Net income	15,035	(6,718)
Earnings common share		
Primary	\$0.13	\$(0.06)
Fully Diluted	\$0.13	\$(0.06)
Common Shares:		
Full Diluted	120,025	108,376
Year-end	113,198	109,638

LINCOLN ELECTRIC HOLDINGS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	2,284,847	1,877,246
Cost & expenses	2,004,238	1,576,626
Operating income	280,609	300,620
Interest expense	13,222	14,984
Other income (expense), net	6,818	6,872
Net before taxes	274,205	292,508
Income taxes	73,991	69,218
Net income	200,214	223,290
Earnings common share		
Primary	\$3.07	\$3.40
Fully Diluted	\$3.03	\$3.35
Common Shares:		
Full Diluted	66,055	66,679
Year-end	64,446	65,756

LITTELFUSE INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Net Sales	1,316,187	916,685
Cost & expenses	1,104,265	730,547
Operating income	173,421	167,731
Interest expense	16,980	9,868
Other income (expense), net	2,362	962
Foreign currency	6,372	1,483
Net before taxes	165,175	160,308
Income taxes	33,275	29,970
Net income	131,900	130,338
Earnings common share		
Primary	\$5.31	\$5.75
Fully Diluted	\$5.23	\$5.69
Common Shares:		
Full Diluted	25,212	22,906
Year-end	25,154	22,713

LIVEPERSON INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	184,114	161,486
Cost & expenses	199,305	172,005
Operating income	(16,463)	(11,931)
Other income (expense), net	(53)	412

Net before taxes	(16,516)	(11,519)
Income taxes	2,051	3,000
Net income	(18,567)	(14,519)
Earnings common share		
Primary	\$(0.32)	\$(0.26)
Fully Diluted	\$(0.32)	\$(0.26)
Common Shares:		
Full Diluted	58,667	56,153
Year-end	63,416	59,525

LKQ CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	8,873,893,000	267,054,000
Cost & expenses	7,959,476,000	428,512,000
Deprec., depl. & amort.	196,322,000	159,178,000
Operating income	718,095,000	679,364,000
Interest expense	107,647,000	73,806,000
Other income (expense), net	9,414,000	10,874,000
Equity earnings	18,326,000	(3,878,000)
Net before taxes	619,862,000	616,432,000
Income taxes	156,427,000	206,206,000
Net income	445,109,000	409,573,000
Earnings common share		
Primary	\$1.42	\$1.33
Fully Diluted	\$1.41	\$1.32
Common Shares:		
Full Diluted	314,951,000	310,495,000
Year-end	318,197,309	309,018,211

LOGICBIO THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016
Research & development	3,558	2,030
General & administrative expenses	2,296	1,373
Total operating expenses	5,854	3,403
Income (loss) from operations	(5,854)	(3,403)
Interest (expense) income, net	54	(1)
Other (expense) income, net	67	(6)
Total other income (expense)	121	(7)
Income before income taxes - United States	(5,832)	(3,363)
Income before income taxes - Foreign (Israel)	99	(47)
Income (loss) before income taxes	(5,733)	(3,410)
Income tax provision	62	18
Net income (loss)	(5,795)	(3,428)
Less: Accruals of dividends of preferred stock	1,940	337
Net income (loss) attributable to common stockholders	(7,735)	(3,765)
Weighted average shares outstanding - basic	1,395	849
Weighted average shares outstanding - diluted	1,395	849
Year end shares outstanding	1,606	979
Net earnings (loss) per share - basic	\$(5.54)	\$(4.43)
Net earnings (loss) per share - diluted	\$(5.54)	\$(4.43)
Number of full time employees	20	...

□ As Is; □ As of July 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	24,575	1,728
Prepayments & other current assets	1,118	86
Total current assets	25,693	1,814
Computer equipment &		

software	23	20
Laboratory equipment	264	206
Office furniture	7	5
Total property & equipment, gross	294	231
Less: Accumulated depreciation & amortization	62	16
Property & equipment, net	232	215
Other non-current assets	249	...
Total assets	26,174	2,029
Accounts payable	1,112	341
Accrued compensation & benefits	290	66
Accrued insurance	20	21
Accrued professional services	64	300
Other accrued expenses	225	192
Accrued expenses & other current liabilities	599	579
Total current liabilities	1,711	920
Total liabilities	1,711	920
Series A convertible preferred stock	4,359	4,359
Series B convertible preferred stock	28,703	...
Common stock	1	1
Additional paid-in capital	1,035	628
Accumulated other comprehensive income (loss)	(14)	...
Retained earnings (accumulated deficit)	(9,621)	(3,879)
Total shareholders' (deficit) equity	(8,599)	(3,250)

Recent Dividends:**1. LogicBio Therapeutics Inc common.**

No dividends paid.

Annual Dividends:**1. LogicBio Therapeutics Inc common.**

No dividends paid.

LOGICBIO THERAPEUTICS INC**Earnings, 6 mos. to Jun 30(Consol. - \$000):**

	2018	2017
Cost & expenses	6,015	1,720
Operating income	(6,015)	(1,720)
Other income (expense), net	(4)	12
Net before taxes	(1,719)	19
Income taxes	19	...
Net income	(5,891)	(1,738)
Balance for common	(10,521)	(2,501)
Earnings common share		
Primary	\$(5.61)	\$(2.02)
Fully Diluted	\$(5.61)	\$(2.02)
Common Shares:		
Full Diluted	1,875	1,236
Year-end	1,943	...

LOGMEIN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	893,794,000	713,750,000
Cost & expenses	698,563,000	643,291,000
Operating income	66,533,000	(26,728,000)
Interest income	1,335,000	924,000
Interest expense	4,213,000	1,088,000
Other income (expense), net	(403,000)	(27,000)
Net before taxes	63,252,000	(26,919,000)
Income taxes	14,269,000	(33,121,000)
Net income	48,983,000	6,202,000
Earnings common share		
Primary	\$0.94	\$0.12
Fully Diluted	\$0.93	\$0.12
Common Shares:		
Full Diluted	52,829,000	50,735,000
Year-end	51,331,000	...

LONESTAR RESOURCES US INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	143,281,000	62,634,000
Cost & expenses	53,330,000	54,182,000
Operating income	30,014,000	(33,551,000)
Interest expense	28,771,000	19,816,000
Other income (expense), net	(65,576,000)	9,791,000
Net before taxes	(64,333,000)	(43,576,000)
Income taxes	(6,493,000)	(15,854,000)
Net income	(57,840,000)	(27,722,000)
Balance for common	(63,636,000)	(29,842,000)
Earnings common share		
Primary	\$(2.59)	\$(1.37)
Fully Diluted	\$(2.59)	\$(1.37)
Common Shares:		
Full Diluted	24,598,816	21,822,015
Year-end	24,637,127	

LOOP INDUSTRIES INC**Earnings, 6 mos. to Aug 31 (Consol. - \$):**

	2018	2017
Cost & expenses	6,856,282	3,516,793
Net income	(7,067,940)	(3,699,054)
Earnings common share		
Primary	\$(0.21)	\$(0.11)
Fully Diluted	\$(0.21)	\$(0.11)
Common Shares:		
Full Diluted	33,768,516	31,830,628
Year-end	33,805,706	32,789,009

LOXO ONCOLOGY, INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	174,273	130,289
Operating income	(50,773)	(130,289)
Interest income	8,425	2,041
Net income	(42,348)	(128,248)
Earnings common share		
Primary	\$(1.40)	\$(4.68)
Fully Diluted	\$(1.40)	\$(4.68)
Common Shares:		
Full Diluted	30,230	27,391
Year-end	30,567	29,916

LSI INDUSTRIES INC.**Earnings, 3 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Net Sales	84,957	87,466
Cost & expenses	82,023	112,280
Operating income	2,934	(24,814)
Interest income	14	8
Interest expense	532	411
Net before taxes	2,416	(25,217)
Income taxes	667	(9,588)
Net income	1,749	(15,629)
Earnings common share		
Primary	\$0.07	\$(0.61)
Fully Diluted	\$0.07	\$(0.61)
Common Shares:		
Full Diluted	26,365	25,791
Year-end	25,799	25,535

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	4,162	
Inventories	49,580	
Current assets	118,345	
Net property & equip.	42,523	
Total assets	235,544	
Liabilities:		
Current liabilities	45,723	
Long-term debt	46,152	
Stockholders' equity	141,063	
Net current assets	72,622	

LUMINEX CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	234,685	228,372
Cost & expenses	201,309	193,660
Operating income	26,878	28,023
Other income (expense), net	465	(6)
Net before taxes	27,343	28,017
Income taxes	6,540	(4,371)
Net income	20,803	32,388
Earnings common share		

	2018	2017
Primary	\$0.47	\$0.74
Fully Diluted	\$0.46	\$0.71
Common Shares:		
Full Diluted	44,193	43,216
Year-end	43,839	43,304

MACROGENICS, INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	44,327,000	5,383,000
Cost & expenses	173,855,000	132,495,000
Operating income	(129,528,000)	127,112,000
Other income (expense), net	2,719,000	1,759,000
Net income	(126,809,000)	125,353,000
Earnings common share		
Primary	\$(3.13)	\$(3.50)
Fully Diluted	\$(3.13)	\$(3.50)
Common Shares:		
Full Diluted	40,462,658	35,847,449
Year-end	42,248,075	36,807,112

MADDEN (STEVEN) LTD.**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Net Sales	1,243,249,000	181,728,000
Cost & expenses	1,094,904,000	104,610,000
Operating income	148,345,000	138,118,000
Net before taxes	150,847,000	140,074,000
Income taxes	32,885,000	45,703,000
Net income	117,962,000	94,371,000
Earnings common share		
Primary	\$1.43	\$1.13
Fully Diluted	\$1.35	\$1.07
Common Shares:		
Full Diluted	86,273,000	86,841,000
Year-end	87,407,000	88,599,000

MAGELLAN HEALTH INC.**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	5,469,506	4,144,168
Cost & expenses	5,301,491	3,976,434
Deprec., depl. & amort.	97,302	82,896
Operating income	70,713	84,838
Net before taxes	70,713	84,838
Income taxes	18,565	29,206
Net income	52,148	55,632
Earnings common share		
Primary	\$2.13	\$2.41
Fully Diluted	\$2.06	\$2.30
Common Shares:		
Full Diluted	25,316	24,241
Year-end	24,255	23,517

MAGENTA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	42,033	27,557
Operating income	(42,033)	(27,557)
Other income (expense), net	1,197	102
Net income	(40,836)	(27,455)
Balance for common	(40,924)	(27,471)
Earnings common share		
Primary	\$(3.05)	\$(15.90)
Fully Diluted	\$(3.05)	\$(15.90)
Common Shares:		
Full Diluted	13,397	1,728
Year-end	34,328	

MALIBU BOATS INC**Earnings, 3 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Net Sales	123,483	103,541
Cost & expenses	105,451	91,281
Operating income	16,752	10,952
Interest expense	1,171	2,199
Other income (expense), net	17	(2,597)
Net before taxes	15,598	6,156
Income taxes	3,583	(258)
Net income	12,015	6,414
Earnings common share		
Primary	\$0.55	\$0.31
Fully Diluted	\$0.54	\$0.31
Common Shares:		

Full Diluted	20,750	19,304
Year-end	20,777	20,285

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	72,169	
Inventories	52,784	
Current assets	151,584	
Net property & equip.	41,527	
Total assets	384,667	
Liabilities:		
Current liabilities	69,128	
Long-term debt	108,581	
Stockholders' equity	147,590	
Net current assets	82,456	

MAMMOTH ENERGY SERVICES INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

	2018	2017
Total Revenues	1,411,886,000	322,533,000
Cost & expenses	976,577,000	272,830,000
Operating income	345,591,000	(14,651,000)
Other income (expense), net	(914,000)	(707,000)
Gains or losses		4,012,000
Net before taxes	342,023,000	(14,275,000)
Income taxes	174,265,000	(7,323,000)
Net income	167,758,000	(6,952,000)
Earnings common share		
Primary	\$3.75	\$(0.17)
Fully Diluted	\$3.73	\$(0.17)
Common Shares:		
Full Diluted	45,012,000	40,526,000
Year-end	44,755,678	44,502,223

MANHATTAN ASSOCIATES, INC.**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	414,791	450,513
Cost & expenses	308,564	301,575
Operating income	99,611	142,075
Other income (expense), net	3,245	(232)
Net before taxes	102,856	141,843
Net income	78,775	91,967
Earnings common share		
Primary	\$1.18	\$1.33
Fully Diluted	\$1.18	\$1.32
Common Shares:		
Full Diluted	66,717	69,614
Year-end	65,378	68,930

MANTECH INTERNATIONAL CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	1,461,485	1,254,733
Cost & expenses	1,377,336	1,182,268
Operating income	84,149	72,465
Other income (expense), net	63	235
Equity earnings	(27)	(77)
Net before taxes	82,290	71,924
Income taxes	20,412	26,230
Net income	61,905	45,711
Earnings common share		
Primary	\$1.57	\$1.18
Fully Diluted	\$1.55	\$1.17
Common Shares:		
Full Diluted	26,633	25,845
Year-end	39,730	38,968

MARCHEX INC

Acquisition Completed On Nov. 5, 2018, Co.'s wholly-owned Canadian subsidiary, Marchex CA Corp., acquired all the issued and outstanding shares of Telmetrics Inc., a call and text tracking and analytics company that enables, tracks and analyzes offline interactions to increase engagement and return on advertising spend, for \$10,100,000 in cash at closing and up to \$3,000,000 in cash based upon the achievement of targeted financial goals over the two (2) twelve (12) month periods following the closing date.

MARIN SOFTWARE INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

--	--	--

	2018	2017
Total Revenues	42,806	57,299
Cost & expenses	82,072	80,098
Operating income	(39,266)	(22,799)
Other income (expense), net	1,008	(445)
Net before taxes	(38,258)	(23,244)
Income taxes	624	976
Net income	(38,882)	(24,220)
Earnings common share		
Primary	\$(6.75)	\$(4.31)
Fully Diluted	\$(6.75)	\$(4.31)
Common Shares:		
Full Diluted	5,763	5,625
Year-end	5,790	5,653

MARINUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Cost & expenses	26,906,000	14,106,000
Operating income	(26,906,000)	(14,106,000)
Interest income	292,000	116,000
Interest expense		159,000
Other income (expense), net		(11,000)
Net income	(26,614,000)	(14,160,000)
Earnings common share		
Primary	\$(0.66)	\$(0.60)
Fully Diluted	\$(0.66)	\$(0.60)
Common Shares:		
Full Diluted	40,392,084	23,531,745
Year-end	40,525,013	40,430,196

MARLIN BUSINESS SERVICES CORP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	74,133	72,282
Operating income	24,020	14,668
Net before taxes	24,020	14,668
Income taxes	5,462	5,270
Net income	18,558	9,398
Balance for common	18,226	9,157
Earnings common share		
Primary	\$1.49	\$0.75
Fully Diluted	\$1.49	\$0.75
Common Shares:		
Full Diluted	12,269	12,255
Year-end	12,400	

MARRIOTT INTERNATIONAL, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$Millions):

	2018	2017
Total Revenues	15,401	15,201
Cost & expenses	13,427	12,945
Operating income	1,810	2,080
Interest income	16	24
Interest expense	246	216
Other income (expense), net	286	60
Net before taxes	1,866	1,948
Income taxes	375	603
Net income	1,491	1,345
Earnings common share		
Primary	\$4.23	\$3.55
Fully Diluted	\$4.18	\$3.51
Common Shares:		
Full Diluted	357	383
Year-end	341	

Consolidated Balance Sheet Items, as of (\$Millions):

Assets:	2018	2017
Cash & equivalents	373	373
Current assets	2,803	2,803
Net property & equip.	1,967	1,967
Total assets	23,833	23,833
Liabilities:		
Current liabilities	6,051	6,051
Long-term debt	8,710	8,710
Stockholders' equity	2,324	2,324
Net current assets	(3,248)	(3,248)

MARTIN MIDSTREAM PARTNERS LP

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	719,822	640,375
Net Sales	561,641	476,303
Cost & expenses	627,717	544,170
Deprec., depl. & amort.	58,842	65,948

Operating income	33,263	30,257
Interest income	15	949
Other income (expense), net	18	605
Net before taxes	(6,310)	(3,815)
Income taxes	372	301
Income contin. oper.	(6,682)	(4,116)
Net income	45,018	(1,714)
Earnings common share		
Primary	\$1.13	\$(0.04)
Fully Diluted	\$1.13	\$(0.04)
Common Shares:		
Full Diluted	38,889	38,016
Year-end	39,036	

MASIMO CORP.

Earnings, 9 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Total Revenues	635,157	582,309
Cost & expenses	481,019	443,248
Operating income	154,138	139,061
Other income (expense), net	4,080	1,319
Net before taxes	158,218	140,380
Income taxes	11,609	7,856
Net income	146,609	132,524
Earnings common share		
Primary	\$2.78	\$2.57
Fully Diluted	\$2.59	\$2.37
Common Shares:		
Full Diluted	56,555	55,967
Year-end	52,996	51,671

MASTERCRAFT BOAT HOLDINGS INC

New Name On Nov. 20, 2018, Co. changed its name from MCBC Holdings Inc to MasterCraft Boat Holdings Inc.

MATCH GROUP INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,272,506	951,754
Cost & expenses	844,240	694,073
Operating income	402,293	232,854
Other income (expense), net	4,677	(25,453)
Net before taxes	352,512	149,831
Income taxes	(6,474)	(214,039)
Net income	358,608	359,223
Earnings common share		
Primary	\$1.31	\$1.38
Fully Diluted	\$1.22	\$1.21
Common Shares:		
Full Diluted	297,317	297,307
Year-end	278,427	273,019

MATRIX SERVICE CO.

Earnings, 3 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	316,291	262,589
Operating income	2,220	7,321
Interest income	282	39
Interest expense	292	618
Other income (expense), net	546	149
Net before taxes	2,756	6,891
Income taxes	451	3,067
Net income	2,305	3,824
Earnings common share		
Primary	\$0.09	\$0.14
Fully Diluted	\$0.08	\$0.14
Common Shares:		
Full Diluted	27,589	26,762
Year-end	27,020	26,728

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	74,736	6,514
Inventories	6,514	6,514
Current assets	385,549	385,549
Net property & equip.	71,498	71,498
Total assets	587,194	587,194
Liabilities:		
Current liabilities	261,144	261,144
Long-term debt	1,549	1,549
Stockholders' equity	322,781	322,781
Net current assets	124,405	124,405

MATTEL INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Net Sales	2,986,571	3,271,078
Cost & expenses	3,330,469	3,359,477
Operating income	(343,898)	(88,399)
Other income (expense), net	(4,366)	(7,532)
Net before taxes	(475,335)	(158,151)
Income taxes	70,571	614,402
Net income	(545,906)	(772,553)
Earnings common share		
Primary	\$(1.58)	\$(2.25)
Fully Diluted	\$(1.58)	\$(2.25)
Common Shares:		
Full Diluted	344,774	343,304
Year-end	343,700	343,700

MAXIM INTEGRATED PRODUCTS, INC.

Earnings, 3 mos. to (Consol. – \$000):

	09/29/18	09/23/17
Total Revenues	638,495	575,676
Cost & expenses	403,539	388,758
Operating income	234,183	185,166
Net before taxes	233,637	180,952
Income taxes	36,214	26,419
Net income	197,423	154,533
Earnings common share		
Primary	\$0.71	\$0.55
Fully Diluted	\$0.70	\$0.54
Common Shares:		
Full Diluted	282,454	286,437
Year-end	277,063	281,487

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	1,598,772	1,598,772
Inventories	275,374	275,374
Current assets	3,311,525	3,311,525
Net property & equip.	573,014	573,014
Total assets	4,548,552	4,548,552
Liabilities:		
Current liabilities	928,277	928,277
Long-term debt	991,506	991,506
Stockholders' equity	1,912,323	1,912,323
Net current assets	2,383,248	2,383,248

MAXWELL TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	91,607	99,605
Cost & expenses	119,193	131,009
Operating income	(27,586)	(31,404)
Other income (expense), net	656	506
Foreign currency	(383)	(50)
Net before taxes	(30,588)	(31,260)
Income taxes	(358)	3,117
Net income	(30,230)	(34,377)
Earnings common share		
Primary	\$(0.77)	\$(0.98)
Fully Diluted	\$(0.77)	\$(0.98)
Common Shares:		
Full Diluted	39,381	34,929
Year-end	45,867	37,076

MCGRATH RENTCORP

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	365,215,000	339,807,000
Cost & expenses	282,900,000	271,853,000
Operating income	82,315,000	67,954,000
Foreign currency	(505,000)	273,000
Net before taxes	72,677,000	59,503,000
Income taxes	17,520,000	23,307,000
Net income	55,157,000	36,196,000
Earnings common share		
Primary	\$2.29	\$1.51
Fully Diluted	\$2.25	\$1.50
Common Shares:		
Full Diluted	24,550,000	24,201,000
Year-end	24,176,000	24,032,000

MEDICINES CO (THE)

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	6,138,000	36,194,000
Cost & expenses	171,817,000	541,203,000
Operating income	(165,679,000)	505,009,000
Interest expense	36,498,000	36,753,000
Other income (expense), net	5,294,000	3,875,000
Gains or losses	(41,416,000)	
Net before taxes	(238,299,000)	537,887,000
Income taxes	(47,375,000)	(89,608,000)
Income contin. oper.	(190,924,000)	448,279,000
Income discount. oper.	110,242,000	(81,834,000)
Net income	(80,682,000)	530,113,000
Earnings common share		
Primary	\$(1.10)	\$(7.39)
Fully Diluted	\$(1.10)	\$(7.39)
Common Shares:		
Full Diluted	73,564,000	71,763,000
Year-end	73,864,822	

MEDPACE HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	512,474	323,470
Cost & expenses	413,038	239,175
Operating income	70,382	49,421
Interest expense	6,558	5,508
Other income (expense), net	807	(642)
Net before taxes	64,631	43,271
Income taxes	14,207	15,440
Net income	50,424	27,831
Balance for common	50,220	27,789
Earnings common share		
Primary	\$1.41	\$0.70
Fully Diluted	\$1.36	\$0.69
Common Shares:		
Full Diluted	36,795	40,537
Year-end	35,588	37,404

MELINTA THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	60,941,000	7,449,000
Cost & expenses	180,932,000	53,182,000
Operating income	(119,991,000)	(45,733,000)
Interest income	521,000	896,000
Interest expense	32,332,000	677,000
Other income (expense), net	38,730,000	
Net income	(113,072,000)	(45,514,000)
Balance for common	(113,072,000)	
Earnings common share		
Primary	\$(2.66)	\$(4.35)
Fully Diluted	\$(2.66)	\$(4.35)
Common Shares:		
Full Diluted	42,501,123	10,494,114
Year-end	56,015,254	10,501,856

MENLO THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Cost & expenses	46,735	21,923
Operating income	(36,095)	(20,116)
Net income	(33,852)	(19,800)
Balance for common	(33,852)	(19,800)
Earnings common share		
Primary	\$(1.60)	\$(3.89)
Fully Diluted	\$(1.60)	\$(3.89)
Common Shares:		
Full Diluted	21,164	5,093
Year-end	23,232	

MERCADOLIBRE INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	1,011,634,000	858,479,000
Cost & expenses	1,080,298,000	737,597,000
Operating income	(68,664,000)	120,882,000
Foreign currency	22,102,000	(19,475,000)
Net before taxes	(58,621,000)	118,741,000
Income taxes	(24,372,000)	37,241,000
Net income	(34,249,000)	81,500,000
Earnings common share		
Primary	\$(0.77)	\$1.85
Fully Diluted	\$(0.77)	\$1.85
Common Shares:		

Full Diluted	44,302,724	44,157,364
Year-end	45,201,662	44,157,364

MERCANTIL BANK HOLDING CORP**Earnings, 6 mos. to Jun 30**(Consol. - \$000):

	2018	2017
Cost & expenses	145,572	132,986
Operating income	27,120	24,212
Net before taxes	27,120	24,212
Income taxes	7,268	7,315
Net income	19,852	16,897
Earnings common share		
Primary	\$0.48	\$0.39
Fully Diluted	\$0.48	\$0.39
Common Shares:		
Full Diluted	42,489	42,489
Year-end	42,489	42,489

MERCANTIL BANK HOLDING CORP

Stock Split Announcement On Oct. 23, 2018, Co. reported that the one-for-three combination equivalent to a reverse stock split (the "Split") of each of Co.'s Class A common stock and Co.'s Class B common stock became effective as of Oct. 23, 2018. Co.'s Board of Directors approved the Split as of Oct. 11, 2018. As a result of the Split, every three shares of Co.'s Class A common stock and Co.'s Class B common stock issued and outstanding was automatically combined and reclassified into one share of Co. Class A common stock and one share of Co. Class B common stock, respectively. Co.'s Class A common stock and Class B common stock began trading on Oct. 24, 2018 on the Nasdaq Global Select Market, on a split-adjusted basis. The post-Split Class A common stock will have the symbol "AMTB" and CUSIP number 58734F 305. The post-Split Class B common stock will have the symbol "AMTBB" and CUSIP number 58734F 404. Fractional shares were issued in connection with the Split. No cash in lieu of fractional shares were paid by Co. in connection with the Split.

MERCER INTERNATIONAL INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	1,045,493	831,459
Cost & expenses	868,623	729,588
Operating income	176,870	101,871
Other income (expense), net	(29,094)	(10,497)
Net before taxes	111,804	50,662
Income taxes	28,224	21,897
Net income	83,580	28,765
Earnings common share		
Primary	\$1.28	\$0.44
Fully Diluted	\$1.27	\$0.44
Common Shares:		
Full Diluted	65,692	65,344
Year-end	65,202	65,017

MERCURY SYSTEMS INC**Earnings, 3 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	144,056	106,069
Cost & expenses	123,065	90,061
Operating income	13,810	10,371
Interest income	66	19
Interest expense	2,259	3
Other income (expense), net	(1,009)	(815)
Net before taxes	10,608	9,572
Income taxes	3,129	(8,381)
Net income	7,479	17,953
Earnings common share		
Primary	\$0.16	\$0.39
Fully Diluted	\$0.16	\$0.38
Common Shares:		
Full Diluted	47,697	47,489
Year-end	47,169	46,736

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	72,869
Inventories	121,156
Current assets	364,179
Net property & equip.	50,829
Total assets	1,126,974
Liabilities:	
Current liabilities	82,756
Long-term debt	240,000
Stockholders' equity	776,621
Net current assets	281,423

MERITAGE HOSPITALITY GROUP INC**Earnings, 9 mos. to** (Consol. - \$):

	09/30/18	10/01/17
Cost & expenses	299,337,130	208,503,605
Deprec., depl. & amort.	8,817,370	6,057,694
Operating income	19,379,792	12,777,279
Interest expense	5,800,279	3,753,833
Other income (expense), net	260,284	2,359,567
Net before taxes	13,839,797	11,383,013
Income taxes	3,123,455	3,906,814
Net income	10,716,342	7,476,199
Earnings common share		
Common Shares:		
Year-end	6,243,470	6,119,741

MERRIMACK PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Cost & expenses	51,303	78,752
Operating income	(51,303)	(78,752)
Interest income	863	646
Interest expense	472	30,400
Other income (expense), net	(1,778)	(592)
Gains or losses		12,551
Net before taxes	(52,690)	(96,547)
Income taxes	(4,798)	(32,372)
Income contin. oper.	(47,892)	(64,175)
Net income	(31,562)	483,819
Earnings common share		
Primary	\$(2.37)	\$36.75
Fully Diluted	\$(2.37)	\$36.75
Common Shares:		
Full Diluted	13,343	13,197
Year-end	13,343	

MGE ENERGY INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	419,689	422,825
Cost & expenses	287,718	283,791
Operating income	90,217	99,428
Interest expense	14,547	14,507
Other income (expense), net	13,980	12,038
Net before taxes	89,650	96,959
Income taxes	21,792	35,487
Net income	67,858	61,472
Earnings common share		
Primary	\$1.96	\$1.77
Fully Diluted	\$1.96	\$1.77
Common Shares:		
Full Diluted	34,668	34,668
Year-end	34,668	34,668

MGP INGREDIENTS INC (NEW)**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Net Sales	271,239	259,255
Cost & expenses	237,703	226,878
Operating income	33,536	32,377
Other income (expense), net		11,033
Net before taxes	32,706	42,476
Income taxes	7,244	13,292
Net income	25,462	29,184
Balance for common	24,971	28,378
Earnings common share		
Primary	\$1.48	\$1.70
Fully Diluted	\$1.48	\$1.70
Common Shares:		
Full Diluted	16,862	16,735
Year-end	16,852	16,724

MICROCHIP TECHNOLOGY INC**Earnings, 6 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Net Sales	2,644,900	1,984,300
Cost & expenses	2,106,400	1,295,500
Operating income	234,900	447,000
Interest income	6,600	8,100
Interest expense	229,000	98,900
Other income (expense), net	(14,200)	(3,800)
Net before taxes	(1,700)	352,400
Income taxes	(133,700)	(7,300)
Net income	132,000	359,700
Earnings common share		

Primary	\$0.56	\$1.55
Fully Diluted	\$0.52	\$1.55
Common Shares:		
Full Diluted	252,000	243,800
Year-end	236,208	233,847

MICROSOFT CORPORATION

Earnings, 3 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	29,084,000	24,538,000
Cost & expenses	19,129,000	16,830,000
Operating income	9,955,000	7,708,000
Other income (expense), net	11,000	(89,000)
Invest. income	243,000	573,000
Foreign currency	5,000	(9,000)
Net before taxes	10,221,000	7,984,000
Income taxes	1,397,000	1,408,000
Net income	8,824,000	6,576,000
Earnings common share		
Primary	\$1.15	\$0.85
Fully Diluted	\$1.14	\$0.84
Common Shares:		
Full Diluted	7,766,000	7,799,000
Year-end	7,680,000	7,720,000

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	15,137,000	
Inventories	3,614,000	
Current assets	164,195,000	
Net property & equip.	31,430,000	
Total assets	257,619,000	
Liabilities:		
Current liabilities	56,277,000	
Long-term debt	69,733,000	
Stockholders' equity	85,967,000	
Net current assets	107,918,000	

MICROVISION INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	15,774,000	7,332,000
Cost & expenses	31,057,000	24,696,000
Operating income	(15,283,000)	(17,364,000)
Other income (expense), net	(19,000)	(3,000)
Net income	(15,302,000)	(17,367,000)
Earnings common share		
Primary	\$(0.18)	\$(0.25)
Fully Diluted	\$(0.18)	\$(0.25)
Common Shares:		
Full Diluted	84,388,000	70,828,000
Year-end	93,073,000	

MID-CON ENERGY PARTNERS LP

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	31,132	46,176
Cost & expenses	35,774	46,454
Deprec., depl. & amort.	11,646	13,850
Operating income	(16,288)	(14,128)
Interest expense	4,369	4,615
Other income (expense), net	32	57
Net income	(20,622)	(18,678)
Earnings common share		
Primary	\$(0.78)	\$(0.69)
Fully Diluted	\$(0.78)	\$(0.69)
Common Shares:		
Full Diluted	30,292	29,972
Year-end	30,436	30,091

MIDDLEBY CORP

Earnings, 9 mos. to (Consol. – \$000):	09/29/18	09/30/17
Net Sales	1,966,259	1,702,683
Cost & expenses	1,660,280	1,386,974
Operating income	305,979	315,709
Other income (expense), net	27,675	24,662
Net before taxes	295,284	322,314
Income taxes	72,971	99,372
Net income	222,313	222,942
Earnings common share		
Primary	\$4.00	\$3.91
Fully Diluted	\$4.00	\$3.91
Common Shares:		
Full Diluted	55,575	57,070
Year-end	55,847	55,913

MINDBODY INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	179,216	132,933
Cost & expenses	214,080	144,323
Operating income	(34,864)	(11,390)
Interest income	2,581	808
Interest expense	5,374	933
Other income (expense), net	27	(56)
Net before taxes	(37,630)	(11,571)
Income taxes	(1,811)	343
Net income	(35,819)	(11,914)
Earnings common share		
Primary	\$(0.75)	\$(0.27)
Fully Diluted	\$(0.75)	\$(0.27)
Common Shares:		
Full Diluted	47,491	43,475
Year-end	47,913	46,586

MKS INSTRUMENTS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	1,614,567,000	1,404,177,000
Cost & expenses	1,181,806,000	1,082,613,000
Operating income	399,975,000	286,618,000
Interest income	4,077,000	1,896,000
Interest expense	13,071,000	23,001,000
Other income (expense), net	(1,179,000)	(3,741,000)
Gains or losses		74,856,000
Net before taxes	389,802,000	336,628,000
Income taxes	68,542,000	75,134,000
Net income	321,260,000	261,494,000
Earnings common share		
Primary	\$5.89	\$4.84
Fully Diluted	\$5.82	\$4.75
Common Shares:		
Full Diluted	55,171,000	55,020,000
Year-end	53,984,623	54,291,361

MOBILE MINI, INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	432,360,000	386,853,000
Net Sales	25,700,000	24,817,000
Cost & expenses	385,542,000	267,055,000
Deprec., depl. & amort.	50,206,000	46,941,000
Operating income	(3,388,000)	72,857,000
Interest income	6,000	20,000
Interest expense	30,179,000	26,412,000
Foreign currency	69,000	(29,000)
Net before taxes	(33,492,000)	46,436,000
Income taxes	(11,182,000)	16,279,000
Net income	(22,310,000)	30,157,000
Earnings common share		
Primary	\$(0.50)	\$0.68
Fully Diluted	\$(0.50)	\$0.68
Common Shares:		
Full Diluted	44,275,000	44,190,000
Year-end	44,692,000	44,327,000

MOBILEIRON INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	139,069	130,695
Cost & expenses	174,380	176,357
Operating income	(35,311)	(45,662)
Other income (expense), net	479	701
Net before taxes	(34,832)	(44,961)
Income taxes	1,043	881
Net income	(35,875)	(45,842)
Earnings common share		
Primary	\$(0.35)	\$(0.49)
Fully Diluted	\$(0.35)	\$(0.49)
Common Shares:		
Full Diluted	101,369	92,825
Year-end	105,420	

MOMENTA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	32,767,000	74,274,000
Cost & expenses	204,424,000	179,458,000
Operating income	(171,657,000)	105,184,000
Other income (expense), net	3,841,000	3,329,000

Net income	(167,816,000)	101,855,000
Earnings common share		
Primary	\$(2.20)	\$(1.40)
Fully Diluted	\$(2.20)	\$(1.40)
Common Shares:		
Full Diluted	76,415,000	72,585,000
Year-end	78,378,000	76,394,000

MONARCH CASINO & RESORT, INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	180,536,000	174,670,000
Cost & expenses	135,690,000	130,744,000
Operating income	33,765,000	32,529,000
Interest expense	177,000	639,000
Net before taxes	33,588,000	31,890,000
Income taxes	6,749,000	10,749,000
Net income	26,839,000	21,141,000
Earnings common share		
Primary	\$1.51	\$1.20
Fully Diluted	\$1.44	\$1.16
Common Shares:		
Full Diluted	18,582,000	18,212,000
Year-end	17,894,057	17,670,679

MONDELEZ INTERNATIONAL INC

Earnings, 9 mos. to Sep 30 (Consol. – \$Millions):	2018	2017
Total Revenues	19,165	18,930
Cost & expenses	16,591	16,165
Operating income	2,442	2,632
Other income (expense), net	(33)	63
Equity earnings	(1,156)	(249)
Net before taxes	2,075	2,400
Income taxes	662	510
Net income	2,569	2,139
Earnings common share		
Primary	\$1.73	\$1.41
Fully Diluted	\$1.72	\$1.39
Common Shares:		
Full Diluted	1,491	1,537
Year-end	1,457	1,495

MONEYGRAM INTERNATIONAL INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	1,101,800	1,193,900
Cost & expenses	1,039,300	1,068,500
Operating income	4,800	69,600
Other income (expense), net	25,600	(4,400)
Net before taxes	(9,400)	31,600
Income taxes	2,100	8,900
Net income	(11,500)	22,700
Earnings common share		
Primary	\$(0.18)	\$0.36
Fully Diluted	\$(0.18)	\$0.34
Common Shares:		
Full Diluted	64,200	66,200
Year-end	55,608	54,218

MONOLITHIC POWER SYSTEMS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	428,885,000	341,499,000
Cost & expenses	348,474,000	289,128,000
Operating income	80,411,000	52,371,000
Interest income	4,606,000	3,938,000
Other income (expense), net	(1,083,000)	(1,494,000)
Gains or losses	949,000	1,902,000
Foreign currency	915,000	(473,000)
Net before taxes	85,798,000	56,244,000
Income taxes	8,168,000	3,112,000
Net income	77,630,000	53,132,000
Earnings common share		
Primary	\$1.84	\$1.29
Fully Diluted	\$1.75	\$1.22
Common Shares:		
Full Diluted	44,450,000	43,384,000
Year-end	42,408,000	41,508,000

MONOTYPE IMAGING HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	175,339	170,773
Cost & expenses	163,260	159,509
Operating income	9,239	8,213
Interest income	403	309
Interest expense	2,756	2,365
Other income (expense), net	6	(24)
Gains or losses	138	(290)
Foreign currency	30	(4,544)
Net before taxes	7,060	1,299
Income taxes	4,243	1,609
Net income	2,817	(310)
Balance for common	2,226	(310)
Earnings common share		
Primary	\$0.06	\$(0.01)
Fully Diluted	\$0.06	\$(0.01)
Common Shares:		
Full Diluted	40,455	39,576
Year-end	41,859	41,782

MONRO INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/18	09/23/17
Net Sales	602,916	556,507
Cost & expenses	535,336	488,938
Operating income	67,580	67,569
Other income (expense), net	488	238
Net before taxes	54,685	55,948
Income taxes	12,280	21,096
Net income	42,405	34,852
Balance for common	42,201	34,668
Earnings common share		
Primary	\$1.28	\$1.06
Fully Diluted	\$1.26	\$1.05
Common Shares:		
Full Diluted	33,546	33,300
Year-end	32,955	32,771

MONSTER BEVERAGE CORP (NEW)**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	2,882,953,000	558,690,000
Cost & expenses	1,905,845,000	627,015,000
Operating income	977,108,000	931,675,000
Net before taxes	982,377,000	933,778,000
Income taxes	228,480,000	314,422,000
Net income	753,897,000	619,356,000
Earnings common share		
Primary	\$1.35	\$1.09
Fully Diluted	\$1.33	\$1.07
Common Shares:		
Full Diluted	566,791,000	577,964,000
Year-end	552,952,000	563,959,000

MULTI-COLOR CORP.**Earnings, 6 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	891,044	498,474
Cost & expenses	798,349	446,161
Operating income	92,695	52,313
Interest expense	37,889	13,004
Other income (expense), net	(2,904)	1,477
Net before taxes	51,902	40,786
Income taxes	10,005	11,454
Net income	41,897	29,332
Earnings common share		
Primary	\$2.05	\$1.73
Fully Diluted	\$2.04	\$1.71
Common Shares:		
Full Diluted	20,550	17,168
Year-end	20,444	17,055

MYOKARDIA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	21,158	8,488
Cost & expenses	76,928	56,409
Operating income	(55,770)	(47,921)
Net income	(52,022)	(46,944)
Balance for common	(52,022)	(46,944)
Earnings common share		
Primary	\$(1.38)	\$(1.47)
Fully Diluted	\$(1.38)	\$(1.47)
Common Shares:		

	Full Diluted	2018	2017
		37,766	31,952
		40,241	

MYR GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,084,824	1,029,816
Cost & expenses	1,050,944	1,013,721
Operating income	32,901	15,502
Interest income	13	4
Interest expense	2,518	1,793
Other income (expense), net	(2,020)	212
Net before taxes	28,376	13,925
Income taxes	7,940	6,350
Net income	20,436	7,575
Earnings common share		
Primary	\$1.24	\$0.47
Fully Diluted	\$1.23	\$0.46
Common Shares:		
Full Diluted	16,580	16,476
Year-end	16,564	16,459

MYRIAD GENETICS, INC.**Earnings, 3 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	202,300,000	178,800,000
Cost & expenses	201,100,000	94,800,000
Operating income	1,200,000	84,000,000
Other income (expense), net	1,100,000	(300,000)
Net before taxes	800,000	83,200,000
Income taxes	1,600,000	4,500,000
Net income	(800,000)	78,700,000
Earnings common share		
Primary	\$(0.01)	\$1.15
Fully Diluted	\$(0.01)	\$1.12
Common Shares:		
Full Diluted	73,000,000	70,400,000
Year-end	74,700,000	69,200,000

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	93,300,000	
Inventories	35,900,000	
Current assets	341,900,000	
Net property & equip.	60,000,000	
Total assets	1,573,600,000	
Liabilities:		
Current liabilities	108,000,000	
Long-term debt	258,000,000	
Stockholders' equity	1,102,200,000	
Net current assets	233,900,000	

NANOSTRING TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	76,700	79,672
Net Sales	59,882	50,990
Cost & expenses	128,503	110,495
Operating income	(51,803)	(30,823)
Interest income	826	549
Interest expense	4,798	4,585
Other income (expense), net	(330)	185
Net before taxes	(56,105)	(34,674)
Income taxes	185	137
Net income	(56,290)	(34,811)
Earnings common share		
Primary	\$(2.09)	\$(1.50)
Fully Diluted	\$(2.09)	\$(1.50)
Common Shares:		
Full Diluted	26,882	23,172
Year-end	30,769	25,339

NANTHEALTH INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	66,603	64,378
Cost & expenses	104,876	111,875
Operating income	(41,436)	(50,660)
Interest expense	12,766	12,049
Other income (expense), net	(90,440)	(46,045)
Net before taxes	(144,642)	(108,754)
Income taxes	(3,429)	85
Income contin. oper.	(141,213)	(108,839)
Net income	(143,030)	(153,577)
Earnings common share		

	Primary	Fully Diluted	2018	2017
			\$(1.31)	\$(1.28)
			\$(1.31)	\$(1.28)
Common Shares:				
Full Diluted			109,060	119,745
Year-end			109,491	

NASDAQ INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,141,000	2,929,000
Cost & expenses	2,195,000	2,039,000
Deprec., depl. & amort.	159,000	140,000
Operating income	787,000	750,000
Other income (expense), net	13,000	10,000
Gains or losses	40,000	2,000
Net before taxes	736,000	661,000
Income taxes	234,000	178,000
Net income	502,000	483,000
Earnings common share		
Primary	\$3.03	\$2.91
Fully Diluted	\$2.99	\$2.85
Common Shares:		
Full Diluted	167,884	169,566
Year-end	163,949	

NATERA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	190,689	157,575
Cost & expenses	275,590	246,285
Operating income	(84,901)	(88,710)
Net before taxes	(95,978)	(90,138)
Income taxes	335	273
Net income	(96,313)	(90,411)
Earnings common share		
Primary	\$(1.71)	\$(1.70)
Fully Diluted	\$(1.71)	\$(1.70)
Common Shares:		
Full Diluted	56,462	53,100
Year-end	61,673	

NATHAN'S FAMOUS, INC.**Earnings, 6 mos. to (Consol. - \$000):**

	09/23/18	09/24/17
Total Revenues	59,498	62,274
Cost & expenses	41,247	44,355
Operating income	17,567	17,184
Interest income	176	70
Interest expense	5,301	7,326
Other income (expense), net	540	42
Net before taxes	12,982	9,970
Income taxes	3,703	3,928
Net income	9,279	6,042
Earnings common share		
Primary	\$2.22	\$1.45
Fully Diluted	\$2.19	\$1.43
Common Shares:		
Full Diluted	4,229	4,213
Year-end	4,192	4,185

NATHAN'S FAMOUS, INC.

Interest Sale Completed On Oct. 23, 2018, Co.'s wholly-owned subsidiary, Nathan's Famous Operating Corp., sold its at 86th Street in Bay Ridge, New York, including the real estate, to 660 86 LLC for cash consideration of \$12,250,000.

NATIONAL CINEMEDIA INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/27/18	09/28/17
Total Revenues	304,000	285,400
Cost & expenses	181,000	173,500
Deprec., depl. & amort.	29,500	28,200
Operating income	93,500	83,700
Interest income	1,000	1,000
Other income (expense), net	3,800	700
Net before taxes	56,000	46,000
Income taxes	16,700	1,000
Net income	39,300	45,000
Earnings common share		
Primary	\$0.18	\$0.29
Fully Diluted	\$0.16	\$0.28
Common Shares:		
Full Diluted	156,988	62,075
Year-end	76,932	75,230

NATIONAL GENERAL HOLDINGS CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	3,421,206	3,355,330
Cost & expenses	3,233,786	3,211,652
Operating income	187,420	143,678
Net before taxes	187,420	143,678
Income taxes	38,261	40,751
Net income	149,159	102,927
Balance for common	157,513	84,275
Earnings common share		
Primary	\$1.47	\$0.79
Fully Diluted	\$1.44	\$0.78
Common Shares:		
Full Diluted	109,316	108,690
Year-end	107,133	106,671

NATIONAL RESEARCH CORP**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	89,047,000	87,661,000
Cost & expenses	59,171,000	58,727,000
Operating income	25,880,000	25,558,000
Other income (expense), net	222,000	76,000
Net before taxes	25,169,000	25,624,000
Income taxes	2,923,000	9,198,000
Net income	22,246,000	16,426,000
Earnings common share		
Primary	\$0.76	\$0.39
Fully Diluted	\$0.73	\$0.38
Common Shares:		
Full Diluted	27,711,000	25,132,000
Year-end	24,762,212	24,483,029

NATUS MEDICAL INC.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	389,900	369,531
Cost & expenses	385,892	354,023
Operating income	(9,426)	3,667
Interest income	324	413
Interest expense	5,250	3,291
Other income (expense), net	(355)	19
Foreign currency	337	1,591
Net before taxes	(14,370)	2,399
Income taxes	(3,069)	15,597
Net income	(11,301)	(13,198)
Earnings common share		
Primary	\$(0.34)	\$(0.41)
Fully Diluted	\$(0.34)	\$(0.41)
Common Shares:		
Full Diluted	32,982	32,536
Year-end	33,756	33,150

NAVIENT CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	3,732,000	3,202,000
Operating income	421,000	582,000
Net before taxes	421,000	582,000
Income taxes	98,000	206,000
Net income	323,000	376,000
Earnings common share		
Primary	\$1.23	\$1.35
Fully Diluted	\$1.21	\$1.32
Common Shares:		
Full Diluted	267,000	285,000
Year-end	258,000	

NEKTAR THERAPEUTICS**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	1,153,497	212,245
Cost & expenses	365,270	247,853
Operating income	788,227	(35,608)
Net before taxes	782,775	(62,432)
Income taxes	3,250	434
Net income	779,525	(62,866)
Earnings common share		
Primary	\$4.63	\$(0.41)
Fully Diluted	\$4.34	\$(0.41)
Common Shares:		
Full Diluted	179,619	155,153
Year-end	173,057	156,953

NEOS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	70,855	63,359
Operating income	(36,260)	(45,449)
Interest expense	6,712	7,250
Other income (expense), net	634	578
Net income	(42,338)	(52,121)
Earnings common share		
Primary	\$(1.45)	\$(2.23)
Fully Diluted	\$(1.45)	\$(2.23)
Common Shares:		
Full Diluted	29,213	23,405
Year-end	29,708	

NET 1 UEPS TECHNOLOGIES INC**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	125,884	152,558
Cost & expenses	114,194	118,586
Operating income	896	25,006
Interest income	1,876	5,044
Interest expense	2,759	2,121
Equity earnings	(1,373)	(2,075)
Net before taxes	13	27,929
Income taxes	6,490	10,277
Net income	(5,104)	19,727
Earnings common share		
Primary	\$(0.09)	\$0.34
Fully Diluted	\$(0.09)	\$0.34
Common Shares:		
Full Diluted	56,001	56,609
Year-end	56,834	56,928

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	183,333	
Inventories	10,369	
Current assets	427,003	
Net property & equip.	25,222	
Total assets	1,200,605	
Liabilities:		
Current liabilities	309,918	
Long-term debt	11,660	
Stockholders' equity	632,892	
Net current assets	117,085	

NETAPP, INC.**Earnings, 6 mos. to (Consol. – \$000):**

	10/26/18	10/27/17
Total Revenues	2,991,000	2,736,000
Cost & expenses	2,451,000	2,380,000
Operating income	540,000	356,000
Other income (expense), net	7,000	6,000
Net before taxes	565,000	367,000
Income taxes	41,000	62,000
Net income	524,000	305,000
Earnings common share		
Primary	\$2.02	\$1.13
Fully Diluted	\$1.96	\$1.10
Common Shares:		
Full Diluted	267,000	277,000
Year-end	254,000	

NETGEAR INC**Earnings, 9 mos. to (Consol. – \$000):**

	09/30/18	10/01/17
Total Revenues	1,112,379	1,009,863
Cost & expenses	1,097,276	942,587
Operating income	15,103	67,276
Interest income	3,310	1,388
Other income (expense), net	638	1,384
Net before taxes	19,051	70,048
Income taxes	9,541	18,678
Net income	9,510	51,370
Earnings common share		
Primary	\$0.33	\$1.59
Fully Diluted	\$0.31	\$1.54
Common Shares:		
Full Diluted	32,826	33,269
Year-end	31,746	31,731

NETSCOUT SYSTEMS INC**Earnings, 6 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	428,908	482,619
Cost & expenses	487,632	480,732

Operating income	(100,170)	(34,794)
Interest expense	12,315	5,116
Other income (expense), net	(557)	(2,232)
Net before taxes	(110,809)	(41,252)
Income taxes	(21,877)	(14,562)
Net income	(88,932)	(26,690)
Earnings common share		
Primary	\$(1.12)	\$(0.30)
Fully Diluted	\$(1.12)	\$(0.30)
Common Shares:		
Full Diluted	79,490	89,878
Year-end	77,705	87,141

NEUROCRINE BIOSCIENCES, INC.**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	319,748,000	67,109,000
Cost & expenses	304,724,000	210,304,000
Operating income	15,024,000	143,195,000
Interest expense	22,767,000	12,104,000
Other income (expense), net	10,776,000	5,863,000
Net income	3,033,000	149,436,000
Earnings common share		
Primary	\$0.03	\$(1.70)
Fully Diluted	\$0.03	\$(1.70)
Common Shares:		
Full Diluted	95,272,000	87,894,000
Year-end	90,673,214	

NEURONETICS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	37,141	28,325
Cost & expenses	51,314	37,700
Operating income	(14,173)	(9,375)
Interest expense	2,749	2,068
Other income (expense), net	(1,032)	308
Net income	(17,954)	(11,135)
Earnings common share		
Primary	\$(2.99)	\$(62.56)
Fully Diluted	\$(2.99)	\$(62.56)
Common Shares:		
Full Diluted	6,014	178
Year-end	17,579	

NEW CENTURY RESOURCES CORP

New Accountant On Oct. 22, 2018, Anton & Chia, LLP re-signed as Co.'s independent public accounting firm, subsequently, Co. engaged AJ Robbins CPA, LLC as its new independent public accounting firm.

NEWLINK GENETICS CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	12,272	18,613
Cost & expenses	63,764	77,443
Operating income	(51,492)	(58,830)
Interest income	1,510	353
Interest expense	51	116
Other income (expense), net	16	(101)
Net before taxes	(50,017)	(58,694)
Income taxes	(6,991)	(429)
Net income	(43,026)	(58,265)
Earnings common share		
Primary	\$(1.16)	\$(1.98)
Fully Diluted	\$(1.16)	\$(1.98)
Common Shares:		
Full Diluted	37,179	29,462
Year-end	37,217	31,320

NEWS CORP (NEW)**Earnings, 3 mos. to Sep 30(Consol. – \$Millions):**

	2018	2017
Total Revenues	2,524	2,058
Cost & expenses	2,203	1,829
Deprec., depl. & amort.	163	97
Operating income	163	135
Other income (expense), net	5	3
Gains or losses	15	6
Net before taxes	178	141
Income taxes	50	54
Net income	128	87
Balance for common	101	67
Earnings common share		
Primary	\$0.17	\$0.12

Fully Diluted	\$0.17	\$0.12
Common Shares:		
Full Diluted	586	583
Year-end	585	583

Consolidated Balance Sheet Items, as of (\$Millions):

Assets:		2018
Cash & equivalents	1,886	
Inventories	388	
Current assets	4,469	
Net property & equip.	2,512	
Total assets	16,288	
Liabilities:		
Current liabilities	3,545	
Long-term debt	1,186	
Stockholders' equity	9,261	
Net current assets	924	

NEXSTAR MEDIA GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,968,674	1,778,302
Cost & expenses	1,247,420	1,136,117
Operating income	485,003	368,965
Other income (expense), net	1,890	(26,573)
Net before taxes	319,786	153,865
Income taxes	86,011	58,394
Net income	233,775	95,471
Earnings common share		
Primary	\$5.17	\$2.11
Fully Diluted	\$4.99	\$2.05
Common Shares:		
Full Diluted	47,388	47,029
Year-end	45,603	

NEXTGEN HEALTHCARE INC**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	263,521,000	263,529,000
Cost & expenses	242,333,000	241,394,000
Operating income	18,899,000	18,076,000
Interest income	69,000	21,000
Interest expense	1,499,000	1,517,000
Other income (expense), net	611,000	(7,000)
Net before taxes	18,080,000	16,573,000
Income taxes	2,338,000	4,647,000
Net income	15,742,000	11,926,000
Earnings common share		
Primary	\$0.25	\$0.19
Fully Diluted	\$0.24	\$0.19
Common Shares:		
Full Diluted	64,362,000	63,089,000
Year-end	64,382,000	63,685,000

NIC INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	266,251,000	253,036,000
Cost & expenses	197,110,000	187,011,000
Operating income	62,490,000	60,914,000
Interest income	212,000	
Net before taxes	62,702,000	60,914,000
Income taxes	14,280,000	20,140,000
Net income	48,422,000	40,774,000
Balance for common	47,897,000	40,393,000
Earnings common share		
Primary	\$0.72	\$0.61
Fully Diluted	\$0.72	\$0.61
Common Shares:		
Full Diluted	66,507,000	66,188,000
Year-end	66,567,000	66,268,000

NII HOLDINGS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	478,986	681,512
Cost & expenses	489,371	876,273
Operating income	(32,240)	(223,212)
Interest income	8,866	35,956
Interest expense	78,940	91,245
Other income (expense), net	(25,972)	(5,104)
Foreign currency	(60,092)	12,197
Net before taxes	(271,408)	(5,778)
Income taxes	(5,778)	
Income contin. oper.	(188,378)	(265,630)

Net income	(191,324)	(263,063)
Earnings common share		
Primary	\$(1.91)	\$(2.62)
Fully Diluted	\$(1.91)	\$(2.62)
Common Shares:		
Full Diluted	100,458	100,314
Year-end	100,744	

NN, INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	571,180	463,658
Cost & expenses	510,099	392,607
Deprec., depl. & amort.	51,798	39,006
Operating income	9,283	32,045
Interest expense	46,592	39,916
Other income (expense), net	(21,444)	(38,433)
Equity earnings	(1,744)	(4,139)
Net before taxes	(58,753)	(46,304)
Income taxes	(12,732)	(14,204)
Income contin. oper.		(27,961)
Net income	(44,277)	112,234
Earnings common share		
Primary	\$(1.59)	\$4.10
Fully Diluted	\$(1.59)	\$4.10
Common Shares:		
Full Diluted	27,784	27,403
Year-end	42,104	

NOODLES & CO**Earnings, 9 mos. to (Consol. - \$000):**

	10/02/18	10/03/17
Total Revenues	344,648	343,718
Cost & expenses	331,949	358,926
Operating income	(4,708)	(33,937)
Interest expense	3,385	2,828
Other income (expense), net	(626)	
Net before taxes	(8,719)	(36,765)
Income taxes	(259)	230
Net income	(8,460)	(36,995)
Balance for common	(8,460)	(44,962)
Earnings common share		
Primary	\$(0.20)	\$(1.23)
Fully Diluted	\$(0.20)	\$(1.23)
Common Shares:		
Full Diluted	41,799	36,639
Year-end	43,916	41,119

NORTHFIELD BANCORP INC (DE)**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	78,380	69,677
Operating income	37,450	37,776
Net before taxes	37,450	37,776
Income taxes	7,318	11,292
Net income	30,132	26,484
Earnings common share		
Primary	\$0.65	\$0.59
Fully Diluted	\$0.64	\$0.57
Common Shares:		
Full Diluted	47,137	46,834
Year-end	49,535	48,881

NORTHWEST PIPE CO.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	114,605	97,153
Cost & expenses	120,277	104,887
Operating income	(5,672)	(7,734)
Interest income	256	
Other income (expense), net	249	(54)
Gains or losses	21,880	
Net before taxes	16,328	(8,157)
Income taxes	(3,836)	(1,607)
Income contin. oper.		(6,550)
Income discont. oper.		(1,455)
Net income	20,164	(8,005)
Earnings common share		
Primary	\$2.07	\$(0.83)
Fully Diluted	\$2.07	\$(0.83)
Common Shares:		
Full Diluted	9,732	9,611
Year-end	9,735	9,620

NOVAVAX, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	28,161,000	20,764,000
Cost & expenses	155,567,000	144,690,000
Operating income	(127,406,000)	123,926,000
Other income (expense), net	111,000	20,000
Gains or losses	2,090,000	1,528,000
Net income	(135,414,000)	132,927,000
Earnings common share		
Primary	\$(0.37)	\$(0.47)
Fully Diluted	\$(0.37)	\$(0.47)
Common Shares:		
Full Diluted	365,236,000	284,767,000
Year-end	382,730,563	

NUANCE COMMUNICATIONS INC

Interest Sale Development On Nov. 12, 2018, Co. announced a definitive agreement to sell its Document Imaging division to Kofax, Inc. for \$400,000,000 in cash. The deal is expected to close in Q1 2019.

NUTRISYSTEM INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	561,496	565,720
Cost & expenses	493,806	487,889
Deprec., depl. & amort.	11,531	11,321
Operating income	56,159	66,510
Net before taxes	56,671	66,584
Income taxes	11,738	19,638
Net income	44,933	46,946
Balance for common	44,572	46,542
Earnings common share		
Primary	\$1.51	\$1.57
Fully Diluted	\$1.50	\$1.54
Common Shares:		
Full Diluted	29,797	30,164
Year-end	29,419	30,040

NUVASIVE INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	813,387	755,463
Cost & expenses	747,673	638,345
Operating income	(7,609)	53,271
Interest income	380	355
Interest expense	28,458	28,780
Other income (expense), net	(7,843)	(382)
Net before taxes	(7,609)	53,271
Income taxes	(7,931)	(3,543)
Net income	322	56,814
Earnings common share		
Primary	\$0.01	\$1.14
Fully Diluted	\$0.01	\$1.03
Common Shares:		
Full Diluted	52,296	56,304
Year-end	56,567	

NVIDIA CORP**Earnings, 9 mos. to (Consol. - \$000):**

	10/28/18	10/29/17
Total Revenues	9,511,000	6,803,000
Cost & expenses	6,001,000	4,666,000
Operating income	3,510,000	2,137,000
Other income (expense), net	12,000	(22,000)
Net before taxes	3,572,000	2,117,000
Income taxes	(3,000)	189,000
Net income	3,575,000	1,928,000
Earnings common share		
Primary	\$5.88	\$3.23
Fully Diluted	\$5.71	\$3.05
Common Shares:		
Full Diluted	626,000	633,000
Year-end	610,000	606,000

NXSTAGE MEDICAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	322,390,000	290,340,000
Cost & expenses	323,347,000	302,360,000
Operating income	(957,000)	(12,020,000)
Interest expense	266,000	595,000
Other income (expense), net	(858,000)	(565,000)
Net before taxes	(2,081,000)	(13,180,000)

Income taxes	1,148,000	(166,000)
Net income	(3,229,000)	(13,014,000)
Balance for common	(3,235,000)	(12,204,000)
Earnings common share		
Primary	\$(0.05)	\$(0.19)
Fully Diluted	\$(0.05)	\$(0.19)
Common Shares:		
Full Diluted	66,522,000	65,723,000
Year-end	66,673,615	66,196,933

O'REILLY AUTOMOTIVE, INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	7,221,471	6,786,918
Cost & expenses	5,834,327	5,464,353
Operating income	1,387,144	1,322,565
Interest income	1,838	1,768
Interest expense	90,661	64,555
Other income (expense), net	2,609	1,302
Net before taxes	1,300,930	1,261,080
Income taxes	276,800	429,591
Net income	1,024,130	831,489
Earnings common share		
Primary	\$12.50	\$9.28
Fully Diluted	\$12.36	\$9.15
Common Shares:		
Full Diluted	82,841	90,869
Year-end	80,346	85,338

OBALON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	35,370	30,691
Operating income	(28,305)	(24,469)
Interest expense	164	110
Other income (expense), net	(155)	(66)
Net income	(28,624)	(24,645)
Earnings common share		
Primary	\$(1.60)	\$(1.48)
Fully Diluted	\$(1.60)	\$(1.48)
Common Shares:		
Full Diluted	17,837	16,649
Year-end	23,280	17,372

OCULAR THERAPEUTIX INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	1,486	1,436
Cost & expenses	43,321	50,643
Operating income	(41,835)	(49,207)
Interest income	621	320
Interest expense	1,365	1,402
Other income (expense), net		5
Net income	(42,579)	(50,284)
Earnings common share		
Primary	\$(1.15)	\$(1.76)
Fully Diluted	\$(1.15)	\$(1.76)
Common Shares:		
Full Diluted	37,111	28,601
Year-end	40,524	29,388

OFS CAPITAL CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	30,263	25,134
Cost & expenses	17,199	13,076
Net income	13,064	12,058
Earnings common share		
Primary	\$0.98	\$1.00
Fully Diluted	\$0.98	\$1.00
Common Shares:		
Full Diluted	13,347	12,090
Year-end	13,353	13,335

OLYMPIC STEEL INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	1,285,491	1,022,530
Cost & expenses	1,217,356	983,377
Operating income	55,278	25,970
Other income (expense), net	(122)	(76)
Net before taxes	47,577	20,514
Net income	35,076	14,776
Earnings common share		

Primary	\$3.07	\$1.30
Fully Diluted	\$3.07	\$1.30
Common Shares:		
Full Diluted	11,427	11,384
Year-end	11,008	10,972

OMEGA FLEX INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Net Sales	79,443	74,335
Cost & expenses	60,909	57,786
Operating income	18,534	16,549
Other income (expense), net	(80)	(18)
Net before taxes	18,729	16,607
Income taxes	4,504	5,294
Net income	14,225	11,313
Earnings common share		
Primary	\$1.40	\$1.11
Fully Diluted	\$1.40	\$1.11
Common Shares:		
Full Diluted	10,092	10,092
Year-end	10,154	10,092

OMEROS CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Cost & expenses	101,599	80,841
Operating income	(93,747)	(29,774)
Interest expense	11,104	8,166
Other income (expense), net	1,628	1,010
Net income	(103,223)	(36,930)
Earnings common share		
Primary	\$(2.13)	\$(0.83)
Fully Diluted	\$(2.13)	\$(0.83)
Common Shares:		
Full Diluted	48,438	44,709
Year-end	49,009	47,986

ON SEMICONDUCTOR CORP**Earnings, 9 mos. to** (Consol. – \$000):

	09/28/18	09/30/17
Total Revenues	4,375,200	4,165,600
Cost & expenses	3,667,400	3,556,500
Operating income	624,500	514,100
Interest income	3,300	1,800
Interest expense	95,300	108,000
Other income (expense), net	28,800	6,100
Gains or losses	5,000	12,500
Net before taxes	566,300	426,500
Income taxes	102,400	144,500
Net income	463,900	282,000
Earnings common share		
Primary	\$1.08	\$0.67
Fully Diluted	\$1.05	\$0.66
Common Shares:		
Full Diluted	441,200	426,500
Year-end	423,885	422,898

ONCOMED PHARMACEUTICALS INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	34,237	17,515
Cost & expenses	39,266	66,733
Operating income	(5,029)	(49,218)
Net before taxes	(3,818)	(48,513)
Income taxes	(383)	12
Net income	(3,435)	(48,525)
Earnings common share		
Primary	\$(0.09)	\$(1.29)
Fully Diluted	\$(0.09)	\$(1.29)
Common Shares:		
Full Diluted	38,381	37,521
Year-end	38,526	37,758

OPKO HEALTH INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	768,412	805,022
Cost & expenses	798,199	869,929
Operating income	(81,184)	(118,811)
Interest income	111	634
Interest expense	7,933	4,771
Other income (expense), net	13,142	5,074
Equity earnings	11,542	11,771

Net before taxes	(75,864)	(117,874)
Income taxes	(10,437)	(42,309)
Net income	(76,969)	(87,336)
Earnings common share		
Primary	\$(0.14)	\$(0.16)
Fully Diluted	\$(0.14)	\$(0.16)
Common Shares:		
Full Diluted	559,601	559,065
Year-end	559,828	559,405

ORASURE TECHNOLOGIES INC.**Earnings, 9 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	131,497,000	115,036,000
Cost & expenses	115,580,000	84,959,000
Operating income	15,917,000	30,077,000
Other income (expense), net	1,658,000	676,000
Net before taxes	17,575,000	30,753,000
Income taxes	7,477,000	7,121,000
Net income	10,098,000	23,632,000
Earnings common share		
Primary	\$0.17	\$0.40
Fully Diluted	\$0.16	\$0.39
Common Shares:		
Full Diluted	62,539,000	60,569,000
Year-end	61,237,000	60,631,000

ORBCOMM INC**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
Total Revenues	209,803	178,244
Cost & expenses	176,585	180,277
Deprec., depl. & amort.	36,146	34,463
Operating income	(2,928)	(36,496)
Other income (expense), net	108	(4,078)
Net before taxes	(16,977)	(52,518)
Income taxes	3,410	1,192
Net income	(20,387)	(53,710)
Balance for common	(20,614)	(53,777)
Earnings common share		
Primary	\$(0.27)	\$(0.74)
Fully Diluted	\$(0.27)	\$(0.74)
Common Shares:		
Full Diluted	77,158	72,396
Year-end	78,769	74,084

ORGANOVO HOLDINGS INC**Earnings, 6 mos. to Sep 30**(Consol. – \$):

	2018	2017
Total Revenues	1,632,000	2,345,000
Cost & expenses	15,218,000	22,124,000
Operating income	(13,586,000)	(19,779,000)
Interest income	334,000	216,000
Gains or losses	2,000	
Income taxes	3,000	
Net income	(13,253,000)	(19,563,000)
Earnings common share		
Primary	\$(0.12)	\$(0.19)
Fully Diluted	\$(0.12)	\$(0.19)
Common Shares:		
Full Diluted	112,732,767	105,497,939
Year-end	115,200,421	106,904,525

ORIGINAL SIXTEEN TO ONE MINE, INC.**Earnings, 6 mos. to Jun 30**(Consol. – \$):

	2018	2017
Total Revenues	138,097	149,171
Cost & expenses	258,670	335,006
Operating income	(133,259)	(196,919)
Other income (expense), net	(11,547)	(10,101)
Net before taxes	(144,806)	(207,020)
Income taxes	1,600	800
Net income	(146,406)	(207,820)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	14,338,855	14,338,855
Year-end	14,338,855	14,338,855

ORTHOPEDIATRICS CORP**Earnings, 9 mos. to Sep 30**(Consol. – \$000):

	2018	2017
--	------	------

	2018	2017
Total Revenues	42,991	33,939
Cost & expenses	50,678	36,207
Operating income	(7,687)	(2,268)
Interest expense	1,722	1,857
Other income (expense), net	(148)	38
Net income	(9,557)	(4,087)
Balance for common	(9,557)	(8,451)
Earnings common share		
Primary	\$(0.77)	\$(4.82)
Fully Diluted	\$(0.77)	\$(4.82)
Common Shares:		
Full Diluted	12,418	1,755
Year-end	12,808	2,488

OTONOMY INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	537	966
Cost & expenses	39,278	73,197
Operating income	(38,741)	(72,231)
Interest income	1,218	934
Net income	(37,523)	(71,297)
Earnings common share		
Primary	\$(1.23)	\$(2.35)
Fully Diluted	\$(1.23)	\$(2.35)
Common Shares:		
Full Diluted	30,598	30,280
Year-end	30,630	30,337

OVERSTOCK.COM INC (DE)

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,369,044	1,288,466
Cost & expenses	1,537,806	1,312,385
Operating income	(168,762)	(23,919)
Interest income	1,547	450
Interest expense	1,370	2,139
Other income (expense), net	(1,489)	2,751
Net before taxes	(170,074)	(22,857)
Income taxes	(445)	(7,727)
Net income	(169,629)	(15,130)
Balance for common	(163,743)	(14,188)
Earnings common share		
Primary	\$(5.47)	\$(0.55)
Fully Diluted	\$(5.47)	\$(0.55)
Common Shares:		
Full Diluted	29,256	25,024
Year-end	31,941	

OXFORD SQUARE CAPITAL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	16,060,363	24,877,428
Net income	25,023,611	23,097,902
Earnings common share		
Primary	\$0.50	\$0.45
Fully Diluted	\$0.50	\$0.45
Common Shares:		
Full Diluted	50,153,321	59,727,707
Year-end	49,146,266	51,479,409

PACCAR INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	14,648,800	11,919,900
Operating income	2,057,800	1,569,000
Gains or losses	41,000	25,800
Net before taxes	2,057,800	1,569,000
Income taxes	440,800	483,000
Net income	1,617,000	1,086,000
Earnings common share		
Primary	\$4.60	\$3.09
Fully Diluted	\$4.59	\$3.08
Common Shares:		
Full Diluted	352,500	352,800
Year-end	349,800	351,500

PACIFIC BIOSCIENCES OF CALIFORNIA INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	59,100	68,533
Cost & expenses	129,464	137,788
Operating income	(70,364)	(69,255)

	396	125
Other income (expense), net	396	125
Net income	(71,763)	(71,427)
Earnings common share		
Primary	\$(0.55)	\$(0.70)
Fully Diluted	\$(0.55)	\$(0.70)
Common Shares:		
Full Diluted	130,302	102,117
Year-end	148,894	116,239

PACIFIC BIOSCIENCES OF CALIFORNIA INC

Sale Development On Nov. 1, 2018, Co. announced that it has entered into an agreement to be acquired by Illumina Inc (Illumina) for approximately \$1,200,000,000 in cash. Under the agreement, which has been approved by both companies' boards of directors, Illumina will pay \$8.00 per Co. share, representing a 71 % premium over Co. 30 trading-day volume weighted average share price as of the market close on Oct. 31, and a total value of about \$1,200,000,000 on a fully diluted basis.

PACIRA PHARMACEUTICALS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	242,163	207,552
Cost & expenses	238,510	240,953
Operating income	3,653	(33,401)
Interest income	4,493	2,805
Interest expense	16,195	12,942
Other income (expense), net	(699)	(3,563)
Net before taxes	(8,748)	(47,101)
Income taxes	8	105
Net income	(8,756)	(47,206)
Earnings common share		
Primary	\$(0.21)	\$(1.19)
Fully Diluted	\$(0.21)	\$(1.19)
Common Shares:		
Full Diluted	40,833	39,540
Year-end	41,061	40,565

PAPA JOHN'S INTERNATIONAL, INC.

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	09/24/17
Total Revenues	1,199,335	1,315,753
Cost & expenses	1,125,786	1,169,048
Operating income	38,694	114,413
Net before taxes	22,114	108,278
Income taxes	4,663	30,728
Net income	17,451	77,550
Earnings common share		
Primary	\$0.48	\$2.05
Fully Diluted	\$0.47	\$2.02
Common Shares:		
Full Diluted	32,489	37,047
Year-end	31,366	35,309

PAPA MURPHY'S HOLDINGS INC

Earnings, 9 mos. to (Consol. - \$000):

	10/01/18	10/02/17
Total Revenues	94,395	109,971
Cost & expenses	81,419	119,293
Deprec., depl. & amort.	5,677	8,359
Operating income	7,299	(17,681)
Interest expense	3,842	3,818
Other income (expense), net	(160)	(149)
Net before taxes	3,297	(21,648)
Income taxes	970	(7,678)
Net income	2,327	(13,970)
Earnings common share		
Primary	\$0.04	\$(0.83)
Fully Diluted	\$0.04	\$(0.83)
Common Shares:		
Full Diluted	16,963	16,863
Year-end	17,032	

PARATEK PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Cost & expenses	84,151,000	71,257,000
Operating income	(84,050,000)	(63,713,000)
Interest expense	7,793,000	3,666,000
Other income (expense), net	(14,000)	(23,000)
Net before taxes	(66,423,000)	(67,060,000)
Income taxes		753,000
Net income	(89,565,000)	(67,176,000)
Earnings common share		
Primary	\$(2.86)	\$(2.54)

Fully Diluted	\$(2.86)	\$(2.54)
Common Shares:		
Full Diluted	31,301,249	26,453,219
Year-end	31,781,488	27,892,040

PARK PLACE ENERGY INC

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	2,835,499	3,316,194
Operating income	(761,163)	(1,643,555)
Interest income	5,582	
Interest expense	37,098	40,661
Other income (expense), net	229,739	(9,934)
Gains or losses		15,695
Foreign currency	(26,164)	(7,873)
Net income	(589,104)	(1,686,328)
Earnings common share		
Primary	\$(0.01)	\$(0.03)
Fully Diluted	\$(0.01)	\$(0.03)
Common Shares:		
Full Diluted	62,048,754	55,927,491
Year-end	68,663,904	56,243,904

PARK-OHIO HOLDINGS CORP.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	1,252,200	1,046,900
Cost & expenses	1,178,100	984,600
Operating income	74,100	62,300
Interest expense	26,100	23,100
Other income (expense), net	6,400	(6,300)
Net before taxes	54,400	32,900
Income taxes	14,500	9,400
Net income	39,900	23,500
Earnings common share		
Primary	\$3.15	\$1.87
Fully Diluted	\$3.09	\$1.83
Common Shares:		
Full Diluted	12,500	12,400
Year-end	12,702	12,531

PATRICK INDUSTRIES INC

Earnings, 9 mos. to (Consol. - \$):

	09/30/18	09/24/17
Net Sales	1,731,850,000	1,600,830,000
Cost & expenses	1,567,188,000	1,458,048,000
Operating income	139,522,000	87,796,000
Interest expense	17,980,000	6,159,000
Net before taxes	121,542,000	81,637,000
Net income	92,862,000	56,672,000
Earnings common share		
Primary	\$3.82	\$2.35
Fully Diluted	\$3.77	\$2.32
Common Shares:		
Full Diluted	24,619,000	24,476,000
Year-end	24,006,927	25,232,817

PATTERSON-UTI ENERGY INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	2,531,060,000	2,569,350,000
Cost & expenses	1,938,519,000	2,268,054,000
Operating income	(111,387,000)	270,891,000
Interest income	4,600,000	1,149,000
Interest expense	38,668,000	26,292,000
Other income (expense), net	666,000	226,000
Net before taxes	(144,789,000)	296,445,000
Income taxes	(24,617,000)	106,953,000
Net income	(120,172,000)	189,492,000
Balance for common	(120,172,000)	189,492,000
Earnings common share		
Primary	\$(0.55)	\$(0.99)
Fully Diluted	\$(0.55)	\$(0.99)
Common Shares:		
Full Diluted	219,635,000	191,237,000
Year-end	217,209,292	213,652,526

PC CONNECTION, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	1,989,969	2,149,616
Cost & expenses	1,920,185	2,085,270
Deprec., depl. & amort.	10,400	8,700
Operating income	59,369	55,631

Net before taxes	59,781	55,651
Income taxes	16,489	21,517
Net income	43,292	34,134
Earnings common share		
Primary	\$1.62	\$1.28
Fully Diluted	\$1.61	\$1.27
Common Shares:		
Full Diluted	26,883	26,886
Year-end	26,730	26,816

PDC ENERGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	753,848,000	732,100,000
Cost & expenses	522,335,000	591,285,000
Operating income	(178,439,000)	219,752,000
Interest income	405,000	1,487,000
Interest expense	52,561,000	58,359,000
Net before taxes	(230,595,000)	276,624,000
Income taxes	(53,765,000)	(71,483,000)
Net income	(176,830,000)	205,141,000
Earnings common share		
Primary	\$(2.68)	\$(3.12)
Fully Diluted	\$(2.68)	\$(3.12)
Common Shares:		
Full Diluted	66,032,000	65,825,000
Year-end	66,074,162	65,865,523

PDF SOLUTIONS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	66,069	75,094
Cost & expenses	71,983	75,447
Operating income	(6,240)	(644)
Net before taxes	(5,957)	(949)
Income taxes	(1,355)	(2,246)
Net income	(4,602)	1,297
Earnings common share		
Primary	\$(0.14)	\$0.04
Fully Diluted	\$(0.14)	\$0.04
Common Shares:		
Full Diluted	32,105	33,317
Year-end	32,257	31,882

PDL BIOPHARMA INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	152,991,000	252,024,000
Cost & expenses	222,830,000	69,680,000
Operating income	(84,093,000)	163,906,000
Other income (expense), net		3,995,000
Net before taxes	(88,484,000)	153,545,000
Income taxes	(3,346,000)	65,180,000
Net income	(85,138,000)	88,365,000
Earnings common share		
Primary	\$(0.58)	\$0.56
Fully Diluted	\$(0.58)	\$0.56
Common Shares:		
Full Diluted	147,159,000	157,529,000
Year-end	145,976,000	154,339,000

PEGASYSYSTEMS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	635,224	633,862
Cost & expenses	667,709	579,203
Operating income	(32,485)	54,659
Other income (expense), net	363	287
Foreign currency	558	(6,549)
Net before taxes	(29,488)	48,944
Income taxes	(23,692)	(9,009)
Net income	(5,796)	57,953
Earnings common share		
Primary	\$(0.07)	\$0.75
Fully Diluted	\$(0.07)	\$0.70
Common Shares:		
Full Diluted	78,525	82,717
Year-end	78,081	

PENN NATIONAL GAMING INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,432,649	2,378,934
Cost & expenses	1,747,116	1,754,307

Deprec., depl. & amort.	175,801	205,688
Operating income	509,732	418,939
Interest income	736	3,185
Interest expense	346,457	350,000
Other income (expense), net	11,540	(11,242)
Net before taxes	175,551	60,882
Income taxes	40,001	(750,641)
Net income	135,550	811,523
Earnings common share		
Primary	\$1.48	\$8.93
Fully Diluted	\$1.43	\$8.74
Common Shares:		
Full Diluted	95,015	92,903
Year-end	92,428	90,887

PERCEPTRON, INC.**Earnings, 3 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	21,442	19,269
Cost & expenses	19,983	17,724
Operating income	1,459	1,545
Other income (expense), net		30
Foreign currency	(202)	(22)
Net before taxes	1,230	1,511
Income taxes	338	(47)
Net income	892	1,558
Earnings common share		
Primary	\$0.09	\$0.16
Fully Diluted	\$0.09	\$0.16
Common Shares:		
Full Diluted	9,772	9,502
Year-end	9,593	9,487

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	7,416	7,416
Inventories	11,664	11,664
Current assets	55,201	55,201
Net property & equip.	6,827	6,827
Total assets	75,290	75,290
Liabilities:		
Current liabilities	24,095	24,095
Stockholders' equity	48,539	48,539
Net current assets	31,106	31,106

PERFICIENT INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	366,672,000	351,783,000
Cost & expenses	327,043,000	313,057,000
Operating income	24,543,000	24,041,000
Other income (expense), net	(43,000)	84,000
Net before taxes	22,782,000	22,681,000
Income taxes	5,699,000	10,535,000
Net income	17,083,000	12,146,000
Earnings common share		
Primary	\$0.52	\$0.37
Fully Diluted	\$0.50	\$0.36
Common Shares:		
Full Diluted	33,846,000	34,085,000
Year-end	31,920,534	33,445,194

PERSHING GOLD CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	11,482,279	9,130,709
Operating income	(11,482,279)	(9,130,709)
Other income (expense), net		9,673
Foreign currency	(2,029)	(9,981)
Net income	(11,472,140)	(9,129,929)
Balance for common	(11,472,140)	(9,129,929)
Earnings common share		
Primary	\$(0.34)	\$(0.32)
Fully Diluted	\$(0.34)	\$(0.32)
Common Shares:		
Full Diluted	33,618,007	28,396,928
Year-end	33,676,921	28,402,389

PETMED EXPRESS INC**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	158,786,000	146,368,000
Cost & expenses	128,718,000	118,646,000
Operating income	28,960,000	26,664,000
Interest income	807,000	226,000

Other income (expense), net	572,000	490,000
Net before taxes	30,339,000	27,380,000
Income taxes	7,005,000	9,344,000
Net income	23,334,000	18,036,000
Earnings common share		
Primary	\$1.14	\$0.89
Fully Diluted	\$1.14	\$0.88
Common Shares:		
Full Diluted	20,485,000	20,442,000
Year-end	20,674,000	20,604,000

PHARMA-BIO SERV INC**Earnings, 9 mos. to Jul 31(Consol. - \$):**

	2018	2017
Total Revenues	13,832,217	11,947,598
Cost & expenses	13,593,970	12,850,417
Operating income	238,247	(902,819)
Other income (expense), net	436,599	38,145
Net before taxes	674,846	(864,674)
Income taxes	2,736,575	3,206
Net income	(2,061,729)	(867,880)
Earnings common share		
Primary	\$(0.09)	\$(0.04)
Fully Diluted	\$(0.09)	\$(0.04)
Common Shares:		
Full Diluted	23,080,758	23,094,105
Year-end	23,062,531	23,101,931

PHASEBIO PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

	2017	2016
Research & development	6,210	7,376
General & administrative expenses	2,328	2,125
Total operating expenses	8,538	9,501
Income (loss) from operations	(8,538)	(9,501)
Interest income	52	29
Interest expense	2,723	...
Change in fair value of warrant liability	1,019	252
Change in fair value of derivative liability	(57)	...
Total other income (expense)	(1,709)	281
Net income (loss)	(10,247)	(9,220)
Weighted average shares outstanding - basic	743	743
Weighted average shares outstanding - diluted	743	743
Year end shares outstanding	746	776
Net earnings (loss) per share - basic	\$(13.78)	\$(12.41)
Net earnings (loss) per share - diluted	\$(13.78)	\$(12.41)
Number of full time employees	18	...

□ As of September 30, 2018; □ As Is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	13,406	3,715
Prepayments & other current assets	340	169
Total current assets	13,746	3,884
Lab equipment	1,681	1,483
Computer hardware, software & telephone	174	159
Furniture & fixtures	70	67
Leasehold improvements	22	22
Total property & equipment, gross	1,947	1,731
Less: Accumulated depreciation & amortization	1,645	1,549
Property & equipment, net	302	182
Other non-current assets	51	51
Total assets	14,099	4,117

Convertible promissory notes, net of discount	12,095	...
Derivative liability	3,028	...
Current portion of long-term debt	761	...
Accounts payable	430	433
Payroll & related costs	346	190
Research & development expenses	197	181
Professional fees & other services	100	40
Interest payable	628	...
Other accrued expenses	10	...
Accrued expenses	1,281	411
Total current liabilities	17,595	844
Preferred stock warrant liability	1,656	880
Deferred rent	5	8
Long-term debt, net	2,625	...
Total liabilities	21,881	1,732
Redeemable convertible preferred stock	89,634	89,567
Common stock	1	1
Treasury stock	24	24
Additional paid-in capital	1,672	1,659
Retained earnings (accumulated deficit)	(99,065)	(88,818)
Total shareholders' (deficit) equity	(97,416)	(87,182)

Recent Dividends:

1. PhaseBio Pharmaceuticals Inc common.
No dividends paid.

Annual Dividends:

1. PhaseBio Pharmaceuticals Inc common.
No dividends paid.

PHASEBIO PHARMACEUTICALS INC

Earnings, 6 mos. to Jun 30(Consol. - \$000):

	2018	2017
Cost & expenses	6,985	4,192
Operating income	(6,985)	(4,192)
Interest income	72	15
Interest expense	2,851	987
Other income (expense), net	(1,313)	12
Net income	(11,077)	(5,152)
Earnings common share		
Primary	\$(14.85)	\$(6.93)
Fully Diluted	\$(14.85)	\$(6.93)
Common Shares:		
Full Diluted	746	743
Year-end	746	746

PLURALSIGHT INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	164,769	119,416
Cost & expenses	251,082	174,684
Operating income	(86,313)	(55,268)
Interest expense	6,476	8,376
Other income (expense), net	(3,396)	(1,758)
Net before taxes	(96,185)	(65,402)
Income taxes	506	216
Net income	(96,691)	(65,618)
Balance for common	(244,682)	(122,818)
Earnings common share		
Primary	\$(0.41)	\$(0.41)
Fully Diluted	\$(0.41)	\$(0.41)
Common Shares:		
Full Diluted	62,400	...
Year-end	135,075	...

POOL CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	2,455,015	2,278,005
Cost & expenses	2,167,095	2,010,893
Operating income	287,920	267,112
Equity earnings	(167)	(121)
Net before taxes	273,471	255,504
Income taxes	55,989	89,951
Net income	217,649	165,674
Earnings common share		

Primary	\$5.39	\$4.04
Fully Diluted	\$5.20	\$3.89
Common Shares:		
Full Diluted	41,831	42,691
Year-end	40,480	40,123

PORTOLA PHARMACEUTICALS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	24,832	12,743
Cost & expenses	282,971	199,571
Operating income	(258,139)	(186,828)
Interest expense	12,642	8,243
Net income	(261,658)	(194,119)
Balance for common	(261,675)	(194,309)
Earnings common share		
Primary	\$(3.97)	\$(3.38)
Fully Diluted	\$(3.97)	\$(3.38)
Common Shares:		
Full Diluted	65,856	57,570
Year-end	66,434	...

POTBELLY CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	320,260	315,962
Net Sales	317,866	313,568
Cost & expenses	307,961	296,149
Operating income	(5,232)	853
Interest expense	109	101
Net before taxes	(5,341)	752
Income taxes	(1,111)	252
Net income	(4,230)	500
Earnings common share		
Primary	\$(0.18)	\$0.01
Fully Diluted	\$(0.18)	\$0.01
Common Shares:		
Full Diluted	25,355	25,857
Year-end	25,102	24,804

POTLATCHDELTIC CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	757,329	503,351
Cost & expenses	582,339	390,088
Operating income	174,990	113,263
Interest expense	25,125	19,654
Other income (expense), net	(5,707)	(4,788)
Net before taxes	144,158	88,821
Income taxes	23,077	13,956
Net income	121,081	74,865
Earnings common share		
Primary	\$2.06	\$1.83
Fully Diluted	\$2.03	\$1.82
Common Shares:		
Full Diluted	59,542	41,183
Year-end	62,755	40,611

POWER INTEGRATIONS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	322,648	323,506
Cost & expenses	275,043	280,334
Operating income	47,605	43,172
Other income (expense), net	2,819	1,866
Net before taxes	50,424	45,038
Income taxes	3,176	531
Net income	47,248	44,507
Earnings common share		
Primary	\$1.60	\$1.50
Fully Diluted	\$1.56	\$1.46
Common Shares:		
Full Diluted	30,281	30,472
Year-end	29,329	29,717

PRA GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	671,514,000	617,312,000
Cost & expenses	504,238,000	446,391,000
Operating income	153,046,000	155,824,000
Interest income	2,453,000	4,279,000
Other income (expense), net	65,000	...
Gains or losses	48,474,000	...

Foreign currency	3,609,000	(1,421,000)
Net before taxes	69,191,000	133,215,000
Income taxes	11,783,000	52,857,000
Net income	57,408,000	80,358,000
Earnings common share		
Primary	\$1.12	\$1.64
Fully Diluted	\$1.11	\$1.64
Common Shares:		
Full Diluted	45,420,000	45,991,000
Year-end	45,303,000	45,169,000

PRA HEALTH SCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	2,142,274	1,603,493
Cost & expenses	1,873,555	1,380,735
Deprec., depl. & amort.	84,163	50,146
Operating income	184,556	172,612
Interest expense	43,860	31,088
Other income (expense), net	(655)	(3,289)
Equity earnings	(118)	(92)
Foreign currency	(1,416)	(35,004)
Net before taxes	138,625	103,231
Income taxes	55,392	(165)
Net income	83,351	103,488
Earnings common share		
Primary	\$1.29	\$1.66
Fully Diluted	\$1.24	\$1.57
Common Shares:		
Full Diluted	66,258	65,683
Year-end	64,915	63,329

PREFORMED LINE PRODUCTS CO.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	315,467,000	281,320,000
Cost & expenses	290,374,000	262,958,000
Operating income	25,093,000	18,362,000
Interest income	340,000	325,000
Interest expense	992,000	831,000
Other income (expense), net	267,000	259,000
Net before taxes	24,708,000	18,115,000
Income taxes	3,390,000	6,163,000
Net income	21,318,000	11,952,000
Earnings common share		
Primary	\$4.23	\$2.34
Fully Diluted	\$4.19	\$2.33
Common Shares:		
Full Diluted	5,088,000	5,129,000
Year-end	5,012,109	5,091,381

PREMIER INC

Earnings, 3 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	401,546	390,564
Cost & expenses	295,203	306,186
Operating income	92,705	70,480
Other income (expense), net	749	5,715
Gains or losses	...	(1,320)
Net before taxes	92,766	73,380
Income taxes	10,793	12,764
Net income	81,973	60,616
Balance for common	(681,333)	336,430
Earnings common share		
Primary	\$(12.80)	\$6.36
Fully Diluted	\$(12.80)	\$0.30
Common Shares:		
Full Diluted	53,221	140,046
Year-end	133,310	139,626

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	142,422
Inventories	68,236
Current assets	626,202
Net property & equip.	211,248
Total assets	2,516,552

Liabilities:	2018
Current liabilities	469,832
Long-term debt	5,447
Stockholders' equity	(1,955,817)
Net current assets	156,370

PRESIDIO INC

Earnings, 3 mos. to Sep 30(Consol. - \$000):

	2018	2017	Total operating expenses			Total number of employees			
Total Revenues	749,900	731,200	3,040,650	2,860,399	2,768,453		8,680	7,903	7,835
Net Sales	619,600	604,700	Operating income			Number of common stockholders			
Cost & expenses	696,900	666,300	126,052	136,229	136,723		30,137	23,510	26,532
Operating income	31,500	44,300	1,415	1,809	1,307		Foreign currency translation adjustments		
Interest expense	11,200	12,400	Interest expense on loans						
Other income (expense), net	100	100	5,224	5,636	4,991		(12,890)	(6,297)	(1,702)
Gains or losses	(500)	(700)	Interest expense related to hedging activity						
Net before taxes	19,900	31,300	981	1,588	1,982		Reclassified to conform with 2018 presentation; As is; Approximately; As of October 17, 2018; As of October 18, 2017; As of October 20, 2016		
Income taxes	5,200	11,400	Capitalized interest						
Net income	14,700	19,900	1,134	447	1,082		Consolidated Balance Sheet, Years Ended Aug. 31 (\$000):		
Earnings common share			Interest expense						
Primary	\$0.16	\$0.22	5,071	6,777	5,891		2018	2017	
Fully Diluted	\$0.15	\$0.21	Other income (expense), net						
Common Shares:			192	1,482	(899)		93,460	162,434	
Full Diluted	95,034	96,047	Total other income (expense)						
Year-end	82,298		(3,464)	(3,486)	(5,483)		405	460	
Consolidated Balance Sheet Items, as of (\$000):			Income (loss) before income taxes			Cash & cash equivalents			
Assets:			- United States			Short-term restricted cash			
Cash & equivalents			Income (loss) before income taxes			Short-term investments			
Inventories			- foreign			Receivables, gross			
Current assets			Income (loss) before provision for income taxes & income (loss) of unconsolidated affiliates			Less: allowance for doubtful accounts			
Net property & equip.			Current provision (benefit) for income taxes - U.S.			Merchandise inventories			
Total assets			Current provision (benefit) for income taxes - foreign			Prepaid expenses & other current assets			
Liabilities:			Valuation allowance change			Total current assets			
Current liabilities			Total deferred provision (benefit) for income taxes			Long-term restricted cash			
Long-term debt			Provision (benefit) for income taxes			Land			
Stockholders' equity			Income (loss) of unconsolidated affiliates			Building & improvements			
Net current assets			Net income (loss) available to common stockholders			Fixtures & equipment			
			Weighted average shares outstanding			Construction in progress			
			- basic			Total property & equipment, historical cost			
			- diluted			Less: accumulated depreciation			
			Year end shares outstanding			Property & equipment, net			
			Net income (loss) per share - basic			Goodwill			
			Net income (loss) per share - diluted			Other intangibles, net			
			Dividends per share			Deferred tax assets			
						Other non-current assets			
						Investment in unconsolidated affiliates			
						Total assets			
						Accounts payable			
						Accrued salaries & benefits			
						Deferred income			
						Income taxes payable			
						Other accrued expenses			
						Long-term debt, current portion			
						Total current liabilities			
						Deferred tax liability			
						Long-term portion of deferred rent			
						Long-term income taxes payable, net of current portion			
						Loans			
						Less: current portion			
						Long-term debt, net of current portion			
						Other long-term liabilities			
						Total liabilities			
						Common stock			
						Additional paid-in capital			
						Tax benefit from share-based compensation			
						Foreign-currency translation adjustments			
						Defined benefit pension plans			
						Derivative instruments			
						Accumulated other comprehensive income (loss)			
						Retained earnings (accumulated deficit)			
						Less: treasury stock at cost			

PRGX GLOBAL, INC.**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	122,143	114,546
Cost & expenses	113,286	109,455
Operating income	1,037	(537)
Other income (expense), net	(16)	177
Foreign currency	(730)	1,927
Net before taxes	(1,009)	1,340
Income taxes	1,573	2,436
Income contin. oper.	(2,582)	(1,096)
Income discount. oper.	(684)	(1,029)
Net income	(3,266)	(2,125)
Earnings common share		
Primary	\$(0.14)	\$(0.10)
Fully Diluted	\$(0.14)	\$(0.10)
Common Shares:		
Full Diluted	23,142	22,225
Year-end	23,612	22,391

PRICESMART INC**Annual Report****Consolidated Income Statement, Years Ended Aug. 31 (\$000):**

	2018	2017 (revised)	2016 (revised)
Net merchandise sales	3,053,754	2,910,062	2,820,740
Export sales	40,581	34,244	33,813
Membership income	50,821	47,743	45,781
Other revenue & income	21,546	4,579	4,842
Total revenues	3,166,702	2,996,628	2,905,176
Cost of goods sold - net merchandise sales	2,610,111	2,487,146	2,417,366
Cost of goods sold - export	38,740	32,606	32,260
Cost of goods sold - non-merchandise	7,669		
Selling, general & administrative - warehouse club operations expenses	291,488	268,629	252,130
Selling, general & administrative - general & administrative expenses	88,461	70,013	64,344
Pre-opening expenses	913	44	1,191
Asset impairment	1,929		
Gain (loss) on disposal of assets	(1,339)	(1,961)	(1,162)

Total stockholders' equity attributable to PriceSmart, Inc. stockholders	758,002	708,767
Noncontrolling interest in consolidated subsidiaries	636	...
Total stockholders' equity	758,638	708,767

□ Includes amounts for the fair value of derivative instruments - Other non-current assets: \$4,364,000; □ Includes amounts for the fair value of derivative instruments - Other non-current assets: \$2,547,000; □ Includes amounts for the fair value of derivative instruments - Other long-term liabilities: \$502,000; □ Includes amounts for post employment plans - Other long-term liabilities: \$4,715,000; □ Includes amounts for the fair value of derivative instruments - Other long-term liabilities: \$682,000; □ Includes amounts for post employment plans - Other long-term liabilities: \$5,051,000

Recent Dividends:**1. PriceSmart Inc common.**

ExDate	Amt	Declared	Record	Payable
02/11/2015	0.35	02/04/2015	02/13/2015	02/27/2015
08/12/2015	0.35	02/04/2015	08/14/2015	08/31/2015
02/10/2016	0.35	02/04/2016	02/15/2016	02/29/2016
08/11/2016	0.35	02/04/2016	08/15/2016	08/31/2016
02/13/2017	0.35	02/02/2017	02/15/2017	02/28/2017
08/11/2017	0.35	02/02/2017	08/15/2017	08/31/2017
02/13/2018	0.35	01/24/2018	02/14/2018	02/28/2018
08/14/2018	0.35	01/24/2018	08/15/2018	08/31/2018

2. PriceSmart Inc series A convertible preferred.

No dividends paid.

3. PriceSmart Inc series B convertible preferred.

No dividends paid.

Annual Dividends:**1. PriceSmart Inc common.**

2015	0.70	2016	0.70	2017	0.70
2018	0.70				

2. PriceSmart Inc series A convertible preferred.

No dividends paid.

3. PriceSmart Inc series B convertible preferred.

No dividends paid.

PRIMO WATER CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	231,231	217,762
Cost & expenses	259,441	188,362
Operating income	(46,575)	9,829
Interest expense	18,909	15,177
Other income (expense), net	(3,220)	(3,220)
Net before taxes	(65,484)	(8,568)
Income taxes	(8,907)	823
Net income	(56,577)	(9,391)
Earnings common share		
Primary	\$(1.55)	\$(0.28)
Fully Diluted	\$(1.55)	\$(0.28)
Common Shares:		
Full Diluted	36,410	33,086
Year-end	38,527	29,908

PROGENICS PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	12,384,000	7,809,000
Cost & expenses	64,188,000	52,927,000
Operating income	(51,804,000)	(45,118,000)
Net before taxes	(54,502,000)	(48,348,000)
Income taxes	(1,549,000)	(52,953,000)
Net income	(52,953,000)	(48,348,000)
Earnings common share		
Primary	\$(0.70)	\$(0.69)
Fully Diluted	\$(0.70)	\$(0.69)
Common Shares:		
Full Diluted	75,648,000	70,233,000
Year-end	84,542,000	

PROGRESS SOFTWARE CORP.**Earnings, 9 mos. to Aug 31(Consol. - \$000):**

	2018	2017	2018	2017
Total Revenues	285,832	281,493	1,211,689,000	1,178,183,000
Cost & expenses	214,137	229,967	20,317,000	19,716,000
Operating income	61,739	41,805	7,153,000	19,095,000
Interest expense	3,774	3,455	918,000	983,000
Foreign currency	(2,017)	(1,561)	(669,000)	
Net before taxes	56,909	37,506	2,551,000	11,615,000
Income taxes	11,848	16,518	807,000	(600,000)
Net income	45,061	20,988	8,924,000	29,127,000
Earnings common share				
Primary	\$0.99	\$0.43	7,755,000	8,391,000
Fully Diluted	\$0.97	\$0.43	1,169,000	20,736,000
Common Shares:			485,000	(6,000,000)
Full Diluted	46,380	48,631	Net income	1,654,000
Year-end	45,133	47,797	Balance for common	(1,939,000)
			8,927,000	

PROOFPOINT INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	518,515	372,762
Cost & expenses	599,187	415,944
Operating income	(80,672)	(43,182)
Other income (expense), net	(715)	884
Net before taxes	(96,492)	(59,845)
Income taxes	(13,978)	3,410
Net income	(82,514)	(63,255)
Earnings common share		
Primary	\$(1.61)	\$(1.44)
Fully Diluted	\$(1.61)	\$(1.44)
Common Shares:		
Full Diluted	51,214	43,850
Year-end	54,483	

PROTAGONIST THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	55,429	43,165
Operating income	(26,857)	(34,384)
Interest income	1,798	479
Net income	(25,059)	(33,905)
Earnings common share		
Primary	\$(1.15)	\$(2.01)
Fully Diluted	\$(1.15)	\$(2.01)
Common Shares:		
Full Diluted	21,751	16,852
Year-end	24,138	16,944

PROTEON THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	15,987	24,772
Operating income	(15,987)	(24,772)
Other income (expense), net	206	198
Gains or losses	311	161
Net income	(15,470)	(24,413)
Balance for common	(15,470)	(31,160)
Earnings common share		
Primary	\$(0.87)	\$(1.82)
Fully Diluted	\$(0.87)	\$(1.82)
Common Shares:		
Full Diluted	17,725	17,158
Year-end	19,221	17,619

PROTEOSTASIS THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,840	3,719
Cost & expenses	48,526	50,185
Operating income	(45,686)	(46,466)
Interest income	530	515
Other income (expense), net	224	(57)
Net income	(44,932)	(46,008)
Balance for common	(44,932)	(46,008)
Earnings common share		
Primary	\$(1.26)	\$(1.84)
Fully Diluted	\$(1.26)	\$(1.84)
Common Shares:		
Full Diluted	35,734	25,052
Year-end	36,697	25,113

PROVIDENCE SERVICE CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	1,211,689,000	1,178,183,000
Deprec., depl. & amort.	20,317,000	19,716,000
Operating income	7,153,000	19,095,000
Interest expense	918,000	983,000
Other income (expense), net	(669,000)	
Gains or losses	2,551,000	11,615,000
Foreign currency	807,000	(600,000)
Net before taxes	8,924,000	29,127,000
Income taxes	7,755,000	8,391,000
Income contin. oper.	1,169,000	20,736,000
Income discont. oper.	485,000	(6,000,000)
Net income	1,654,000	14,736,000
Balance for common	(1,939,000)	8,927,000
Earnings common share		
Primary	\$(0.15)	\$0.66
Fully Diluted	\$(0.15)	\$0.65
Common Shares:		
Full Diluted	12,992,403	13,676,468
Year-end	12,810,747	13,502,502

PTC THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	178,396,000	116,362,000
Cost & expenses	232,128,000	176,152,000
Operating income	(70,547,000)	(69,742,000)
Interest expense	9,306,000	8,648,000
Other income (expense), net	1,066,000	(1,373,000)
Net before taxes	(78,787,000)	(79,763,000)
Income taxes	964,000	507,000
Net income	(79,751,000)	(80,270,000)
Balance for common	(79,751,000)	(80,270,000)
Earnings common share		
Primary	\$(1.76)	\$(2.09)
Fully Diluted	\$(1.76)	\$(2.09)
Common Shares:		
Full Diluted	45,310,690	38,433,749
Year-end	50,432,655	41,463,121

PUMA BIOTECHNOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	179,912,000	6,077,000
Cost & expenses	256,030,000	234,901,000
Operating income	(76,118,000)	228,824,000
Interest income	1,093,000	1,035,000
Interest expense	7,165,000	
Other income (expense), net	(690,000)	(88,000)
Net income	(82,880,000)	227,877,000
Balance for common	(82,880,000)	227,877,000
Earnings common share		
Primary	\$(2.19)	\$(6.15)
Fully Diluted	\$(2.19)	\$(6.15)
Common Shares:		
Full Diluted	37,855,249	37,046,765
Year-end	38,125,122	37,384,975

QORVO INC**Earnings, 6 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Total Revenues	1,577,113	1,462,414
Cost & expenses	1,505,851	1,440,679
Operating income	71,262	21,735
Interest income	4,974	1,824
Interest expense	24,042	27,049
Other income (expense), net	(81,487)	(1,126)
Net before taxes	(29,293)	(4,616)
Income taxes	(31,384)	(9,911)
Net income	2,091	5,295
Earnings common share		
Primary	\$0.02	\$0.04
Fully Diluted	\$0.02	\$0.04
Common Shares:		
Full Diluted	128,977	131,062
Year-end	125,046	127,137

QUALCOMM INC**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

	09/30/18	09/24/17	09/25/16
Equipment & services revenues	17,400,000	16,647,000	15,467,000

Licensing revenues	5,332,000	5,644,000	8,087,000	attributable to				Unearned revenues	1,620,000	2,003,000
Total revenues	22,732,000	22,291,000	23,554,000	Qualcomm, Inc.	(4,864,000)	2,466,000	5,705,000	Income taxes payable	2,312,000	...
Cost of revenues	10,244,000	9,792,000	9,749,000	Weighted average				Notes	15,500,000	21,000,000
Research & development expenses	5,625,000	5,485,000	5,151,000	shares outstanding - basic	1,463,000	1,477,000	1,484,000	Unamortized discount, including debt issuance costs	(85,000)	(106,000)
Selling, general & administrative expenses	2,986,000	2,658,000	2,385,000	Weighted average shares outstanding - diluted	1,463,000	1,490,000	1,498,000	Hedge accounting fair value adjustments	(50,000)	...
Other expenses	3,135,000	1,742,000	(226,000)	Year end shares outstanding	1,219,000	1,474,000	1,476,000	Less: short-term	...	1,496,000
Total costs & expenses	21,990,000	19,677,000	17,059,000	Net earnings (loss) per share - basic	\$(3.32)	\$1.67	\$3.84	Long-term debt	15,365,000	19,398,000
Operating income (loss)	742,000	2,614,000	6,495,000	Net earnings (loss) per share - diluted	\$(3.32)	\$1.65	\$3.81	Other liabilities	1,225,000	2,432,000
Interest expense	768,000	494,000	297,000	Dividends per share announced	\$2.38	\$2.20	\$2.02	Total liabilities	31,758,000	34,740,000
Interest & dividend income	625,000	619,000	611,000	Total number of employees	35,400	33,800	30,500	Common stock	...	274,000
Net realized gains on marketable securities	41,000	456,000	239,000	Number of common stockholders	6,887	7,310	7,484	Retained earnings (accumulated deficit)	663,000	30,088,000
Net realized gains (losses) on other investments	83,000	74,000	49,000	Foreign currency translation adjustments	(136,000)	309,000	(22,000)	Foreign currency translation	11,000	147,000
Impairment losses on marketable securities	6,000	131,000	112,000	Reclassified to conform with 2018 presentation; As is; As of November 5, 2018; As of October 30, 2017; As of October 31, 2016				Noncredit other-than-temporary impairment losses & subsequent changes in fair value for certain available-for-sale debt securities, net of income taxes	23,000	23,000
Impairment losses on other investments	69,000	46,000	60,000					Net unrealized gain (loss) on other available-for-sale securities, net of income taxes	243,000	218,000
Net gains (losses) on derivative instruments	(27,000)	32,000	(8,000)					Net unrealized gain (loss) on derivative instruments, net of income taxes	(13,000)	(8,000)
Equity in net earnings (losses) of investees	(145,000)	(74,000)	(84,000)					Other gains	1,000	4,000
Net gains (losses) on foreign currency transactions	37,000	(30,000)	...					Accumulated other comprehensive income (loss)	265,000	384,000
Investment & other income, net	539,000	900,000	635,000					Total Qualcomm, Inc. stockholders' equity	928,000	30,746,000
Income (loss) from continuing operations before income taxes - United States	(1,713,000)	(762,000)	3,032,000					Total stockholders' equity	928,000	30,746,000
Income (loss) from continuing operations before income taxes - foreign	2,226,000	3,782,000	3,801,000							
Income (loss) before income taxes	513,000	3,020,000	6,833,000							
Current federal income tax provision (benefit)	2,559,000	72,000	4,000							
Current state income tax provision (benefit)	(1,000)	3,000	4,000							
Current foreign income tax provision (benefit)	777,000	1,256,000	1,411,000							
Total current income tax provision (benefit)	3,335,000	1,331,000	1,419,000							
Deferred federal income tax provision (benefit)	1,867,000	(586,000)	(184,000)							
Deferred state income tax provision (benefit)	1,000	4,000	6,000							
Deferred foreign income tax provision (benefit)	174,000	(194,000)	(110,000)							
Total deferred income tax provision (benefit)	2,042,000	(776,000)	(288,000)							
Income tax expense (benefit)	5,377,000	555,000	1,131,000							
Net income (loss)	(4,864,000)	2,465,000	5,702,000							
Net loss attributable to noncontrolling interests	...	1,000	3,000							
Net income (loss)										

Consolidated Balance Sheet, Years Ended (\$000):			
	09/30/18	09/24/17 (revised)	
Cash & cash equivalents	11,777,000	35,029,000	
Marketable securities	311,000	2,279,000	
Accounts receivable - trade, gross	2,904,000	3,587,000	
Allowances for doubtful accounts	56,000	11,000	
Accounts receivable - trade, net	2,848,000	3,576,000	
Long-term contracts	20,000	40,000	
Other accounts receivable	36,000	16,000	
Raw materials	72,000	103,000	
Work-in-process	715,000	799,000	
Finished goods	906,000	1,133,000	
Inventories	1,693,000	2,035,000	
Other current assets	699,000	618,000	
Total current assets	17,384,000	43,593,000	
Marketable securities	35,000	1,270,000	
Deferred tax assets	904,000	2,900,000	
Land	186,000	195,000	
Buildings & improvements	1,575,000	1,595,000	
Computer equipment & software	1,419,000	1,609,000	
Machinery & equipment	3,792,000	3,528,000	
Furniture & office equipment	85,000	109,000	
Leasehold improvements	325,000	310,000	
Construction in progress	79,000	73,000	
Property, plant & equipment, gross	7,461,000	7,419,000	
Less accumulated depreciation & amortization	4,486,000	4,203,000	
Property, plant & equipment, net	2,975,000	3,216,000	
Goodwill	6,498,000	6,623,000	
Other intangible assets, net	2,955,000	3,737,000	
Other assets	1,935,000	4,147,000	
Total assets	32,686,000	65,486,000	
Trade accounts payable	1,825,000	1,971,000	
Payroll & other benefits related liabilities	1,081,000	1,183,000	
Unearned revenues	500,000	502,000	
Short-term debt	1,005,000	2,495,000	
Customer incentives & other customer-related liabilities	3,347,000	2,804,000	
Income taxes payable	453,000	312,000	
Accrual for TFTC	1,167,000	778,000	
RF360 holdings put & call option	1,137,000	...	
Other current liabilities	721,000	862,000	
Total current liabilities	11,236,000	10,907,000	

Recent Dividends:				
I. Qualcomm Inc common.				
ExDate	Amt	Declared	Record	Payable
03/02/2015	0.42	01/14/2015	03/04/2015	03/25/2015
06/01/2015	0.48	04/08/2015	06/03/2015	06/24/2015
08/31/2015	0.48	07/07/2015	09/02/2015	09/23/2015
11/27/2015	0.48	10/09/2015	12/01/2015	12/18/2015
02/29/2016	0.48	01/12/2016	03/02/2016	03/23/2016
05/27/2016	0.53	04/08/2016	06/01/2016	06/22/2016
08/29/2016	0.53	07/12/2016	08/31/2016	09/21/2016
11/28/2016	0.53	10/06/2016	11/30/2016	12/16/2016
02/27/2017	0.53	01/12/2017	03/01/2017	03/22/2017
05/26/2017	0.57	04/12/2017	05/31/2017	06/21/2017
08/28/2017	0.57	07/13/2017	08/30/2017	09/20/2017
11/28/2017	0.57	10/10/2017	11/29/2017	12/15/2017
02/27/2018	0.57	01/12/2018	02/28/2018	03/21/2018
05/29/2018	0.62	04/17/2018	05/30/2018	06/20/2018
09/04/2018	0.62	07/12/2018	09/05/2018	09/26/2018

Annual Dividends:				
I. Qualcomm Inc common.				
2015	2016	2017	2018	
1.86	2.07	2.24		

QUALYS, INC.			
Earnings, 9 mos. to Sep 30(Consol. - \$000):			
		2018	2017
Total Revenues		204,689	167,913
Cost & expenses		167,271	140,399
Operating income		37,418	27,514
Interest income		4,193	1,775
Interest expense		112	3
Other income (expense), net		(836)	(288)
Net before taxes		40,663	28,998
Income taxes		(2,241)	(8,586)
Net income		42,904	37,584
Earnings common share			
Primary		\$1.10	\$1.01

Fully Diluted	\$1.02	\$0.95
Common Shares:		
Full Diluted	42,113	39,601
Year-end	39,341	37,897

QUANTENNA COMMUNICATIONS INC**Earnings, 9 mos. to (Consol. – \$000):**

	09/30/18	10/01/17
Total Revenues	157,893	135,084
Cost & expenses	158,151	132,695
Operating income	(258)	2,389
Interest expense		442
Other income (expense), net	807	610
Net before taxes	549	2,557
Income taxes	(1,115)	470
Net income	1,664	2,087
Earnings common share		
Primary	\$0.05	\$0.06
Fully Diluted	\$0.04	\$0.05
Common Shares:		
Full Diluted	39,425	38,419
Year-end	37,347	35,085

QUANTERIX CORP**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	26,755	16,285
Cost & expenses	48,892	35,197
Operating income	(22,137)	(18,912)
Other income (expense), net	(86)	10
Net income	(22,202)	(19,637)
Balance for common	(22,202)	(22,986)
Earnings common share		
Primary	\$(1.01)	\$(9.51)
Fully Diluted	\$(1.01)	\$(9.51)
Common Shares:		
Full Diluted	21,918	2,417
Year-end	22,151	

QUIDEL CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	389,697	162,853
Cost & expenses	321,306	157,188
Operating income	68,391	5,665
Interest expense	19,475	8,387
Other income (expense), net	(8,262)	
Net before taxes	40,654	(2,722)
Income taxes	(1,050)	355
Net income	41,704	(3,077)
Earnings common share		
Primary	\$1.11	\$(0.09)
Fully Diluted	\$1.08	\$(0.09)
Common Shares:		
Full Diluted	42,467	33,538
Year-end	39,001	33,984

QUINNSTREET, INC.**Earnings, 3 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	112,869	87,418
Cost & expenses	107,556	86,061
Operating income	5,313	1,357
Interest income	66	37
Other income (expense), net	(67)	43
Net before taxes	5,312	1,437
Income taxes	15	(8)
Net income	5,297	1,445
Earnings common share		
Primary	\$0.11	\$0.03
Fully Diluted	\$0.10	\$0.03
Common Shares:		
Full Diluted	52,441	46,728
Year-end	49,146	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	70,519	
Current assets	141,484	
Net property & equip.	4,126	
Total assets	223,058	
Liabilities:		
Current liabilities	66,025	
Stockholders' equity	153,025	
Net current assets	75,459	

QURATE RETAIL INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	9,694,000	7,060,000
Cost & expenses	8,316,000	5,791,000
Deprec., depl. & amort.	489,000	594,000
Operating income	889,000	675,000
Interest expense	288,000	267,000
Other income (expense), net	(5,000)	159,000
Net before taxes	596,000	567,000
Income taxes	60,000	127,000
Income contin. oper.	536,000	440,000
Net income	677,000	1,011,000
Earnings common share		
Primary	\$3.67	\$8.44
Fully Diluted	\$3.63	\$8.35
Common Shares:		
Full Diluted	471,000	454,000
Year-end	455,513	

R1 RCM INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	605,600	309,500
Cost & expenses	639,900	333,300
Operating income	(34,300)	(23,800)
Net before taxes	(49,900)	(23,700)
Income taxes	(10,300)	(5,100)
Net income	(39,600)	(18,600)
Balance for common	(53,800)	(31,700)
Earnings common share		
Primary	\$(0.50)	\$(0.31)
Fully Diluted	\$(0.50)	\$(0.31)
Common Shares:		
Full Diluted	107,921	102,022
Year-end	110,232	104,505

RA PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	49,729	39,707
Operating income	(49,729)	(39,707)
Other income (expense), net	981	409
Net income	(48,748)	(39,298)
Earnings common share		
Primary	\$(1.60)	\$(1.74)
Fully Diluted	\$(1.60)	\$(1.74)
Common Shares:		
Full Diluted	30,652	22,579
Year-end	32,388	

RADISYS CORP.**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	77,626	101,476
Cost & expenses	84,690	128,423
Operating income	(7,657)	(29,756)
Interest expense	4,206	927
Other income (expense), net	1,598	(543)
Net before taxes	(10,265)	(31,226)
Income taxes	2,687	1,747
Net income	(12,952)	(32,973)
Earnings common share		
Primary	\$(0.33)	\$(0.85)
Fully Diluted	\$(0.33)	\$(0.85)
Common Shares:		
Full Diluted	39,496	38,922
Year-end	39,621	39,149

RADIUS HEALTH INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Cost & expenses	232,529	196,677
Operating income	(167,714)	(182,228)
Interest income	4,433	1,983
Interest expense	17,041	2,763
Other income (expense), net	83	(212)
Net income	(180,239)	(183,220)
Balance for common	(180,239)	(183,220)
Earnings common share		
Primary	\$(3.98)	\$(4.21)
Fully Diluted	\$(3.98)	\$(4.21)
Common Shares:		
Full Diluted	45,291	43,536
Year-end	45,540	44,532

RAMACO RESOURCES INC**Earnings, 9 mos. to Sep 30(Consol. – \$):**

	2018	2017
Total Revenues	183,386,943	37,016,753
Cost & expenses	152,575,461	48,917,592
Operating income	22,070,823	(13,235,822)
Interest expense	1,006,118	22,841
Other income (expense), net	2,038,426	150,104
Net before taxes	23,129,520	
Income taxes	1,448,479	
Net income	21,681,041	(12,816,658)
Earnings common share		
Primary	\$0.54	\$(0.35)
Fully Diluted	\$0.54	\$(0.35)
Common Shares:		
Full Diluted	40,271,159	36,912,362
Year-end	40,082,467	39,509,311

RAPID7 INC**Earnings, 9 mos. to Sep 30(Consol. – \$000):**

	2018	2017
Total Revenues	175,321	143,209
Cost & expenses	217,547	178,618
Operating income	(42,226)	(35,409)
Interest income	1,520	666
Interest expense	1,681	81
Other income (expense), net	(67)	349
Net before taxes	(42,454)	(34,475)
Income taxes	71	(2,009)
Net income	(42,525)	(32,466)
Earnings common share		
Primary	\$(0.92)	\$(0.76)
Fully Diluted	\$(0.92)	\$(0.76)
Common Shares:		
Full Diluted	46,140	42,693
Year-end	47,287	43,857

RBC BEARINGS INC**Earnings, 6 mos. to (Consol. – \$000):**

	09/29/18	09/30/17
Net Sales	348,901	328,214
Cost & expenses	277,019	270,818
Operating income	71,882	57,396
Interest expense	3,157	3,943
Other income (expense), net	(1,370)	(754)
Net before taxes	67,355	52,699
Income taxes	9,777	16,067
Net income	57,578	36,632
Earnings common share		
Primary	\$2.38	\$1.53
Fully Diluted	\$2.34	\$1.51
Common Shares:		
Full Diluted	24,635	24,251
Year-end	24,448	24,949

RCM TECHNOLOGIES, INC.

Acquisition Completed On Nov. 8, 2018, Co.'s wholly-owned subsidiary, RCM Technologies (USA), Inc. (the "Buyer") purchased from Thermal Kinetics Engineering, PLLC, a New York professional limited liability company ("TKE"), Thermal Kinetics Systems, LLC, a New York limited liability company (together with TKE, each a "Seller" and collectively, "Sellers") substantially all of the assets of Sellers utilized in connection with the business of supplying equipment and providing engineering, development, and design services. The purchase price consisted of \$1,765,000, inclusive of estimated net assumed liabilities of \$700,000, resulting in \$1,065,000 being paid at closing in cash, 440,751 shares of Co.'s Common Stock, \$0.10 par value, which shares are subject to a 36-month lock-up agreement, and a series of Earn-out Payments (as defined in the Purchase Agreement) based on the net operating income of the Business (the "NOI") over the fiscal year of Co. ending on the last day of September in each of 2019, 2020 and 2021 (the "First Earn-Out Period," "Second Earn-Out Period" and "Third Earn-Out Period," respectively). With respect to the Earn-out Payments, Buyer shall pay Sellers, in accordance with the terms and provisions of the Purchase Agreement, an amount equal to \$600,000 for each Earn-Out period where the NOI is greater than a hurdle amount of \$1,900,000 (for the First Earn-Out Period), \$2,000,000 (for the Second Earn-Out Period) and \$2,100,000 (for the Third Earn-Out Period), plus, for any such period, an Second-Tier Earn-out Payment amount equal to 50% of the NOI for such period in excess of the applicable hurdle amount; provided, that the Second-Tier Earn-out Payment for any given year cannot exceed \$2,000,000.

REALNETWORKS, INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$):		
	2018	2017
Total Revenues	52,953,000	59,853,000
Cost & expenses	69,668,000	75,727,000
Operating income	(16,715,000)	(15,874,000)
Interest income	270,000	353,000
Other income (expense), net	(932,000)	(1,386,000)
Net before taxes	(17,377,000)	(16,907,000)
Income taxes	708,000	954,000
Income contin. oper.		(17,861,000)
Net income	(18,085,000)	(17,144,000)
Earnings common share		
Primary	\$(0.48)	\$(0.46)
Fully Diluted	\$(0.48)	\$(0.46)
Common Shares:		
Full Diluted	37,549,000	37,112,000
Year-end	37,652,000	

REALPAGE INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	642,506	483,283
Cost & expenses	562,533	452,485
Operating income	53,650	20,197
Interest income	1,554	859
Interest expense	24,733	9,596
Other income (expense), net	(1,825)	188
Net before taxes	28,646	11,648
Income taxes	193	(9,594)
Net income	28,453	21,242
Earnings common share		
Primary	\$0.33	\$0.27
Fully Diluted	\$0.31	\$0.26
Common Shares:		
Full Diluted	90,451	82,051
Year-end	94,025	

REATA PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	45,137	38,094
Cost & expenses	96,781	68,142
Deprec., depl. & amort.	311	336
Operating income	(54,948)	(30,991)
Interest expense	3,773	956
Other income (expense), net	(1,007)	(3)
Gains or losses	1,787	352
Net before taxes	(54,948)	(30,991)
Income taxes	15	2
Net income	(54,963)	(30,993)
Earnings common share		
Primary	\$(2.03)	\$(1.34)
Fully Diluted	\$(2.03)	\$(1.34)
Common Shares:		
Full Diluted	27,022	23,196
Year-end	29,698	26,114

RED ROBIN GOURMET BURGERS INC

Earnings, 9 mos. to (Consol. – \$):		
	10/07/18	10/01/17
Total Revenues	1,031,784,000	043,639,000
Cost & expenses	953,839,000	942,284,000
Operating income	4,610,000	30,880,000
Net before taxes	(3,477,000)	23,411,000
Income taxes	(7,692,000)	2,199,000
Net income	4,215,000	21,212,000
Earnings common share		
Primary	\$0.32	\$1.65
Fully Diluted	\$0.32	\$1.63
Common Shares:		
Full Diluted	13,064,000	12,986,000
Year-end	12,996,000	12,935,000

RED ROCK RESORTS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	1,249,559	1,241,829
Cost & expenses	815,918	988,678
Operating income	300,250	118,430
Interest expense	96,299	100,127
Other income (expense), net	28,672	491
Net before taxes	232,623	18,794
Income taxes	26,324	1,230

Net income	206,299	17,564
Earnings common share		
Primary	\$2.15	\$0.09
Fully Diluted	\$1.66	\$0.08
Common Shares:		
Full Diluted	117,006	115,877
Year-end	116,547	

REGENERON PHARMACEUTICALS, INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	4,783,003	4,289,780
Cost & expenses	2,966,661	2,749,000
Operating income	1,816,342	1,540,780
Interest expense	20,851	19,084
Other income (expense), net	81,842	2,048
Net before taxes	1,877,333	1,523,744
Income taxes	253,286	498,752
Net income	1,624,047	1,024,992
Earnings common share		
Primary	\$15.06	\$9.66
Fully Diluted	\$14.14	\$8.84
Common Shares:		
Full Diluted	114,843	115,994
Year-end	106,299	109,255

REGENXBIO INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	177,728	8,353
Cost & expenses	92,078	67,640
Operating income	85,650	(59,287)
Gains or losses	4,177	2,115
Net before taxes	98,189	
Income taxes	2,558	
Net income	95,631	(57,172)
Balance for common		
	95,631	(57,172)
Earnings common share		
Primary	\$2.94	\$(1.94)
Fully Diluted	\$2.67	\$(1.94)
Common Shares:		
Full Diluted	35,875	29,440
Year-end	35,704	31,109

RENEWABLE ENERGY GROUP, INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	1,867,155	1,580,979
Cost & expenses	1,601,208	1,600,924
Operating income	265,947	(19,945)
Interest expense	13,579	13,740
Other income (expense), net	19,906	(26,434)
Gains or losses	4,454	942
Net before taxes	276,728	(59,177)
Income taxes	3,486	2,919
Net income	273,242	(62,096)
Balance for common		
	266,243	(62,096)
Earnings common share		
Primary	\$7.04	\$(1.61)
Fully Diluted	\$6.20	\$(1.61)
Common Shares:		
Full Diluted	42,911	38,684
Year-end	37,300	38,833

RENT-A-CENTER INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	1,998,715	2,063,586
Cost & expenses	1,903,928	2,015,824
Operating income	42,513	(8,166)
Interest income	756	492
Other income (expense), net		(1,936)
Net before taxes	10,607	(43,956)
Income taxes	3,779	(15,785)
Net income	6,828	(28,171)
Earnings common share		
Primary	\$0.13	\$(0.53)
Fully Diluted	\$0.13	\$(0.53)
Common Shares:		
Full Diluted	54,401	53,272
Year-end	53,509	53,312

REPLIGEN CORP.

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	142,090,000	99,624,000
Cost & expenses	123,955,000	88,881,000
Operating income	18,135,000	10,743,000
Interest expense	5,008,000	4,804,000
Other income (expense), net	187,000	(548,000)
Gains or losses	1,251,000	308,000
Net before taxes	14,565,000	5,699,000
Income taxes	3,586,000	(10,476,000)
Net income	10,979,000	16,175,000
Earnings common share		
Primary	\$0.25	\$0.44
Fully Diluted	\$0.24	\$0.43
Common Shares:		
Full Diluted	45,132,115	37,386,333
Year-end	43,853,389	43,559,081

RESTORATION ROBOTICS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Total Revenues	15,298	15,441
Cost & expenses	33,954	28,917
Operating income	(18,656)	(13,476)
Interest expense	1,489	1,607
Other income (expense), net	(567)	(1,646)
Net before taxes	(20,712)	(16,729)
Income taxes	32	50
Net income	(20,744)	(16,779)
Balance for common		
	(20,744)	(16,779)
Earnings common share		
Primary	\$(0.67)	\$(10.36)
Fully Diluted	\$(0.67)	\$(10.36)
Common Shares:		
Full Diluted	31,055	1,620
Year-end	40,676	1,624

RESTORBIO INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):		
	2018	2017
Cost & expenses	33,345	11,359
Operating income	(33,345)	(11,359)
Other income (expense), net	1,488	635
Net income	(31,857)	(10,724)
Earnings common share		
Primary		
Fully Diluted	25,896	3,839
Year-end	28,048	

RF INDUSTRIES LTD.

Interest Sale Completed On Oct. 31, 2018, Co. sold 100% of the issued and outstanding shares of Comnet Telecom Supply, Inc., a New York corporation to RAP Acquisition Inc., a New Jersey corporation for \$4,200,000 in cash.

RISE GOLD CORP

Annual Report
Consolidated Income Statement, Years Ended Jul. 31
(Can\$):

	2018	2017	2016
		(revised)	(revised)
Bad debt expense	7,126
Consulting expenses	78,500	505,842	102,420
Depreciation	2,306
Directors' fees	99,571	17,288	...
Filing & regulatory	87,395	53,661	30,927
Foreign exchange	14,749	(6,931)	(1,959)
Gain on settlement of payables	41,982
Gain on settlement of debt	37,068	12,355	...
General & administrative expenses	287,052	152,920	20,839
Geological, mineral, & prospect costs	2,057,877	375,980	...
Interest expense	2,602
Professional fees	562,694	273,738	107,197
Promotion & shareholder communication	443,696	983,851	10,408
Property investigation costs	...	55,253	20,201

Salaries	350,627	104,751	5,365
Share-based payments	673,360	1,010,064	369,006
Settlement payment	100,000	...
Write off mineral property costs	563,031	...
Net income (loss) & comprehensive income (loss) for the year	(4,593,863)	(4,190,955)	(633,466)
Weighted average shares outstanding-basic	87,171,446	49,516,659	31,556,200
Weighted average shares outstanding-diluted ..	87,171,446	49,516,659	31,556,200
Year end shares outstanding	[Ⓔ] 116,105,982	[Ⓔ] 66,707,655	32,866,261
Net earnings (loss) per share-basic	Can\$(0.05)	Can\$(0.08)	Can\$(0.02)
Net earnings (loss) per share-diluted	Can\$(0.05)	Can\$(0.08)	Can\$(0.02)
Number of full time employees	8	1	...
Total number of employees	[Ⓔ] 1
Number of common stockholders	[Ⓔ] 129	[Ⓔ] 253	[Ⓔ] 200

[Ⓔ] Reclassified to conform with 2018 presentation; [Ⓕ] Reclassified to conform with 2017 presentation; [Ⓖ] Shares increased due to the effect of issuance of common shares for cash and debt and exercised of warrants; [Ⓗ] Shares increased due to the effect of shares issued for cash, mineral property, compensation, warrant exercised and option exercised; [Ⓙ] As of June 12, 2017; [Ⓚ] Approximately

Consolidated Balance Sheet, Years Ended Jul. 31 (Can\$):

	2018	[Ⓔ] 2017
		(revised)
Cash	69,616	337,099
Receivables	17,059	18,083
Promotion & shareholder communication	429,166	76,393
Rent	32,937
Insurance	102,723	41,250
Other prepaid expenses	500	14,538
Prepaid expenses	532,389	165,118
Total current assets	619,064	520,300
Mineral property interests	5,447,674	3,789,854
Drilling equipment, cost	713,672	...
Less: accumulate depreciation - drilling equipment	2,306	...
Equipment	711,366	...
Total assets	6,778,104	4,310,154
Accounts payable & accrued liabilities	521,058	296,792
Loan from related parties	49,150	38,079
Current portion of equipment loan	305,710	...
Total current liabilities	875,918	334,871
Equipment loan	293,955	...
Total liabilities	1,169,873	334,871
Capital stock	116,106	66,708
Additional paid-in capital	16,280,575	10,103,162
Cumulative translation adjustment	(166,663)	(166,663)
Retained earnings (deficit) accumulated	(10,621,787)	(6,027,924)
Total stockholders' equity (deficit)	5,608,231	3,975,283

[Ⓔ] Reclassified to conform with 2018 presentation

Recent Dividends:

1. Rise Gold Corp common.
No dividends paid.

Annual Dividends:

1. Rise Gold Corp common.
No dividends paid.

RISE GOLD CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Davidson & Company LLP Chartered Accountants, as it appeared in Co.'s 2018 10-K: "We have audited the accompanying consolidated balance sheets of Rise Gold Corp. (the "Company"), as of July 31, 2018 and 2017, and the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years ended July 31, 2018 and 2017, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Rise Gold Corp. as of July 31, 2018 and 2017, and the results of its operations and its cash flows for the years ended July 31, 2018 and 2017 in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1 The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ROBINSON (C.H.) WORLDWIDE, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	12,493,264	10,909,594
Cost & expenses	11,836,698	10,345,351
Operating income	656,566	564,243
Net before taxes	634,212	535,089
Income taxes	156,857	182,752
Net income	477,355	352,337
Earnings common share		
Primary	\$3.42	\$2.50
Fully Diluted	\$3.39	\$2.49
Common Shares:		
Full Diluted	140,720	141,403
Year-end	138,000	139,871

ROCKWELL MEDICAL, INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	46,534,358	42,462,265
Cost & expenses	69,548,590	59,163,987
Operating income	(23,014,232)	(16,701,722)
Net income	(22,749,945)	(16,882,001)
Earnings common share		
Primary	\$(0.44)	\$(0.33)
Fully Diluted	\$(0.44)	\$(0.33)
Common Shares:		
Full Diluted	51,288,462	50,995,079
Year-end	51,769,294	51,761,040

ROCKY BRANDS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	185,508,077	186,202,989
Cost & expenses	172,297,980	178,093,343
Operating income	13,210,097	8,109,646
Other income (expense), net	(147,995)	(245,760)
Net before taxes	13,062,102	7,863,886
Income taxes	2,116,830	2,674,000
Net income	10,945,272	5,189,886
Earnings common share		
Primary	\$1.48	\$0.70
Fully Diluted	\$1.47	\$0.70
Common Shares:		
Full Diluted	7,453,764	7,441,378
Year-end	7,421,317	7,403,195

ROCKY MOUNTAIN CHOCOLATE FACTORY INC (DE)

Earnings, 6 mos. to Aug 31(Consol. - \$):

	2018	2017
Total Revenues	16,166,173	17,613,138
Cost & expenses	13,744,780	14,428,122
Deprec., depl. & amort.	597,737	389,924
Operating income	1,823,656	2,795,092
Interest income	9,204	13,431
Interest expense	42,057	67,277
Net before taxes	1,790,803	2,741,246
Income taxes	463,044	999,290
Net income	1,327,759	1,741,956
Earnings common share		

Primary	\$0.22	\$0.30
Fully Diluted	\$0.22	\$0.29
Common Shares:		
Full Diluted	5,982,919	5,979,620
Year-end	5,948,660	5,903,436

ROYAL GOLD INC

Earnings, 3 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	99,992,000	112,476,000
Cost & expenses	32,108,000	31,064,000
Operating income	25,333,000	41,720,000
Other income (expense), net	(1,468,000)	...
Net before taxes	16,091,000	34,092,000
Income taxes	4,115,000	7,544,000
Net income	11,976,000	26,548,000
Earnings common share		
Primary	\$0.23	\$0.44
Fully Diluted	\$0.23	\$0.44
Common Shares:		
Full Diluted	65,497,159	65,404,680
Year-end	65,394,898	65,306,271

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	117,078,000
Inventories	10,011,000
Current assets	159,430,000
Total assets	2,672,866,000
Liabilities:	
Current liabilities	37,371,000
Long-term debt	354,939,000
Stockholders' equity	2,103,221,000
Net current assets	122,059,000

RTI SURGICAL, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	209,639,000	208,747,000
Cost & expenses	212,082,000	176,101,000
Operating income	(2,443,000)	32,646,000
Interest income	31,000	...
Interest expense	2,223,000	2,475,000
Other income (expense), net	(309,000)	...
Foreign currency	(23,000)	5,000
Net before taxes	(4,967,000)	30,176,000
Income taxes	(1,646,000)	16,251,000
Net income	(3,321,000)	13,925,000
Balance for common	(5,441,000)	11,153,000
Earnings common share		
Primary	\$(0.09)	\$0.19
Fully Diluted	\$(0.09)	\$0.19
Common Shares:		
Full Diluted	63,517,958	59,954,964
Year-end	63,461,700	60,544,896

RUSH ENTERPRISES INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	3,965,748	3,505,779
Cost & expenses	3,773,889	3,357,713
Deprec., depl. & amort.	57,395	37,374
Operating income	134,464	110,692
Interest expense	13,268	8,716
Net before taxes	121,196	101,976
Income taxes	29,103	35,714
Net income	92,093	66,262
Earnings common share		
Primary	\$2.33	\$1.68
Fully Diluted	\$2.27	\$1.62
Common Shares:		
Full Diluted	40,635	40,830
Year-end	38,861	39,790

SABRE CORP

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	2,943,028	2,716,622
Cost & expenses	2,502,031	2,357,782
Operating income	440,997	358,840
Interest expense	116,809	116,577
Other income (expense), net	(8,924)	(19,032)
Net before taxes	315,264	223,231
Income taxes	61,371	56,836
Income contin. oper.	253,893	166,395

Net income	257,110	164,167
Balance for common	253,131	160,441
Earnings common share		
Primary	\$0.92	\$0.58
Fully Diluted	\$0.91	\$0.57
Common Shares:		
Full Diluted	276,819	279,648
Year-end	275,294	274,756

SAGE THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Cost & expenses	319,011	202,706
Operating income	(229,011)	(202,706)
Interest income	14,483	2,056
Other income (expense), net	34	(48)
Net income	(214,494)	(200,698)
Earnings common share		
Primary	\$(4.68)	\$(5.37)
Fully Diluted	\$(4.68)	\$(5.37)
Common Shares:		
Full Diluted	45,867	37,368
Year-end	46,831	37,222

SAIA INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,247,099	1,044,505
Cost & expenses	1,064,293	908,117
Operating income	107,841	71,781
Interest expense	4,090	3,762
Other income (expense), net	384	(57)
Net before taxes	104,135	67,962
Income taxes	24,534	24,623
Net income	79,601	43,339
Earnings common share		
Primary	\$3.09	\$1.70
Fully Diluted	\$3.02	\$1.67
Common Shares:		
Full Diluted	26,328	26,050
Year-end	25,694	25,490

SALEM MEDIA GROUP, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	195,595	196,525
Cost & expenses	168,672	165,491
Operating income	13,289	18,443
Interest income	4	3
Interest expense	13,779	12,156
Other income (expense), net	222	(2,498)
Net before taxes	(264)	3,792
Income taxes	(132)	1,506
Net income	(132)	2,286
Earnings common share		
Primary	\$(0.01)	\$0.09
Fully Diluted	\$(0.01)	\$0.09
Common Shares:		
Full Diluted	26,178	26,455
Year-end	26,186	26,163

SANFILIPPO (JOHN B) & SON INC

Earnings, 3 mos. to (Consol. – \$000):

	09/27/18	09/28/17
Net Sales	204,288	215,664
Cost & expenses	194,236	198,049
Operating income	10,052	17,615
Interest expense	879	781
Other income (expense), net	(776)	(1,114)
Net before taxes	8,397	15,720
Income taxes	1,791	5,009
Net income	6,606	10,711
Earnings common share		
Primary	\$0.58	\$0.94
Fully Diluted	\$0.57	\$0.94
Common Shares:		
Full Diluted	11,492	11,442
Year-end	11,345	11,297

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	1,215
Inventories	181,031
Current assets	245,323
Net property & equip.	110,632

Total assets	415,427
Liabilities:	
Current liabilities	140,002
Long-term debt	25,537
Stockholders' equity	221,347
Net current assets	105,321

SANGAMO THERAPEUTICS INC

Acquisition Completed On Nov. 1, 2018, Co., directly or through a subsidiary, acquired a further 7,044,697 ordinary shares of TxCell S.A. ("TxCell") at Euro2.58 per share, from certain shareholders of TxCell, bringing the total number of shares of 20,203,733 acquired as of Nov. 1, 2018, representing approximately 79% of the outstanding share capital and voting rights of TxCell.

SANGAMO THERAPEUTICS INC

Acquisition Completed On Oct. 31, 2018, Co., directly or through a subsidiary, acquired 13,519,036 ordinary shares of TxCell S.A. ("TxCell") at Euro2.58 per share, from certain shareholders of TxCell, representing 53% of the outstanding share capital and voting rights of TxCell.

SANGAMO THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	57,615,000	23,490,000
Cost & expenses	113,993,000	66,085,000
Operating income	(56,378,000)	(42,595,000)
Net income	(49,670,000)	(41,477,000)
Earnings common share		
Primary	\$(0.52)	\$(0.55)
Fully Diluted	\$(0.52)	\$(0.55)
Common Shares:		
Full Diluted	95,165,000	75,814,000
Year-end	101,839,668	84,104,791

SAREPTA THERAPEUTICS INC

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	216,619,000	97,307,000
Cost & expenses	420,235,000	244,961,000
Operating income	(204,265,000)	(148,491,000)
Other income (expense), net	4,553,000	1,215,000
Gains or losses		125,000,000
Net before taxes	(220,936,000)	(22,788,000)
Income taxes	87,000	3,902,000
Net income	(221,023,000)	(26,690,000)
Earnings common share		
Primary	\$(3.38)	\$(0.47)
Fully Diluted	\$(3.38)	\$(0.47)
Common Shares:		
Full Diluted	65,454,000	57,166,000
Year-end	66,693,348	64,567,418

SCANSOURCE, INC.

Earnings, 3 mos. to Sep 30(Consol. – \$):

	2018	2017
Net Sales	972,900,000	924,559,000
Cost & expenses	943,200,000	908,710,000
Operating income	21,432,000	7,598,000
Other income (expense), net	(32,000)	(114,000)
Net before taxes	19,224,000	6,780,000
Income taxes	4,902,000	2,633,000
Net income	14,322,000	4,147,000
Earnings common share		
Primary	\$0.56	\$0.16
Fully Diluted	\$0.56	\$0.16
Common Shares:		
Full Diluted	25,755,000	25,579,000
Year-end	25,607,664	25,440,316

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	18,858,000
Inventories	672,696,000
Current assets	1,433,696,000
Net property & equip.	71,625,000
Total assets	2,021,399,000
Liabilities:	
Current liabilities	776,159,000
Long-term debt	281,524,000
Stockholders' equity	877,897,000
Net current assets	657,537,000

SCHEIN (HENRY) INC

Earnings, 9 mos. to (Consol. – \$000):

Net Sales	9,826,793	9,143,489
Cost & expenses	9,253,376	8,525,311
Operating income	573,417	618,178
Other income (expense), net	(802)	489
Equity earnings	(15,622)	(12,244)
Net before taxes	531,578	594,815
Income taxes	124,084	156,276
Net income	423,116	450,783

Earnings common share

Primary	\$2.63	\$2.64
Fully Diluted	\$2.62	\$2.61
Common Shares:		
Full Diluted	153,982	158,866
Year-end	152,438	156,953

SCHNITZER STEEL INDUSTRIES INC**Annual Report**

Consolidated Income Statement, Years Ended Aug. 31 (\$000):

	2018	2017	2016
Revenues	2,364,715	1,687,591	1,352,543
Cost of goods sold	2,010,485	1,464,508	1,175,988
Selling, general & administrative expenses	208,877	171,570	148,908
Income from joint ventures	1,953	3,674	819
Goodwill impairment charges	8,845
Other asset impairment charges (recoveries), net	(1,021)	(717)	20,682
Restructuring charges & other exit-related activities	(661)	(109)	6,781
Operating income (loss)	148,988	56,013	(7,842)
Interest expense	8,983	8,081	8,889
Other income (expense), net	1,848	758	1,226
Income (loss) before income taxes - United States	131,518	43,871	(4,303)
Income (loss) before income taxes - foreign	10,335	4,819	(11,202)
Income (loss) from continuing operations before income taxes	141,853	48,690	(15,505)
Current federal income tax expense (benefit)	19,511	(1,130)	23
Current state income tax expense (benefit)	894	190	180
Current foreign income tax expense (benefit)	...	(16)	25
Total current income tax expense (benefit)	20,405	(956)	228
Deferred federal income tax expense (benefit)	(5,700)	2,046	502
Deferred state income tax expense (benefit)	(1,962)	232	54
Deferred foreign income tax expense (benefit)	(30,333)	...	(49)
Total deferred income tax expense (benefit)	(37,995)	2,278	507
Income tax expense (benefit)	(17,590)	1,322	735
Income (loss) from continuing operations	159,443	47,368	(16,240)
Income (loss) from discontinued operations, net of			

tax	346	(390)	(1,348)	equipment, gross	1,147,272	1,147,123
Net income (loss)	159,789	46,978	(17,588)	Less: accumulated depreciation	731,561	756,494
Net income attributable to noncontrolling interests	(3,338)	(2,467)	(1,821)	Property, plant & equipment, net	415,711	390,629
Net income (loss) attributable to Schnitzer Steel Industries, Inc.	156,451	44,511	(19,409)	Investments in joint ventures	11,532	11,204
Weighted average shares outstanding - basic	27,645	27,537	27,229	Goodwill	168,065	167,835
Weighted average shares outstanding - diluted	28,589	28,141	27,229	Intangibles, net	4,358	4,424
Year end shares outstanding	26,702	27,059	26,788	Deferred income taxes	30,333	...
Income (loss) per share from continuing operations - basic	\$5.65	\$1.63	\$(0.66)	Other assets	26,459	21,713
Income (loss) per share from discontinued operations - basic	\$0.01	\$(0.01)	\$(0.05)	Total assets	1,104,817	933,755
Net income (loss) per share - basic	\$5.66	\$1.62	\$(0.71)	Short-term borrowings	1,139	721
Income (loss) per share from continuing operations - diluted	\$5.46	\$1.60	\$(0.66)	Accounts payable	128,495	94,674
Income (loss) per share from discontinued operations - diluted	\$0.01	\$(0.01)	\$(0.05)	Accrued payroll & related liabilities	46,410	41,593
Net income (loss) per share - diluted	\$5.47	\$1.58	\$(0.71)	Environmental liabilities	6,682	2,007
Dividends declared per common share	\$0.75	\$0.75	\$0.75	Accrued income taxes	...	9
Number of full time employees	3,575	3,183	2,818	Other accrued liabilities	71,951	37,256
Number of class A common stockholders	177	192	198	Total current liabilities	254,677	176,260
Number of class B common stockholders	1	1	1	Deferred income taxes	11,742	19,147
Foreign currency translation adjustments	(2,301)	2,711	(530)	Bank revolving credit facilities	100,000	140,000
				Capital lease obligations	6,787	4,418
				Other debt obligations	589	706
				Less current maturities	1,139	721
				Long-term debt, net of current maturities	106,237	144,403
				Environmental liabilities, net of current portion	47,150	46,391
				Other long-term liabilities	14,901	10,061
				Total liabilities	434,707	396,262
				Class A common stock	26,502	26,859
				Class B common stock	200	200
				Additional paid-in capital	36,929	38,050
				Retained earnings (accumulated deficit)	639,684	503,770
				Foreign currency translation adjustment	(34,129)	(31,828)
				Pension obligations, net	(3,108)	(3,465)
				Accumulated other comprehensive income (loss)	(37,237)	(35,293)
				Total Schnitzer Steel Industries Inc. shareholders' equity (deficit)	666,078	533,586
				Noncontrolling interests	4,032	3,907
				Total equity	670,110	537,493

As of September 30, 2018; As is; As of September 30, 2017; As of September 30, 2016; As of October 22, 2018; As of October 20, 2017; As of October 21, 2016

Reclassified to conform with 2018 presentation

Consolidated Balance Sheet, Years Ended Aug. 31 (\$000):

	2018	2017 (revised)
Cash & cash equivalents	4,723	7,287
Accounts receivable, gross	172,004	141,278
Less allowance for doubtful accounts	2,586	2,280
Accounts receivable, net	169,418	138,998
Processed & unprocessed scrap metal	111,658	88,441
Semi-finished goods	15,551	3,243
Finished goods	39,809	40,462
Supplies	38,859	34,796
Inventories	205,877	166,942
Refundable income taxes	4,668	2,366
Prepaid expenses & other current assets	63,673	22,357
Total current assets	448,359	337,950
Machinery & equipment	679,520	683,364
Land & improvements	269,382	260,854
Buildings & leasehold improvements	108,882	111,077
ERP systems	17,760	17,884
Office equipment & other software licenses	43,175	48,517
Construction in progress	28,553	25,427
Property, plant &		

Recent Dividends:

1. Schnitzer Steel Industries Inc class B common.

ExDate	Amt	Declared	Record	Payable
02/05/2015	0.19	01/30/2015	02/09/2015	02/23/2015
05/07/2015	0.19	04/29/2015	05/11/2015	05/26/2015
08/06/2015	0.19	07/30/2015	08/10/2015	08/24/2015
11/05/2015	0.19	10/29/2015	11/09/2015	11/23/2015
02/04/2016	0.19	01/28/2016	02/08/2016	02/22/2016
05/05/2016	0.19	04/28/2016	05/09/2016	05/23/2016
08/04/2016	0.19	07/28/2016	08/08/2016	08/22/2016
11/03/2016	0.19	10/27/2016	11/07/2016	11/21/2016
02/02/2017	0.19	01/26/2017	02/06/2017	02/21/2017
05/04/2017	0.19	04/28/2017	05/08/2017	05/22/2017
08/03/2017	0.19	07/28/2017	08/07/2017	08/21/2017
11/10/2017	0.19	10/27/2017	11/13/2017	11/27/2017
02/09/2018	0.19	02/01/2018	02/12/2018	02/26/2018
05/11/2018	0.19	04/30/2018	05/14/2018	05/29/2018
08/10/2018	0.19	08/03/2018	08/13/2018	08/27/2018
11/08/2018	0.19	11/02/2018	11/12/2018	11/26/2018

2. Schnitzer Steel Industries Inc class A common.

No dividends paid.

Annual Dividends:

1. Schnitzer Steel Industries Inc class B common.

2015	0.75	2016	0.75	2017	0.75
2018	0.75				

2. Schnitzer Steel Industries Inc class A common.

No dividends paid.

SCIENTIFIC GAMES CORP

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	2,477,500	2,260,600
Cost & expenses	2,006,600	1,451,500
Operating income	(55,600)	295,900
Other income (expense), net	(49,500)	(16,700)
Net before taxes	(553,400)	(180,300)
Income taxes	5,800	18,900
Net income	(559,200)	(199,200)
Earnings common share		
Primary	\$(6.15)	\$(2.24)
Fully Diluted	\$(6.15)	\$(2.24)
Common Shares:		
Full Diluted	90,900	88,900
Year-end	91,400	89,600

SCRIPPS (EW) COMPANY (THE)

Acquisition Development On Oct. 29, 2018, Co. announced that is acquiring 15 television stations in 10 markets from Cordillera Communications LLC, a company that owns and operates broadcast television stations for households in the United States and owned by Evening Post Industries Inc., a company engaged in television, publishing, interactive, and real estate businesses, for \$521,000,000. The deal is expected to close in the first quarter of 2019.

SCRIPPS (EW) COMPANY (THE)

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	840,312	615,226
Cost & expenses	731,746	593,601
Operating income	62,166	(19,792)
Other income (expense), net	(6,841)	(5,074)
Net before taxes	28,284	(43,029)
Income taxes	8,160	(19,547)
Income contin. oper.	20,124	(23,482)
Net income	(2,230)	(20,078)
Earnings common share		
Primary	\$(0.02)	\$(0.24)
Fully Diluted	\$(0.02)	\$(0.24)
Common Shares:		
Full Diluted	82,097	82,140
Year-end	80,673	

SEASPIKE HOLDINGS CORP

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	105,418	97,832
Cost & expenses	126,709	120,463
Operating income	(23,667)	(25,007)
Other income (expense), net	(327)	387
Net before taxes	(23,994)	(24,620)
Income taxes	4	(12)
Net income	(23,998)	(24,608)
Earnings common share		
Primary	\$(1.66)	\$(2.04)
Fully Diluted	\$(1.66)	\$(2.04)
Common Shares:		
Full Diluted	14,477	12,079
Year-end	14,792	13,429

SEATTLE GENETICS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	480,187,000	352,645,000
Net Sales	344,776,000	223,841,000
Cost & expenses	649,874,000	503,434,000
Operating income	(169,687,000)	150,789,000
Other income (expense), net	66,799,000	84,460,000
Net income	(102,888,000)	(66,329,000)
Earnings common share		
Primary	\$(0.66)	\$(0.46)
Fully Diluted	\$(0.66)	\$(0.46)
Common Shares:		
Full Diluted	156,799,000	142,876,000
Year-end	160,053,203	143,803,000

SEI INVESTMENTS CO

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	1,219,110	1,118,333
Cost & expenses	822,149	769,673
Operating income	339,026	289,981

Interest expense	511	571
Other income (expense), net	123,406	109,213
Gains or losses	(460)	1,036
Net before taxes	470,607	404,587
Income taxes	80,773	122,342
Net income	389,834	282,245
Earnings common share		
Primary	\$2.48	\$1.78
Fully Diluted	\$2.41	\$1.74
Common Shares:		
Full Diluted	162,053	161,866
Year-end	155,475	157,405

SELECTA BIOSCIENCES INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	190	190
Cost & expenses	50,523	44,697
Operating income	(50,523)	(44,507)
Interest expense	1,099	847
Other income (expense), net	11	(689)
Gains or losses	829	379
Foreign currency	97	(113)
Net income	(50,685)	(45,777)
Earnings common share		
Primary	\$(2.27)	\$(2.31)
Fully Diluted	\$(2.27)	\$(2.31)
Common Shares:		
Full Diluted	22,369	19,804
Year-end	22,426	

SENECA FOODS CORP.

Earnings, 6 mos. to (Consol. – \$000):

	09/29/18	09/30/17
Net Sales	564,753	568,839
Cost & expenses	569,609	565,873
Operating income	(4,856)	2,966
Interest expense	7,723	5,578
Other income (expense), net	2,042	2,957
Net before taxes	(10,537)	345
Income taxes	(2,743)	(465)
Income contin. oper.	(7,794)	810
Net income	361	(1,942)
Earnings common share		
Primary	\$0.03	\$(0.20)
Fully Diluted	\$0.03	\$(0.20)
Common Shares:		
Full Diluted	9,729	9,872
Year-end	9,693	

SENOMYX INC

Merger Completed On Nov. 2, 2018, Firmenich Inc. ("Parent"), a wholly-owned subsidiary of Firmenich SA, a private Swiss company engaged in the fragrance and flavor business, wholly-owned subsidiary, Sentry Merger Sub, Inc. ("Purchaser"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each outstanding shares of common stock of Co., \$0.001 par value per share (the "Shares") were converted into the right to receive \$1.50 per Share in cash (the "Offer Price"), without any interest thereon and less applicable withholding taxes. In addition, each of Co.'s stock options ("Co.'s Options") that were outstanding as of immediately prior to the effective time of the Merger (the "Effective Time") accelerated and became fully vested and exercisable effective immediately prior to the Effective Time and have been cancelled and converted into the right to receive cash in an amount, less any applicable withholding taxes, equal to the product of (i) the total number of Shares subject to the vested portion of such Co. Option immediately prior to the Effective Time (taking into account any acceleration of vesting), multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per Share under such Co. Option. No holder of a Co. Option that had an exercise price per Share that was equal to or greater than the Merger Consideration was entitled to any payment with respect to such cancelled Co. Option before or after the Effective Time. The total consideration paid for the Shares in the Offer and the Merger was approximately \$73,600,000. These amounts excluded fees and expenses related to the Offer and the Merger.

SERVICESOURCE INTERNATIONAL, INC.

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	176,869	173,103
Cost & expenses	195,101	197,341

Operating income	(18,232)	(24,238)
Gains or losses	(1,958)	2,100
Net before taxes	(26,870)	(29,693)
Income taxes	294	227
Net income	(27,164)	(29,920)
Earnings common share		
Primary	\$(0.30)	\$(0.34)
Fully Diluted	\$(0.30)	\$(0.34)
Common Shares:		
Full Diluted	91,271	88,907
Year-end	92,614	88,304

SHENANDOAH TELECOMMUNICATIONS CO

Earnings, 9 mos. to Sep 30(Consol. – \$):

	2018	2017
Total Revenues	469,370,000	458,920,000
Cost & expenses	278,486,000	298,223,000
Operating income	66,252,000	28,400,000
Interest expense	27,184,000	28,312,000
Other income (expense), net	2,770,000	3,482,000
Gains or losses	112,000	395,000
Net before taxes	41,950,000	3,965,000
Income taxes	10,207,000	(1,830,000)
Net income	31,743,000	5,795,000
Earnings common share		
Primary	\$0.64	\$0.12
Fully Diluted	\$0.63	\$0.12
Common Shares:		
Full Diluted	50,044,000	49,869,000
Year-end	49,559,000	49,265,000

SHUTTERFLY INC

Earnings, 9 mos. to Sep 30(Consol. – \$000):

	2018	2017
Total Revenues	1,011,853	596,447
Cost & expenses	1,155,410	713,869
Operating income	(143,557)	(117,422)
Interest expense	44,063	18,617
Net before taxes	(183,454)	(135,352)
Income taxes	(56,234)	(53,713)
Net income	(127,220)	(81,639)
Earnings common share		
Primary	\$(3.84)	\$(2.45)
Fully Diluted	\$(3.84)	\$(2.45)
Common Shares:		
Full Diluted	33,139	33,363
Year-end	33,534	32,798

SI-BONE INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

	2017	2016
Revenues	47,983	42,101
Cost of goods sold	5,112	5,165
Gross profit (loss)	42,871	36,936
Sales & marketing expenses	41,646	35,215
Research & development	5,513	6,380
General & administrative expenses	13,062	12,906
Total operating expenses	60,221	54,501
Income (loss) from operations	(17,350)	(17,565)
Interest income	175	71
Interest expense	6,204	3,308
Other income (expense), net	340	213
Net income (loss)	(23,039)	(20,589)
Weighted average shares outstanding - basic	3,467	3,314
Weighted average shares outstanding - diluted	3,467	3,314
Year end shares outstanding	3,603	3,446
Net earnings (loss) per share - basic	\$(6.65)	\$(6.21)
Net earnings (loss) per share - diluted	\$(6.65)	\$(6.21)
Total number of employees	168	
Number of common stockholders	422	

As Is; As of June 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	22,408	27,900
Accounts receivable, gross	7,684	6,267
Allowance for doubtful accounts	268	316
Accounts receivable, net	7,416	5,951
Inventories	2,553	1,514
Prepayments & other current assets	1,252	959
Total current assets	33,629	36,324
Machinery & equipment	3,428	2,942
Construction in progress	879	1,131
Computer & office equipment	310	275
Leasehold improvements	272	272
Furniture & fixtures	29	25
Total property & equipment, gross	4,918	4,645
Less: Accumulated depreciation & amortization	3,022	2,037
Property & equipment, net	1,896	2,608
Intangible assets, net	40	47
Other non-current assets	269	457
Total assets	35,834	39,436
Accounts payable	1,814	1,025
Accrued compensation, travel & related expenses	3,732	2,842
Sales tax payable	466	448
Accrued professional services	341	360
Liability for early exercise of unvested stock options	65	168
Accrued interest	831	86
Sales & warranty reserves	149	10
Others	140	211
Accrued liabilities & other	5,724	4,125
Short term borrowings		8,236
Total current liabilities	7,538	13,386
Redeemable convertible preferred stock warrants	422	588
Long-term debt, net	38,704	21,074
Total liabilities	46,664	35,048
Redeemable convertible preferred stock	118,548	113,121
Common stock	1	1
Additional paid-in capital	9,943	8,000
Stockholders' notes receivable		(521)
Accumulated other comprehensive income (loss)	402	472
Retained earnings (accumulated deficit)	(139,724)	(116,685)
Total shareholders' (deficit) equity	(129,378)	(108,733)
Recent Dividends:		
1. SI-BONE Inc common.		
No dividends paid.		
Annual Dividends:		
1. SI-BONE Inc common.		
No dividends paid.		
SI-BONE INC		
Earnings, 6 mos. to Jun 30(Consol. – \$000):		
	2018	2017
Total Revenues	26,375	22,531
Cost & expenses	30,989	33,201
Operating income	(4,614)	(10,670)
Interest income	130	73
Interest expense	2,544	1,920
Other income (expense), net	(320)	66
Net income	(7,348)	(12,451)

Earnings common share			Income taxes	(9,383)	1,469		09/28/18	09/29/17	09/30/16
Primary	\$(2.04)	\$(3.63)	Net income	68,446	51,944			(revised)	(revised)
Fully Diluted	\$(2.04)	\$(3.63)	Earnings common share			Net revenue	3,868,000	3,651,400	3,289,000
Common Shares:			Primary	\$1.59	\$1.23	Cost of goods sold	1,917,300	1,809,600	1,623,800
Full Diluted	3,603	3,427	Fully Diluted	\$1.55	\$1.20	Gross profit	1,950,700	1,841,800	1,665,200
Year-end	3,707		Common Shares:			Research & development expenses	404,500	355,200	312,400
			Full Diluted	44,135	43,194	Selling, general & administrative expenses	207,800	204,600	195,900
			Year-end	43,147	42,562	Amortization of intangibles	18,300	27,600	33,400

SIENTRA INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	49,104	25,477
Cost & expenses	104,493	70,957
Operating income	(55,389)	(45,480)
Interest income	214	112
Interest expense	2,474	603
Other income (expense), net	(347)	(151)
Net before taxes	(46,122)	(46,122)
Income taxes	70	70
Net income	(57,996)	(46,192)
Earnings common share		
Primary	\$(2.39)	\$(2.42)
Fully Diluted	\$(2.39)	\$(2.42)
Common Shares:		
Full Diluted	24,312	19,080
Year-end	28,578	19,365

SIERRA ONCOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	40,768	31,814
Operating income	(40,768)	(31,814)
Other income (expense), net	1,333	506
Net before taxes	(39,435)	(31,308)
Income taxes	(383)	108
Net income	(39,052)	(31,416)
Earnings common share		
Primary	\$(0.56)	\$(0.64)
Fully Diluted	\$(0.56)	\$(0.64)
Common Shares:		
Full Diluted	69,517	49,080
Year-end	74,364	

SIGA TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	475,484,474	10,856,601
Cost & expenses	114,843,926	24,835,093
Operating income	360,640,548	(13,978,492)
Other income (expense), net	(5,120,049)	(615,806)
Net before taxes	344,004,396	(25,590,198)
Income taxes	(25,412,498)	342,563
Net income	369,416,894	(25,932,761)
Earnings common share		
Primary	\$4.64	\$(0.33)
Fully Diluted	\$4.53	\$(0.33)
Common Shares:		
Full Diluted	82,744,227	78,842,611
Year-end	80,320,535	78,908,929

SILGAN HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Net Sales	3,378,383	3,094,150
Cost & expenses	3,043,629	2,823,590
Operating income	334,754	270,560
Other income (expense), net	(2,493)	(7,052)
Net before taxes	243,659	183,301
Income taxes	57,857	59,762
Net income	185,802	123,539
Earnings common share		
Primary	\$1.68	\$1.12
Fully Diluted	\$1.66	\$1.11
Common Shares:		
Full Diluted	111,609	111,323
Year-end	110,618	110,373

SILICON LABORATORIES INC**Earnings, 9 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Total Revenues	652,733	567,849
Cost & expenses	585,887	509,265
Operating income	66,846	58,584
Interest expense	14,703	9,265
Net before taxes	59,063	53,413

SILVERCREST ASSET MANAGEMENT GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	73,840	66,887
Cost & expenses	57,927	51,670
Operating income	15,913	15,217
Other income (expense), net	(5)	24
Net before taxes	16,071	15,189
Income taxes	3,935	4,575
Net income	12,136	10,614
Earnings common share		
Primary	\$0.81	\$0.67
Fully Diluted	\$0.81	\$0.67
Common Shares:		
Full Diluted	8,271	8,109
Year-end	13,452	13,201

SINCLAIR BROADCAST GROUP INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,161,756	1,923,702
Cost & expenses	1,482,108	1,251,491
Operating income	396,707	379,924
Interest expense	237,766	160,020
Other income (expense), net	(42,210)	(24)
Net before taxes	116,731	219,880
Income taxes	(21,573)	70,577
Net income	138,304	149,303
Earnings common share		
Primary	\$1.32	\$1.34
Fully Diluted	\$1.31	\$1.32
Common Shares:		
Full Diluted	102,898	100,173
Year-end	100,649	

SIRIUS XM HOLDINGS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	4,274,784,000	2,231,000
Cost & expenses	2,784,664,000	546,937,000
Operating income	1,267,775,000	244,158,000
Interest expense	262,924,000	257,085,000
Other income (expense), net	82,334,000	40,218,000
Net before taxes	1,087,185,000	227,291,000
Income taxes	162,344,000	342,387,000
Net income	924,841,000	684,904,000
Balance for common	924,841,000	684,904,000
Earnings common share		
Primary	\$0.21	\$0.15
Fully Diluted	\$0.20	\$0.14
Common Shares:		
Full Diluted	4,586,346,000	734,841,000
Year-end	4,449,194,000	601,941,000

SKYWEST INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	2,418,190	2,351,351
Cost & expenses	1,819,026	1,840,677
Operating income	352,778	295,259
Interest income	5,692	3,398
Interest expense	86,485	78,713
Other income (expense), net	3,470	
Net before taxes	275,455	219,944
Income taxes	62,189	80,966
Net income	213,266	138,978
Earnings common share		
Primary	\$4.10	\$2.68
Fully Diluted	\$4.03	\$2.62
Common Shares:		
Full Diluted	52,976	53,087
Year-end	51,928	

SKYWORKS SOLUTIONS, INC.**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

Net revenue	3,868,000	3,651,400	3,289,000
Cost of goods sold	1,917,300	1,809,600	1,623,800
Gross profit	1,950,700	1,841,800	1,665,200
Research & development expenses	404,500	355,200	312,400
Selling, general & administrative expenses	207,800	204,600	195,900
Amortization of intangibles	18,300	27,600	33,400
Restructuring & other charges (credits)	800	600	4,800
Total operating expenses	631,400	588,000	546,500
Operating income (loss)	1,319,300	1,253,800	1,118,700
Other income (expense), net	12,800	3,200	(6,600)
Merger termination fee			(88,500)
Income (loss) before income taxes - United States	712,200	681,200	697,500
Income (loss) before income taxes - foreign	619,900	575,800	503,100
Income (loss) before income taxes	1,332,100	1,257,000	1,200,600
Current tax expense (benefit) - federal	347,700	215,700	181,800
Current tax expense (benefit) - state	300	300	100
Current tax expense (benefit) - foreign	31,200	24,400	25,800
Total current tax expense (benefit)	379,200	240,400	207,700
Deferred tax expense (benefit) - federal	20,300	5,000	(800)
Deferred tax expense (benefit) - foreign	14,200	1,400	(1,500)
Total deferred tax expense (benefit)	34,500	6,400	(2,300)
Provision (benefit) for income taxes	413,700	246,800	205,400
Net income (loss)	918,400	1,010,200	995,200
Weighted average shares outstanding - basic	181,300	184,300	188,700
Weighted average shares outstanding - diluted	183,200	186,700	192,100
Year end shares outstanding	177,400	183,100	184,900
Net earnings (loss) per share - basic	\$5.06	\$5.48	\$5.27
Net earnings (loss) per share - diluted	\$5.01	\$5.41	\$5.18
Cash dividends declared & paid per share	\$1.34	\$1.16	\$1.06
Total number of employees	9,400	8,400	7,300
Number of common stockholders	12,404	14,389	19,882

□ As is; □ Approximately; □ As of November 7, 2018; □ As of November 3, 2017; □ As of November 14, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	09/28/18	09/29/17
Cash & cash equivalents	733,300	1,616,800
Marketable securities	294,100	
Receivables, gross	656,400	455,200
Allowance for doubtful accounts	600	500
Receivables, net	655,800	454,700
Raw materials	20,200	24,600

Work-in-process	340,700	330,600
Finished goods	124,800	123,000
Finished goods held on consignment by customers	4,500	15,300
Inventory	490,200	493,500
Other current assets	88,800	68,700
Total current assets	2,262,200	2,633,700
Land & improvements	11,600	11,600
Buildings & improvements	238,000	137,800
Furniture & fixtures	31,500	29,500
Machinery & equipment	2,089,600	1,715,300
Construction in progress	179,000	164,800
Property, plant & equipment, gross	2,549,700	2,059,000
Accumulated depreciation	1,408,800	1,176,700
Property, plant & equipment, net	1,140,900	882,300
Goodwill	1,189,800	883,000
Intangible assets, net	143,700	67,800
Deferred tax assets, net	36,500	66,500
Marketable securities	22,800	...
Other assets	33,000	40,300
Total assets	4,828,900	4,573,600
Accounts payable	229,900	258,400
Accrued compensation & benefits	85,200	68,100
Other current liabilities	74,600	61,400
Total current liabilities	389,700	387,900
Long-term tax liabilities	310,500	92,900
Other long-term liabilities	31,700	27,100
Total liabilities	731,900	507,900
Common stock	44,400	45,800
Additional paid-in capital	3,061,000	2,893,800
Treasury stock, at cost	2,732,500	1,925,000
Retained earnings (accumulated deficit)	3,732,900	3,059,600
Accumulated other comprehensive income (loss)	(8,800)	(8,500)
Total stockholders' equity	4,097,000	4,065,700

Recent Dividends:**1. Skyworks Solutions, Inc. common.**

ExDate	Amt	Declared	Record	Payable
02/03/2015	0.13	01/21/2015	02/05/2015	03/03/2015
05/12/2015	0.13	04/30/2015	05/14/2015	06/04/2015
08/04/2015	0.26	06/18/2015	08/06/2015	08/27/2015
11/17/2015	0.26	11/05/2015	11/19/2015	12/10/2015
02/09/2016	0.26	01/28/2016	02/11/2016	03/03/2016
05/10/2016	0.26	04/28/2016	05/12/2016	06/02/2016
08/02/2016	0.28	07/21/2016	08/04/2016	08/25/2016
11/15/2016	0.28	11/03/2016	11/17/2016	12/08/2016
01/31/2017	0.28	01/19/2017	02/02/2017	02/23/2017
05/12/2017	0.28	04/27/2017	05/16/2017	06/06/2017
08/04/2017	0.32	07/20/2017	08/08/2017	08/29/2017
11/20/2017	0.32	11/06/2017	11/21/2017	12/12/2017
02/21/2018	0.32	02/06/2018	02/22/2018	03/15/2018
05/21/2018	0.32	05/03/2018	05/22/2018	06/12/2018
08/06/2018	0.38	07/19/2018	08/07/2018	08/28/2018

Annual Dividends:**1. Skyworks Solutions, Inc. common.**

2015	0.78	2016	1.08	2017	1.20
2018	1.02				

SLEEP NUMBER CORP**Earnings, 9 mos. to (Consol. - \$000):**

Net Sales	1,119,750	1,081,218
Cost & expenses	1,065,442	1,009,422
Operating income	54,308	71,796
Net before taxes	50,494	71,128
Income taxes	7,945	21,842
Net income	42,549	49,286
Earnings common share		
Primary	\$1.18	\$1.18
Fully Diluted	\$1.15	\$1.16
Common Shares:		
Full Diluted	37,077	42,559
Year-end	33,216	...

SMART SAND INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	160,222	94,176
Cost & expenses	127,389	79,654
Operating income	31,668	14,145
Other income (expense), net	149	197
Net before taxes	30,379	14,002
Income taxes	7,258	3,354
Net income	23,121	10,648
Earnings common share		
Primary	\$0.57	\$0.27
Fully Diluted	\$0.57	\$0.26
Common Shares:		
Full Diluted	40,548	40,257
Year-end	40,550	40,393

SMTC CORP.

Acquisition Completed On Nov. 8, 2018, Co. purchased all of the issued and outstanding shares of capital stock of MC Assembly Holdings, Inc., a Delaware corporation (the "Target") from the stockholders of the Target (such transaction, the "MC Acquisition"). The MC Acquisition includes an initial purchase price of approximately \$65,000,000 in cash plus a potential earnout of up to \$5,000,000 in cash payable by Co. upon the achievement of certain performance milestones determined after the completion of Co.'s first fiscal quarter of 2019.

SMTC CORP.**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Total Revenues	135,276	100,590
Cost & expenses	132,901	106,681
Operating income	2,375	(6,091)
Interest expense	1,195	625
Net before taxes	1,180	(6,716)
Income taxes	405	225
Net income	775	(6,941)
Earnings common share		
Primary	\$0.04	\$(0.41)
Fully Diluted	\$0.04	\$(0.41)
Common Shares:		
Full Diluted	18,518	16,764
Year-end	23,081	16,825

SOLAR CAPITAL LTD**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	58,852	54,703
Net income	56,438	49,724
Earnings common share		
Common Shares:		
Full Diluted	42,261	42,257
Year-end	42,261	42,261

SOLAR SENIOR CAPITAL LTD**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	12,755	6,168
Net income	17,070	16,952
Earnings common share		
Common Shares:		
Full Diluted	16,040	16,030
Year-end	16,040	16,034

SOLAREEDGE TECHNOLOGIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	673,567	417,705
Cost & expenses	558,101	361,190
Operating income	115,466	56,515
Other income (expense), net	(2,585)	7,671
Net before taxes	112,881	64,186
Income taxes	(3,016)	(484)
Net income	115,897	64,670
Earnings common share		
Primary	\$2.57	\$1.55
Fully Diluted	\$2.41	\$1.44
Common Shares:		
Full Diluted	48,091	44,938
Year-end	45,750	...

SOLARWINDOW TECHNOLOGIES INC

New Accountant On Oct. 22, 2018, Co. dismissed Peterson Sullivan LLP and engaged Marcum LLP as its new independent public accounting firm.

SONIC CORP.**Annual Report****Consolidated Income Statement, Years Ended Aug. 31 (\$):**

	2018	2017	2016
		(revised)	(revised)
Company drive-in sales	240,722,000	296,101,000	425,795,000
Franchise drive-ins - franchise fees & royalties	172,443,000	170,527,000	170,319,000
Franchise drive-ins - lease revenue	7,804,000	7,436,000	7,459,000
Other revenues	2,621,000	3,203,000	2,747,000
Total revenues	423,590,000	477,267,000	606,320,000
Company drive-ins - food & packaging expense	66,583,000	80,971,000	118,136,000
Company drive-ins - payroll & other employee benefits expense	88,008,000	107,477,000	150,260,000
Company drive-ins - other operating expenses	48,586,000	61,463,000	88,424,000
Total cost of Company drive-In sales	203,177,000	249,911,000	356,820,000
Selling, general & administrative expenses	80,077,000	78,687,000	82,089,000
Depreciation & amortization expense	38,355,000	39,248,000	44,418,000
Provision for impairment of long-lived assets	664,000	1,140,000	232,000
Other operating income (expense), net	5,086,000	14,994,000	4,691,000
Total costs & expenses	317,187,000	353,992,000	478,868,000
Income (loss) from operations	106,403,000	123,275,000	127,452,000
Interest expense	33,058,000	29,206,000	26,714,000
Interest income	1,904,000	1,398,000	516,000
Gain (loss) from debt transactions	(1,310,000)	...	(8,750,000)
Net interest income (expense)	(32,464,000)	(27,808,000)	(34,948,000)
Income (loss) before income taxes	73,939,000	95,467,000	92,504,000
Current provision for federal income taxes	15,597,000	30,352,000	20,137,000
Current provision for state income taxes	2,949,000	3,921,000	3,791,000
Total current provision for income taxes	18,546,000	34,273,000	23,928,000
Deferred provision for (benefit from) federal income taxes	(16,460,000)	(2,378,000)	4,372,000
Deferred provision for (benefit from) state income taxes	648,000	(91,000)	137,000
Total deferred provision for (benefit from) income taxes	(15,812,000)	(2,469,000)	4,509,000
Provision for (benefit from) income taxes	2,734,000	31,804,000	28,437,000
Net income (loss)	71,205,000	63,663,000	64,067,000
Weighted average shares outstanding - basic	37,618,000	43,306,000	48,703,000
Weighted average shares outstanding - diluted	38,086,000	44,043,000	49,669,000
Year end shares outstanding	35,575,000	40,228,000	46,639,000
Net income (loss)			

per share - basic	\$1.89	\$1.47	\$1.32	within one year	4,250,000	...
Net income (loss)				Deferred income taxes	24,226,000	40,101,000
per share - diluted	\$1.87	\$1.45	\$1.29	Other non-current		
Cash dividends				liabilities	19,194,000	20,502,000
declared per common				Common stock	1,183,000	1,183,000
share	\$0.64	\$0.56	\$0.44	Paid-in capital	238,369,000	236,895,000
Number of full time				Retained earnings		
employees	9,620	(accumulated deficit)	981,251,000	934,017,000
Total number of				Treasury stock, at cost	1,509,649,000	1,373,853,000
employees	9,041	6,173	...	Total stockholders'		
Number of common				equity (deficit)	(288,846,000)	(201,758,000)
stockholders	949	598	625			

□ Approximately; □ As of October 12, 2018; □ As of October 13, 2017; □ As of October 14, 2016

Consolidated Balance Sheet, Years Ended Aug. 31 (\$):

	2018	2017
Cash & cash equivalents	39,835,000	22,340,000
Restricted cash	19,598,000	19,736,000
Royalties & other trade		
receivables	20,177,000	19,571,000
Notes receivable from		
franchisees	2,006,000	1,441,000
Receivables from system		
funds	2,480,000	6,360,000
Other accounts & notes		
receivable	11,080,000	7,475,000
Allowance for doubtful		
accounts & notes		
receivable	776,000	1,089,000
Inventories	1,774,000	2,343,000
Prepaid expenses	6,481,000	5,455,000
Property held for sale	1,310,000	5,150,000
Other current assets	464,000	402,000
Total current assets	104,429,000	89,184,000
Noncurrent restricted		
cash	7,909,000	42,120,000
Investment in direct		
financing leases	11,391,000	11,853,000
Notes receivable, net	10,932,000	9,801,000
Land	120,352,000	117,402,000
Buildings & improvements	243,434,000	251,695,000
Drive-In equipment	62,679,000	75,410,000
Brand technology		
development & other		
equipment	133,020,000	126,179,000
Property & equipment, at		
cost	559,485,000	570,686,000
Accumulated depreciation	271,940,000	272,233,000
Capital leases	39,204,000	45,315,000
Accumulated amortization		
- capital lease	28,527,000	31,388,000
Property, equipment &		
capital leases, net	298,222,000	312,380,000
Goodwill	75,344,000	75,756,000
Debt origination costs,		
net	1,191,000	2,439,000
Other assets, net	21,716,000	18,211,000
Total assets	531,134,000	561,744,000
Accounts payable	10,338,000	9,213,000
Franchisee deposits	723,000	1,093,000
Wages & other employee		
benefit costs	16,338,000	17,705,000
Property taxes, sales &		
use taxes & employment		
taxes	4,677,000	5,634,000
Unredeemed gift cards	13,184,000	11,319,000
Other accrued liabilities	10,115,000	10,188,000
Accrued liabilities	44,314,000	44,846,000
Current maturities of		
long-term debt & capital		
leases	6,704,000	3,464,000
Total current liabilities	62,079,000	58,616,000
Obligations under capital		
leases due after one year	13,003,000	16,167,000
Senior secured fixed rate		
notes	717,396,000	577,521,000
Senior secured variable		
funding notes	60,000,000
Less unamortized debt		
issuance costs	(11,668,000)	(9,405,000)
Less long-term debt due		

Recent Dividends:

1. Sonic Corp. common.

ExDate	Amt	Declared	Record	Payable
02/09/2015	0.09	01/29/2015	02/11/2015	02/20/2015
05/11/2015	0.09	04/09/2015	05/13/2015	05/22/2015
08/10/2015	0.09	07/09/2015	08/12/2015	08/21/2015
11/06/2015	0.11	10/15/2015	11/11/2015	11/20/2015
02/08/2016	0.11	01/28/2016	02/10/2016	02/19/2016
05/09/2016	0.11	04/07/2016	05/11/2016	05/20/2016
08/08/2016	0.11	07/07/2016	08/10/2016	08/19/2016
11/07/2016	0.14	10/20/2016	11/09/2016	11/18/2016
02/06/2017	0.14	01/19/2017	02/08/2017	02/17/2017
05/08/2017	0.14	04/20/2017	05/10/2017	05/19/2017
08/07/2017	0.14	07/06/2017	08/09/2017	08/18/2017
11/07/2017	0.16	10/26/2017	11/08/2017	11/17/2017
02/06/2018	0.16	01/12/2018	02/07/2018	02/16/2018
05/08/2018	0.16	04/12/2018	05/09/2018	05/18/2018
08/07/2018	0.16	07/12/2018	08/08/2018	08/17/2018

Annual Dividends:

1. Sonic Corp. common.

2015	0.38	2016	0.47	2017	0.58
2018	0.48				

SPARK ENERGY INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	777,414	563,279
Net Sales	773,616	563,960
Cost & expenses	729,476	490,176
Operating income	8,141	42,668
Interest expense	7,323	8,760
Net before taxes	1,525	34,010
Income taxes	602	5,265
Net income	923	28,745
Balance for common	(5,298)	3,590
Earnings common share		
Primary	\$(0.40)	\$0.27
Fully Diluted	\$(0.40)	\$0.27
Common Shares:		
Full Diluted	13,254	13,315
Year-end	34,879	34,631

SPARTAN MOTORS, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales	583,203,000	526,029,000
Cost & expenses	569,260,000	515,952,000
Operating income	13,943,000	10,077,000
Interest expense	817,000	582,000
Net before taxes	15,707,000	9,933,000
Income taxes	2,527,000	(3,561,000)
Net income	13,180,000	13,494,000
Earnings common share		
Primary	\$0.37	\$0.39
Fully Diluted	\$0.37	\$0.39
Common Shares:		
Full Diluted	35,179,000	34,882,000
Year-end	35,170,000	35,087,000

SPARTANNASH CO.

Earnings, 9 mos. to (Consol. - \$):

	10/06/18	10/07/17
Net Sales	6,167,756,000	6,078,299,000
Cost & expenses	6,085,384,000	6,203,752,000
Operating income	82,372,000	125,453,000
Other income (expense), net	655,000	445,000
Net before taxes	60,199,000	144,136,000
Income contin. oper.	47,818,000	(87,327,000)
Income discont. oper.	(238,000)	(125,000)

Net income	47,580,000	(87,452,000)
Earnings common share		
Primary	\$1.32	\$(2.33)
Fully Diluted	\$1.32	\$(2.33)
Common Shares:		
Full Diluted	35,258,000	36,941,000
Year-end	35,938,000	36,974,000

SPECTRUM PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	79,930	99,797
Net Sales	76,419	88,235
Cost & expenses	147,726	134,651
Operating income	(88,600)	(55,572)
Interest expense	484	6,196
Other income (expense), net	18,300	(2,335)
Net before taxes	(70,784)	(64,103)
Income taxes	8	(1,412)
Net income	(70,792)	(62,691)
Earnings common share		
Primary	\$(0.69)	\$(0.78)
Fully Diluted	\$(0.69)	\$(0.78)
Common Shares:		
Full Diluted	102,572	80,177
Year-end	106,061	...

SPOK HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	126,218	127,405
Cost & expenses	121,056	111,859
Operating income	(2,600)	7,118
Other income (expense), net	(56)	415
Net before taxes	(1,647)	8,023
Income taxes	(701)	1,945
Net income	(946)	6,078
Earnings common share		
Primary	\$(0.05)	\$0.30
Fully Diluted	\$(0.05)	\$0.30
Common Shares:		
Full Diluted	19,743	20,363
Year-end	19,449	19,977

SPRING PHARMACEUTICAL GROUP INC

History: Incorporated in Florida in Jan. 1989 as Southstar Productions, Inc. Name subsequently changed to Medical Technology & Innovations Inc. Reincorporated in Delaware on Apr. 4, 2007. Name changed to itLinkz Group, Inc., on Apr. 5, 2007. Name changed to China YCT International Group Inc. on Nov. 23, 2007. Present name adopted on Aug. 31, 2018.

In Oct. 1995, Co. acquired Medical Technology, Inc.

On Aug. 1, 1996, Co. acquired the net assets and the right to the name of Steridyne Corporation.

On Apr. 1, 1999, Co. acquired certain key operating assets of the thermometer business of Florida Medical Corporation.

On Sept. 6, 2002, Co. disposed of all of its assets and ceased operations pertaining to the medical products side of the business.

On June 22, 2005, Co. formed a subsidiary called World Nurse Space, Inc.

On Sept. 25, 2006, Co. formed a subsidiary called itLinkz Corporation.

On Sept. 28, 2007, Co. acquired the outstanding capital stock of Landway Nano Bio-Tech Group for a consideration of 500 shares of Series B Preferred Stock.

In Mar. 2010, Co. purchased a patent from Shandong Yong Chun Tang for \$6,740,000, which enables Co. to manufacture and distribute the Huoliyuan Capsule.

On Feb. 28, 2011, Co. acquired U.S. patent No. 6,475,531 B1 titled Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function (the Influenza Patent) through a purchase agreement with L.Y. Research Corp. and its subsidiary, and LY. (HK) Biotech Limited., as amended as of Aug. 15, 2011 (the Acquisition Agreement.) In consideration for the purchase of the patent, Co. issued LY Holding Limited, an affiliate of LY Research Corp., 44,254,952 shares of common stock, which consideration may increase to a maximum of 75,865,631 shares of Co.'s common stock pursuant to the Acquisition Agreement. The total value of the consideration on the acquisition date is \$32,748,665 which is calculated by the total issuing shares, multiplying Co.'s quoted stock price \$0.74 per share on Feb. 28, 2011. On Oct. 21, 2011, Co. entered into an Amendment Agreement

with L.Y. Research to amend the purchase agreement, dated as of Feb. 28, 2011, and amended and restated as of Aug. 15, 2011 (the Purchase Agreement) with respect to the acquisition of U.S. Patent #6,475,531B titled Safe Botanical Drug for Treatment and Prevention of Influenza and Increasing Immune Function (the LY Patent). The Amendment Agreement added the following terms: in the event that Co. cannot, within one year from Oct. 21, 2011, either raise a minimum of \$20,000,000 in gross proceeds from a debt or equity financing, or a series of debt and/or equity financings, or list its common stock on NASDAQ or a foreign stock exchange, then the shares issued pursuant to the Purchase Agreement shall be returned to Co. and the LY Patent shall be returned to LY Research and the Purchase Agreement, as amended, shall be cancelled and of no further force or effect; and LY Research agrees that it waives its right to vote the shares and receive any dividends or other distributions from Co. until the earlier of (a) completion of the financing or (b) the listing of the shares of common stock of Co. on NASDAQ or a foreign stock exchange.

On Oct. 19, 2018, Paritz & Company, P.A. resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Prager Metis CPAs LLC as its new independent public accounting firm.

Business: Spring Pharmaceutical Group is a health care company, which is engaged in developing, manufacturing and selling Chinese medicines, including manufacturing its medicines made primarily from panax ginseng leaves extract, developing acer truncatum bunge planting bases, processing and selling acer truncatum bunge seed oils, and distributing health care products manufactured by another company in the People's Republic of China. The Huoliyuan capsule is used with respect to various medical conditions for the human cardiovascular system and as an aid in the treatment of chronic hepatitis, diabetes, insomnia, memory loss, menopause syndrome, and other maladies.

Property: Co. maintains its principal executive offices in Shandong Province, China.

Co.'s subsidiary, Shandong Spring Pharmaceutical Co., Ltd., operates on a property of approx. 56,894 sq. m. (approx. 14.06 acres) in Shandong Province. Besides housing Co.'s executive offices, the property includes a manufacturing facility measuring 17,200 sq. m. (approx. 185,139.25 sq. ft.) and a research facility measuring 3,000 sq. m. (approx. 32,291.73 sq. ft.).

As of Mar. 31, 2018, Co. leased a total of approx. 2,324.77 acres of farmland.

Subsidiaries

(wholly owned unless otherwise noted)

Landway Nano Bio-Tech Group, Inc.
Shandong Spring Pharmaceutical Co., Ltd. (China (Peoples Rep. Of)) (97%)

Officers

Tinghe Yan, Chairman; Chief Executive Officer; Subsidiary Officer
Li Chuanmin, Chief Financial Officer; Subsidiary Officer
Sun Maogang, Subsidiary Officer
Zhang Qiang, Subsidiary Officer
Ding Xuzhong, Subsidiary Officer
Shao Zecheng, Subsidiary Officer

Directors

Tinghe Yan, Chairman
Jirui Zhang, Director
Dong Li, Director
Robert J. Fanella, Director
Wengao Zhang, Director

Auditors: Prager Metis CPAs, LLC

Transfer agent and Registrar: Interwest Transfer Co., Inc, Holdaday, UT

Annual Meeting: In October

Shareholder Relations: Zecheng Shao, Vice President Tel: 86 537 4268271

No. of Stockholders: Aug. 29, 2018, 777, record

No. of Employees: June 15, 2018, 313

Address: 11 Quanxing Road Sishui County, Shandong Province 373200, China (Peoples Rep. Of)

Tel: 86 537 4268271

Web: www.yctgroup.com

Email: yct@yongchuntang.com

Consolidated Income Statement, Years Ended Mar. 31 (\$):

	2018	2017	2016
		(revised)	(revised)
Sales	64,942,737	56,463,164	47,827,108
Cost of goods sold	39,603,995	33,284,237	26,554,022

Gross profit	25,338,742	23,178,927	21,273,086
Selling expenses	4,984,794	3,934,334	3,759,920
General & administrative expenses	4,719,402	4,248,095	4,446,983
Research & development expenses	492,078	809,485	724,287
Impairment of assets	332,090	986,406	1,114,942
Total operating expenses	10,528,364	9,978,320	10,046,132
Income (loss) from operations	14,810,378	13,200,607	11,226,954
Gain on disposal of acer truncatum bunge plants	642,532
Interest income (expense)	124,410	54,672	30,850
Income (loss) before tax provision	15,577,320	13,255,279	11,257,804
Current income taxes	3,499,474	3,520,126	3,055,958
Deferred income taxes	339,358	(319,501)	(214,923)
Income tax provision	3,838,832	3,200,625	2,841,035
Net income (loss)	11,738,488	10,054,654	8,416,769
Less: Net loss attributable to non-controlling interest	(352,155)	23,649	...
Net income attributable to company	11,386,333	10,078,303	8,416,769
Weighted average outstanding shares - basic	29,789,168	29,763,531	29,709,706
Weighted average outstanding shares - diluted	29,789,168	29,763,531	29,709,706
Year end shares outstanding	29,789,168	29,789,168	29,720,690
Net income (loss) per share - basic	\$0.38	\$0.34	\$0.28
Net income (loss) per share - diluted	\$0.38	\$0.34	\$0.28
Number of full time employees	313	312	313
Number of common stockholders	777	770	768

Reclassified to conform with 2017 presentation; Including amount from a related party - cost of good sold: \$14,404,967; Including amount from a related party - cost of good sold: \$11,015,268; Including amount from a related party - cost of good sold: \$8,623,417; As of June 15, 2018; As of August 29, 2018

Consolidated Balance Sheet, Years Ended Mar. 31 (\$):

	2018	2017
		(revised)
Cash & cash equivalents	25,353,360	10,308,622
Accounts receivable	174,558	1,134,967
Raw materials	233,138	1,276,254
Packaging materials	652,179	476,803
Work-in-process	686,234	1,373,919
Finished goods	811,831	2,356,064
Inventories	2,383,382	5,483,040
Purchase deposit to related party	1,412,864	650,790
Prepaid leases - current portion	741,583	900,547
Total current assets	30,065,747	18,477,966
Prepaid leases	641,349	1,265,252
Development cost of acer truncatum bunge planting	48,984,881	42,055,972
Machinery & equipment	3,594,861	2,254,813
Office equipment & automobiles	769,589	717,259
Building	13,606,722	12,401,320
Leasehold improvements	4,240,568	2,803,052
Property, plant &		

equipment, gross	22,211,740	18,176,444
Less: accumulated depreciation & amortization	5,418,327	3,689,309
Plant, property & equipment, net	16,793,413	14,487,135
Intangible assets, net	11,862,017	12,042,758
Deferred tax assets	200,387	508,521
Security deposit to related party	1,590,305	1,449,422
Total assets	110,138,099	90,287,026
Accounts payable to related party	...	706,048
Accounts payable & other accrued expense	372,782	251,307
Advance from customer	445,829	...
Corporate income tax	519,875	1,382,382
Value-added tax	580,429	576,086
Other tax & fees	63,894	69,722
Taxes payable	1,164,198	2,028,190
Total current liabilities	1,982,809	2,985,545
Preferred stock	22,500	22,500
Common stock	29,789	29,789
Additional paid-in capital	4,322,838	4,322,838
Statutory reserve	1,828,504	1,828,504
Retained earnings (accumulated deficit)	94,447,937	83,061,604
Accumulated other comprehensive income	4,455,017	(4,386,845)
Total stockholders' equity attributable to the Company	105,106,585	84,878,390
Non-controlling interests	3,048,705	2,423,091
Total stockholders' equity	108,155,290	87,301,481

Reclassified to conform with 2018 presentation

Capital Stock: 1. Spring Pharmaceutical Group Inc 12% series A noncumulative preferred; par \$ 500..

AUTHORIZED-45 shs.

OUTSTANDING-Mar. 31, 2018, 45 shs; par \$ 500..

CONVERTIBLE-The preferred stock is convertible into 599 shares of Co.'s common stock.

CAPITAL HISTORY-On Apr. 4, 2007, the number of shares authorized preferred stock was changed to 45, \$500 par value.

2. Spring Pharmaceutical Group Inc common; par \$ 0.001. AUTHORIZED-100,000,000 shs.

OUTSTANDING-Mar. 31, 2018, 29,789,168 shs; par \$ 0.001.

STOCK SPLITS-No par shares reverse split 1-for-25 Dec. 4, 2001

\$0.001 par shares reverse split 1-for-28 Nov. 26, 2007.

OWNERSHIP-As of June 29, 2018, officers and directors as a group beneficially owned 38.19% of Co.'s outstanding common stock.

OPTIONS-Mar. 31, 2016, outstanding, 2,600,000.

PRIMARY EXCHANGE-National Bulletin Board (NBB): CYIG.

OFFERED-(2,300,000 shares) at \$0.13 a share on Jan. 16, 2007.

PAR CHANGE-To \$0.00 in 2007. (From no par)

CAPITAL HISTORY-On Apr. 4, 2007, the number of shares of authorized common stock was increased from 28,000,000 shares, no par value, to 100,000,000 shares, \$0.001 par value.

SPRING PHARMACEUTICAL GROUP INC

New Accountant On Oct. 19, 2018, Paritz & Company, P.A. resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Prager Metis CPAs LLC as its new independent public accounting firm.

SPROUTS FARMERS MARKET INC

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Net Sales	3,937,998	3,520,679
Cost & expenses	3,743,831	3,331,693
Operating income	194,167	188,986
Interest expense	20,028	15,447
Other income (expense), net	325	388
Net before taxes	174,464	173,927
Income taxes	28,631	55,186
Net income	145,833	118,741
Earnings common share		
Primary	\$1.13	\$0.87
Fully Diluted	\$1.12	\$0.86
Common Shares:		

Full Diluted	130,537	138,860
Year-end	127,604	133,071

Full Diluted	18,822,000	18,282,000
Year-end	18,168,000	17,337,000

attributable to noncontrolling interests	300	(200)	(1,200)
Net earnings attributable to Starbucks Corporation	4,518,300	2,884,700	2,817,700

SPS COMMERCE, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	183,051	162,028
Cost & expenses	161,443	148,879
Operating income	18,522	9,689
Other income (expense), net	(541)	(356)
Net before taxes	19,570	10,037
Income taxes	2,839	2,908
Net income	16,731	7,129
Earnings common share		
Primary	\$0.97	\$0.42
Fully Diluted	\$0.95	\$0.41
Common Shares:		
Full Diluted	17,557	17,394
Year-end	17,303	

SS&C TECHNOLOGIES HOLDINGS INC

Acquisition Completed On Nov. 16, 2018, Co. acquired from Impala Private Holdings I, LLC (the "Seller"), an affiliate of Siris Capital Group, LLC, all the outstanding membership interests of Impala Private Holdings II, LLC ("Intralinks"), which in turn owned 100% interest in Intralinks Holdings, Inc., a financial technology provider for the global banking, deal making and capital markets communities, in exchange for (i) approximately \$1,000,000,000 in cash and (ii) approximately \$500,000,000 in shares of Co.'s common stock (approximately 9,900,000 common shares), with the per share price of the stock based on the volume weighted average trading price for 30 trading days prior to closing (the "Equity Consideration").

SS&C TECHNOLOGIES HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	2,310,100	1,236,900
Cost & expenses	2,093,400	953,300
Operating income	216,700	283,600
Interest expense	173,700	81,600
Other income (expense), net	(26,800)	(6,100)
Net before taxes	16,200	195,900
Income taxes	(28,300)	32,400
Net income	44,500	163,500
Earnings common share		
Primary	\$0.20	\$0.80
Fully Diluted	\$0.19	\$0.77
Common Shares:		
Full Diluted	239,500	211,100
Year-end	240,400	205,829

STAAR SURGICAL CO.

Earnings, 9 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Net Sales	92,768	65,759
Cost & expenses	87,360	68,130
Operating income	5,408	(2,371)
Other income (expense), net	526	417
Foreign currency	(545)	738
Net before taxes	5,324	(1,304)
Income taxes	1,452	697
Net income	3,872	(2,001)
Earnings common share		
Primary	\$0.09	\$(0.05)
Fully Diluted	\$0.09	\$(0.05)
Common Shares:		
Full Diluted	44,618	40,939
Year-end	44,104	41,156

STAMPS.COM INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	416,699,000	336,242,000
Cost & expenses	276,337,000	224,242,000
Operating income	140,362,000	112,000,000
Interest expense	1,908,000	2,779,000
Foreign currency	(957,000)	
Net before taxes	137,672,000	109,530,000
Income taxes	11,691,000	(873,000)
Net income	125,981,000	110,403,000
Earnings common share		
Primary	\$7.02	\$6.51
Fully Diluted	\$6.69	\$6.04
Common Shares:		

STARBUCKS CORP.**Annual Report**

Consolidated Income Statement, Years Ended (\$000):

	09/30/18	[□] 10/01/17 (revised)	[□] 10/02/16 (revised)
Company-operated stores revenues	19,690,300	17,650,700	16,844,100
Licensed stores revenues	2,652,200	2,355,000	2,154,200
Global consumer products group (CPG), foodservice & other revenues	2,377,000	2,381,100	2,317,600
Total net revenues	24,719,500	22,386,800	21,315,900
Cost of sales including occupancy costs	10,174,500	9,034,300	8,509,000
Store operating expenses	7,193,200	6,493,300	6,064,300
Other operating expenses	539,300	500,300	499,200
Depreciation & amortization expenses	1,247,000	1,011,400	980,800
General & administrative expenses	1,759,000	1,450,700	1,408,900
Restructuring & impairments	224,400	153,500	...
Income from equity investees	301,200	391,400	318,200
Operating income (loss)	3,883,300	4,134,700	4,171,900
Gain resulting from acquisition of joint venture	1,376,400
Net gain resulting from divestiture of certain operations	499,200	93,500	5,400
Interest income & other income, net	191,400	181,800	102,600
Interest expense	170,300	92,500	81,300
Earnings (loss) before income taxes - United States	4,826,000	3,393,000	3,415,700
Earnings (loss) before income taxes - Current United States federal income taxes expense (benefit)	156,200	931,000	704,100
Current United States state & local income taxes expense (benefit)	52,000	170,800	166,500
Current foreign income taxes expense (benefit)	327,000	216,600	218,500
Total current income taxes expense (benefit)	535,200	1,318,400	1,089,100
Deferred United States federal income taxes expense (benefit)	633,700	121,200	351,300
Deferred United States state & local income taxes expense (benefit)	101,500	14,200	25,800
Deferred foreign income taxes expense (benefit)	(8,400)	(21,200)	(86,500)
Total deferred income taxes expense (benefit)	726,800	114,200	290,600
Income tax expense (benefit)	1,262,000	1,432,600	1,379,700
Net earnings (loss) including noncontrolling interests	4,518,000	2,884,900	2,818,900
Net earnings (loss)			

Weighted average shares outstanding - basic	1,382,700	1,449,500	1,471,600
Weighted average shares outstanding - diluted	1,394,600	1,461,500	1,486,700
Year end shares outstanding	1,309,100	1,431,600	1,460,500
Net earnings (loss) per share - basic	\$3.27	\$1.99	\$1.91
Net earnings (loss) per share - diluted	\$3.24	\$1.97	\$1.90
Total number of employees	[□] 291,000	[□] 277,000	[□] 254,000
Number of common stockholders	[□] 18,100	[□] 18,100	[□] 18,100
Foreign currency translation adjustments	954,000	924,500	782,900

[□] Reclassified to conform with 2018 presentation; [□] As is; [□] Approximately; [□] As of November 9, 2018; [□] As of November 11, 2016

Consolidated Balance Sheet, Years Ended (\$000):

	09/30/18	[□] 10/01/17 (revised)
Cash & cash equivalents	8,756,300	2,462,300
Short-term investments - available-for-sale securities	106,200	151,700
Short-term investments - trading securities	75,300	76,900
Short-term investments	181,500	228,600
Accounts receivable, gross	701,100	880,200
Allowance for doubtful accounts	8,000	9,800
Accounts receivable, net	693,100	870,400
Coffee - unroasted	588,600	541,000
Coffee - roasted	281,200	301,100
Other merchandise held for sale	273,100	301,100
Packaging & other supplies	257,600	220,800
Inventories	1,400,500	1,364,000
Prepaid expenses & other current assets	1,462,800	358,100
Total current assets	12,494,200	5,283,400
Long-term investments	267,700	542,300
Equity method investments		
	296,000	432,800
Cost method investments	38,700	48,800
Land	46,800	46,900
Buildings	557,300	481,700
Leasehold improvements	7,372,800	6,401,000
Store equipment	2,400,200	2,110,700
Roasting equipment	658,800	619,800
Furniture, fixtures & other property, plant & equipment	1,659,300	1,514,100
Work in progress	501,900	409,800
Accumulated depreciation	7,268,000	6,664,500
Property, plant & equipment, net	5,929,100	4,919,500
Deferred income taxes, net	134,700	795,400
Other long-term assets	412,200	362,800
Other intangible assets	1,042,200	441,400
Goodwill	3,541,600	1,539,200
Total assets	24,156,400	14,365,600
Accounts payable	1,179,300	782,500
Accrued compensation & related costs	656,800	524,500
Accrued occupancy costs	164,200	151,300
Accrued taxes	286,600	226,600
Accrued dividend payable	445,400	429,500

Accrued capital & other operating expenditures	745,400	602,600
Insurance reserves	213,700	215,200
Stored value card liability	1,642,900	1,288,500
Current portion of long-term debt	349,900	...
Total current liabilities	5,684,200	4,220,700
Senior notes	...	3,955,300
Aggregate unamortized premium (discount)	...	(17,500)
Hedge accounting fair value adjustment	...	(5,200)
Deferred revenue	6,775,700	4,400
Other long-term liabilities	1,430,500	750,900
Total liabilities	22,980,600	8,908,600
Common stock	1,300	1,400
Additional paid-in capital	41,100	41,100
Retained earnings (accumulated deficit)	1,457,400	5,563,200
Available-for-sale securities	(4,900)	(2,500)
Cash flow hedges	17,700	(4,100)
Net investment hedges	19,600	14,000
Translation adjustment & other accumulated comprehensive income	(362,700)	(163,000)
Accumulated other comprehensive income (loss)	(330,300)	(155,600)
Total shareholders' equity	1,169,500	5,450,100
Noncontrolling interests	6,300	6,900
Total equity	1,175,800	5,457,000

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. Starbucks Corp. common.

ExDate	Amt	Declared	Record	Payable
02/03/2015	0.32	01/22/2015	02/05/2015	02/20/2015

After 100% split:

ExDate	Amt	Declared	Record	Payable
05/05/2015	0.16	03/17/2015	05/07/2015	05/22/2015
08/04/2015	0.16	07/23/2015	08/06/2015	08/21/2015
11/09/2015	0.20	10/29/2015	11/12/2015	11/27/2015
02/02/2016	0.20	11/10/2015	02/04/2016	02/19/2016
05/03/2016	0.20	04/21/2016	05/05/2016	05/20/2016
08/02/2016	0.20	05/11/2016	08/04/2016	08/19/2016
11/15/2016	0.25	11/03/2016	11/17/2016	12/02/2016
02/07/2017	0.25	01/26/2017	02/09/2017	02/24/2017
05/09/2017	0.25	03/21/2017	05/11/2017	05/26/2017
08/08/2017	0.25	06/28/2017	08/10/2017	08/25/2017
11/15/2017	0.30	09/13/2017	11/16/2017	12/01/2017
02/07/2018	0.30	11/15/2017	02/08/2018	02/23/2018
05/09/2018	0.30	03/20/2018	05/10/2018	05/25/2018
08/08/2018	0.36	06/19/2018	08/09/2018	08/24/2018
11/14/2018	0.36	09/12/2018	11/15/2018	11/30/2018

Annual Dividends:

1. Starbucks Corp. common.

2015	0.32		
After 100% split:			
2015	0.52	2016	0.85
2018	1.32	2017	1.05

STEEL DYNAMICS INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Net Sales	8,917,947	7,202,318
Cost & expenses	7,540,745	6,309,264
Operating income	1,356,856	870,934
Interest expense	94,968	102,019
Other income (expense), net	16,601	4,968
Net before taxes	1,278,489	773,883
Income taxes	292,536	271,258
Net income	985,953	502,625
Earnings common share		
Primary	\$4.20	\$2.11
Fully Diluted	\$4.17	\$2.09

Common Shares:		
Full Diluted	236,772	242,816
Year-end	233,422	

STERICYCLE INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	2,633,200	2,692,900
Cost & expenses	2,448,400	2,677,100
Operating income	184,800	15,800
Interest expense	77,300	71,500
Other income (expense), net	(6,800)	(5,500)
Net before taxes	100,700	(61,200)
Income taxes	27,100	(14,600)
Net income	73,600	(46,600)
Balance for common	65,100	(59,900)
Earnings common share		
Primary	\$0.76	\$(0.70)
Fully Diluted	\$0.76	\$(0.70)
Common Shares:		
Full Diluted	86,100	85,300
Year-end	90,600	

STERLING CONSTRUCTION INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	782,492	704,047
Cost & expenses	749,291	684,840
Operating income	33,201	19,207
Other income (expense), net	...	(755)
Net before taxes	24,540	11,972
Income taxes	1,551	469
Net income	22,989	11,503
Earnings common share		
Primary	\$0.73	\$0.33
Fully Diluted	\$0.72	\$0.33
Common Shares:		
Full Diluted	27,174	26,260
Year-end	27,068	27,023

STITCH FIX INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

	07/28/18	07/29/17	07/30/16
Revenue, net	1,226,505	977,139	730,313
Cost of goods sold	690,483	542,718	407,064
Gross profit	536,022	434,421	323,249
Selling, general & administrative expenses	492,998	402,781	259,021
Operating income (loss)	43,024	31,640	64,228
Remeasurement of preferred stock warrant liability	10,685	(18,881)	(3,019)
Other income, net	1,004	42	13
Income (loss) before income taxes - United States	56,978	12,801	61,222
Income (loss) before income taxes - Foreign	(2,265)
Income (loss) before income taxes	54,713	12,801	61,222
Current federal provision (benefit) for income taxes	2,732	17,027	29,204
Current state provision (benefit) for income taxes	493	3,096	4,706
Total current provision (benefit) for income taxes	3,225	20,123	33,910
Deferred federal provision (benefit) for income taxes	7,917	(6,009)	(5,458)
Deferred state provision (benefit) for income taxes	(1,329)	(719)	(411)
Total deferred provision (benefit) for income taxes	6,588	(6,728)	(5,869)
Provision for			

income taxes	9,813	13,395	28,041
Net income (loss) & comprehensive income (loss)	44,900	(594)	33,181
Less: noncumulative dividends to preferred stockholders	768	...	2,533
Less: undistributed earnings to participating securities	8,591	...	22,437
Net income (loss) attributable to common stockholders	35,541	(594)	8,211
Weighted average shares outstanding - basic	75,948	24,974	22,730
Weighted average shares outstanding - diluted	81,288	24,974	27,883
Year end shares outstanding	98,800	26,835	25,873
Net earnings (loss) per share - basic	\$0.47	\$(0.02)	\$0.36
Net earnings (loss) per share - diluted	\$0.34	\$(0.02)	\$0.34
Total number of employees	6,600	5,800	...
Number of common stockholders	106

□ Reclassified to conform with 2018 presentation; □ Shares increased due to the effect of issuance of common stock upon offering and conversion of convertible preferred stock, exercise of stock options and reclassification of warrant liability; □ As is; □ As of July 29, 2017; □ As of September 27, 2018

Consolidated Balance Sheet, Years Ended (\$000):

	07/28/18	07/29/17
Cash & cash equivalents	297,516	110,608
Restricted cash	250	250
Inventory, net	85,092	67,592
Prepaid expenses & other current assets	34,148	19,312
Total current assets	417,006	197,762
Computer equipment	2,920	5,086
Office furniture & equipment	9,829	4,514
Leasehold improvements	16,091	14,693
Capitalized software	24,982	11,481
Construction in progress	356	1,618
Building & land	402	...
Total property & equipment, gross	54,580	37,392
Less accumulated depreciation & amortization	20,411	10,659
Property & equipment, net	34,169	26,733
Deferred tax assets	14,107	19,991
Restricted cash, net of current portion	12,600	9,100
Other long-term assets	3,703	3,619
Total assets	481,585	257,205
Accounts payable	79,782	44,238
Compensation & related benefits	10,680	9,632
Inventory purchases	506	11,186
Advertising	10,456	9,995
Sales taxes	7,066	3,702
Shipping & freight	4,801	3,390
Accrued accounts payable	4,567	4,814
Other accrued liabilities	4,961	3,644
Accrued liabilities - Preferred stock warrant liability	43,037	46,363
Gift card liability	...	26,679
Deferred revenue	6,814	5,190
Other current liabilities	8,870	7,150
Total current liabilities	3,729	4,298
Total current liabilities - Deferred rent, net of current portion	142,232	133,918
Deferred rent, net of current portion	15,288	11,781

Other long-term liabilities	8,993	7,423
Total liabilities	166,513	153,122
Convertible preferred stock	42,222	
Class A common stock	1	
Class B common stock	1	1
Additional paid-in capital	235,312	27,002
Retained earnings (accumulated deficit)	79,758	34,858
Total stockholders' equity	315,072	61,861

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. **Stitch Fix Inc class B common.**
No dividends paid.
2. **Stitch Fix Inc class A common.**
No dividends paid.

Annual Dividends:

1. **Stitch Fix Inc class B common.**
No dividends paid.
2. **Stitch Fix Inc class A common.**
No dividends paid.

STRATEGIC EDUCATION INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	392,082	336,144
Cost & expenses	423,419	295,623
Operating income	(41,615)	40,521
Other income (expense), net	1,846	256
Net before taxes	(39,769)	40,777
Income taxes	(1,643)	13,670
Net income	(38,126)	27,107
Earnings common share		
Primary	\$(2.90)	\$2.54
Fully Diluted	\$(2.90)	\$2.43
Common Shares:		
Full Diluted	13,141	11,174
Year-end	21,708	11,167

STRATTEC SECURITY CORP.

Earnings, 3 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Net Sales	117,159	102,460
Cost & expenses	113,007	99,039
Operating income	4,152	3,421
Interest income		4
Other income (expense), net	841	703
Gains or losses	251	547
Foreign currency	(428)	(137)
Net before taxes	4,409	4,335
Income taxes	(20)	1,066
Net income	4,429	3,269
Earnings common share		
Primary	\$0.95	\$0.68
Fully Diluted	\$0.93	\$0.67
Common Shares:		
Full Diluted	3,711	3,681
Year-end	3,673	3,628

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	10,345
Inventories	46,279
Current assets	155,618
Net property & equip.	118,001
Total assets	312,948
Liabilities:	
Current liabilities	72,469
Long-term debt	49,000
Stockholders' equity	166,012
Net current assets	83,149

SUN HYDRAULICS CORP.

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Net Sales	369,322	258,689
Cost & expenses	298,645	198,416
Operating income	53,503	53,887
Other income (expense), net	(1,113)	(9,220)
Foreign currency	(3,770)	64
Net before taxes	39,364	42,021

Income taxes	9,058	13,231
Net income	30,306	28,790
Earnings common share		
Primary	\$0.97	\$1.07
Fully Diluted	\$0.97	\$1.07
Common Shares:		
Full Diluted	31,093	27,017
Year-end	31,957	27,065

SUNPOWER CORP

Interest Sale Completed On Nov. 5, 2018, Co. sold 49% membership interest of its wholly-owned subsidiary, SunStrong Capital Holdings, LLC, which owned Co.'s residential lease portfolio, to HA SunStrong Capital LLC, an affiliate of Hannon Armstrong Sustainable Infrastructure Capital, Inc., for \$10,000,000.

SUNRUN INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	519,861	380,277
Cost & expenses	631,935	511,670
Operating income	(115,227)	(134,547)
Interest expense	94,552	65,746
Other income (expense), net	5,701	(589)
Net before taxes	(204,078)	(200,882)
Income taxes	6,593	30,698
Net income	(210,671)	(231,580)
Earnings common share		
Primary	\$0.30	\$0.54
Fully Diluted	\$0.28	\$0.52
Common Shares:		
Full Diluted	116,052	107,893
Year-end	111,652	

SUPERIOR GROUP OF COMPANIES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Net Sales	251,349,000	194,365,000
Cost & expenses	235,650,000	177,435,000
Operating income	15,699,000	17,948,000
Gains or losses		1,018,000
Net before taxes	15,699,000	17,948,000
Income taxes	3,310,000	4,810,000
Net income	12,389,000	13,138,000
Earnings common share		
Primary	\$0.83	\$0.91
Fully Diluted	\$0.80	\$0.87
Common Shares:		
Full Diluted	15,505,642	15,066,616
Year-end	15,299,207	14,859,231

SUPERNUS PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	292,963	213,803
Cost & expenses	188,374	148,606
Operating income	104,589	65,197
Interest income	9,331	2,002
Other income (expense), net		(219)
Net before taxes	101,409	65,558
Income taxes	16,309	21,932
Net income	85,100	43,626
Earnings common share		
Primary	\$1.64	\$0.86
Fully Diluted	\$1.57	\$0.82
Common Shares:		
Full Diluted	54,098	53,227
Year-end	52,257	51,262

SYKES ENTERPRISES, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	1,210,489,000	1,166,761,000
Cost & expenses	1,120,351,000	1,045,946,000
Operating income	35,190,000	63,646,000
Interest income	529,000	468,000
Interest expense	3,523,000	5,585,000
Other income (expense), net	(2,618,000)	1,067,000
Gains or losses	3,155,000	567,000
Net before taxes	32,733,000	60,163,000
Income taxes	855,000	10,911,000
Net income	31,878,000	49,252,000
Earnings common share		
Primary	\$0.76	\$1.18
Fully Diluted	\$0.76	\$1.17

Common Shares:		
Full Diluted	42,201,000	42,006,000
Year-end	42,656,000	42,774,000

SYMANTEC CORP Annual Report

Consolidated Income Statement, Years Ended (\$000):

	03/30/18	03/31/17 (revised)	04/01/16 (revised)
Net revenue	4,834,000	4,019,000	3,600,000
Cost of revenues	1,032,000	853,000	615,000
Gross profit	3,802,000	3,166,000	2,985,000
Sales & marketing expense	1,593,000	1,459,000	1,292,000
Research & development expense	956,000	823,000	748,000
General & administrative expense	574,000	564,000	295,000
Amortization of intangible assets	220,000	147,000	57,000
Restructuring, separation, transition, & other	410,000	273,000	136,000
Total operating expenses	3,753,000	3,266,000	2,528,000
Operating income (loss)	49,000	(100,000)	457,000
Interest expense	256,000	208,000	75,000
Gain on divestiture	653,000		
Other income (expense), net	(9,000)	46,000	10,000
Income (loss) from continuing operations before income taxes	437,000	(262,000)	392,000
Current income tax expense (benefit) - federal	1,011,000	108,000	69,000
Current income tax expense (benefit) - state	40,000	6,000	13,000
Current income tax expense (benefit) - international	107,000	68,000	46,000
Total current income tax expense (benefit)	1,158,000	182,000	128,000
Deferred income tax expense (benefit) - federal	(1,664,000)	(177,000)	1,060,000
Deferred income tax expense (benefit) - state	(151,000)	(17,000)	15,000
Deferred income tax expense (benefit) - international	(33,000)	(14,000)	10,000
Total deferred income tax expense (benefit)	(1,848,000)	(208,000)	1,085,000
Income tax expense (benefit)	(690,000)	(26,000)	1,213,000
Income (loss) from continuing operations	1,127,000	(236,000)	(821,000)
Income (loss) from discontinued operations, net of income taxes	11,000	130,000	3,309,000
Net income (loss)	1,138,000	(106,000)	2,488,000
Weighted average shares outstanding - basic	616,000	618,000	670,000
Weighted average shares outstanding - diluted	668,000	618,000	670,000
Year end shares outstanding	624,000	608,019	612,000
Income (loss) per share from continuing operations - basic	\$1.83	\$(0.38)	\$(1.23)
Income (loss) per share from			

discontinued operations - basic	\$0.02	\$0.21	\$4.94	comprehensive income (loss)	4,000	12,000
Net income (loss) per share - basic	\$1.85	\$(0.17)	\$3.71	Retained earnings (accumulated deficit)	328,000	(761,000)
Income (loss) per share from continuing operations - diluted	\$1.69	\$(0.38)	\$(1.23)	Total Symantec Corp. stockholders' equity	5,023,000	3,487,000
Income (loss) per share from discontinued operations - diluted	\$0.02	\$0.21	\$4.94	Total stockholders' equity	5,023,000	3,487,000
Net income (loss) per share - diluted	\$1.70	\$(0.17)	\$3.71			
Total number of employees	11,800	13,000	11,000			
Number of common stockholders	1,665	1,763	1,849			
Foreign currency translation adjustments	(4,000)	(8,000)	(6,000)			

Reclassified to conform with 2018 presentation; As is; Approximately

Consolidated Balance Sheet, Years Ended (\$000):

	03/30/18	03/31/17 (revised)
Cash & cash equivalents	1,774,000	4,247,000
Short-term investments	388,000	9,000
Accounts receivable, net	809,000	649,000
Other current assets	522,000	419,000
Total current assets	3,493,000	5,324,000
Land	66,000	73,000
Computer hardware & software	1,081,000	1,100,000
Office furniture & equipment	110,000	99,000
Buildings	365,000	425,000
Leasehold improvements	339,000	336,000
Construction in progress	29,000	22,000
Less accumulated depreciation & amortization	1,212,000	1,118,000
Property & equipment, net	778,000	937,000
Intangible assets, net	2,643,000	3,004,000
Goodwill	8,319,000	8,627,000
Other long-term assets	526,000	282,000
Total assets	15,759,000	18,174,000
Accounts payable	168,000	180,000
Accrued compensation & benefits	262,000	272,000
Current portion of long-term debt	...	1,310,000
Deferred revenue	2,368,000	2,353,000
Other current liabilities	372,000	507,000
Total current liabilities	3,170,000	4,622,000
Senior notes	2,250,000	2,850,000
Senior term loans	1,100,000	3,710,000
Convertible senior notes	1,750,000	1,750,000
Less: unamortized discount & issuance costs	(74,000)	(124,000)
Less: current portion	...	1,310,000
Long-term deferred revenue	735,000	434,000
Long-term deferred tax liabilities	592,000	2,401,000
Long-term income taxes payable	1,126,000	251,000
Other long-term obligations	87,000	103,000
Total liabilities	10,736,000	14,687,000
Common stock & additional paid-in capital	4,691,000	4,236,000
Foreign currency translation adjustments	...	7,000
Unrealized gain on available-for-sale securities	...	5,000
Accumulated other

Reclassified to conform with 2018 presentation

Recent Dividends:

1. Symantec Corp common.

ExDate	Amt	Declared	Record	Payable
02/24/2015	0.15	02/05/2015	02/26/2015	03/18/2015
06/08/2015	0.15	05/14/2015	06/10/2015	06/24/2015
08/24/2015	0.15	08/11/2015	08/26/2015	09/16/2015
11/19/2015	0.15	11/05/2015	11/23/2015	12/16/2015
02/18/2016	0.15	02/04/2016	02/22/2016	03/16/2016
03/04/2016	4.00	02/04/2016	03/08/2016	03/22/2016
06/06/2016	0.07	05/12/2016	06/08/2016	06/22/2016
08/18/2016	0.07	08/04/2016	08/22/2016	09/14/2016
11/17/2016	0.07	11/03/2016	11/21/2016	12/14/2016
02/15/2017	0.07	02/01/2017	02/20/2017	03/15/2017
06/05/2017	0.07	05/10/2017	06/07/2017	06/21/2017
08/17/2017	0.07	08/10/2017	08/21/2017	09/13/2017
11/17/2017	0.07	11/01/2017	11/20/2017	12/13/2017
02/21/2018	0.07	01/31/2018	02/22/2018	03/14/2018
06/07/2018	0.07	05/10/2018	06/08/2018	06/20/2018
08/17/2018	0.07	08/02/2018	08/20/2018	09/12/2018

Annual Dividends:

1. Symantec Corp common.

2015	0.60	2016	4.38	2017	0.30
2018	0.23				

SYMANTEC CORP

Earnings, 3 mos. to (Consol. - \$000):

	06/29/18	06/30/17
Total Revenues	1,156,000	1,175,000
Cost & expenses	1,101,000	1,160,000
Operating income	2,000	(44,000)
Interest expense	52,000	84,000
Other income (expense), net	(17,000)	2,000
Foreign currency	(9,000)	(14,000)
Net before taxes	(69,000)	(134,000)
Income taxes	(4,000)	(24,000)
Income contin. oper.	(65,000)	(110,000)
Net income	(60,000)	(133,000)
Earnings common share		
Primary	\$(0.10)	\$(0.22)
Fully Diluted	\$(0.10)	\$(0.22)

Common Shares:

Full Diluted	624,000	609,000
Year-end	631,000	610,991

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	2,001,000	2,001,000
Current assets	3,328,000	3,328,000
Net property & equip.	758,000	758,000
Total assets	16,248,000	16,248,000
Liabilities:		
Current liabilities	2,875,000	2,875,000
Long-term debt	5,032,000	5,032,000
Stockholders' equity	5,918,000	5,918,000
Net current assets	453,000	453,000

SYMANTEC CORP

Earnings, 6 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Total Revenues	2,331,000	2,415,000
Cost & expenses	2,123,000	2,354,000
Operating income	104,000	(53,000)
Interest expense	104,000	141,000
Other income (expense), net	(47,000)	1,000
Foreign currency	(12,000)	(21,000)
Net before taxes	(41,000)	(203,000)
Income taxes	32,000	(77,000)
Income contin. oper.	(73,000)	(126,000)
Net income	(68,000)	(145,000)
Earnings common share		
Primary	\$(0.11)	\$(0.24)
Fully Diluted	\$(0.11)	\$(0.24)

Common Shares:

Full Diluted	627,000	612,000
Year-end	632,000	619,633

SYNAPTICS INC

Earnings, 3 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	417,600	417,400
Cost & expenses	408,900	430,200
Operating income	5,800	(16,900)
Equity earnings	400	400
Net before taxes	3,900	(22,900)
Income taxes	(300)	3,200
Net income	3,800	(26,500)
Earnings common share		
Primary	\$0.11	\$(0.79)
Fully Diluted	\$0.11	\$(0.79)

Common Shares:

Full Diluted	36,100	33,500
Year-end	34,528	33,736

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	263,300	263,300
Inventories	161,200	161,200
Current assets	789,000	789,000
Net property & equip.	110,900	110,900
Total assets	1,524,800	1,524,800
Liabilities:		
Current liabilities	325,700	325,700
Long-term debt	455,100	455,100
Stockholders' equity	710,100	710,100
Net current assets	463,300	463,300

SYNCHROSS TECHNOLOGIES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	243,737	296,102
Cost & expenses	295,370	321,384
Operating income	(121,963)	(96,380)
Other income (expense), net	(9,109)	4,000
Net before taxes	(127,489)	(131,239)
Income taxes	(1,604)	(17,973)
Income contin. oper.	(125,885)	(113,266)
Net income	(125,885)	(127,333)
Balance for common	(141,839)	(120,353)
Earnings common share		
Primary	\$(3.51)	\$(2.70)
Fully Diluted	\$(3.51)	\$(2.70)
Common Shares:		
Full Diluted	40,405	44,576
Year-end	42,655	47,393

SYNDAX PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	1,138	915
Cost & expenses	57,681	43,380
Operating income	(56,543)	(42,465)
Other income (expense), net	(3)	(193)
Net income	(55,124)	(41,699)
Balance for common	(55,124)	(41,699)
Earnings common share		
Primary	\$(2.21)	\$(2.08)
Fully Diluted	\$(2.21)	\$(2.08)
Common Shares:		
Full Diluted	24,889	20,004
Year-end	24,051	22,313

SYNEOS HEALTH INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	3,244,644	1,595,381
Cost & expenses	2,960,373	1,542,679
Operating income	80,714	(43,886)
Interest income	3,498	765
Interest expense	97,727	33,818
Other income (expense), net	(5,886)	(704)
Gains or losses	2,146	(9,298)
Foreign currency	14,927	(6,264)
Net before taxes	(2,328)	(93,205)
Income taxes	19,058	30,217
Net income	(21,386)	(123,422)
Earnings common share		
Primary	\$(0.21)	\$(1.90)

Fully Diluted	\$(0.21)	\$(1.90)
Common Shares:		
Full Diluted	103,453	65,097
Year-end	103,223	104,219

SYNERGY PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Net Sales	31,945,000	7,420,000
Cost & expenses	129,298,000	191,430,000
Operating income	(97,353,000)	184,010,000
Interest expense	9,697,000	2,361,000
Other income (expense), net	7,845,000	(993,000)
Net before taxes	(99,205,000)	
Income taxes	1,133,000	
Net income	(100,338,000)	187,364,000
Earnings common share		
Primary	\$(0.41)	\$(0.84)
Fully Diluted	\$(0.41)	\$(0.84)
Common Shares:		
Full Diluted	247,221,231	221,854,099
Year-end	248,037,301	224,954,941

T-MOBILE US INC**Earnings, 9 mos. to Sep 30**(Consol. - \$Millions):

	2018	2017
Total Revenues	31,865	29,845
Cost & expenses	22,847	21,570
Deprec., depl. & amort.	4,846	4,499
Operating income	4,172	3,776
Interest income	17	15
Other income (expense), net	(51)	(89)
Net before taxes	3,079	2,447
Income taxes	831	618
Net income	2,248	1,829
Balance for common	2,248	1,788
Earnings common share		
Primary	\$2.65	\$2.15
Fully Diluted	\$2.62	\$2.10
Common Shares:		
Full Diluted	858	872
Year-end	848	832

T2 BIOSYSTEMS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	8,708	3,005
Cost & expenses	40,204	42,491
Operating income	(31,496)	(39,486)
Other income (expense), net	402	260
Net income	(36,004)	(44,234)
Earnings common share		
Primary	\$(0.91)	\$(1.43)
Fully Diluted	\$(0.91)	\$(1.43)
Common Shares:		
Full Diluted	39,363	30,874
Year-end	44,039	35,797

TACTILE SYSTEMS TECHNOLOGY INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	97,303	74,397
Cost & expenses	96,449	75,426
Operating income	854	(1,029)
Other income (expense), net	351	204
Net before taxes	1,205	(825)
Income taxes	(3,063)	(4,450)
Net income	4,268	3,625
Earnings common share		
Primary	\$0.23	\$0.21
Fully Diluted	\$0.22	\$0.19
Common Shares:		
Full Diluted	19,329	18,819
Year-end	18,416	17,651

TAKE-TWO INTERACTIVE SOFTWARE, INC.**Earnings, 6 mos. to Sep 30**(Consol. - \$):

	2018	2017
Total Revenues	880,649,000	861,778,000
Cost & expenses	764,806,000	796,252,000
Deprec., depl. & amort.	19,011,000	26,626,000
Operating income	96,832,000	38,900,000
Net before taxes	108,408,000	33,123,000
Income taxes	11,348,000	(24,417,000)

Net income	97,060,000	57,540,000
Earnings common share		
Primary	\$0.86	\$0.54
Fully Diluted	\$0.84	\$0.53
Common Shares:		
Full Diluted	115,801,000	108,448,000
Year-end	113,804,000	

TANDEM DIABETES CARE INC**Earnings, 9 mos. to Sep 30**(Consol. - \$):

	2018	2017
Net Sales	107,667,000	67,306,000
Cost & expenses	152,859,000	120,667,000
Operating income	(45,192,000)	(53,361,000)
Other income (expense), net	(74,355,000)	
Net income	(126,299,000)	(61,627,000)
Earnings common share		
Primary	\$(2.81)	\$(13.79)
Fully Diluted	\$(2.81)	\$(13.79)
Common Shares:		
Full Diluted	44,993,000	4,468,000
Year-end	57,364,000	

TCG BDC INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Cost & expenses	72,120	49,687
Operating income	79,095	65,804
Net before taxes	79,095	65,804
Income taxes	70	169
Net income	79,025	65,635
Earnings common share		
Primary	\$0.64	\$1.15
Fully Diluted	\$0.64	\$1.15
Common Shares:		
Full Diluted	62,546	49,915
Year-end	62,569	61,860

TECHTARGET INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	89,513	78,253
Cost & expenses	73,738	69,688
Operating income	12,371	5,190
Net before taxes	11,165	4,743
Income taxes	882	1,337
Net income	10,283	3,406
Earnings common share		
Primary	\$0.37	\$0.12
Fully Diluted	\$0.36	\$0.12
Common Shares:		
Full Diluted	28,711	28,275
Year-end	28,002	27,597

TELENAV, INC.**Earnings, 3 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	52,168	56,962
Cost & expenses	61,071	67,029
Operating income	(8,903)	(10,067)
Other income (expense), net	1,590	(47)
Net before taxes	(7,313)	(10,114)
Income taxes	630	255
Net income	(7,943)	(10,369)
Earnings common share		
Primary	\$(0.18)	\$(0.24)
Fully Diluted	\$(0.18)	\$(0.24)
Common Shares:		
Full Diluted	45,018	44,079
Year-end	45,260	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	13,596	
Current assets	148,392	
Net property & equip.	6,412	
Total assets	236,100	
Liabilities:		
Current liabilities	74,442	
Stockholders' equity	102,235	
Net current assets	73,950	

TENABLE HOLDINGS INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
--	------	------

	2018	2017
Total Revenues	192,139	133,610
Cost & expenses	245,129	162,747
Operating income	(52,990)	(29,137)
Other income (expense), net	240	(65)
Net before taxes	(52,750)	(29,202)
Income taxes	1,157	151
Net income	(53,907)	(29,353)
Balance for common	(54,341)	(29,923)

Earnings common share		
Primary	\$(1.34)	\$(1.36)
Fully Diluted	\$(1.34)	\$(1.36)
Common Shares:		
Full Diluted	40,688	22,004
Year-end	93,040	

TERADYNE, INC.**Earnings, 9 mos. to** (Consol. - \$000):

	09/30/18	10/01/17
Net Sales	1,581,244	1,657,191
Cost & expenses	1,191,084	1,203,328
Operating income	361,527	430,718
Interest income	17,620	11,329
Interest expense	18,087	16,283
Other income (expense), net	(4,385)	565
Net before taxes	356,675	426,329
Income taxes	48,684	62,713
Net income	307,991	363,616
Earnings common share		
Primary	\$1.62	\$1.83
Fully Diluted	\$1.57	\$1.81
Common Shares:		
Full Diluted	196,300	201,413
Year-end	183,289	196,711

TERRAFORM POWER INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	553,477	474,932
Cost & expenses	252,384	226,592
Operating income	61,916	62,301
Interest expense	176,862	206,749
Other income (expense), net	(2,870)	4,882
Gains or losses		37,116
Foreign currency	4,257	5,695
Net before taxes	(113,559)	(96,755)
Income taxes	9,417	(2,256)
Net income	(122,976)	(94,499)
Balance for common	27,869	(47,491)
Earnings common share		
Primary	\$0.16	\$(0.59)
Fully Diluted	\$0.16	\$(0.59)
Common Shares:		
Full Diluted	173,186	92,228
Year-end	209,142	

TESLA INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	14,235,395	8,470,502
Cost & expenses	15,037,004	9,504,447
Operating income	(801,609)	(1,033,945)
Other income (expense), net	36,071	(83,696)
Net before taxes	(1,236,701)	(1,429,131)
Income taxes	35,959	40,640
Net income	(1,272,660)	(1,469,771)
Earnings common share		
Primary	\$(6.56)	\$(7.80)
Fully Diluted	\$(6.56)	\$(7.80)
Common Shares:		
Full Diluted	170,019	164,897
Year-end	171,578	168,017

TETRAPHASE PHARMACEUTICALS, INC**Earnings, 9 mos. to Sep 30**(Consol. - \$000):

	2018	2017
Total Revenues	14,620	7,138
Cost & expenses	66,512	99,034
Operating income	(51,892)	(91,896)
Other income (expense), net	1,215	620
Net income	(50,677)	(91,276)
Earnings common share		
Primary	\$(0.97)	\$(2.23)
Fully Diluted	\$(0.97)	\$(2.23)

Common Shares:		
Full Diluted	52,131	40,942
Year-end	53,545	51,180

TEXAS INSTRUMENTS INC.

Earnings, 9 mos. to Sep 30 (Consol. – \$Millions):	2018	2017
Total Revenues	12,067	11,211
Cost & expenses	6,870	6,691
Operating income	5,197	4,520
Other income (expense), net	75	67
Net before taxes	5,183	4,530
Income taxes	842	1,192
Net income	4,341	3,338
Balance for common	4,307	3,307
Earnings common share		
Primary	\$4.41	\$3.33
Fully Diluted	\$4.32	\$3.26
Common Shares:		
Full Diluted	997	1,014
Year-end	965	986

THERAPEUTICSMD INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	11,009,937	12,653,495
Cost & expenses	102,910,929	68,444,623
Operating income	(92,099,537)	(55,948,071)
Interest expense	2,584,459	
Other income (expense), net	1,457,817	442,322
Net income	(93,226,179)	(55,498,050)
Earnings common share		
Primary	\$(0.42)	\$(0.27)
Fully Diluted	\$(0.42)	\$(0.27)
Common Shares:		
Full Diluted	220,466,673	203,282,335
Year-end	236,464,789	216,429,642

TILE SHOP HOLDINGS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Net Sales	273,307,000	266,020,000
Cost & expenses	255,874,000	236,510,000
Operating income	17,433,000	29,510,000
Other income (expense), net	112,000	132,000
Net before taxes	15,679,000	28,204,000
Income taxes	4,157,000	10,034,000
Net income	11,522,000	18,170,000
Earnings common share		
Primary	\$0.22	\$0.35
Fully Diluted	\$0.22	\$0.35
Common Shares:		
Full Diluted	52,056,136	52,011,208
Year-end	52,679	

TILRAY INC

Acquisition Completed On Nov. 13, 2018, Co. acquired 1,428,571 common shares of IntelGenx Technologies Corp. ("IntelGenx"), through a private placement, at \$0.70 per common share. The Common Shares issued to Co. was subject to a four-month statutory hold period which expires Mar. 14, 2019. Additionally, under the Private Placement purchase agreement, Co. agreed that until May 14, 2019 it would not cause or permit any transfer of any Common Shares.

TIVO CORP

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	527,406	612,220
Cost & expenses	417,175	469,405
Operating income	(25,484)	1,846
Interest expense	36,241	31,827
Other income (expense), net		(15,043)
Gains or losses	7,185	(1,374)
Net before taxes	(51,569)	(42,579)
Income taxes	13,305	13,816
Income contin. oper.	(64,874)	
Net income	(61,136)	(56,395)
Earnings common share		
Primary	\$(0.50)	\$(0.47)
Fully Diluted	\$(0.50)	\$(0.47)
Common Shares:		
Full Diluted	122,756	119,994
Year-end	123,875	121,895

TOCAGEN INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Cost & expenses	44,772	26,972
Operating income	(26,745)	(26,941)
Interest income	1,087	354
Interest expense	2,184	1,541
Other income (expense), net		37
Net before taxes	(27,842)	(28,091)
Income taxes	1,510	1
Net income	(29,352)	(28,092)
Earnings common share		
Primary	\$(1.47)	\$(2.19)
Fully Diluted	\$(1.47)	\$(2.19)
Common Shares:		
Full Diluted	19,927	12,847
Year-end	19,953	19,809

TPI COMPOSITES INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Net Sales	739,567	701,695
Cost & expenses	711,199	649,919
Operating income	28,368	51,776
Interest income	129	78
Interest expense	8,376	9,215
Other income (expense), net	606	968
Gains or losses	(12,957)	(2,575)
Net before taxes	4,770	41,032
Income taxes	(6,357)	4,505
Net income	14,127	36,527
Earnings common share		
Primary	\$0.41	\$1.08
Fully Diluted	\$0.39	\$1.05
Common Shares:		
Full Diluted	35,946	34,748
Year-end	34,511	33,994

TRACON PHARMACEUTICALS INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Cost & expenses	30,009	20,611
Operating income	(27,009)	(11,856)
Interest expense	204	681
Other income (expense), net	10	(6)
Net income	(27,203)	(12,543)
Earnings common share		
Primary	\$(1.05)	\$(0.76)
Fully Diluted	\$(1.05)	\$(0.76)
Common Shares:		
Full Diluted	25,962	16,551
Year-end	29,841	17,393

TRACTOR SUPPLY CO.

Earnings, 9 mos. to (Consol. – \$000):	09/29/18	09/30/17
Cost & expenses	5,125,037	4,678,303
Deprec., depl. & amort.	131,383	122,701
Operating income	521,355	502,540
Net before taxes	507,449	492,919
Income taxes	111,943	180,063
Net income	395,506	312,856
Earnings common share		
Primary	\$3.22	\$2.44
Fully Diluted	\$3.20	\$2.43
Common Shares:		
Full Diluted	123,570	128,910
Year-end	122,120	125,853

TRAVELCENTERS OF AMERICA LLC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Total Revenues	4,697,925	3,915,836
Cost & expenses	4,608,772	3,870,329
Deprec., depl. & amort.	62,076	66,875
Operating income	27,077	(21,368)
Interest expense	21,963	22,738
Other income (expense), net	(1,627)	1,490
Net before taxes	3,487	(42,616)
Income taxes	(713)	(76,437)
Income contin. oper.	4,200	33,821
Income discount. oper.	(118,682)	(3,828)
Net income	(114,482)	29,993
Earnings common share		

Primary	\$(2.87)	\$0.76
Fully Diluted	\$(2.87)	\$0.76
Common Shares:		
Full Diluted	38,137	37,458
Year-end	39,768	

TRAVELZOO

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Total Revenues	84,260,000	79,527,000
Cost & expenses	78,811,000	76,061,000
Operating income	5,449,000	3,466,000
Other income (expense), net	100,000	111,000
Net before taxes	5,549,000	3,577,000
Income taxes	2,452,000	2,660,000
Income contin. oper.		917,000
Net income	3,097,000	2,855,000
Earnings common share		
Primary	\$0.25	\$0.22
Fully Diluted	\$0.25	\$0.22
Common Shares:		
Full Diluted	12,630,000	13,040,000
Year-end	12,244,000	12,465,000

TREVENA INC

Earnings, 9 mos. to Sep 30 (Consol. – \$):	2018	2017
Cost & expenses	28,046,000	56,272,000
Operating income	(22,546,000)	(56,272,000)
Interest income	693,000	505,000
Interest expense	1,790,000	2,041,000
Other income (expense), net	1,425,000	681,000
Gains or losses	148,000	1,000
Foreign currency	7,000	(19,000)
Net before taxes	(22,063,000)	
Net income	(22,808,000)	(57,145,000)
Balance for common	(22,808,000)	(57,145,000)
Earnings common share		
Primary	\$(0.32)	\$(0.98)
Fully Diluted	\$(0.32)	\$(0.98)
Common Shares:		
Full Diluted	70,604,827	58,475,079
Year-end	82,323,291	61,688,322

TRIBUNE PUBLISHING CO (NEW)

Earnings, 9 mos. to (Consol. – \$000):	09/30/18	09/24/17
Total Revenues	747,173	719,565
Cost & expenses	751,922	681,126
Operating income	(42,316)	3,334
Other income (expense), net	1,449	(7,402)
Net before taxes	(52,540)	(23,378)
Income taxes	(8,719)	1,612
Income contin. oper.	(43,821)	(24,990)
Net income	246,844	5,908
Earnings common share		
Primary	\$7.01	\$0.17
Fully Diluted	\$7.01	\$0.17
Common Shares:		
Full Diluted	35,166	34,124
Year-end	37,551	

TRIMAS CORP (NEW)

Earnings, 9 mos. to Sep 30 (Consol. – \$000):	2018	2017
Net Sales	665,790	622,530
Cost & expenses	569,180	551,910
Operating income	96,610	70,620
Interest expense	10,660	10,360
Other income (expense), net	(2,330)	(7,930)
Net before taxes	83,620	52,330
Income taxes	17,030	17,360
Net income	66,590	34,970
Earnings common share		
Primary	\$1.45	\$0.77
Fully Diluted	\$1.44	\$0.76
Common Shares:		
Full Diluted	46,199	45,954
Year-end	45,846	45,721

TRIMBLE INC

Earnings, 9 mos. to (Consol. – \$000):

	09/28/18	09/29/17
Total Revenues	2,322,900	1,946,700
Cost & expenses	2,034,100	1,720,100
Operating income	231,100	180,000
Interest expense	50,800	18,400
Other income (expense), net	29,100	35,000
Foreign currency	600	3,000
Net before taxes	210,000	199,600
Income taxes	13,500	45,300
Net income	196,500	154,300
Earnings common share		
Primary	\$0.79	\$0.61
Fully Diluted	\$0.78	\$0.60
Common Shares:		
Full Diluted	253,000	257,000
Year-end	251,100	251,900

TRIPADVISOR INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	1,024,000	1,038,000
Operating income	160,000	115,000
Interest expense	10,000	11,000
Net before taxes	150,000	107,000
Income taxes	45,000	42,000
Net income	105,000	65,000
Earnings common share		
Primary	\$0.76	\$0.46
Fully Diluted	\$0.75	\$0.46
Common Shares:		
Full Diluted	140,151	141,681
Year-end	137,613	138,837

TRIUMPH BANCORP INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Cost & expenses	155,063	112,307
Operating income	43,697	46,466
Net before taxes	43,697	46,466
Income taxes	10,074	16,551
Net income	33,623	29,915
Balance for common	33,045	29,335
Earnings common share		
Primary	\$1.37	\$1.58
Fully Diluted	\$1.35	\$1.53
Common Shares:		
Full Diluted	24,974	19,488
Year-end	26,280	20,821

TRUECAR INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	262,497	240,016
Cost & expenses	268,042	245,259
Deprec., depl. & amort.	16,808	17,517
Operating income	(22,353)	(22,760)
Interest income	2,242	784
Interest expense	1,985	1,955
Net before taxes	(22,096)	(23,931)
Income taxes	(168)	443
Net income	(21,928)	(24,374)
Earnings common share		
Primary	\$(0.22)	\$(0.26)
Fully Diluted	\$(0.22)	\$(0.26)
Common Shares:		
Full Diluted	101,503	93,108
Year-end	103,819	99,893

TRUPANION INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	221,316	176,122
Cost & expenses	222,163	177,602
Operating income	(847)	(1,480)
Interest expense	887	370
Other income (expense), net	1,071	1,239
Net before taxes	(663)	(611)
Income taxes	(11)	54
Net income	(652)	(665)
Earnings common share		
Primary	\$(0.02)	\$(0.02)
Fully Diluted	\$(0.02)	\$(0.02)
Common Shares:		
Full Diluted	31,376	29,501
Year-end	33,416	30,033

TTEC HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,090,038	1,050,742
Cost & expenses	984,885	939,590
Operating income	53,101	63,879
Interest income	3,940	2,020
Interest expense	22,634	8,699
Other income (expense), net	(8,786)	6,573
Gains or losses	(2,000)	(3,178)
Net before taxes	23,621	60,595
Income taxes	4,648	9,059
Net income	18,973	51,536
Earnings common share		
Primary	\$0.34	\$1.06
Fully Diluted	\$0.33	\$1.05
Common Shares:		
Full Diluted	46,390	46,348
Year-end	46,192	45,847

TTM TECHNOLOGIES INC

Earnings, 9 mos. to (Consol. - \$):

	10/01/18	10/02/17
Net Sales	2,136,306,000	919,243,000
Cost & expenses	1,978,062,000	759,800,000
Operating income	116,285,000	141,716,000
Other income (expense), net	7,284,000	(15,287,000)
Net before taxes	67,144,000	86,313,000
Income taxes	(53,958,000)	10,902,000
Net income	121,102,000	75,411,000
Earnings common share		
Primary	\$1.17	\$0.74
Fully Diluted	\$0.98	\$0.65
Common Shares:		
Full Diluted	134,871,000	131,914,000
Year-end	103,677,000	101,815,000

TURTLE BEACH CORP

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	176,118,000	69,439,000
Cost & expenses	147,541,000	80,620,000
Operating income	28,577,000	(11,181,000)
Other income (expense), net	(473,000)	517,000
Net before taxes	23,748,000	(16,381,000)
Income taxes	762,000	1,098,000
Net income	22,986,000	(17,479,000)
Earnings common share		
Primary	\$1.73	\$(1.40)
Fully Diluted	\$1.56	\$(1.40)
Common Shares:		
Full Diluted	14,757,000	12,332,000
Year-end	14,229,736	12,346,502

TWENTY-FIRST CENTURY FOX INC

Earnings, 3 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	7,177,000	7,002,000
Cost & expenses	5,330,000	5,250,000
Deprec., depl. & amort.	158,000	142,000
Operating income	1,484,000	1,295,000
Interest income	8,000	10,000
Interest expense	300,000	313,000
Other income (expense), net	87,000	(12,000)
Net before taxes	1,484,000	1,295,000
Income taxes	126,000	391,000
Income contin. oper.	1,358,000	904,000
Net income	1,351,000	920,000
Earnings common share		
Primary	\$0.69	\$0.46
Fully Diluted	\$0.69	\$0.46
Common Shares:		
Full Diluted	1,863,000	1,853,000
Year-end	1,852,553	1,852,530

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	7,083,000	
Inventories	3,804,000	
Current assets	19,128,000	
Net property & equip.	1,949,000	
Total assets	54,512,000	
Liabilities:		
Current liabilities	7,802,000	
Long-term debt	18,379,000	

Stockholders' equity	20,698,000
Net current assets	11,326,000

TWENTY-FIRST CENTURY FOX INC

Interest-First Development On Nov. 6, 2018, Walt Disney's \$71,300,000,000 offer to buy Co.'s entertainment assets won approval from the European Commission on Tuesday, subject to Disney selling interests in factual TV channels in Europe. The EU competition regulator said in a statement that Disney had committed to divest its interests in channels including History and Lifetime in the European Economic Area (EEA) to avoid harming competition following its purchase from Co.

TWIN DISC INCORPORATED

Earnings, 3 mos. to (Consol. - \$000):

	09/28/18	09/29/17
Net Sales	74,689	45,064
Cost & expenses	69,863	45,684
Operating income	4,826	(620)
Interest expense	717	64
Other income (expense), net	(319)	(569)
Net before taxes	3,790	(1,253)
Income taxes	887	(4,658)
Net income	2,903	3,405
Earnings common share		
Primary	\$0.24	\$0.29
Fully Diluted	\$0.24	\$0.29
Common Shares:		
Full Diluted	11,799	11,259
Year-end	13,066	11,573

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	16,557	
Inventories	123,439	
Current assets	202,398	
Net property & equip.	68,302	
Total assets	340,757	
Liabilities:		
Current liabilities	78,062	
Long-term debt	54,516	
Stockholders' equity	177,940	
Net current assets	124,336	

U.S. AUTO PARTS NETWORK INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Net Sales	224,821	234,848
Cost & expenses	223,164	230,531
Operating income	1,517	4,046
Interest expense	1,218	1,247
Other income (expense), net	1,396	50
Net before taxes	1,695	2,849
Income taxes	1,007	(25,804)
Net income	688	28,094
Balance for common	568	
Earnings common share		
Primary	\$0.02	\$0.81
Fully Diluted	\$0.02	\$0.72
Common Shares:		
Full Diluted	35,279	39,858
Year-end	34,984	35,528

UBIQUITI NETWORKS INC

Earnings, 3 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	282,905	245,868
Cost & expenses	183,287	158,805
Operating income	99,618	87,063
Net before taxes	97,091	85,702
Income taxes	11,388	10,777
Net income	85,703	74,925
Earnings common share		
Primary	\$1.16	\$0.93
Fully Diluted	\$1.16	\$0.92
Common Shares:		
Full Diluted	73,963	81,748
Year-end	72,858	78,210

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	480,812	
Inventories	139,926	
Current assets	931,746	
Net property & equip.	13,471	
Total assets	1,003,497	
Liabilities:		

Current liabilities	152,160
Long-term debt	454,253
Stockholders' equity	270,639
Net current assets	779,586

UHF LOGISTICS GROUP INC**Annual Report**

Consolidated Income Statement, Years Ended Feb. 28 (\$):			
	2018	2017	2016
Amortization expense	817
Bank charges & interest expense	374
Filing & transfer agent fees	4,000
Management fees	22,500
Office expense	10,983
Professional services expense	4,587	4,586	61,740
Travel & promotion expense	74,070
Total expenses	4,587	4,586	...
Income (loss) from operations	(4,587)	(4,586)	(174,484)
Impairment of loan receivable	200,000
Net income (loss)	(4,587)	(4,586)	(374,484)
Weighted average shares outstanding - basic	58,816,666	58,816,666	46,816,665
Weighted average shares outstanding - diluted	58,816,666	58,816,666	46,816,665
Year end shares outstanding	58,816,666	58,816,666	46,816,665
Net income (loss) per share - basic	\$0.00	\$0.00	\$(0.01)
Net income (loss) per share - diluted	\$0.00	\$0.00	\$(0.01)
Total number of employees	2
Number of common stockholders	29

□ As reported from the February 28, 2018 Annual Report

Consolidated Balance Sheet, Years Ended Feb. 28 (\$):			
	2018	2017	2016
Accounts payable	9,173	4,586	...
Total current liabilities	9,173	4,586	...
Total liabilities	9,173	4,586	...
Common stock	58,817	58,817	...
Additional paid in capital	6,261,967	6,261,967	...
Retained earnings (accumulated deficit)	(6,329,957)	(6,325,370)	...
Total stockholders' equity (deficit)	(9,173)	(4,586)	...

□ As reported from the February 28, 2018 Annual Report

Recent Dividends:**1. UHF Logistics Group Inc common.**

No dividends paid.

Annual Dividends:**1. UHF Logistics Group Inc common.**

No dividends paid.

ULTIMATE SOFTWARE GROUP, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	835,744,000	689,296,000
Cost & expenses	778,034,000	664,794,000
Operating income	57,710,000	24,502,000
Other income (expense), net	2,532,000	364,000
Net before taxes	59,677,000	24,182,000
Income taxes	7,918,000	8,070,000
Net income	51,759,000	16,112,000
Earnings common share		
Primary	\$1.69	\$0.54
Fully Diluted	\$1.65	\$0.52
Common Shares:		
Full Diluted	31,409,000	30,727,000
Year-end	31,265,229	...

ULTRAGENYX PHARMACEUTICAL INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	35,234	198
Cost & expenses	316,267	232,306
Operating income	(281,033)	(232,108)
Interest income	6,915	3,350
Other income (expense), net	(5,601)	8,368
Gains or losses	170,322	...
Net before taxes	(109,397)	(220,390)
Income taxes	388	18
Net income	(109,785)	(220,408)
Earnings common share		
Primary	\$(2.22)	\$(5.22)
Fully Diluted	\$(2.22)	\$(5.22)
Common Shares:		
Full Diluted	49,448	42,222
Year-end	50,533	...

ULTRALIFE CORP**Earnings, 9 mos. to (Consol. - \$000):**

	09/30/18	10/01/17
Total Revenues	66,263	63,022
Cost & expenses	60,775	58,596
Operating income	5,488	4,426
Other income (expense), net	40	(53)
Net before taxes	5,461	4,226
Income taxes	219	370
Net income	5,242	3,856
Earnings common share		
Primary	\$0.33	\$0.25
Fully Diluted	\$0.32	\$0.24
Common Shares:		
Full Diluted	16,407	15,818
Year-end	15,957	15,591

UNITED NATURAL FOODS INC.

Merger Completed On Oct. 22, 2018, Co.'s wholly-owned subsidiary, Jedi Merger Sub, Inc. ("Merger Sub"), merged with and into Supervalu Inc. ("Supervalu"), with Supervalu continuing as the surviving corporation and became a wholly-owned subsidiary of Co. As the result of the merger, each outstanding share of common stock of Supervalu, par value \$0.01 per share ("Common Stock") (other than shares owned by Supervalu, Co. or any of their respective subsidiaries (except for shares of common stock held on behalf of third parties), dissenting shares and any Supervalu restricted share) was automatically converted into the right to receive \$32.50 in cash (the "Merger Consideration"). In addition, each Supervalu stock option that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, was converted into an option to purchase shares of the common stock of Co., with the number of shares subject to the option and the exercise equitably adjusted in accordance with the terms of the Merger Agreement. Also, each Supervalu restricted share award, restricted stock unit award, deferred share unit award and performance share unit award that was outstanding as of immediately prior to the Effective Time was converted into a Co. award payable, at Co.'s election, in cash and/or an equal value in shares of common stock of Co. in accordance with the terms of the Merger Agreement, having a value equal to the product of (i) the number of shares of Common Stock (determined in accordance with the terms of the Merger Agreement and the applicable award agreement) and (ii) the Merger Consideration. The total aggregate consideration payable in the Acquisition was approximately \$1,350,000,000, not including related transaction fees and expenses.

UNITED STATES LIME & MINERALS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	109,801	109,605
Cost & expenses	93,787	90,572
Operating income	16,014	19,033
Interest expense	191	174
Other income (expense), net	1,307	665
Net before taxes	17,130	19,524
Income taxes	1,676	3,959
Net income	15,454	15,565
Earnings common share		
Primary	\$2.76	\$2.79
Fully Diluted	\$2.76	\$2.79
Common Shares:		
Full Diluted	5,602	5,586
Year-end	5,598	5,577

UNITY BIOTECHNOLOGY INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	56,658	32,822
Operating income	(56,658)	(32,822)
Interest income	2,246	734
Other income (expense), net	(70)	(25)
Net income	(54,482)	(32,113)
Earnings common share		
Primary	\$(2.29)	\$(10.17)
Fully Diluted	\$(2.29)	\$(10.17)
Common Shares:		
Full Diluted	23,762	3,158
Year-end	42,318	...

UNIVERSAL DISPLAY CORP**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	177,271,000	219,762,000
Cost & expenses	119,330,000	114,910,000
Operating income	41,462,000	88,367,000
Other income (expense), net	(66,000)	(7,000)
Net before taxes	46,551,000	90,688,000
Income taxes	6,960,000	19,616,000
Net income	39,591,000	71,072,000
Balance for common	39,110,000	69,923,000
Earnings common share		
Primary	\$0.83	\$1.50
Fully Diluted	\$0.83	\$1.49
Common Shares:		
Full Diluted	46,893,768	46,793,429
Year-end	47,310,901	47,108,224

UNIVERSAL ELECTRONICS INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Net Sales	509,938,000	514,638,000
Cost & expenses	514,175,000	503,488,000
Operating income	(4,237,000)	11,150,000
Other income (expense), net	63,000	342,000
Gains or losses	32,964,000	(340,000)
Net before taxes	25,264,000	9,476,000
Income taxes	2,233,000	2,945,000
Net income	23,031,000	6,531,000
Earnings common share		
Primary	\$1.65	\$0.45
Fully Diluted	\$1.63	\$0.44
Common Shares:		
Full Diluted	14,116,000	14,689,000
Year-end	13,815,405	...

UNIVERSAL FOREST PRODUCTS INC.**Earnings, 9 mos. to (Consol. - \$):**

	09/29/18	09/30/17
Net Sales	3,500,999,000	975,091,000
Cost & expenses	3,339,174,000	835,100,000
Operating income	161,825,000	139,991,000
Interest expense	5,971,000	4,825,000
Other income (expense), net	...	25,000
Net before taxes	156,963,000	135,732,000
Income taxes	36,183,000	44,855,000
Net income	120,780,000	90,877,000
Earnings common share		
Primary	\$1.91	\$1.44
Fully Diluted	\$1.91	\$1.44
Common Shares:		
Full Diluted	60,520,000	60,420,000
Year-end	61,656,181	61,174,197

UNIVERSAL HOSPITAL SERVICES, INC.**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	421,175,000	382,633,000
Cost & expenses	349,169,000	348,669,000
Operating income	72,006,000	33,964,000
Net before taxes	31,878,000	(6,402,000)
Income taxes	767,000	888,000
Net income	31,111,000	(7,290,000)
Earnings common share		
Common Shares:		
Year-end	1,000	1,000

UPWORK INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2017	2016
Total revenues	202,552	164,445
Cost of revenue	65,443	62,578
Gross profit	137,109	101,867
Research & development	45,604	37,902
Sales & marketing	53,044	37,437
General & administrative expenses	37,334	35,446
Provision for transaction losses	4,250	5,550
Total operating expenses	140,232	116,335
Income (loss) from operations	(3,123)	(14,468)
Interest expense	960	858
Other income (expense), net	(62)	(908)
Income before income taxes - Domestic	(4,145)	(16,271)
Income before income taxes - Foreign	8	37
Income (loss) before provision for income taxes	(4,145)	(16,234)
Current state income taxes	(1)	(2)
Current foreign income taxes	(21)	1
Current income taxes	(22)	(1)
Provision for (benefit from) income taxes	(22)	(1)
Net income (loss)	(4,123)	(16,233)
Premium paid on repurchase of redeemable convertible preferred stock	6,506	...
Net income (loss) attributable to common stockholders	(10,629)	(16,233)
Weighted average shares outstanding - basic	32,945	32,072
Weighted average shares outstanding - diluted	32,945	32,072
Year end shares outstanding	33,740	32,178
Net earnings (loss) per share - basic	\$(0.32)	\$(0.51)
Net earnings (loss) per share - diluted	\$(0.32)	\$(0.51)
Total number of employees	395	...

As Is; As of June 30, 2018

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2017	2016
Cash & cash equivalents	21,595	27,326
Funds held in escrow, including funds in transit	87,195	59,833
Trade & client receivables - gross	32,339	27,793
Allowance for doubtful accounts	1,577	2,473
Trade & client receivables - net	30,762	25,320
Prepaid expenses & other current assets	4,574	4,139
Total current assets	144,126	116,618
Computer equipment & software	5,385	5,038
Internal-use software & platform development costs	2,318	1,829
Leasehold improvements	2,189	1,738
Office furniture & fixtures	1,550	1,283
Total property & equipment, gross	11,442	9,888
Less: Accumulated depreciation	7,928	7,283
Property & equipment, net	3,514	2,605
Goodwill	118,219	118,219
Intangible assets, net	8,672	11,399

	2017	2016
Other assets	658	759
Total assets	275,189	249,600
Accounts payable	462	370
Escrow funds payable	87,195	59,833
Debt, current	10,342	2,992
Accrued compensation & related benefits	8,399	3,630
Accrued freelancer costs	134	10,943
Accrued indirect taxes	1,861	1,761
Accrued vendor expenses	4,198	2,034
Accrued payment processing fees	593	1,337
Accrued legal settlement	...	1,095
Other accrued expenses & other current liabilities	845	824
Accrued expenses & other current liabilities	16,030	21,624
Deferred revenue	614	594
Total current liabilities	114,643	85,413
Term loan	24,000	14,000
Line of credit	10,000	3,000
Total debt	34,000	17,000
Less: Unamortized debt discount issuance costs	(167)	(38)
Debt, current	10,342	2,992
Debt, noncurrent	23,491	13,970
Other liabilities, noncurrent	1,936	1,563
Total liabilities	140,070	100,946
Redeemable convertible preferred stock	166,486	178,785
Common stock	3	3
Additional paid-in capital	92,222	89,335
Retained earnings (accumulated deficit)	(123,592)	(119,469)
Total stockholders' equity (deficit)	(31,367)	(30,131)

Recent Dividends:

1. Upwork Inc common.

No dividends paid.

Annual Dividends:

1. Upwork Inc common.

No dividends paid.

UPWORK INC

Earnings, 6 mos. to Jun 30 (Consol. - \$000):

	2018	2017
Total Revenues	121,899	95,531
Cost & expenses	127,579	93,906
Operating income	(5,680)	1,625
Interest expense	1,085	430
Other income (expense), net	(422)	185
Net before taxes	(7,187)	1,380
Income taxes	9	11
Net income	(7,196)	1,369
Balance for common	(7,196)	...
Earnings common share		
Primary	\$(0.21)	\$(0.21)
Fully Diluted	\$(0.21)	\$(0.21)
Common Shares:		
Full Diluted	34,651	32,487
Year-end	35,880	...

US ECOLOGY, INC.

Acquisition Completed On Nov. 14, 2018, Co. acquired Ecoserv Industrial Disposal, LLC from Ecoserv, LLC for \$87,200,000, and is subject to customary post-closing adjustments. Co. funded the purchase from cash on hand and Co.'s existing credit facility.

US ECOLOGY, INC.

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	408,387	370,345
Cost & expenses	354,671	327,001
Operating income	53,716	43,344
Interest income	97	49
Interest expense	8,782	15,387
Other income (expense), net	2,493	537
Foreign currency	(456)	521
Net before taxes	47,068	29,064
Income taxes	11,178	10,465
Net income	35,890	18,599

	2018	2017
Earnings common share		
Primary	\$1.64	\$0.86
Fully Diluted	\$1.63	\$0.85
Common Shares:		
Full Diluted	22,027	21,893
Year-end	22,032	21,847

UTAH MEDICAL PRODUCTS, INC.

New Accountant On Nov. 13, 2018, Jones Simkins LLC re-signed as Co.'s independent public accounting firm. On Nov. 14, 2018, Co. engaged Haynie & Company as its new independent public accounting firm.

VARONIS SYSTEM INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	182,770	142,389
Cost & expenses	216,405	163,555
Operating income	(33,635)	(21,166)
Other income (expense), net	266	2,041
Net before taxes	(33,369)	(19,125)
Income taxes	1,677	1,539
Net income	(35,046)	(20,664)
Earnings common share		
Primary	\$(1.21)	\$(0.76)
Fully Diluted	\$(1.21)	\$(0.76)
Common Shares:		
Full Diluted	28,859	27,292
Year-end	29,424	27,827

VEECO INSTRUMENTS INC (DE)

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Net Sales	443,110	336,025
Cost & expenses	691,529	371,186
Operating income	(276,521)	(56,883)
Interest income	2,266	1,932
Interest expense	16,113	14,301
Net before taxes	(290,368)	(69,252)
Income taxes	(27,954)	(26,334)
Net income	(262,414)	(42,918)
Earnings common share		
Primary	\$(5.55)	\$(1.00)
Fully Diluted	\$(5.55)	\$(1.00)
Common Shares:		
Full Diluted	47,283	43,100
Year-end	47,793	48,294

VERASTEM INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	25,508	...
Net Sales	508	...
Cost & expenses	86,001	49,752
Operating income	(60,524)	(49,752)
Interest income	1,297	416
Interest expense	1,858	231
Net income	(61,085)	(49,567)
Earnings common share		
Primary	\$(0.99)	\$(1.33)
Fully Diluted	\$(0.99)	\$(1.33)
Common Shares:		
Full Diluted	61,995	37,207
Year-end	73,703	...

VERISIGN INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

	2018	2017
Total Revenues	907,517	869,594
Cost & expenses	334,091	338,304
Operating income	573,426	531,290
Interest expense	92,211	95,869
Other income (expense), net	(5,495)	(263)
Gains or losses	...	10,421
Net before taxes	495,614	456,965
Income taxes	95,320	102,554
Net income	400,294	354,411
Earnings common share		
Primary	\$3.60	\$3.51
Fully Diluted	\$3.25	\$2.85
Common Shares:		
Full Diluted	123,079	124,162
Year-end	121,158	98,865

VERISK ANALYTICS INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

	2018	2017
Total Revenues	1,781,200,000	1,574,900,000
Cost & expenses	943,200,000	810,700,000
Operating income	617,900,000	591,200,000
Interest expense	97,100,000	87,300,000
Other income (expense), net	19,300,000	7,900,000
Net before taxes	540,100,000	511,800,000
Income taxes	87,600,000	161,300,000
Net income	452,500,000	350,500,000
Earnings common share		
Primary	\$2.74	\$2.12
Fully Diluted	\$2.68	\$2.08
Common Shares:		
Full Diluted	168,614,835	168,807,405
Year-end	164,810,578	164,516,754

VERITEX HOLDINGS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	74,887	36,823
Operating income	36,825	17,697
Net before taxes	36,825	17,697
Income taxes	7,309	5,802
Net income	29,516	11,895
Balance for common	29,516	11,853
Earnings common share		
Primary	\$1.22	\$0.70
Fully Diluted	\$1.20	\$0.69
Common Shares:		
Full Diluted	24,587	17,232
Year-end	24,192	22,644

VERRICA PHARMACEUTICALS INC**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Cost & expenses	15,192	3,023
Operating income	(15,192)	(3,023)
Interest income	621	
Other income (expense), net	(1)	
Net income	(14,572)	(3,024)
Earnings common share		
Primary	\$(1.30)	\$(1.06)
Fully Diluted	\$(1.30)	\$(1.06)
Common Shares:		
Full Diluted	11,230	2,850
Year-end	25,696	

VERTEX PHARMACEUTICALS, INC.**Earnings, 9 mos. to Sep 30 (Consol. - \$000):**

	2018	2017
Total Revenues	2,177,491	1,837,018
Cost & expenses	1,670,063	1,839,512
Operating income	507,428	(2,494)
Interest expense	29,346	45,003
Other income (expense), net	89,662	(80,634)
Net before taxes	567,744	(128,131)
Income taxes	5,737	(117,581)
Net income	562,007	(10,550)
Earnings common share		
Primary	\$2.15	\$0.66
Fully Diluted	\$2.11	\$0.64
Common Shares:		
Full Diluted	258,972	252,095
Year-end	255,611	

VIACOM INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$000):**

	2018	2017	2016
Revenues	12,943,000	13,263,000	12,488,000
Operating expense	6,879,000	7,436,000	6,684,000
Selling, general & administrative expense	3,056,000	3,005,000	2,851,000
Depreciation & amortization expenses	213,000	223,000	221,000
Restructuring & related costs	225,000	237,000	206,000
Total expenses	10,373,000	10,901,000	9,962,000
Gain on asset sale	127,000		
Operating income	2,570,000	2,489,000	2,526,000

Interest expense, net	(560,000)	(618,000)	(616,000)
Equity in earnings (losses) of investee companies	9,000	81,000	87,000
Gain on sale of EPIX		285,000	
Other items, net	22,000	25,000	7,000
Earnings (loss) from continuing operations before provision for income taxes - United States	1,351,000	1,647,000	1,479,000
Earnings (loss) from continuing operations before provision for income taxes - international	646,000	565,000	511,000
Earnings (loss) from continuing operations before provision for income taxes - Current federal	148,000	312,000	112,000
Current state & local provision for income taxes	32,000	43,000	31,000
Current international provision for income taxes	134,000	112,000	122,000
Total current provision for income taxes	314,000	467,000	265,000
Deferred provision (benefit) for income taxes	(45,000)	(174,000)	254,000
Provision for income taxes	269,000	293,000	519,000
Net earnings from continuing operations	1,728,000	1,919,000	1,471,000
Discontinued operations, net of tax	31,000	3,000	2,000
Net earnings (Viacom & noncontrolling interests)	1,759,000	1,922,000	1,473,000
Net losses (earnings) attributable to noncontrolling interests	(40,000)	(48,000)	(35,000)
Net earnings attributable to Viacom	1,719,000	1,874,000	1,438,000
Weighted average shares outstanding-basic	402,700	399,900	396,500
Weighted average shares outstanding-diluted	403,000	400,600	398,000
Year end shares outstanding	403,100	402,400	397,000
Earnings (loss) per share from continuing operations-basic	\$4.19	\$4.68	\$3.62
Earnings (loss) per share-discontinued operations-basic	\$0.08	\$0.01	\$0.01
Net earnings (loss) per share-basic	\$4.27	\$4.69	\$3.63
Earnings (loss) per share from continuing operations-diluted	\$4.19	\$4.67	\$3.61
Earnings (loss) per share-discontinued			

operations-diluted	\$0.08	\$0.01	...
Net earnings (loss) per share-diluted	\$4.27	\$4.68	\$3.61
Dividends declared per share of Class A & Class B common stock	\$0.80	\$0.80	\$1.40
Total number of employees	10,400	11,650	9,300
Number of class A common stockholders	1,258	1,330	1,397
Number of class B common stockholders	18,306	19,524	20,802
Foreign currency translation adjustments			(101,000)

□ Approximately; □ As is; □ As of October 31, 2018; □ As of October 31, 2017; □ As of October 31, 2016

Consolidated Balance Sheet, Years Ended Sept. 30 (\$000):

	2018	2017
Cash & cash equivalents	1,557,000	1,389,000
Receivables, gross	3,250,000	3,098,000
Sales returns & allowances	(64,000)	(79,000)
Allowance for doubtful accounts	45,000	49,000
Receivables, net	3,141,000	2,970,000
Inventory, net	896,000	919,000
Prepaid & other assets	482,000	523,000
Total current assets	6,076,000	5,801,000
Land	251,000	261,000
Buildings	468,000	491,000
Capital leases	193,000	201,000
Equipment & other property & equipment	2,101,000	2,020,000
Gross property & equipment	3,013,000	2,973,000
Less: accumulated depreciation	2,094,000	1,995,000
Property & equipment, net	919,000	978,000
Inventory, net	3,848,000	3,982,000
Goodwill	11,609,000	11,665,000
Intangibles, net	313,000	313,000
Other assets	1,018,000	959,000
Total assets	23,783,000	23,698,000
Accounts payable	433,000	431,000
Accrued expenses	848,000	869,000
Participants' share & residuals	719,000	825,000
Program obligations	662,000	712,000
Deferred revenue	398,000	463,000
Current portion of debt	567,000	19,000
Other liabilities	427,000	434,000
Total current liabilities	4,054,000	3,753,000
Senior notes	4,573,000	5,045,000
Senior debentures	4,195,000	4,736,000
Junior debentures	1,284,000	1,284,000
Capital leases & other obligations	30,000	54,000
Less current portion	567,000	19,000
Noncurrent portion of debt	9,515,000	11,100,000
Participants' share & residuals	523,000	384,000
Program obligations	498,000	477,000
Deferred tax liabilities, net	296,000	294,000
Other liabilities	1,186,000	1,323,000
Redeemable noncontrolling interest	246,000	248,000
Additional paid-in capital	10,145,000	10,119,000
Treasury stock	20,562,000	20,590,000
Retained earnings	18,561,000	17,124,000
Foreign currency translation adjustments	(568,000)	(405,000)
Defined benefit pension plans	(229,000)	(221,000)
Cash flow hedges	6,000	8,000
Available for sale		

securities	54,000	...
Accumulated other comprehensive income (loss)	(737,000)	(618,000)
Total Viacom stockholders' equity	7,407,000	6,035,000
Noncontrolling interests	58,000	84,000
Total equity	7,465,000	6,119,000

Recent Dividends:**1. Viacom Inc class B common.**

ExDate	Amt	Declared	Record	Payable
12/11/2014	0.33	11/12/2014	12/15/2014	01/02/2015
03/11/2015	0.33	01/15/2015	03/13/2015	04/01/2015
06/11/2015	0.40	05/20/2015	06/15/2015	07/01/2015
09/11/2015	0.40	08/04/2015	09/15/2015	10/01/2015
12/11/2015	0.40	11/11/2015	12/15/2015	01/04/2016
03/09/2016	0.40	01/14/2016	03/13/2016	04/01/2016
06/13/2016	0.40	05/18/2016	06/15/2016	07/01/2016
09/22/2016	0.20	09/21/2016	09/26/2016	10/03/2016
12/13/2016	0.20	10/31/2016	12/15/2016	01/03/2017
03/13/2017	0.20	02/06/2017	03/15/2017	04/03/2017
06/13/2017	0.20	05/18/2017	06/15/2017	07/03/2017
09/14/2017	0.20	08/02/2017	09/15/2017	10/02/2017
12/14/2017	0.20	11/10/2017	12/15/2017	01/02/2018
03/14/2018	0.20	03/08/2018	03/15/2018	04/03/2018
06/14/2018	0.20	05/21/2018	06/15/2018	07/02/2018
09/14/2018	0.20	08/01/2018	09/17/2018	10/01/2018

2. Viacom Inc class A common.

ExDate	Amt	Declared	Record	Payable
12/11/2014	0.33	11/12/2014	12/15/2014	01/02/2015
03/11/2015	0.33	01/15/2015	03/13/2015	04/01/2015
06/11/2015	0.40	05/20/2015	06/15/2015	07/01/2015
09/11/2015	0.40	08/04/2015	09/15/2015	10/01/2015
12/11/2015	0.40	11/11/2015	12/15/2015	01/04/2016
03/09/2016	0.40	01/14/2016	03/13/2016	04/01/2016
06/13/2016	0.40	05/18/2016	06/15/2016	07/01/2016
09/22/2016	0.20	09/21/2016	09/26/2016	10/03/2016
12/13/2016	0.20	10/31/2016	12/15/2016	01/03/2017
03/13/2017	0.20	02/06/2017	03/15/2017	04/03/2017
06/13/2017	0.20	05/18/2017	06/15/2017	07/03/2017
09/14/2017	0.20	08/02/2017	09/15/2017	10/02/2017
12/14/2017	0.20	11/10/2017	12/15/2017	01/02/2018
03/14/2018	0.20	03/08/2018	03/15/2018	04/03/2018
06/14/2018	0.20	05/21/2018	06/15/2018	07/02/2018
09/14/2018	0.20	08/01/2018	09/17/2018	10/01/2018

Annual Dividends:**1. Viacom Inc class B common.**

2015	1.46	2016	1.40	2017	0.80
2018	0.80				

2. Viacom Inc class A common.

2015	1.46	2016	1.40	2017	0.80
2018	0.80				

VIASAT INC**Earnings, 6 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	956,343,000	773,118,000
Cost & expenses	1,027,505,000	800,348,000
Operating income	(76,050,000)	(33,810,000)
Interest income	65,000	270,000
Interest expense	25,398,000	253,000
Other income (expense), net	(10,217,000)	
Equity earnings	(1,379,000)	(228,000)
Net before taxes	(101,383,000)	(44,010,000)
Income taxes	(38,909,000)	(20,644,000)
Net income	(61,095,000)	(23,138,000)
Earnings common share		
Primary	\$(1.00)	\$(0.39)
Fully Diluted	\$(1.00)	\$(0.39)
Common Shares:		
Full Diluted	59,470,000	58,039,000
Year-end	59,650,229	58,206,637

VIAMI SOLUTIONS INC**Earnings, 3 mos. to (Consol. - \$000):**

	09/29/18	09/30/17
Total Revenues	268,500	190,900

Cost & expenses	259,900	181,100
Operating income	(1,200)	6,700
Gains or losses	(200)	
Net before taxes	(9,600)	(5,600)
Income taxes	5,700	2,000
Net income	(15,300)	(7,600)
Earnings common share		
Primary	\$(0.07)	\$(0.03)
Fully Diluted	\$(0.07)	\$(0.03)
Common Shares:		
Full Diluted	227,200	228,100
Year-end	228,000	228,000

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	600,700	
Inventories	89,500	
Current assets	1,026,200	
Net property & equip.	170,800	
Total assets	1,888,800	
Liabilities:		
Current liabilities	429,600	
Long-term debt	589,800	
Stockholders' equity	709,600	
Net current assets	596,600	

VICOR CORP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	217,500	169,059
Cost & expenses	192,455	170,875
Operating income	25,045	(1,816)
Other income (expense), net	530	903
Gains or losses	88	91
Net before taxes	25,663	(822)
Income taxes	724	539
Net income	24,939	(1,361)
Earnings common share		
Primary	\$0.62	\$(0.04)
Fully Diluted	\$0.61	\$(0.04)
Common Shares:		
Full Diluted	40,645	39,177
Year-end	40,166	39,339

VIDEO DISPLAY CORP**Earnings, 6 mos. to Aug 31(Consol. - \$000):**

	2018	2017
Net Sales	7,342	7,058
Cost & expenses	7,597	8,129
Operating income	(255)	(1,071)
Other income (expense), net	248	603
Gains or losses	70	(6)
Net before taxes	(482)	5
Income taxes	5	(487)
Net income	49	(487)
Earnings common share		
Primary	\$0.01	\$(0.08)
Fully Diluted	\$0.01	\$(0.08)
Common Shares:		
Full Diluted	6,080	5,891
Year-end	5,878	5,891

VIEWRAY INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Total Revenues	60,299,000	14,122,000
Cost & expenses	113,896,000	49,430,000
Operating income	(53,597,000)	(35,308,000)
Interest income	6,000	3,000
Interest expense	5,758,000	5,372,000
Other income (expense), net	(307,000)	(6,853,000)
Net income	(59,656,000)	(47,530,000)
Balance for common	(62,384,000)	(47,530,000)
Earnings common share		
Primary	\$(0.82)	\$(0.85)
Fully Diluted	\$(0.82)	\$(0.85)
Common Shares:		
Full Diluted	76,185,346	56,064,562
Year-end	95,195,872	

VIKING THERAPEUTICS INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

	2018	2017
Cost & expenses	19,124,000	14,643,000
Operating income	(19,124,000)	(14,643,000)

Other income (expense), net	1,398,000	(288,000)
Net income	(16,823,000)	(16,493,000)
Earnings common share		
Primary	\$(0.32)	\$(0.67)
Fully Diluted	\$(0.32)	\$(0.67)
Common Shares:		
Full Diluted	52,943,273	24,665,941
Year-end	71,284,604	28,498,847

VIPER ENERGY PARTNERS LP**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	216,452	112,807
Cost & expenses	21,660	13,224
Operating income	153,475	70,996
Other income (expense), net	6,644	526
Net before taxes	151,058	
Income taxes	(71,114)	
Net income	222,172	69,408
Earnings common share		
Primary	\$1.85	\$0.69
Fully Diluted	\$1.85	\$0.69
Common Shares:		
Full Diluted	78,319	101,143
Year-end	124,072	113,882

VIRTU FINANCIAL INC

Merger Development On Nov. 6, 2018, Co. and Investment Technology Group, Inc. ("ITG") entered into a definitive agreement (the "ITG Merger Agreement") whereby Co. will acquire ITG in a cash transaction valued at \$30.30 per ITG share, or a total of approximately \$1,000,000,000 (the "ITG Acquisition"). The ITG Acquisition is expected to close during the first half of 2019 after receipt of all required regulatory approvals and ITG shareholder approval.

VIRTUS INVESTMENT PARTNERS INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	414,170	297,583
Cost & expenses	309,394	257,976
Operating income	83,871	30,020
Other income (expense), net	2,323	1,129
Gains or losses	(3,231)	19,436
Net before taxes	97,628	50,235
Income taxes	22,641	15,939
Net income	74,987	34,296
Balance for common	67,115	25,262
Earnings common share		
Primary	\$9.33	\$3.64
Fully Diluted	\$8.67	\$3.52
Common Shares:		
Full Diluted	8,463	7,168
Year-end	7,147	7,158

VIRTUSA CORP**Earnings, 6 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Total Revenues	605,551	475,519
Cost & expenses	577,608	459,170
Operating income	27,943	16,349
Interest income	1,353	1,932
Interest expense	8,768	3,071
Other income (expense), net	1,443	884
Foreign currency	(20,113)	(1,557)
Net before taxes	1,858	14,537
Income taxes	5,463	2,298
Net income	(3,605)	12,239
Balance for common	(6,966)	6,638
Earnings common share		
Primary	\$(0.23)	\$0.23
Fully Diluted	\$(0.23)	\$0.22
Common Shares:		
Full Diluted	29,700	30,036
Year-end	29,890	

VITAL THERAPIES INC**Earnings, 9 mos. to Sep 30(Consol. - \$000):**

	2018	2017
Cost & expenses	39,473	37,875
Operating income	(39,473)	(37,875)
Interest income	445	453
Other income (expense), net	17	(68)
Net income	(39,011)	(37,490)
Earnings common share		

portion of long-term debt	800,000	
Short-term borrowings	23,600,000	20,000,000
Income taxes payable	2,125,000	1,306,000
Total current liabilities	85,903,000	75,423,000
Revolving credit facility	44,000,000	134,000,000
Series A notes	18,800,000	
Long-term borrowings	62,800,000	134,000,000
Deferred tax liabilities, net	11,050,000	18,949,000
Other long-term liabilities	1,817,000	1,958,000
Total liabilities	161,570,000	230,330,000
Common stock	20,000	20,000
Additional paid-in capital	153,469,000	150,692,000
Retained earnings (accumulated deficit)	351,266,000	315,764,000
Accumulated other comprehensive income (loss)	(27,636,000)	(28,075,000)
Common stock held in treasury, at cost	321,630,000	299,014,000
Total shareholders' equity (deficit)	155,489,000	139,387,000

□ Reclassified to conform with 2018 presentation

Recent Dividends:

1. WD-40 Co common.

ExDate	Amt	Declared	Record	Payable
12/31/2014	0.38	12/09/2014	01/05/2015	01/30/2015
04/14/2015	0.38	03/24/2015	04/16/2015	04/30/2015
07/15/2015	0.38	06/23/2015	07/17/2015	07/31/2015
10/14/2015	0.38	10/02/2015	10/16/2015	10/30/2015
01/13/2016	0.42	12/08/2015	01/15/2016	01/29/2016
04/13/2016	0.42	03/22/2016	04/15/2016	04/29/2016
07/13/2016	0.42	06/21/2016	07/15/2016	07/29/2016
10/19/2016	0.42	10/11/2016	10/21/2016	10/31/2016
01/18/2017	0.49	12/13/2016	01/20/2017	01/31/2017
04/11/2017	0.49	03/21/2017	04/14/2017	04/28/2017
07/19/2017	0.49	06/20/2017	07/21/2017	07/31/2017
10/19/2017	0.49	10/10/2017	10/20/2017	10/31/2017
01/18/2018	0.54	12/12/2017	01/19/2018	01/31/2018
04/19/2018	0.54	03/20/2018	04/20/2018	04/30/2018
07/19/2018	0.54	06/19/2018	07/20/2018	07/31/2018
10/18/2018	0.54	10/09/2018	10/19/2018	10/31/2018

Annual Dividends:

1. WD-40 Co common.

2015	1.52	2016	1.68	2017	1.96
2018	2.16				

WEIGHT WATCHERS INTERNATIONAL INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	1,183,735	994,422
Cost & expenses	875,097	776,605
Operating income	308,638	217,817
Interest expense	107,238	82,227
Other income (expense), net	(1,978)	1,276
Net before taxes	199,422	136,866
Income taxes	19,580	36,457
Net income	179,842	100,409
Earnings common share		
Primary	\$2.72	\$1.57
Fully Diluted	\$2.57	\$1.48
Common Shares:		
Full Diluted	70,117	67,939
Year-end	66,836	64,525

WENDY'S CO (THE)

Earnings, 9 mos. to (Consol. - \$000):

	09/30/18	10/01/17
Total Revenues	1,192,116	914,161
Net Sales	486,316	467,914
Cost & expenses	893,374	674,300
Deprec., depl. & amort.	94,649	91,690
Operating income	204,093	148,171
Interest expense	89,939	87,887
Other income (expense), net	441,380	3,108
Net before taxes	555,534	63,392
Income taxes	114,250	28,639
Net income	441,284	34,753

Earnings common share		
Primary	\$1.85	\$0.14
Fully Diluted	\$1.79	\$0.14
Common Shares:		
Full Diluted	246,446	253,176
Year-end	238,318	

WERNER ENTERPRISES, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	1,811,549	1,549,372
Cost & expenses	1,491,826	1,287,994
Operating income	149,284	98,759
Interest income	2,079	2,556
Interest expense	1,842	1,892
Other income (expense), net	(172)	(293)
Net before taxes	149,349	99,130
Income taxes	35,764	37,375
Net income	113,585	61,755
Earnings common share		
Primary	\$1.58	\$0.85
Fully Diluted	\$1.57	\$0.85
Common Shares:		
Full Diluted	72,300	72,517
Year-end	71,194	

WEYCO GROUP, INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Net Sales	208,789,000	203,479,000
Cost & expenses	195,228,000	190,328,000
Operating income	13,561,000	13,151,000
Other income (expense), net	(414,000)	(243,000)
Net before taxes	13,876,000	13,473,000
Income taxes	3,385,000	5,135,000
Net income	10,491,000	8,338,000
Earnings common share		
Primary	\$1.07	\$0.82
Fully Diluted	\$1.05	\$0.81
Common Shares:		
Full Diluted	10,419,000	10,360,000
Year-end	10,135,680	10,192,905

WHEREVERTV BROADCASTING CORP

Earnings, 6 mos. to Jun 30(Consol. - \$):

	2018	2017
Cost & expenses	875,168	819,378
Operating income	(885,330)	(864,878)
Net income	(885,330)	(864,878)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	116,414,637	74,412,587
Year-end	117,749,709	78,066,879

WILLDAN GROUP INC

Acquisition Completed On Nov. 9, 2018, Co. acquired Lime Energy Co. ("Lime Energy") (the "Acquisition") as its new subsidiary through the merger of Co.'s indirect subsidiary, Luna Fruit, Inc. ("Merger Sub"), a Delaware corporation and wholly-owned subsidiary of Willdan Energy Solutions, a California corporation, with and into Lime Energy, with Lime Energy surviving the merger. The aggregate purchase price paid in the Acquisition was \$120,000,000, exclusive of closing holdbacks and adjustments. A portion of the purchase price was deposited into escrow accounts to secure certain potential post-closing obligations of the participating securityholders. Co. paid the purchase price for the Acquisition using a combination of cash on hand (including \$50,000,000 of the \$56,400,000 in net proceeds received from Co.'s recently completed equity offering) and certain proceeds from Co.'s borrowings under its Delayed Draw Term Loan Facility.

WINDSTREAM HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$000):

	2018	2017
Total Revenues	4,319,300	4,355,000
Cost & expenses	2,950,100	3,100,900
Deprec., depl. & amort.	1,136,300	1,066,300
Operating income	232,900	187,800
Interest expense	677,500	642,600
Other income (expense), net	203,200	10,500
Net before taxes	(241,400)	(444,300)
Income taxes	(67,600)	(163,400)

Net income	(173,800)	(280,900)
Balance for common	(173,800)	(282,200)
Earnings common share		
Primary	\$(4.32)	\$(8.50)
Fully Diluted	\$(4.32)	\$(8.50)
Common Shares:		
Full Diluted	40,200	33,200
Year-end	42,900	36,580

WINGSTOP INC

Earnings, 9 mos. to (Consol. - \$000):

	09/29/18	09/30/17
Total Revenues	112,672	98,111
Cost & expenses	79,661	70,297
Deprec., depl. & amort.	3,163	2,407
Operating income	29,848	25,407
Net before taxes	23,225	21,499
Income taxes	3,925	5,631
Net income	19,300	15,868
Earnings common share		
Primary	\$0.66	\$0.55
Fully Diluted	\$0.65	\$0.54
Common Shares:		
Full Diluted	29,561	29,362
Year-end	29,296	

WINMARK CORP

Earnings, 9 mos. to (Consol. - \$):

	09/29/18	09/30/17
Total Revenues	55,439,300	51,971,500
Cost & expenses	23,855,100	23,805,500
Operating income	31,584,200	28,166,000
Interest expense	1,978,600	1,559,300
Net before taxes	29,592,300	26,636,600
Income taxes	7,124,600	9,694,500
Net income	22,467,700	16,942,100
Earnings common share		
Primary	\$5.81	\$4.10
Fully Diluted	\$5.43	\$3.84
Common Shares:		
Full Diluted	4,140,816	4,416,185
Year-end	3,901,202	

WISDOMTREE INVESTMENTS, INC.

Earnings, 9 mos. to Sep 30(Consol. - \$):

	2018	2017
Total Revenues	206,249,000	167,322,000
Cost & expenses	155,791,000	122,428,000
Operating income	49,460,000	43,852,000
Interest income	2,293,000	1,999,000
Interest expense	5,103,000	
Other income (expense), net	(644,000)	6,692,000
Gains or losses	17,630,000	
Net before taxes	63,636,000	52,543,000
Income taxes	15,439,000	25,582,000
Net income	48,197,000	26,961,000
Earnings common share		
Primary	\$0.31	\$0.20
Fully Diluted	\$0.31	\$0.20
Common Shares:		
Full Diluted	155,584,000	135,768,000
Year-end	153,083,000	136,923,000

Primary	\$0.31	\$0.20
Fully Diluted	\$0.31	\$0.20
Common Shares:		
Full Diluted	155,584,000	135,768,000
Year-end	153,083,000	136,923,000

WOODWARD, INC.

Annual Report

Consolidated Income Statement, Years Ended Sept. 30

	2018	2017	□2016
Net sales	2,325,873	2,098,685	2,023,078
Cost of goods sold	1,719,675	1,526,126	1,483,960
Selling, general & administrative expenses	192,757	176,633	174,017
Research & development costs	148,279	126,519	126,170
Restructuring charges	17,013		
Interest expense	31,770	27,430	26,776
Interest income	1,674	1,725	2,025
Equity interest in the earnings of the joint venture (JV)	3,339	2,568	6,204
Net gain (loss) on			

Year-end	513,299	507,763	Income taxes	5,003,000	6,281,000	Foreign currency	(409,010)	361,450
			Net income	24,871,000	7,041,000	Net income	(32,120,932)	(23,893,705)
XENCOR, INC			Earnings common share			Earnings common share		
Earnings, 9 mos. to Sep 30 (Consol. – \$000):			Primary	\$0.88	\$0.25	Primary	\$(2.21)	\$(1.87)
	2018	2017	Fully Diluted	\$0.87	\$0.25	Fully Diluted	\$(2.21)	\$(1.87)
Cost & expenses	87,326	64,450	Common Shares:			Common Shares:		
Operating income	(58,287)	(48,450)	Full Diluted	28,640,000	28,229,000	Full Diluted	14,531,272	12,743,332
Interest income	6,279	3,134	Year-end	27,985,000	27,992,000	Year-end	17,623,873	13,257,279
Other income (expense), net	(202)	86						
Net before taxes	(45,230)		ZEBRA TECHNOLOGIES CORP.					
Income taxes	623		Earnings, 9 mos. to (Consol. – \$000):					
Net income	(52,210)	(45,853)		09/29/18	09/30/17			
Earnings common share			Net Sales	3,081,000	2,696,000			
Primary	\$(0.98)	\$(0.98)	Cost & expenses	2,579,000	2,356,000			
Fully Diluted	\$(0.98)	\$(0.98)	Operating income	431,000	189,000			
Common Shares:			Other income (expense), net	2,000	(5,000)			
Full Diluted	53,166	46,767	Foreign currency	(5,000)	2,000			
Year-end	56,212		Net before taxes	376,000	10,000			
			Income taxes	70,000	(3,000)			
XILINX, INC.			Net income	306,000	13,000			
Earnings, 6 mos. to (Consol. – \$000):			Earnings common share					
	09/29/18	09/30/17	Primary	\$5.72	\$0.25			
Total Revenues	1,430,622	1,230,229	Fully Diluted	\$5.64	\$0.25			
Cost & expenses	980,923	867,773	Common Shares:					
Operating income	448,500	361,241	Full Diluted	54,238	53,631			
Other income (expense), net	(4,651)	(467)	Year-end	53,803	53,191			
Net before taxes	452,061	364,910						
Income taxes	46,311	33,915	ZILLOW GROUP INC					
Net income	405,750	330,995	Earnings, 9 mos. to Sep 30 (Consol. – \$000):					
Earnings common share				2018	2017			
Primary	\$1.61	\$1.33	Total Revenues	968,219	794,464			
Fully Diluted	\$1.59	\$1.26	Cost & expenses	999,475	795,112			
Common Shares:			Operating income	(31,256)	(648)			
Full Diluted	255,057	261,739	Other income (expense), net	13,308	3,970			
Year-end	253,043	250,953	Net before taxes	(44,876)	(17,204)			
			Income taxes	(22,700)	41			
XOMA CORP			Net income	(22,176)	(17,245)			
Earnings, 9 mos. to Sep 30 (Consol. – \$000):			Earnings common share					
	2018	2017	Primary	\$(0.11)	\$(0.09)			
Total Revenues	3,614	47,333	Fully Diluted	\$(0.11)	\$(0.09)			
Cost & expenses	17,049	28,291	Common Shares:					
Operating income	(13,435)	19,042	Full Diluted	195,208	185,447			
Interest expense	557	1,108	Year-end	203,157	188,784			
Other income (expense), net	3,661	(1,436)						
Gains or losses		1,123	ZIX CORP					
Net before taxes		17,621	Earnings, 9 mos. to Sep 30 (Consol. – \$):					
Income taxes		1,706		2018	2017			
Net income	(10,331)	15,915	Total Revenues	52,029,000	48,863,000			
Balance for common	(10,331)	6,609	Cost & expenses	44,048,000	40,671,000			
Earnings common share			Operating income	7,981,000	8,192,000			
Primary	\$(1.24)	\$0.89	Other income (expense), net	662,000	230,000			
Fully Diluted	\$(1.24)	\$0.88	Net before taxes	8,643,000	8,422,000			
Common Shares:			Income taxes	2,455,000	3,603,000			
Full Diluted	8,354	7,617	Net income	6,188,000	4,819,000			
Year-end	8,387	8,144	Earnings common share					
			Primary	\$0.12	\$0.09			
XPERI CORP			Fully Diluted	\$0.12	\$0.09			
Earnings, 9 mos. to Sep 30 (Consol. – \$000):			Common Shares:					
	2018	2017	Full Diluted	53,389,622	54,263,258			
Total Revenues	201,851	247,085	Year-end	54,194,512	55,038,288			
Cost & expenses	200,136	218,105						
Operating income	(79,858)	(55,495)	ZOGENIX INC.					
Interest expense	18,861	20,876	Earnings, 9 mos. to Sep 30 (Consol. – \$000):					
Other income (expense), net	1,113	274		2018	2017			
Gains or losses	(566)		Cost & expenses	108,192	91,421			
Net before taxes	(91,599)	(75,366)	Operating income	(108,192)	(81,600)			
Income taxes	(8,550)	(13,164)	Other income (expense), net	2,920	(2,947)			
Net income	(83,049)	(62,202)	Net before taxes		(86,280)			
Earnings common share			Income taxes		(41)			
Primary	\$(1.69)	\$(1.26)	Income contin. oper.	(101,283)	(86,239)			
Fully Diluted	\$(1.69)	\$(1.26)	Income discont. oper.	(198)	(870)			
Common Shares:			Net income	(101,481)	(87,109)			
Full Diluted	49,005	49,293	Earnings common share					
Year-end	48,663	49,283	Primary	\$(2.78)	\$(3.48)			
			Fully Diluted	\$(2.78)	\$(3.48)			
ZAGG INC			Common Shares:					
Earnings, 9 mos. to Sep 30 (Consol. – \$):			Full Diluted	36,485	25,024			
	2018	2017	Year-end	41,925	26,545			
Net Sales	371,718,000	342,571,000						
Cost & expenses	331,946,000	318,749,000	ZYNERBA PHARMACEUTICALS INC					
Operating income	31,368,000	14,782,000	Earnings, 9 mos. to Sep 30 (Consol. – \$):					
Interest expense	1,132,000	1,527,000		2018	2017			
Other income (expense), net	(362,000)	67,000	Cost & expenses	32,351,624	24,618,505			
Net before taxes	29,874,000	13,322,000	Operating income	(32,351,624)	(24,618,505)			